{"id":"3708949_1","context":"After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"jaundice"},{"annotation":"Treatment","text":"parenteral amiodarone (2300 mg in 3 days) and other measures"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Drug","text":"other measures"},{"annotation":"Treatment.Disorder","text":"congestive heart failure"},{"annotation":"Treatment.Disorder","text":"jaundice"},{"annotation":"Treatment.Disorder","text":"marked increase in serum transaminase levels"},{"annotation":"Treatment.Disorder","text":"fall in prothrombin time"},{"annotation":"Treatment.Disorder","text":"severe centrilobular necrosis"},{"annotation":"Treatment.Drug","text":"other measures"},{"annotation":"Treatment.Disorder","text":"hepatic biopsy"},{"annotation":"Treatment.Drug","text":"parenteral amiodarone"},{"annotation":"Treatment.Drug","text":"other measures"},{"annotation":"Treatment.Disorder","text":"congestive heart failure"},{"annotation":"Treatment.Disorder","text":"jaundice"},{"annotation":"Treatment.Disorder","text":"marked increase in serum transaminase levels"},{"annotation":"Treatment.Disorder","text":"fall in prothrombin time"},{"annotation":"Treatment.Disorder","text":"severe centrilobular necrosis"},{"annotation":"Treatment.Drug","text":"other measures"},{"annotation":"Treatment.Disorder","text":"hepatic biopsy"},{"annotation":"Treatment.Drug","text":"parenteral amiodarone"},{"annotation":"Treatment.Drug","text":"other measures"},{"annotation":"Treatment.Disorder","text":"congestive heart failure"},{"annotation":"Treatment.Disorder","text":"jaundice"},{"annotation":"Treatment.Disorder","text":"marked increase in serum transaminase levels"},{"annotation":"Treatment.Disorder","text":"fall in prothrombin time"},{"annotation":"Treatment.Disorder","text":"severe centrilobular necrosis"},{"annotation":"Treatment.Drug","text":"other measures"},{"annotation":"Treatment.Disorder","text":"hepatic biopsy"},{"annotation":"Treatment.Drug","text":"parenteral amiodarone"},{"annotation":"Treatment.Drug","text":"other measures"},{"annotation":"Treatment.Disorder","text":"congestive heart failure"},{"annotation":"Treatment.Disorder","text":"jaundice"},{"annotation":"Treatment.Disorder","text":"marked increase in serum transaminase levels"},{"annotation":"Treatment.Disorder","text":"fall in prothrombin time"},{"annotation":"Treatment.Disorder","text":"se"}]}]}
{"id":"8467620_3","context":"We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"non-Hodgkin lymphoma"},{"annotation":"Treatment","text":"low dose methotrexate weekly over a 10-month period"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"low dose"},{"annotation":"Treatment.Duration","text":"10 months"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"rheumatoid arthritis"},{"annotation":"Subject.Disorder","text":"non-Hodgkin lymphoma"},{"annotation":"Subject.Age","text":"30 years"}]}]}
{"id":"1422497_6","context":"We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"excessive accumulation and toxicity"},{"annotation":"Effect","text":"toxicity"},{"annotation":"Treatment","text":"alum irrigation"},{"annotation":"Treatment.Disorder","text":"renal impairment"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Attribute Attributes","text":"cautious use"},{"annotation":"Attribute Attributes","text":"monitoring of serum aluminum levels"},{"annotation":"Attribute Attributes","text":"to prevent excessive accumulation and toxicity"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"recommendation"},{"annotation":"Effect","text":"to prevent excessive accumulation and toxicity"},{"annotation":"Treatment","text":"alum irrigation"},{"annotation":"Treatment.Disorder","text":"renal impairment"},{"annotation":"Attribute Attributes","text":"cautious use"},{"annotation":"Attribute Attributes","text":"monitoring of serum aluminum levels"},{"annotation":"Attribute Attributes","text":"to prevent excessive accumulation and toxicity"}]}]}
{"id":"10082597_3","context":"RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presented"},{"annotation":"Effect","text":"tense bullae and cutaneous fragility"},{"annotation":"Treatment","text":"naproxen and oxaprozin"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Treatment.Drug","text":"oxaprozin"},{"annotation":"Treatment.Drug","text":"chronic low back pain"},{"annotation":"Treatment.Drug","text":"rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"chronic low back pain and rheumatoid arthritis"},{"annotation":"Subject","text":"a 44-year-old man and a 20-year-old woman"},{"annotation":"Subject.Age","text":"44-year-old and 20-year-old"},{"annotation":"Subject.Population","text":"2 people"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"chronic low back pain and rheumatoid arthritis"},{"annotation":"Treatment","text":"naproxen and oxaprozin"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Treatment.Drug","text":"oxaprozin"},{"annotation":"Treatment.Drug","text":"chronic low back pain"},{"annotation":"Treatment.Drug","text":"rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"chronic low back pain and rheumatoid arthritis"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Treatment.Drug","text":"oxaprozin"},{"annotation":"Treatment.Disorder","text":"chronic low back pain and rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"chronic low back pain and rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"chronic low back pain and rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"chronic low back pain and rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"chronic low back pain and rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"chronic low back pain and rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"chronic low back pain and rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"chronic low back pain and rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"chronic low back pain and rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"chronic low back pain and rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"chronic low back pain"}]}]}
{"id":"16018164_1","context":"CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"hemorrhage"},{"annotation":"Treatment","text":"ingesting pseudoephedrine daily for one year"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Disease","text":"chronic sinusitis"},{"annotation":"Treatment.Duration","text":"one year"},{"annotation":"Subject","text":"a middle-aged man"},{"annotation":"Subject.Age","text":"middle-aged"},{"annotation":"Subject.Disorder","text":"chronic sinusitis"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Dosage","text":"daily for one year"},{"annotation":"Treatment.Frequency","text":"daily"},{"annotation":"Treatment.Route","text":"ingesting"},{"annotation":"Treatment.Time_elapsed","text":"after one year"}]}]}
{"id":"8467620_1","context":"Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developing"},{"annotation":"Effect","text":"lymphoma"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Duration","text":"taking"},{"annotation":"Treatment.Duration","text":"methotrexate"},{"annotation":"Treatment.Duration","text":"rheumatoid arthritis"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"rheumatoid arthritis"},{"annotation":"Subject.Age","text":"a patient"},{"annotation":"Subject.Gender","text":"a patient"},{"annotation":"Subject.Population","text":"a patient"},{"annotation":"Subject.Race","text":"a patient"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"taking"},{"annotation":"Treatment.Frequency","text":"taking"},{"annotation":"Treatment.Route","text":"taking"},{"annotation":"Treatment.Time_elapsed","text":"taking"},{"annotation":"Treatment.Duration","text":"taking"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Effect","text":"lymphoma"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute"}]}]}
{"id":"14742791_4","context":"The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"suggests"},{"annotation":"Treatment","text":"pantoprazole therapy"},{"annotation":"Treatment.Drug","text":"pantoprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"probable relationship"},{"annotation":"Treatment","text":"pantoprazole therapy"},{"annotation":"Treatment.Disorder","text":"AIN"},{"annotation":"Treatment.Drug","text":"pantoprazole"}]}]}
{"id":"8442800_11","context":"In one case, disulfiram was the only potential teratogen exposed to the fetus.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"exposed"},{"annotation":"Treatment","text":"disulfiram"},{"annotation":"Treatment.Drug","text":"disulfiram"},{"annotation":"Treatment.Disorder","text":"pregnancy"},{"annotation":"Treatment.Drug","text":"teratogen"},{"annotation":"Treatment.Drug","text":"fetus"},{"annotation":"Treatment.Drug","text":"disulfiram"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"disulfiram was not the only potential teratogen exposed to the fetus"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"exposed"},{"annotation":"Effect","text":"pregnancy"},{"annotation":"Treatment","text":"disulfiram"},{"annotation":"Treatment.Drug","text":"disulfiram"},{"annotation":"Treatment.Disorder","text":"pregnancy"},{"annotation":"Treatment.Drug","text":"teratogen"},{"annotation":"Treatment.Drug","text":"fetus"},{"annotation":"Treatment.Drug","text":"disulfiram"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"disulfiram was not the only potential teratogen exposed to the fetus"}]}]}
{"id":"15368548_4","context":"Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"complication"},{"annotation":"Treatment","text":"L-asparaginase"},{"annotation":"Treatment.Disorder","text":"pediatric neoplasms"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Disorder","text":"pancreatitis"},{"annotation":"Treatment.Duration","text":"2-16%"},{"annotation":"Treatment.Duration","text":"of patients undergoing treatment"}]}]}
{"id":"21630612_2","context":"Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"complication of statin therapy"},{"annotation":"Effect","text":"myopathy"},{"annotation":"Treatment","text":"statin therapy"},{"annotation":"Treatment.Drug","text":"statins"},{"annotation":"Treatment.Disorder","text":"myopathy"},{"annotation":"Treatment.Disorder","text":"rhabdomyolysis"}]}]}
{"id":"18855892_1","context":"Management and successful desensitization in methotrexate-induced anaphylaxis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"anaphylaxis"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"methotrexate-induced anaphylaxis"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"management"},{"annotation":"Effect","text":"anaphylaxis"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"methotrexate-induced anaphylaxis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negation","text":"not"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"desensitization"},{"annotation":"Effect","text":"anaphylaxis"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"methotrexate-induced anaphylaxis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negation","text":"not"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"management"},{"annotation":"Effect","text":"anaphylaxis"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"methotrexate-induced anaphylaxis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negation","text":"not"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"management"},{"annotation":"Effect","text":"anaphylaxis"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":""}]}]}
{"id":"12166705_1","context":"Mitomycin-C induced hemolytic uremic syndrome: a case report.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{"annotation":"Treatment","text":"mitomycin-C"},{"annotation":"Treatment.Drug","text":"mitomycin-C"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{"annotation":"Treatment","text":"mitomycin-C"},{"annotation":"Treatment.Drug","text":"mitomycin-C"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{"annotation":"Treatment","text":"mitomycin-C"},{"annotation":"Treatment.Drug","text":"mitomycin-C"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{"annotation":"Treatment","text":"mitomycin-C"},{"annotation":"Treatment.Drug","text":"mitomycin-C"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{"annotation":"Treatment","text":"mitomycin-C"},{"annotation":"Treatment.Drug","text":"mitomycin-C"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{"annotation":"Treatment","text":"mitomycin-C"},{"annotation":"Treatment.Drug","text":"mitomycin-C"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{"annotation":"Treatment","text":"mitomycin-C"},{"annotation":"Treatment.Drug","text":"mitomycin-C"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{"annotation":"Treatment","text":"mitomycin-C"},{"annotation":"Treatment.Drug","text":"mitomycin-C"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{"annotation":"Treatment","text":"mitomycin-C"},{"annotation":"Treatment.Drug","text":"mitomycin-C"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{"annotation":"Treatment","text":"mitomycin-C"},{"annotation":"Treatment.Drug","text":"mitomycin-C"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{"annotation":"Treatment","text":"mitomycin-C"},{"annotation":"Treatment.Drug","text":"mitomycin-C"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{}]}]}
{"id":"15588385_1","context":"Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"complication"},{"annotation":"Effect","text":"hepatic failure"},{"annotation":"Treatment","text":"propylthiouracil (PTU)"},{"annotation":"Treatment.Disorder","text":"hyperthyroidism"},{"annotation":"Treatment.Drug","text":"propylthiouracil"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"hyperthyroidism"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":""}]}]}
{"id":"748238_1","context":"Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"monoclonal gammopathy"},{"annotation":"Effect","text":"multiple myeloma"},{"annotation":"Treatment","text":"chronic diphenylhydantoin therapy"},{"annotation":"Treatment.Disorder","text":"monoclonal gammopathy"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"monoclonal gammopathy"},{"annotation":"Subject.Disorder","text":"multiple myeloma"}]}]}
{"id":"3359700_3","context":"Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"nephrotoxicity"},{"annotation":"Treatment","text":"cyclosporine A"},{"annotation":"Treatment.Disorder","text":"systemic lupus erythematosus and tubulointerstitial renal disease"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"severe"},{"annotation":"Treatment.Duration","text":"reversible"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration"}]}]}
{"id":"9352164_2","context":"As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intoxication"},{"annotation":"Effect","text":"hemorrhagic gastritis"},{"annotation":"Treatment","text":"AZ intoxication"},{"annotation":"Treatment.Drug","text":"AZ"},{"annotation":"Treatment.Drug","text":"intoxication"},{"annotation":"Treatment.Drug","text":"AZ"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"This is the first case report."}]}]}
{"id":"3693034_1","context":"Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"resulted"},{"annotation":"Effect","text":"toxic epidermal necrolysis"},{"annotation":"Treatment","text":"5-fluorocytosine and amphotericin B"},{"annotation":"Treatment.Drug","text":"5-fluorocytosine"},{"annotation":"Treatment.Drug","text":"amphotericin B"},{"annotation":"Treatment.Duration","text":"19 days"},{"annotation":"Treatment.Drug","text":"5-fluorocytosine"},{"annotation":"Treatment.Drug","text":"amphotericin B"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"none"}]}]}
{"id":"16018164_4","context":"Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"phenylpropanolamine"},{"annotation":"Effect","text":"stroke"},{"annotation":"Treatment","text":"phenylpropanolamine"},{"annotation":"Treatment.Disorder","text":"phenylpropanolamine"},{"annotation":"Treatment.Drug","text":"phenylpropanolamine"},{"annotation":"Treatment.Drug","text":"stroke"}]}]}
{"id":"18523232_1","context":"CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"acute hepatitis"},{"annotation":"Treatment","text":"pulse itraconazole therapy"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Duration","text":"24 wk"},{"annotation":"Treatment.Dosage","text":"200 mg orally twice daily"},{"annotation":"Treatment.Dosage","text":"1 wk on, 3 wk off"},{"annotation":"Treatment.Dosage","text":"200 mg orally twice daily"},{"annotation":"Subject","text":"a 61-year-old woman"},{"annotation":"Subject.Disorder","text":"acute hepatitis"}]}]}
{"id":"9352164_4","context":"We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"acute hemorrhagic gastritis associated with AZ intoxication"},{"annotation":"Treatment","text":"chronic renal failure"},{"annotation":"Treatment.Drug","text":"AZ"},{"annotation":"Treatment.Disorder","text":"acute hemorrhagic gastritis"},{"annotation":"Treatment.Disorder","text":"chronic renal failure"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"acute hemorrhagic gastritis"},{"annotation":"Subject.Disorder","text":"chronic renal failure"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"acute hemorrhagic gastritis associated with AZ intoxication"},{"annotation":"Treatment","text":"chronic renal failure"},{"annotation":"Treatment.Drug","text":"AZ"},{"annotation":"Treatment.Disorder","text":"acute hemorrhagic gastritis"},{"annotation":"Treatment.Disorder","text":"chronic renal failure"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"acute hemorrhagic gastritis"},{"annotation":"Subject.Disorder","text":"chronic renal failure"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"acute hemorrhagic gastritis associated with AZ intoxication"},{"annotation":"Treatment","text":"chronic renal failure"},{"annotation":"Treatment.Drug","text":"AZ"},{"annotation":"Treatment.Disorder","text":"acute hemorrhagic gastritis"},{"annotation":"Treatment.Disorder","text":"chronic renal failure"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"acute hemorrhagic gastritis"},{"annotation":"Subject.Disorder","text":"chronic renal failure"}]}]}
{"id":"16192734_1","context":"Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused by"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"oral ritodrine hydrochloride"},{"annotation":"Treatment.Drug","text":"ritodrine"},{"annotation":"Subject","text":"pregnant patient with myotonic dystrophy"},{"annotation":"Subject.Disorder","text":"myotonic dystrophy"},{"annotation":"Treatment.Drug","text":"oral"},{"annotation":"Treatment.Drug","text":"ritodrine"},{"annotation":"Treatment.Drug","text":"hydrochloride"},{"annotation":"Treatment.Combination.Trigger","text":"with"},{"annotation":"Treatment.Combination.Drug","text":"oral ritodrine hydrochloride"},{"annotation":"Treatment.Combination.Drug","text":"myotonic dystrophy"},{"annotation":"Treatment.Combination.Drug","text":"oral"},{"annotation":"Treatment.Combination.Drug","text":"ritodrine"},{"annotation":"Treatment.Combination.Drug","text":"hydrochloride"},{"annotation":"Treatment.Combination.Drug","text":"myotonic dystrophy"},{"annotation":"Treatment.Combination.Drug","text":"oral"},{"annotation":"Treatment.Combination.Drug","text":"ritodrine"},{"annotation":"Treatment.Combination.Drug","text":"hydrochloride"},{"annotation":"Treatment.Combination.Drug","text":"myotonic dystrophy"},{"annotation":"Treatment.Combination.Drug","text":"oral"},{"annotation":"Treatment.Combination.Drug","text":"ritodrine"},{"annotation":"Treatment.Combination.Drug","text":"hydrochloride"},{"annotation":"Treatment.Combination.Drug","text":"myotonic dystrophy"},{"annotation":"Treatment.Combination.Drug","text":"oral"},{"annotation":"Treatment.Combination.Drug","text":"ritodrine"},{"annotation":"Treatment.Combination.Drug","text":"hydrochloride"},{"annotation":"Treatment.Combination.Drug","text":"myotonic dystrophy"},{"annotation":"Treatment.Combination.Drug","text":"oral"},{"annotation":"Treatment.Combination.Drug","text":"ritodrine"},{"annotation":"Treatment.Combination.Drug","text":"hydrochloride"},{"annotation":"Treatment.Combination.Drug","text":"myotonic dystrophy"},{"annotation":"Treatment.Combination.Drug","text":"oral"},{"annotation":"Treatment.Combination.Drug","text":"ritodrine"},{"annotation":"Treatment.Combination.Drug","text":"hydrochloride"},{"annotation":"Treatment.Combination.Drug","text":"myotonic dystrophy"},{"annotation":"Treatment.Combination.Drug","text":"oral"},{"annotation":"Treatment.Combination.Drug","text":"ritodrine"},{"annotation":"Treatment.Combination.Drug","text":"hydrochloride"},{"annotation":"Treatment.Combination.Drug","text":"myotonic dystrophy"},{"annotation":"Treatment.Combination."}]}]}
{"id":"536470_2","context":"While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"prolonged"},{"annotation":"Effect","text":"prothrombin time"},{"annotation":"Treatment","text":"warfarin anticoagulation"},{"annotation":"Treatment.Disorder","text":"renal tubular defect"},{"annotation":"Treatment.Drug","text":"sulindac"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"sulindac"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Subject","text":"normal male volunteers"},{"annotation":"Subject.Disorder","text":"normal male volunteers"},{"annotation":"Subject.Disorder","text":"patient with a renal tubular defect"},{"annotation":"Subject.Disorder","text":"patient with a renal tubular defect"}]}]}
{"id":"8912599_7","context":"Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erosion of psoriatic plaques"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"methotrexate toxicity"},{"annotation":"Treatment.Drug","text":"bone marrow suppression"},{"annotation":"Treatment.Duration","text":"long-term medication"},{"annotation":"Treatment.Disorder","text":"psoriatic"}]}]}
{"id":"16728538_2","context":"Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"combined treatment with pegvisomant and octreotide long-acting repeatable"},{"annotation":"Treatment.Disorder","text":"acromegalic"},{"annotation":"Treatment.Drug","text":"pegvisomant"},{"annotation":"Treatment.Drug","text":"octreotide"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"pegvisomant"},{"annotation":"Treatment.Combination.Drug","text":"octreotide"},{"annotation":"Subject","text":"an acromegalic patient"},{"annotation":"Subject.Disorder","text":"acromegalic"}]}]}
{"id":"7978578_2","context":"We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Response"},{"annotation":"Treatment","text":"flumazenil"},{"annotation":"Treatment.Disorder","text":"promethazine-induced coma"},{"annotation":"Treatment.Drug","text":"flumazenil"}]}]}
{"id":"18425523_3","context":"Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"hypertension"},{"annotation":"Treatment","text":"ranibizumab"},{"annotation":"Treatment.Drug","text":"ranibizumab"},{"annotation":"Treatment.Duration","text":"1 month"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"},{"annotation":"Treatment.Dosage","text":"second injection"},{"annotation":"Treatment.Dosage","text":"first injection"}]}]}
{"id":"12022905_5","context":"Priapism associated with zuclopenthixol.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"zuclopenthixol"},{"annotation":"Treatment.Drug","text":"zuclopenthixol"},{"annotation":"Treatment.Disorder","text":"priapism"},{"annotation":"Effect","text":"priapism"}]}]}
{"id":"12488741_3","context":"Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"metronidazole therapy"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Effect","text":"MR imaging and MR spectroscopy abnormalities"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Dosage","text":"dosage of metronidazole"},{"annotation":"Treatment.Duration","text":"duration of metronidazole therapy"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"}]}]}
{"id":"15857283_3","context":"PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"use of rifabutin"},{"annotation":"Effect","text":"corneal endothelial deposits"},{"annotation":"Treatment","text":"rifabutin"},{"annotation":"Treatment.Drug","text":"rifabutin"}]}]}
{"id":"19318596_3","context":"OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Objective"},{"annotation":"Treatment","text":"calcineurin-induced pain syndrome (CIPS)"},{"annotation":"Treatment.Disorder","text":"child undergoing his second hematopoietic stem cell transplant (HSCT)"},{"annotation":"Treatment.Drug","text":"calcineurin"},{"annotation":"Effect","text":"pain syndrome"}]}]}
{"id":"14684937_4","context":"We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"resulting in"},{"annotation":"Effect","text":"hypercalciuria and hypercalcemia"},{"annotation":"Treatment","text":"tacalcitol ointment and thiazide"},{"annotation":"Treatment.Disorder","text":"psoriasis and hypertension"},{"annotation":"Treatment.Drug","text":"tacalcitol"},{"annotation":"Treatment.Drug","text":"thiazide"},{"annotation":"Treatment.Drug","text":"tacalcitol ointment"},{"annotation":"Treatment.Drug","text":"thiazide"},{"annotation":"Subject","text":"a male patient"},{"annotation":"Subject.Disorder","text":"psoriasis and hypertension"}]}]}
{"id":"16341621_3","context":"To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"reaction"},{"annotation":"Effect","text":"granulomatous"},{"annotation":"Treatment","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Disorder","text":"granulomatous reaction"},{"annotation":"Treatment.Disorder","text":"calcium hydroxylapatite injection"},{"annotation":"Subject","text":"to our knowledge"},{"annotation":"Subject.Disorder","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Disorder","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment.Disorder","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment","text":"calcium hydroxylapatite injection"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{}]}]}
{"id":"15595320_3","context":"Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Effect","text":"clinical manifestations"},{"annotation":"Treatment","text":"MTX and NSAIDs"},{"annotation":"Treatment.Disorder","text":"acute renal failure"},{"annotation":"Treatment.Disorder","text":"pancytopenia"},{"annotation":"Treatment.Disorder","text":"vomiting"},{"annotation":"Treatment.Disorder","text":"diarrhea"},{"annotation":"Treatment.Disorder","text":"elevated liver transaminases"},{"annotation":"Treatment.Disorder","text":"jaundice"},{"annotation":"Treatment.Disorder","text":"mucosal ulcerations"},{"annotation":"Treatment.Disorder","text":"pyrexia"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Trigger","text":"interaction"},{"annotation":"Treatment.Combination.Drug","text":"MTX"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment.Combination.Drug","text":"NSAIDs"},{"annotation":"Treatment"}]}]}
{"id":"3868420_1","context":"We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"mebendazole"},{"annotation":"Treatment.Drug","text":"mebendazole"},{"annotation":"Treatment.Duration","text":"brief"},{"annotation":"Treatment.Side_effect","text":"alopecia and granulocytopenia"},{"annotation":"Subject","text":"a patient with alveolar hydatid disease"},{"annotation":"Subject.Disorder","text":"alveolar hydatid disease"}]}]}
{"id":"3174043_1","context":"Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"causes"},{"annotation":"Effect","text":"toxic cystoid maculopathy"},{"annotation":"Treatment","text":"niacin"},{"annotation":"Treatment.Drug","text":"niacin"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Duration","text":"reversible"},{"annotation":"Treatment.Disorder","text":"toxic cystoid maculopathy"},{"annotation":"Treatment.Drug","text":"niacin"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Duration","text":"reversible"},{"annotation":"Treatment.Disorder","text":"toxic cystoid maculopathy"},{"annotation":"Treatment.Drug","text":"niacin"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Duration","text":"reversible"},{"annotation":"Treatment.Disorder","text":"toxic cystoid maculopathy"},{"annotation":"Treatment.Drug","text":"niacin"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Duration","text":"reversible"},{"annotation":"Treatment.Disorder","text":"toxic cystoid maculopathy"},{"annotation":"Treatment.Drug","text":"niacin"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Duration","text":"reversible"},{"annotation":"Treatment.Disorder","text":"toxic cystoid maculopathy"},{"annotation":"Treatment.Drug","text":"niacin"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Duration","text":"reversible"},{"annotation":"Treatment.Disorder","text":"toxic cystoid maculopathy"},{"annotation":"Treatment.Drug","text":"niacin"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Duration","text":"reversible"},{"annotation":"Treatment.Disorder","text":"toxic cystoid maculopathy"},{"annotation":"Treatment.Drug","text":"niacin"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Duration","text":"reversible"},{"annotation":"Treatment.Disorder","text":"toxic cystoid maculopathy"},{"annotation":"Treatment.Drug","text":"niacin"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Duration","text":"reversible"},{"annotation":"Treatment.Disorder","text":"toxic cystoid maculopathy"},{"annotation":"Treatment.Drug","text":"niacin"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Duration","text":"reversible"},{"annotation":"Treatment.Disorder","text":"toxic cystoid maculopathy"},{"annotation":"Treatment.Drug","text":"niacin"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Duration","text":"reversible"},{}]}]}
{"id":"6854698_1","context":"When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"eat"},{"annotation":"Effect","text":"histamine reaction"},{"annotation":"Treatment","text":"isoniazid"},{"annotation":"Treatment.Disorder","text":"tuberculosis"},{"annotation":"Treatment.Food","text":"certain varieties of fish"},{"annotation":"Treatment.Drug","text":"isoniazid"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"develop"},{"annotation":"Effect","text":"histamine reaction"},{"annotation":"Treatment","text":"isoniazid"},{"annotation":"Treatment.Disorder","text":"tuberculosis"},{"annotation":"Treatment.Food","text":"certain varieties of fish"},{"annotation":"Treatment.Drug","text":"isoniazid"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"12022905_2","context":"CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Effect","text":"priapism"},{"annotation":"Treatment","text":"zuclopenthixol"},{"annotation":"Treatment.Drug","text":"zuclopenthixol"},{"annotation":"Treatment.Disorder","text":"uncommon but potentially serious adverse effect"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"spec"}]}]}
{"id":"14766993_2","context":"To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"thromboembolic events"},{"annotation":"Treatment","text":"warfarin"},{"annotation":"Treatment.Drug","text":"smokeless tobacco"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Trigger","text":"interaction"},{"annotation":"Treatment.Combination.Drug","text":"smokeless tobacco"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"thromboembolic events"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"report"},{"annotation":"Treatment","text":"warfarin"},{"annotation":"Treatment.Disorder","text":"thromboembolic events"},{"annotation":"Treatment.Drug","text":"smokeless tobacco"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"17167851_1","context":"Hepatotoxicity induced by cyproterone acetate: a report of three cases.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"cyproterone acetate"},{"annotation":"Treatment.Drug","text":"cyproterone acetate"},{"annotation":"Treatment.Effect","text":"hepatotoxicity"},{"annotation":"Subject","text":"three cases"},{"annotation":"Subject.Disorder","text":"none"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"cyproterone acetate"},{"annotation":"Treatment.Drug","text":"cyproterone acetoxide"},{"annotation":"Treatment.Effect","text":"hepatotoxicity"},{"annotation":"Subject","text":"three cases"},{"annotation":"Subject.Disorder","text":"none"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"cyproterone acetate"},{"annotation":"Treatment.Drug","text":"cyproterone acetoxide"},{"annotation":"Treatment.Effect","text":"hepatotoxicity"},{"annotation":"Subject","text":"three cases"},{"annotation":"Subject.Disorder","text":"none"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"cyproterone acetate"},{"annotation":"Treatment.Drug","text":"cyproterone acetoxide"},{"annotation":"Treatment.Effect","text":"hepatotoxicity"},{"annotation":"Subject","text":"three cases"},{"annotation":"Subject.Disorder","text":"none"}]}]}
{"id":"14561622_1","context":"Neurotoxicity of intrathecal methotrexate: MR imaging findings.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"neurotoxicity"},{"annotation":"Treatment","text":"intrathecal methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Effect","text":"MR imaging findings"},{"annotation":"Treatment.Dosage","text":"intrathecal methotrexate"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"intrathecal"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Subject","text":"not specified"},{"annotation":"Subject.Age","text":"not specified"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"not specified"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Attribute","text":"not specified"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute.speculated","text":"not specified"},{"annotation":"Attribute.severity","text":"not specified"},{"annotation":"Event type","text":"Adverse_event"},{"annotation":"Event type","text":"Adverse_event"}]}]}
{"id":"11804071_2","context":"Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"anagen effluvium and associated lichenoid eruption"},{"annotation":"Treatment","text":"isonicotinic acid hydrazide"},{"annotation":"Treatment.Drug","text":"isonicotinic acid hydrazide"},{"annotation":"Treatment.Disorder","text":"hair loss"},{"annotation":"Treatment.Disorder","text":"lichenoid eruption"},{"annotation":"Subject","text":"hair loss and associated lichenoid eruption"},{"annotation":"Subject.Disorder","text":"hair loss and associated lichenoid eruption"}]}]}
{"id":"18523232_5","context":"Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurring after pulse therapy with itraconazole for onychomycosis"},{"annotation":"Effect","text":"severe symptomatic hepatitis"},{"annotation":"Treatment","text":"pulse therapy with itraconazole for onychomycosis"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Disorder","text":"onychomycosis"},{"annotation":"Treatment.Duration","text":"pulse therapy"},{"annotation":"Treatment.Frequency","text":"after pulse therapy"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"after pulse therapy"},{"annotation":"Effect","text":"requiring transplantation"}]}]}
{"id":"4066620_3","context":"The elicitation of a movement disorder by trazodone: case report.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"elicitation"},{"annotation":"Effect","text":"movement disorder"},{"annotation":"Treatment","text":"trazodone"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Disorder","text":"movement disorder"},{"annotation":"Attribute","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"elicitation"},{"annotation":"Treatment","text":"trazodone"},{"annotation":"Treatment.Disorder","text":"movement disorder"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"6572542_2","context":"Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"subsequent to"},{"annotation":"Effect","text":"pulmonary fibrosis"},{"annotation":"Treatment","text":"high doses of CCNU for chronic myeloid leukemia"},{"annotation":"Treatment.Drug","text":"CCNU"},{"annotation":"Treatment.Disorder","text":"chronic myeloid leukemia"},{"annotation":"Treatment.Drug","text":"high doses"},{"annotation":"Treatment.Duration","text":"for chronic myeloid leukemia"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"chronic myeloid leukemia"}]}]}
{"id":"9007910_2","context":"PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"describe"},{"annotation":"Treatment","text":"pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency"},{"annotation":"Treatment.Disorder","text":"cancer"},{"annotation":"Treatment.Drug","text":"5-fluorouracil (5-FU)-based chemotherapy"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency does not predispose patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy"}]}]}
{"id":"6697887_3","context":"We report a case of sustained hypotension after administration of parenteral verapamil.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hypotension"},{"annotation":"Treatment","text":"parenteral verapamil"},{"annotation":"Treatment.Drug","text":"verapamil"}]}]}
{"id":"10212021_4","context":"Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"has two roles"},{"annotation":"Treatment","text":"methadone"},{"annotation":"Treatment.Disorder","text":"human immunodeficiency viral infection"},{"annotation":"Treatment.Drug","text":"methadone"},{"annotation":"Treatment.Role","text":"pain management"},{"annotation":"Treatment.Role","text":"treatment of opioid abuse"}]}]}
{"id":"21515865_9","context":"Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.1), which can be explained by residual effects from the phytonadione he received a week earlier.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"supratherapeutic"},{"annotation":"Treatment","text":"anticoagulation therapy"},{"annotation":"Treatment.Drug","text":"phytonadione"},{"annotation":"Effect","text":"INR"},{"annotation":"Treatment.Dosage","text":"residual effects"},{"annotation":"Treatment.Duration","text":"a week earlier"},{"annotation":"Treatment.Duration","text":"fourth treatment"},{"annotation":"Treatment.Dosage","text":"INR of 2.1"},{"annotation":"Treatment.Dosage","text":"residual effects"},{"annotation":"Treatment.Dosage","text":"phytomadione"},{"annotation":"Treatment.Dosage","text":"INR of 2.5"},{"annotation":"Treatment.Dosage","text":"residual effects"},{"annotation":"Treatment.Dosage","text":"phytonadione"},{"annotation":"Treatment.Dosage","text":"INR of 2.1"},{"annotation":"Treatment.Dosage","text":"residual effects"},{"annotation":"Treatment.Dosage","text":"phytonadione"},{"annotation":"Treatment.Dosage","text":"INR of 2.5"},{"annotation":"Treatment.Dosage","text":"residual effects"},{"annotation":"Treatment.Dosage","text":"phytonadione"},{"annotation":"Treatment.Dosage","text":"INR of 2.1"},{"annotation":"Treatment.Dosage","text":"residual effects"},{"annotation":"Treatment.Dosage","text":"phytonadione"},{"annotation":"Treatment.Dosage","text":"INR of 2.5"},{"annotation":"Treatment.Dosage","text":"residual effects"},{"annotation":"Treatment.Dosage","text":"phytonadione"},{"annotation":"Treatment.Dosage","text":"INR of 2.1"},{"annotation":"Treatment.Dosage","text":"residual effects"},{"annotation":"Treatment.Dosage","text":"phytonadione"},{"annotation":"Treatment.Dosage","text":"INR of 2.5"},{"annotation":"Treatment.Dosage","text":"residual effects"},{"annotation":"Treatment.Dosage","text":"phytonadione"},{"annotation":"Treatment.Dosage","text":"INR of 2.1"},{"annotation":"Treatment.Dosage","text":"residual effects"},{"annotation":"Treatment.Dosage","text":"phytonadione"},{"annotation":"Treatment.Dosage","text":"INR of 2.5"},{"annotation":"Treatment.Dosage","text":"residual effects"},{"annotation":"Treatment.Dosage","text":"phytonadione"},{"annotation":"Treatment.Dosage","text":"INR of 2.1"},{"annotation":"Treatment.Dosage","text":"residual effects"},{"annotation":"Treatment.Dosage","text":"phytonadione"},{"annotation":""}]}]}
{"id":"22677303_3","context":"A 70-year-old man had been treated with warfarin for atrial fibrillation.","events":[{"type":"Treatment","annotations":[{"annotation":"Treatment.Disorder","text":"atrial fibrillation"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Therapy_type","text":"anticoagulant therapy"},{"annotation":"Subject","text":"a 70-year-old man"},{"annotation":"Subject.Age","text":"70"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"atrial fibrillation"}]}]}
{"id":"1703754_1","context":"This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"meningitis"},{"annotation":"Treatment","text":"prednisolone and azathioprine"},{"annotation":"Treatment.Disorder","text":"systemic lupus erythematosus"},{"annotation":"Treatment.Drug","text":"prednisolone"},{"annotation":"Treatment.Drug","text":"azathioprine"},{"annotation":"Treatment.Drug","text":"cryptococcus"},{"annotation":"Treatment.Drug","text":"meningitis"},{"annotation":"Subject","text":"a child"},{"annotation":"Subject.Disorder","text":"systemic lupus erythematosus"}]}]}
{"id":"9352164_1","context":"Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Effect","text":"hemorrhagic gastritis"},{"annotation":"Treatment","text":"acetazolamide intoxication"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Treatment.Disorder","text":"chronic renal failure"},{"annotation":"Treatment.Drug","text":"acetazolamide"}]}]}
{"id":"4066620_2","context":"Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"movement disorder"},{"annotation":"Treatment","text":"trazodone"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Disorder","text":"movement disorder"},{"annotation":"Treatment.Combination.Trigger","text":"could not with certainty be attributed"},{"annotation":"Treatment.Combination.Drug","text":"trazodone"},{"annotation":"Treatment.Combination.Drug","text":"alone"},{"annotation":"Attribute Attributes","text":"eliciting agent"}]}]}
{"id":"18523232_2","context":"CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"prolonged exposure"},{"annotation":"Effect","text":"hepatotoxic events"},{"annotation":"Treatment","text":"itraconazole"},{"annotation":"Treatment.Dosage","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Duration","text":"prolonged exposure"},{"annotation":"Treatment.Route","text":"administered"},{"annotation":"Treatment.Frequency","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Disorder","text":"hepatotoxic events"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Dosage","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Frequency","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Route","text":"administered"},{"annotation":"Treatment.Duration","text":"prolonged exposure"},{"annotation":"Treatment.Disorder","text":"hepatotoxic events"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Dosage","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Frequency","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Route","text":"administered"},{"annotation":"Treatment.Duration","text":"prolonged exposure"},{"annotation":"Treatment.Disorder","text":"hepatotoxic events"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Dosage","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Frequency","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Route","text":"administered"},{"annotation":"Treatment.Duration","text":"prolonged exposure"},{"annotation":"Treatment.Disorder","text":"hepatotoxic events"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Dosage","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Frequency","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Route","text":"administered"},{"annotation":"Treatment.Duration","text":"prolonged exposure"},{"annotation":"Treatment.Disorder","text":"hepatotoxic events"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Dosage","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Frequency","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Route","text":"administered"},{"annotation":"Treatment.Duration","text":"prolonged exposure"},{"annotation":"Treatment.Disorder","text":"hepatotoxic events"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Dosage","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Frequency","text":"administered either continuously or intermittently"},{"annotation":"Treatment.Route","text":"administered"},{"annotation":"T"}]}]}
{"id":"507889_1","context":"In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"squamous cell carcinoma"},{"annotation":"Treatment","text":"therapy with psoralens plus long-wave ultraviolet radiation (PUVA)"},{"annotation":"Treatment.Disorder","text":"mycosis fungoides"},{"annotation":"Treatment.Drug","text":"psoralens"},{"annotation":"Treatment.Drug","text":"long-wave ultraviolet radiation"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"therapy with psoralens plus long-wave ultraviolet radiation (PUVA)"},{"annotation":"Treatment.Disorder","text":"mycosis fungoides"},{"annotation":"Treatment.Drug","text":"psoralens"},{"annotation":"Treatment.Drug","text":"long-wave ultraviolet radiation"}]}]}
{"id":"15663666_1","context":"Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"ulceration"},{"annotation":"Treatment","text":"all-trans retinoic acid"},{"annotation":"Treatment.Disorder","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Drug","text":"all-trans retinoic acid"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Drug","text":"all-trans retinoic acid"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Response"},{"annotation":"Treatment","text":"all-trans retinoic acid"},{"annotation":"Treatment.Disorder","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Drug","text":"all-trans retinoic acid"}]}]}
{"id":"6693840_1","context":"A 61 year-old male patient developed gynecomastia after starting theophylline.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"gynecomastia"},{"annotation":"Treatment","text":"theophylline"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Subject","text":"a 61 year-old male patient"},{"annotation":"Subject.Age","text":"61"},{"annotation":"Subject.Gender","text":"male"},{"annotation":"Subject.Population","text":"1 patient"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"not specified"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"gynecomastia"},{"annotation":"Treatment","text":"theophylline"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Subject","text":"a 61 year-old male patient"},{"annotation":"Subject.Age","text":"61"},{"annotation":"Subject.Gender","text":"male"},{"annotation":"Subject.Population","text":"1 patient"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"not specified"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"}]}]}
{"id":"2483959_3","context":"Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Effect","text":"renal failure"},{"annotation":"Treatment","text":"dextran-40"},{"annotation":"Treatment.Disorder","text":"renal failure associated with dextran-40"},{"annotation":"Treatment.Drug","text":"dextran-40"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"moderate severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":""}]}]}
{"id":"20349794_2","context":"We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary"},{"annotation":"Effect","text":"SIADH"},{"annotation":"Treatment","text":"cisplatin therapy"},{"annotation":"Treatment.Disorder","text":"large cell neuroendocrine carcinoma of the cervix"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Treatment.Drug","text":"antidiuretic hormone"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary"},{"annotation":"Effect","text":"SIADH"},{"annotation":"Treatment","text":"cisplatin therapy"},{"annotation":"Treatment.Disorder","text":"large cell neuroendocrine carcinoma of the cervix"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Treatment.Drug","text":"antidiuretic hormone"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary"},{"annotation":"Effect","text":"SIADH"},{"annotation":"Treatment","text":"cisplatin therapy"},{"annotation":"Treatment.Disorder","text":"large cell neuroendocrine carcinoma of the cervix"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Treatment.Drug","text":"antidiuretic hormone"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary"},{"annotation":"Effect","text":"SIADH"},{"annotation":"Treatment","text":"cisplatin therapy"},{"annotation":"Treatment.Disorder","text":"large cell neuroendocrine carcinoma of the cervix"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Treatment.Drug","text":"antidiuretic hormone"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary"},{"annotation":"Effect","text":"SIADH"},{"annotation":"Treatment","text":"cisplatin therapy"},{"annotation":"Treatment.Disorder","text":"large cell neuroendocrine carcinoma of the cervix"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Treatment.Drug","text":"antidiuretic hormone"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary"},{"annotation":"Effect","text":"SIADH"},{"annotation":"Treatment","text":"cisplatin therapy"},{"annotation":"Treatment.Disorder","text":"large cell neuroendocrine carcinoma of the cervix"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Treatment.Drug","text":"antidiuretic hormone"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary"},{"annotation":"Effect","text":"SIADH"},{"annotation":"Treatment","text":"cisplatin therapy"},{"annotation":"Treatment.Disorder","text":"large cell neuroendocrine carcinoma of the cervix"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":""}]}]}
{"id":"18675768_5","context":"An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"propafenone"},{"annotation":"Treatment.Drug","text":"propafenone"},{"annotation":"Treatment.Duration","text":">10 years"},{"annotation":"Subject","text":"an 80-year-old white female"},{"annotation":"Subject.Age","text":"80 years"},{"annotation":"Subject.Disorder","text":"mild cognitive impairment"},{"annotation":"Treatment.Disorder","text":"paroxysmal atrial fibrillation"}]}]}
{"id":"20925534_12","context":"A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"cardiovascular event"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Treatment.Duration","text":"long-term medication"},{"annotation":"Treatment.Disorder","text":"cardiovascular event"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute.Severity","text":"high"},{"annotation":"Attribute.Severity","text":"low"},{"annotation":"Attribute.Negated","text":"not negated"},{"annotation":"Attribute.Negated","text":"not negated"},{"annotation":"Attribute.Speculated","text":"not speculated"},{"annotation":"Attribute","text":"negation"},{"annotation":"Attribute.Negated","text":"negated"},{"annotation":"Attribute","text":"speculation"},{"annotation":"Attribute.Speculated","text":"speculated"},{"annotation":"Attribute","text":"negation"},{"annotation":"Attribute.Negated","text":"negated"},{"annotation":"Attribute","text":"speculation"},{"annotation":"Attribute.Speculated","text":"speculated"},{"annotation":"Attribute","text":"negation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculation"},{"annotation":"Attribute.Speculated","text":"speculated"},{"annotation":"Attribute","text":"negation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculation"},{"annotation":"Attribute.Speculated","text":"speculated"},{"annotation":"Attribute","text":"negation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculation"},{"annotation":"Attribute.Speculated","text":"speculated"},{"annotation":"Attribute","text":"negation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculation"},{"annotation":"Attribute.Speculated","text":"speculated"},{"annotation":"Attribute","text":"negation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculation"},{"annotation":"Attribute.Speculated","text":"speculated"},{"annotation":"Attribute","text":"negation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculation"},{"annotation":"Attribute.Speculated","text":"speculated"},{"annotation":"Attribute","text":"negation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculation"},{"annotation":"Attribute.Speculated","text":"speculated"},{"annotation":"Attribute","text":"negation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculation"},{"annotation":"Attribute.Speculated","text":"speculated"},{"annotation":"Attribute","text":"negation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculation"},{"annotation":"Attribute.Speculated","text":"speculated"},{"annotation":"Attribute","text":"negation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute"}]}]}
{"id":"6731466_10","context":"The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"anaphylactoid reaction"},{"annotation":"Effect","text":"reaction"},{"annotation":"Treatment","text":"zomepirac"},{"annotation":"Treatment.Drug","text":"zomepirac"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"mechanism"},{"annotation":"Effect","text":"mechanism"},{"annotation":"Treatment","text":"zomepirac"},{"annotation":"Treatment.Drug","text":"zomepirac"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"18203308_1","context":"New onset of CD may be considered as an immune-mediated injury induced by etanercept.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"new onset of CD"},{"annotation":"Effect","text":"CD"},{"annotation":"Treatment","text":"etanercept"},{"annotation":"Treatment.Disorder","text":"CD"},{"annotation":"Attribute Attributes","text":"immune-mediated injury induced by etanercept"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"new onset of CD"},{"annotation":"Treatment","text":"etanercept"},{"annotation":"Treatment.Disorder","text":"CD"},{"annotation":"Treatment.Drug","text":"etanercept"}]}]}
{"id":"11109149_2","context":"This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"trigger"},{"annotation":"Treatment","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Disorder","text":"acral vascular toxicity"},{"annotation":"Attribute","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"triggered"},{"annotation":"Effect","text":"acral vascular toxicity"},{"annotation":"Treatment","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"24918555_1","context":"Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"evaluating"},{"annotation":"Treatment","text":"isotretinoin-Lidose"},{"annotation":"Treatment.Disorder","text":"severe recalcitrant nodular acne"},{"annotation":"Treatment.Drug","text":"isotretinoin-Lidose"},{"annotation":"Treatment.Duration","text":"non-inferiority study"},{"annotation":"Attribute","text":"non-inferiority"},{"annotation":"Attribute.Attribute_type","text":"safety and efficacy"},{"annotation":"Attribute.Negated","text":"not negated"},{"annotation":"Attribute.Speculated","text":"not speculated"},{"annotation":"Attribute.Severity","text":"not specified"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"evaluating"},{"annotation":"Treatment","text":"isotretinoin-Lidose"},{"annotation":"Treatment.Disorder","text":"severe recalcitrant nodular acne"},{"annotation":"Treatment.Drug","text":"isotretinoin-Lidose"},{"annotation":"Treatment.Duration","text":"non-inferiority study"},{"annotation":"Attribute","text":"non-inferiority"},{"annotation":"Attribute.Attribute_type","text":"safety and efficacy"},{"annotation":"Attribute.Negated","text":"not negated"},{"annotation":"Attribute.Speculated","text":"not speculated"},{"annotation":"Attribute.Severity","text":"not specified"}]}]}
{"id":"16490518_4","context":"This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"corticosteroid-induced glaucoma"},{"annotation":"Treatment.Disorder","text":"corticosteroid-induced glaucoma"},{"annotation":"Treatment.Drug","text":"corticosteroid"},{"annotation":"Treatment.Drug","text":"induced glaucoma"},{"annotation":"Effect","text":"vision loss"},{"annotation":"Treatment.Drug","text":"corticosteroid"},{"annotation":"Treatment.Drug","text":"induced glaucoma"},{"annotation":"Treatment.Drug","text":"severe"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes"}]}]}
{"id":"3708949_4","context":"Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"acute hepatitis"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"parenteral amiodarone"},{"annotation":"Treatment.Drug","text":"parenteral amiodarone"}]}]}
{"id":"11485141_5","context":"Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"appeared"},{"annotation":"Effect","text":"herpetiform eruption"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Time_elapsed","text":"twenty-four hours"},{"annotation":"Treatment.Duration","text":"after administration"},{"annotation":"Treatment.Route","text":"gemcitabine"},{"annotation":"Treatment.Target_disorder","text":"unknown"},{"annotation":"Subject","text":"unknown"},{"annotation":"Subject.Age","text":"unknown"},{"annotation":"Subject.Gender","text":"unknown"},{"annotation":"Subject.Population","text":"unknown"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Subject.Disorder","text":"unknown"}]}]}
{"id":"20925534_11","context":"The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"reduced"},{"annotation":"Effect","text":"rate of overt upper gastrointestinal bleeding"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Attribute Attributes","text":"hazard ratio, 95% CI, P = 0.001"},{"annotation":"Treatment.Drug","text":"placebo"},{"annotation":"Treatment","text":"as compared with placebo"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"rate of overt upper gastrointestinal bleeding"},{"annotation":"Effect","text":"reduced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Treatment","text":"as compared with placebo"},{"annotation":"Attribute Attributes","text":"hazard ratio, 95% CI, P = 0.001"},{"annotation":"Treatment","text":"placebo"}]}]}
{"id":"8145359_2","context":"The association of phenothiazine overdose and respiratory distress syndrome merits consideration.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"association"},{"annotation":"Treatment","text":"phenothiazine overdose"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Effect","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment.Drug","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment","text":"respiratory distress syndrome"},{"annotation":"Treatment.Drug","text":"phenothiazine"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment"}]}]}
{"id":"6340463_4","context":"Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"high risk"},{"annotation":"Effect","text":"disseminated histoplasmosis"},{"annotation":"Treatment","text":"long-term prednisone for graft-versus-host disease"},{"annotation":"Treatment.Disorder","text":"graft-versus-host disease"},{"annotation":"Treatment.Drug","text":"prednisone"},{"annotation":"Treatment.Drug","text":"histoplasmosis"},{"annotation":"Subject","text":"patients from endemic areas"},{"annotation":"Subject.Population","text":"patients"},{"annotation":"Subject.Disorder","text":"graft-versus-host disease"},{"annotation":"Treatment.Duration","text":"long-term"}]}]}
{"id":"12477460_1","context":"Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"malignant transformation"},{"annotation":"Treatment","text":"tamoxifen"},{"annotation":"Treatment.Disorder","text":"endometriosis"},{"annotation":"Treatment.Drug","text":"tamoxifen"},{"annotation":"Treatment.Effect","text":"malignant transformation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.attribute","text":"precancerous lesion"},{"annotation":"Attribute.attribute","text":"atypical endometriosis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"malignant transformation"},{"annotation":"Treatment","text":"tamoxifen"},{"annotation":"Treatment.Disorder","text":"endometriosis"},{"annotation":"Treatment.Drug","text":"tamoxifen"},{"annotation":"Treatment.Effect","text":"malignant transformation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.attribute","text":"precancerous lesion"},{"annotation":"Attribute.attribute","text":"atypical endometriosis"}]}]}
{"id":"9562211_1","context":"A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"risperidone monotherapy"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Treatment.Disorder","text":"schizophrenic"},{"annotation":"Treatment.Disorder","text":"dyskinetic movements"},{"annotation":"Treatment.Disorder","text":"schizophrenia"},{"annotation":"Treatment.Duration","text":"about one year"},{"annotation":"Subject","text":"a 28 year old white schizophrenic male"},{"annotation":"Subject.Age","text":"28"},{"annotation":"Subject.Disorder","text":"schizophrenia"},{"annotation":"Subject.Race","text":"white"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"risperidone monotherapy"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Treatment.Disorder","text":"schizophrenic"},{"annotation":"Treatment.Disorder","text":"dyskinetic movements"},{"annotation":"Treatment.Disorder","text":"schizophrenia"},{"annotation":"Treatment.Duration","text":"about one year"},{"annotation":"Subject","text":"a 28 year old white schizophrenic male"},{"annotation":"Subject.Age","text":"28"},{"annotation":"Subject.Disorder","text":"schizophrenia"},{"annotation":"Subject.Race","text":"white"}]}]}
{"id":"22047557_8","context":"Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"ivacaftor"},{"annotation":"Treatment.Disorder","text":"pulmonary exacerbation"},{"annotation":"Treatment.Duration","text":"through week 48"},{"annotation":"Treatment.Effect","text":"55% less likely"},{"annotation":"Attribute","text":"P<0.001"}]}]}
{"id":"10759907_2","context":"Spinal cord infarction during use of zolmitriptan: a case report.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"spinal cord infarction"},{"annotation":"Treatment","text":"zolmitriptan"},{"annotation":"Treatment.Drug","text":"zolmitriptan"}]}]}
{"id":"12854039_3","context":"Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction"},{"annotation":"Treatment","text":"recombinant interferon alpha-2b"},{"annotation":"Treatment.Disorder","text":"chronic myelogenous leukemia"},{"annotation":"Treatment.Drug","text":"recombinant interferon alpha-2b"},{"annotation":"Treatment.Duration","text":"22 months"},{"annotation":"Subject","text":"a 29-year-old woman"},{"annotation":"Subject.Age","text":"29 years old"},{"annotation":"Subject.Gender","text":"female"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Subject.Disorder","text":"chronic myelogenous leukemia"},{"annotation":"Treatment.Drug","text":"recombinant interferon alpha-2b"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"22 months"},{"annotation":"Treatment.Disorder","text":"chronic myelogenous leukemia"},{"annotation":"negated","text":"unknown"},{"annotation":"severity","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":"negated","text":"unknown"},{"annotation":""}]}]}
{"id":"6794018_3","context":"These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occur"},{"annotation":"Effect","text":"intrahepatic cholestasis"},{"annotation":"Treatment","text":"glibenclamide therapy"},{"annotation":"Treatment.Drug","text":"glibenclamide"},{"annotation":"Treatment.Drug","text":"chlorpropamide"},{"annotation":"Treatment.Drug","text":"sulphonylurea agent"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not previously reported as side effects of glibenclamide therapy"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"intrahepatic cholestasis may occur with chlorpropamide"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"chlorpropamide"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"sulphonylurea agent"}]}]}
{"id":"9562211_2","context":"Risperidone-induced tardive dyskinesia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"tardive dyskinesia"},{"annotation":"Treatment","text":"risperidone"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Treatment.Disorder","text":"tardive dyskinesia"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"Risperidone"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Effect","text":"tardive dyskinesia"}]}]}
{"id":"9737132_2","context":"Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"toxicity"},{"annotation":"Effect","text":"neuromuscular complication"},{"annotation":"Treatment","text":"pentazocine"},{"annotation":"Treatment.Drug","text":"pentazocine"},{"annotation":"Treatment.Duration","text":"longterm usage"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Treatment.Duration","text":"longterm usage"},{"annotation":"Treatment.Disorder","text":"drug-induced fibrous myopathy and localized neuropathy"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{}]}]}
{"id":"3359700_2","context":"Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.","events":[{"type":"Diagnostic","annotations":[{"annotation":"Trigger","text":"Based upon"},{"annotation":"Effect","text":"suggest"},{"annotation":"Treatment","text":"cyclosporine A"},{"annotation":"Treatment.Disorder","text":"nephrotoxicity"},{"annotation":"Treatment.Target","text":"tubules and/or interstitium"},{"annotation":"Subject","text":"in this case"},{"annotation":"Subject.Disorder","text":"nephrotoxicity"}]}]}
{"id":"3174043_2","context":"Niacin maculopathy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"maculopathy"},{"annotation":"Effect","text":"niacin-induced maculopathy"},{"annotation":"Treatment","text":"niacin"},{"annotation":"Treatment.Drug","text":"niacin"}]}]}
{"id":"22293514_5","context":"We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.","events":[{"type":"Potential_therapeutic_event","annotations":[{"annotation":"Trigger","text":"potential drug interaction"},{"annotation":"Treatment","text":"clobazam and etravirine"},{"annotation":"Treatment.Drug","text":"clobazam"},{"annotation":"Treatment.Drug","text":"etravirine"},{"annotation":"Treatment.Combination.Trigger","text":"may have led to"},{"annotation":"Treatment.Combination.Drug","text":"clobazam"},{"annotation":"Treatment.Combination.Drug","text":"etravirine"},{"annotation":"Treatment.Combination.Drug","text":"clobazam"},{"annotation":"Treatment.Combination.Drug","text":"N-desmethylclobazam"},{"annotation":"Effect","text":"neurotoxic symptoms"},{"annotation":"Treatment","text":"clobazam and etravirine"},{"annotation":"Treatment.Drug","text":"clobazam"},{"annotation":"Treatment.Drug","text":"etravirine"},{"annotation":"Treatment.Combination.Trigger","text":"may have led to"},{"annotation":"Treatment.Combination.Drug","text":"clobazam"},{"annotation":"Treatment.Combination.Drug","text":"etravirine"},{"annotation":"Treatment.Combination.Drug","text":"clobazam"},{"annotation":"Treatment.Combination.Drug","text":"N-desmethylclobazam"},{"annotation":"Treatment.Disorder","text":"neurotoxic symptoms"},{"annotation":"Treatment.Drug","text":"clobazam"},{"annotation":"Treatment.Drug","text":"etravirine"},{"annotation":"Treatment.Drug","text":"clobazam"},{"annotation":"Treatment.Drug","text":"N-desmethylclobazam"},{"annotation":"Treatment.Combination.Trigger","text":"may have led to"},{"annotation":"Treatment.Combination.Drug","text":"clobazam"},{"annotation":"Treatment.Combination.Drug","text":"etravirine"},{"annotation":"Treatment.Combination.Drug","text":"clobazam"},{"annotation":"Treatment.Combination.Drug","text":"N-desmethylclobazam"},{"annotation":"Treatment.Disorder","text":"neurotoxic symptoms"},{"annotation":"Treatment.Drug","text":"clobazam"},{"annotation":"Treatment.Drug","text":"etravirine"},{"annotation":"Treatment.Drug","text":"clobazam"},{"annotation":"Treatment.Drug","text":"N-desmethylclobazam"},{"annotation":"Treatment.Combination.Trigger","text":"may have led to"},{"annotation":"Treatment.Combination.Drug","text":"clobazam"},{"annotation":"Treatment.Combination.Drug","text":"etravirine"},{"annotation":"Treatment.Combination.Drug","text":"clobazam"},{"annotation":"Treatment.Combination.Drug","text":"N-desmethylclobazam"}]}]}
{"id":"11202801_1","context":"A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"long-term cyclophosphamide treatment"},{"annotation":"Effect","text":"hepatic angiosarcoma"},{"annotation":"Treatment","text":"cyclophosphamide"},{"annotation":"Treatment.Disorder","text":"hepatic angiosarcoma"}]}]}
{"id":"18076602_3","context":"We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"cutaneous leucocytoclastic vasculitis"},{"annotation":"Effect","text":"vasculitis"},{"annotation":"Treatment","text":"amphotericin B"},{"annotation":"Treatment.Drug","text":"amphotericin B"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"might presumably be the aetiological factor"}]}]}
{"id":"18364401_5","context":"There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"hyperglycemia"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"within days of initiation of the medication"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Disorder","text":"hyperglycemia"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"}]}]}
{"id":"23970584_2","context":"This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"adverse reactions"},{"annotation":"Treatment","text":"antiretroviral drugs"},{"annotation":"Treatment.Disorder","text":"severe antiretroviral drug adverse reactions"},{"annotation":"Treatment.Drug","text":"antiretroviral drugs"},{"annotation":"Treatment.Drug","text":"antiretroviral drugs"}]}]}
{"id":"16101941_2","context":"We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"anaphylactic reaction and extra-pyramidal syndrome"},{"annotation":"Treatment","text":"thiethylperazine maleate (thiethylperazine)"},{"annotation":"Treatment.Drug","text":"thiethylperazine"},{"annotation":"Effect","text":"anaphylactic reaction and extra-pyramidal syndrome"},{"annotation":"Treatment.Disorder","text":"anaphylactic reaction and extra-pyramidal syndrome"},{"annotation":"Treatment.Drug","text":"thiethylperazine"},{"annotation":"Treatment.Drug","text":"maleate"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"anaphylactic reaction and extra-pyramidal syndrome"},{"annotation":"Treatment","text":"thiethylperazine maleate (thiethylperazine)"},{"annotation":"Treatment.Drug","text":"thiethylperazine"},{"annotation":"Effect","text":"anaphylactic reaction and extra-pyramidal syndrome"},{"annotation":"Treatment.Disorder","text":"anaphylactic reaction and extra-pyramidal syndrome"},{"annotation":"Treatment.Drug","text":"thiethylperazine"},{"annotation":"Treatment.Drug","text":"maleate"}]}]}
{"id":"2483959_2","context":"Renal failure associated with the use of dextran-40.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"renal failure"},{"annotation":"Treatment","text":"dextran-40"},{"annotation":"Treatment.Drug","text":"dextran"},{"annotation":"Treatment.Disorder","text":"renal failure"}]}]}
{"id":"11510798_1","context":"Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"5-fluorouracil and oxaliplatinum combined chemotherapy"},{"annotation":"Treatment.Disorder","text":"acute lung injury"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Drug","text":"oxaliplatinum"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Combination.Drug","text":"oxaliplatinum"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Disorder","text":"acute lung injury"}]}]}
{"id":"11155197_3","context":"Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"heparin"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Disorder","text":"immunological disorder"},{"annotation":"Treatment.Drug","text":"platelet factor 4 complexes"},{"annotation":"Treatment.Disorder","text":"thrombotic complications"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high risk"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"Type II HIT"},{"annotation":"Treatment","text":"platelets"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Disorder","text":"immunological disorder"},{"annotation":"Treatment.Drug","text":"platelet factor 4 complexes"},{"annotation":"Treatment.Disorder","text":"thrombotic complications"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high risk"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"Type II HIT"},{"annotation":"Treatment","text":"platelets"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Disorder","text":"immunological disorder"},{"annotation":"Treatment.Drug","text":"platelet factor 4 complexes"},{"annotation":"Treatment.Disorder","text":"thrombotic complications"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high risk"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"Type II HIT"},{"annotation":"Treatment","text":"platelets"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Disorder","text":"immunological disorder"},{"annotation":"Treatment.Drug","text":"platelet factor 4 complexes"},{"annotation":"Treatment.Disorder","text":"thrombotic complications"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high risk"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"Type II HIT"},{"annotation":"Treatment","text":"platelets"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Disorder","text":"immunological disorder"},{"annotation":"Treatment.Drug","text":"platelet factor 4 complexes"},{"annotation":"Treatment.Disorder","text":"thrombotic complications"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high risk"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"Type II HIT"},{"annotation":"Treatment","text":"platelets"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Disorder","text":"immunological disorder"},{"annotation":"Treatment.Drug","text":"platelet factor "}]}]}
{"id":"7485371_3","context":"RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"vortex keratopathy"},{"annotation":"Treatment","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone vortex keratopathy"},{"annotation":"Attribute Attributes","text":"presumably caused by its lipophilic properties"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"11109149_1","context":"Gangrene of the fingertips after bleomycin and methotrexate.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"bleomycin and methotrexate"},{"annotation":"Effect","text":"gangrene"},{"annotation":"Treatment","text":"bleomycin and methotrexate"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"bleomycin"},{"annotation":"Treatment.Combination.Drug","text":"methotrexate"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"bleomycin"},{"annotation":"Treatment.Combination.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"bleomycin"},{"annotation":"Treatment.Combination.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"bleomycin"},{"annotation":"Treatment.Combination.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"bleomycin"},{"annotation":"Treatment.Combination.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"bleomycin"},{"annotation":"Treatment.Combination.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"bleomycin"},{"annotation":"Treatment.Combination.Drug","text":"methotrexate"},{"annotation":"Treatment."}]}]}
{"id":"8404753_9","context":"These cases demonstrate that CBZ can induce simple motor tics in children.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"CBZ"},{"annotation":"Treatment.Drug","text":"CBZ"},{"annotation":"Treatment.Disorder","text":"simple motor tics"},{"annotation":"Treatment.Age","text":"children"},{"annotation":"Treatment.Drug","text":"CBZ"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Effect","text":"simple motor tics"}]}]}
{"id":"3964363_2","context":"Esophageal spasm following propranolol overdose relieved by glucagon.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following propranolol overdose"},{"annotation":"Treatment","text":"glucagon"},{"annotation":"Effect","text":"esophageal spasm"},{"annotation":"Treatment","text":"propranolol"},{"annotation":"Treatment.Drug","text":"propranolol"},{"annotation":"Treatment.Drug","text":"glucagon"},{"annotation":"Treatment.Dosage","text":"relieved by glucagon"},{"annotation":"Treatment","text":"glucagon"},{"annotation":"Treatment","text":"esophageal spasm"},{"annotation":"Treatment","text":"propranolol overdose"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Age","text":"not specified"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"patient"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment","text":"glucagon"},{"annotation":"Treatment.Drug","text":"glucagon"},{"annotation":"Treatment.Dosage","text":"relieved by glucagon"},{"annotation":"Treatment","text":"glucagon"},{"annotation":"Treatment","text":"esophageal spasm"},{"annotation":"Treatment","text":"propranolol overdose"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Age","text":"not specified"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"patient"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment","text":"glucagon"},{"annotation":"Treatment.Drug","text":"glucagon"},{"annotation":"Treatment.Dosage","text":"relieved by glucagon"},{"annotation":"Treatment","text":"glucagon"},{"annotation":"Treatment","text":"esophageal spasm"},{"annotation":"Treatment","text":"propranolol overdose"},{"annotation":"Treatment.Drug","text":"propranolol"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment","text":"glucagon"},{"annotation":"Treatment","text":"esophageal spasm"},{"annotation":"Treatment","text":"propranolol overdose"},{"annotation":"Treatment.Drug","text":"propranolol"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment","text":"glucagon"},{"annotation":"Treatment","text":"esophageal spasm"},{"annotation":"Treatment","text":"propranolol overdose"},{"annotation":"Treatment.Drug","text":"propranolol"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment","text":"glucagon"},{"annotation":"Treatment","text":"esophageal spasm"},{"annotation":"Treatment","text":"propranolol overdose"},{"annotation":"Treatment.Drug","text":"propranolol"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment","text":"glucagon"},{"annotation":"Treatment","text":"esophageal spasm"},{"annotation":"Treatment","text":"propranolol overdose"},{"annotation":"Treatment.Drug","text":"propranolol"}]}]}
{"id":"9352164_3","context":"She was thus diagnosed as having AZ intoxication.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intoxication"},{"annotation":"Effect","text":"intoxication"},{"annotation":"Treatment","text":"AZ"},{"annotation":"Treatment.Drug","text":"AZ"},{"annotation":"Treatment.Disorder","text":"AZ intoxication"},{"annotation":"Treatment.Drug","text":"AZ"}]}]}
{"id":"10592946_3","context":"Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Treatment","text":"massive ingestion of oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment.Disorder","text":"caffeine intoxication"},{"annotation":"Treatment.Disorder","text":"hyponatremia"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Disorder","text":"caffeine intoxication"},{"annotation":"Treatment.Disorder","text":"hyponatremia"},{"annotation":"Treatment.Disorder","text":"caffeine intoxication"},{"annotation":"Treatment.Disorder","text":"hyponatremia"},{"annotation":"Treatment.Disorder","text":"caffeine intoxication"},{"annotation":"Treatment.Disorder","text":"hyponatremia"},{"annotation":"Treatment.Disorder","text":"caffeine intoxication"},{"annotation":"Treatment.Disorder","text":"hyponatremia"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"oolong tea"}]}]}
{"id":"15663666_2","context":"The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"resisted"},{"annotation":"Effect","text":"ulcer did not respond"},{"annotation":"Treatment","text":"antibiotic treatment"},{"annotation":"Treatment.Drug","text":"ATRA"},{"annotation":"Treatment.Effect","text":"healed"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withholding"},{"annotation":"Effect","text":"ulcer healed"},{"annotation":"Treatment","text":"ATRA"},{"annotation":"Treatment.Drug","text":"ATRA"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"}]}]}
{"id":"9726762_1","context":"Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"drug interaction"},{"annotation":"Treatment","text":"gemfibrozil"},{"annotation":"Treatment.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Effect","text":"hypoprothrombinemia"},{"annotation":"Treatment","text":"gemfibrozil-warfarin drug interaction"},{"annotation":"Treatment.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment","text":"gemfibrozil-warfarin drug interaction"},{"annotation":"Treatment.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment","text":"gemfibrozil-warfarin drug interaction"},{"annotation":"Treatment.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment","text":"gemfibrozil-warfarin drug interaction"},{"annotation":"Treatment"}]}]}
{"id":"17665812_2","context":"Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"eosinophilia"},{"annotation":"Treatment","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Dosage","text":"non-dose-dependent"},{"annotation":"Treatment.Frequency","text":"eosinophilia"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"unknown"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Event type","text":"Adverse_event"}]}]}
{"id":"7485371_4","context":"Vortex keratopathy associated with atovaquone.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Effect","text":"vortex keratopathy"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Age","text":"unknown"},{"annotation":"Subject.Gender","text":"unknown"},{"annotation":"Subject.Population","text":"unknown"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"18037876_1","context":"DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"owing to"},{"annotation":"Effect","text":"ventricular tachycardia"},{"annotation":"Treatment","text":"thalidomide treatment"},{"annotation":"Treatment.Drug","text":"thalidomide"},{"annotation":"Treatment.Disorder","text":"sustained ventricular tachycardia"}]}]}
{"id":"910864_1","context":"In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emergency hospital admission following the substitution of acetohexamide for acetazolamide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"resulting"},{"annotation":"Effect","text":"head trauma and confusion"},{"annotation":"Treatment","text":"substitution of acetohexamide for acetazolamide"},{"annotation":"Treatment.Drug","text":"acetohexamide"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Treatment.Dosage","text":"systemic hypoglycemic reaction"},{"annotation":"Treatment.Duration","text":"following"},{"annotation":"Treatment.Duration","text":"substitution"},{"annotation":"Treatment.Route","text":"substitution"},{"annotation":"Subject","text":"in one instance"},{"annotation":"Subject.Disorder","text":"systemic hypoglycemic reaction"},{"annotation":"Treatment.Drug","text":"acetohexamide"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycemia"},{"annotation":"Treatment.Drug","text":"hypoglycem"}]}]}
{"id":"17182354_1","context":"However, an association of Ritalin with glaucoma has been reported.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"association"},{"annotation":"Effect","text":"glaucoma"},{"annotation":"Treatment","text":"Ritalin"},{"annotation":"Treatment.Drug","text":"Ritalin"},{"annotation":"Treatment.Disorder","text":"glaucoma"},{"annotation":"Subject","text":"not specified"},{"annotation":"Subject.Disorder","text":"not specified"}]}]}
{"id":"12854039_1","context":"After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"episode"},{"annotation":"Effect","text":"neurological manifestations"},{"annotation":"Treatment","text":"natural interferon alpha"},{"annotation":"Treatment.Disorder","text":"interferon-associated neurotoxicity"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Interruption","text":"two-month interruption"},{"annotation":"Treatment.Interruption.Trigger","text":"administration"},{"annotation":"Treatment.Interruption.Duration","text":"two months"},{"annotation":"Treatment","text":"natural interferon alpha"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Interruption","text":"two-month interruption"},{"annotation":"Treatment.Interruption.Duration","text":"two months"},{"annotation":"Treatment","text":"natural interferon alpha"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Interruption","text":"two-month interruption"},{"annotation":"Treatment.Interruption.Duration","text":"two months"},{"annotation":"Treatment","text":"natural interferon alpha"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Interruption","text":"two-month interruption"},{"annotation":"Treatment.Interruption.Duration","text":"two months"},{"annotation":"Treatment","text":"natural interferon alpha"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Interruption","text":"two-month interruption"},{"annotation":"Treatment.Interruption.Duration","text":"two months"},{"annotation":"Treatment","text":"natural interferon alpha"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Interruption","text":"two-month interruption"},{"annotation":"Treatment.Interruption.Duration","text":"two months"},{"annotation":"Treatment","text":"natural interferon alpha"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Interruption","text":"two-month interruption"},{"annotation":"Treatment.Interruption.Duration","text":"two months"},{"annotation":"Treatment","text":"natural interferon alpha"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Interruption","text":"two-month interruption"},{"annotation":"Treatment.Interruption.Duration","text":"two months"},{"annotation":"Treatment","text":"natural interferon alpha"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Interruption","text":"two-month interruption"},{"annotation":"Treatment.Interruption.Duration","text":"two months"},{"annotation":"Treatment","text":"natural interferon alpha"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Interruption","text":"two-month interruption"},{"annotation":"Treatment.Interruption.Duration","text":"two months"},{"annotation":"Treatment","text":"natural interferon alpha"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Interruption","text":"two-month interruption"},{"annotation":"Treat"}]}]}
{"id":"25842648_7","context":"This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Treatment","text":"SSRIs and fentanyl"},{"annotation":"Treatment.Drug","text":"SSRIs"},{"annotation":"Treatment.Drug","text":"fentanyl"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"SSRIs"},{"annotation":"Treatment.Combination.Drug","text":"fentanyl"},{"annotation":"Effect","text":"serotonin syndrome"},{"annotation":"Treatment.Disorder","text":"serotonin syndrome"},{"annotation":"Treatment.Drug","text":"SSRIs"},{"annotation":"Treatment.Drug","text":"fentanyl"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"SSRIs"},{"annotation":"Treatment.Combination.Drug","text":"fentanyl"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{}]}]}
{"id":"2483959_4","context":"While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"dextran"},{"annotation":"Treatment.Drug","text":"dextran"},{"annotation":"Effect","text":"renal failure"},{"annotation":"Treatment","text":"plasma exchange"},{"annotation":"Treatment.Drug","text":"plasma"},{"annotation":"Treatment.Drug","text":"exchange"},{"annotation":"Treatment.Drug","text":"plasma"},{"annotation":"Treatment.Drug","text":"exchange"},{"annotation":"Treatment.Disorder","text":"dextran-associated renal failure"},{"annotation":"Treatment.Disorder","text":"renal failure"},{"annotation":"Treatment.Effect","text":"effective therapy"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":""}]}]}
{"id":"9865241_4","context":"The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary to"},{"annotation":"Treatment","text":"acute vitamin D intoxication"},{"annotation":"Treatment.Disorder","text":"hypercalcemia"},{"annotation":"Treatment.Drug","text":"pamidronate"}]}]}
{"id":"14614357_1","context":"Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"overanticoagulation"},{"annotation":"Treatment","text":"acenocoumarol"},{"annotation":"Treatment.Drug","text":"acenocoumarol"},{"annotation":"Treatment.Dosage","text":"early"},{"annotation":"Treatment.Dosage","text":"over"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"due to"},{"annotation":"Treatment.Time_elapsed","text":"a genetic polymorphism of cytochrome P450 CYP2C9"},{"annotation":"Treatment.Disorder","text":"overanticoagulation"},{"annotation":"Treatment.Drug","text":"acenocoumarol"},{"annotation":"Treatment.Dosage","text":"early"},{"annotation":"Treatment.Dosage","text":"over"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"due to"},{"annotation":"Treatment.Time_elapsed","text":"a genetic polymorphism of cytochrome P450 CYP2C9"},{"annotation":"Treatment.Disorder","text":"overanticoagulation"},{"annotation":"Treatment.Drug","text":"acenocoumarol"},{"annotation":"Treatment.Dosage","text":"early"},{"annotation":"Treatment.Dosage","text":"over"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"due to"},{"annotation":"Treatment.Time_elapsed","text":"a genetic polymorphism of cytochrome P450 CYP2C9"},{"annotation":"Treatment.Disorder","text":"overanticoagulation"},{"annotation":"Treatment.Drug","text":"acenocoumarol"},{"annotation":"Treatment.Dosage","text":"early"},{"annotation":"Treatment.Dosage","text":"over"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"due to"},{"annotation":"Treatment.Time_elapsed","text":"a genetic polymorphism of cytochrome P450 CYP2C9"},{"annotation":"Treatment.Disorder","text":"overanticoagulation"},{"annotation":"Treatment.Drug","text":"acenocoumarol"},{"annotation":"Treatment.Dosage","text":"early"},{"annotation":"Treatment.Dosage","text":"over"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"due to"},{"annotation":"Treatment.Time_elapsed","text":"a genetic polymorphism of cytochrome P450 CYP2C9"},{"annotation":"Treatment.Disorder","text":"overanticoagulation"},{"annotation":"Treatment.Drug","text":"acenocoumarol"},{"annotation":"Treatment.Dosage","text":"early"},{"annotation":"Treatment.Dosage","text":"over"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"due to"},{"annotation":"Treatment.Time_elapsed","text":"a genetic polym"}]}]}
{"id":"8589490_3","context":"We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurring after CHOP chemotherapy"},{"annotation":"Effect","text":"supraventricular hyperpigmentation"},{"annotation":"Treatment","text":"CHOP chemotherapy"},{"annotation":"Treatment.Disorder","text":"supraventricular hyperpigmentation"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurring after CHOP chemotherapy"},{"annotation":"Effect","text":"supraventricular hyperpigmentation"},{"annotation":"Treatment","text":"CHOP chemotherapy"},{"annotation":"Treatment.Disorder","text":"supraventricular hyperpigmentation"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"}]}]}
{"id":"12488741_2","context":"Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"elevation"},{"annotation":"Effect","text":"lactate elevation"},{"annotation":"Treatment","text":"metronidazole"},{"annotation":"Treatment.Disorder","text":"metronidazole treatment"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Duration","text":"persistent"},{"annotation":"Treatment.Duration","text":"lactate elevation"},{"annotation":"Treatment.Duration","text":"metronidazole treatment"},{"annotation":"Attribute Attributes","text":"persistent"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"elevation"},{"annotation":"Effect","text":"lactate elevation"},{"annotation":"Treatment","text":"metronidazole"},{"annotation":"Treatment.Disorder","text":"metronidazole treatment"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Treatment.Duration","text":"persistent"},{"annotation":"Treatment.Duration","text":"lactate elevation"},{"annotation":"Treatment.Duration","text":"metronidazole treatment"},{"annotation":"Attribute Attributes","text":"persistent"}]}]}
{"id":"1422497_1","context":"Encephalopathy and seizures induced by intravesical alum irrigations.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"encephalopathy and seizures"},{"annotation":"Treatment","text":"intravesical alum irrigations"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Time_elapsed","text":"unknown"},{"annotation":"Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"encephalopathy and seizures"},{"annotation":"Subject","text":"unknown"}]}]}
{"id":"15522120_17","context":"Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"dermal side reactions"},{"annotation":"Effect","text":"SSRI-drugs"},{"annotation":"Treatment","text":"SSRI-drugs"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"SSRI-drugs"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"none"},{"annotation":"Event type","text":"Adverse_event"},{"annotation":"Event type","text":"Potential_therapeutic_effect"},{"annotation":"Event type","text":"Adverse_event"},{"annotation":"Event type","text":"Potential_therapeutic_effect"}]}]}
{"id":"12659609_3","context":"CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"diagnosis"},{"annotation":"Treatment","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Dose","text":">5 times the usual dose"},{"annotation":"Effect","text":"febrile"},{"annotation":"Subject","text":"a seaman"},{"annotation":"Subject.Age","text":"36 years old"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Disorder","text":"malaria"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"}]}]}
{"id":"19266307_2","context":"MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"primary and secondary perforation of the bladder"},{"annotation":"Effect","text":"morbidity"},{"annotation":"Treatment","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Dosage","text":"two instillations"},{"annotation":"Treatment.Duration","text":"two instillations"},{"annotation":"Treatment.Route","text":"instillation"},{"annotation":"Treatment.Drug.Type","text":"chemotherapy"},{"annotation":"Treatment.Drug.Target","text":"bladder"}]}]}
{"id":"18628507_2","context":"Angio-oedema as an unusual tolerable side effect of voriconazole therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"angio-oedema"},{"annotation":"Treatment","text":"voriconazole therapy"},{"annotation":"Treatment.Disorder","text":"angio-oedema"},{"annotation":"Treatment.Drug","text":"voriconazole"},{"annotation":"Treatment.Dosage","text":"voriconazole"},{"annotation":"Treatment.Dosage","text":"voriconazole"},{"annotation":"Treatment.Frequency","text":"voriconazole"},{"annotation":"Treatment.Route","text":"voriconazole"},{"annotation":"Treatment.Time_elapsed","text":"voriconazole"},{"annotation":"Treatment.Duration","text":"voriconazole"},{"annotation":"Treatment.Disorder","text":"angio-oedema"},{"annotation":"negated","text":"tolerable"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated","text":"angio-oedema"},{"annotation":"negated","text":"voriconazole"},{"annotation":"negated"}]}]}
{"id":"18262450_8","context":"Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"reduced"},{"annotation":"Effect","text":"pain score"},{"annotation":"Treatment","text":"oxycodone-gabapentin"},{"annotation":"Treatment.Drug","text":"oxycodone"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Treatment.Duration","text":"from baseline to end of treatment"},{"annotation":"Treatment.Duration","text":"33%"},{"annotation":"Subject","text":"pain score"},{"annotation":"Subject.Disorder","text":"pain"}]}]}
{"id":"10435399_2","context":"OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"neutropenia"},{"annotation":"Treatment","text":"clozapine"},{"annotation":"Treatment.Drug","text":"neutropenia"},{"annotation":"Effect","text":"diurnal variation"},{"annotation":"Treatment","text":"white blood cells (WBC)"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Effect","text":"cell count decrease"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"behind"},{"annotation":"Treatment","text":"cell count decrease"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"neutropenia"},{"annotation":"Treatment","text":"diurnal variation"},{"annotation":"Treatment.Drug","text":"white blood cells (WBC)"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment","text":"neutropenia"},{"annotation":"Treatment","text":"cell count decrease"}]}]}
{"id":"11352235_5","context":"RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"begin"},{"annotation":"Treatment","text":"leflunomide therapy"},{"annotation":"Treatment.Drug","text":"leflunomide"},{"annotation":"Effect","text":"significant weight loss"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Drug","text":"leflunomide"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Subject","text":"5 of 70 patients"},{"annotation":"Subject.Population","text":"5 of 70 patients"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"}]}]}
{"id":"16018164_2","context":"Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"consumption"},{"annotation":"Effect","text":"hemorrhage"},{"annotation":"Treatment","text":"phenylpropanolamine"},{"annotation":"Treatment.Disorder","text":"AVM"},{"annotation":"Treatment.Drug","text":"phenylpropanolamine"},{"annotation":"Treatment.Drug","text":"AVM"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"phenylpropanolamine"},{"annotation":"Treatment.Combination.Drug","text":"AVM"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"AVM"}]}]}
{"id":"16101941_1","context":"Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"anaphylactic reaction"},{"annotation":"Effect","text":"anaphylaxis"},{"annotation":"Treatment","text":"thiethylperazine"},{"annotation":"Treatment.Drug","text":"thiethylperazine"},{"annotation":"Treatment.Side_effect","text":"anaphylactic reaction"},{"annotation":"Treatment.Side_effect","text":"known side effects"},{"annotation":"Treatment.Duration","text":"during therapy"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{}]}]}
{"id":"8430717_4","context":"PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"investigate"},{"annotation":"Treatment","text":"acyclovir"},{"annotation":"Treatment.Disorder","text":"severe acyclovir-induced neurotoxicity"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Attribute","text":"purpose"},{"annotation":"Attribute.Attribute","text":"investigate"},{"annotation":"Attribute.Attribute","text":"summarize"},{"annotation":"Attribute","text":"information"},{"annotation":"Attribute","text":"available"},{"annotation":"Attribute","text":"literature"},{"annotation":"Attribute","text":"central nervous system"},{"annotation":"Attribute","text":"side effects"},{"annotation":"Attribute","text":"due"},{"annotation":"Attribute","text":"acyclovir"}]}]}
{"id":"16317298_3","context":"Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"radiation recall"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Effect","text":"recall"},{"annotation":"Treatment.Disorder","text":"radiation recall"},{"annotation":"Treatment.Disorder","text":"gemcitabine"},{"annotation":"Treatment.Route","text":"systemic"},{"annotation":"Treatment.Time_elapsed","text":"any site that has been previously irradiated"},{"annotation":"Treatment.Duration","text":"any site that has been previously irradiated"},{"annotation":"Treatment.Disorder","text":"gemcitabine"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"radiation recall does not exist"}]}]}
{"id":"15368548_3","context":"Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with L-asparaginase toxicity"},{"annotation":"Treatment","text":"nasogastric decompression and intravenous hyperalimentation"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Disorder","text":"pancreatitis"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Combination","text":"and"},{"annotation":"Treatment.Combination","text":"nasogastric decompression"},{"annotation":"Treatment.Combination","text":"intravenous hyperalimentation"},{"annotation":"Effect","text":"self-limiting and respond favorably"},{"annotation":"Subject","text":"most cases"},{"annotation":"Subject.Disorder","text":"pancreatitis"},{"annotation":"Treatment","text":"nasogastric decompression and intravenous hyperalimentation"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Combination","text":"and"},{"annotation":"Treatment.Combination","text":"nasogastric decompression"},{"annotation":"Treatment.Combination","text":"intravenous hyperalimentation"},{"annotation":"Effect","text":"self-limiting and respond favorably"},{"annotation":"Treatment","text":"nasogastric decompression and intravenous hyperalimentation"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Combination","text":"and"},{"annotation":"Treatment.Combination","text":"nasogastric decompression"},{"annotation":"Treatment.Combination","text":"intravenous hyperalimentation"},{"annotation":"Effect","text":"self-limiting and respond favorably"},{"annotation":"Treatment","text":"nasogastric decompression and intravenous hyperalimentation"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Combination","text":"and"},{"annotation":"Treatment.Combination","text":"nasogastric decompression"},{"annotation":"Treatment.Combination","text":"intravenous hyperalimentation"},{"annotation":"Effect","text":"self-limiting and respond favorably"},{"annotation":"Treatment","text":"nasogastric decompression and intravenous hyperalimentation"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Combination","text":"and"},{"annotation":"Treatment.Combination","text":"nasogastric decompression"},{}]}]}
{"id":"23970584_6","context":"Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"commencing the drug"},{"annotation":"Effect","text":"severe adverse drug reaction"},{"annotation":"Treatment","text":"Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome"},{"annotation":"Treatment.Drug","text":"unknown drug"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"shortly after commencing"},{"annotation":"Effect","text":"Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome"},{"annotation":"Treatment","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{"annotation":"Treatment.Drug","text":"unknown drug"},{}]}]}
{"id":"9562211_3","context":"This report presents a potential case of risperidone-induced tardive dyskinesia.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"tardive dyskinesia"},{"annotation":"Treatment","text":"risperidone"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Treatment.Disorder","text":"tardive dyskinesia"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes.severity","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not explicitly remarked"},{"annotation":"Attribute Attributes","text":"neg"}]}]}
{"id":"16288069_4","context":"The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"infusion"},{"annotation":"Effect","text":"coldness"},{"annotation":"Treatment","text":"penicillin"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Treatment.Dosage","text":"first dose"},{"annotation":"Treatment.Time_elapsed","text":"one hour"},{"annotation":"Treatment.Route","text":"infusion"},{"annotation":"Treatment.Side_effect","text":"coldness"},{"annotation":"Treatment.Side_effect","text":"worsening headache"},{"annotation":"Treatment.Side_effect","text":"chills"}]}]}
{"id":"15927910_4","context":"Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Effect","text":"heart block"},{"annotation":"Treatment","text":"pentamidine"},{"annotation":"Treatment.Drug","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"early-onset"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Dosage","text":"pentamidine"},{"annotation":"Treatment.Frequency","text":"pentamidine"},{"annotation":"Treatment.Route","text":"pentamidine"},{"annotation":"Treatment.Time_elapsed","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"pentamidine"}]}]}
{"id":"15286697_1","context":"Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with BCNU"},{"annotation":"Effect","text":"fatal pulmonary fibrosis"},{"annotation":"Treatment","text":"BCNU"},{"annotation":"Treatment.Disorder","text":"pulmonary fibrosis"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"role of platelet-derived growth factor-B"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes"}]}]}
{"id":"10492493_1","context":"CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"losartan"},{"annotation":"Treatment.Disorder","text":"late-onset angioedema"},{"annotation":"Treatment.Duration","text":"in patients with normal renal function"},{"annotation":"Treatment.Duration","text":"after initial resolution of the symptoms"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"}]}]}
{"id":"3211830_1","context":"Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"vasculitis"},{"annotation":"Treatment","text":"diltiazem"},{"annotation":"Treatment.Drug","text":"diltiazem"}]}]}
{"id":"10492493_4","context":"The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"incidence"},{"annotation":"Treatment","text":"losartan"},{"annotation":"Treatment.Disorder","text":"angioedema"},{"annotation":"Treatment.Drug","text":"losartan"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"unknown"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"18347524_2","context":"We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"leflunomide"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"leflunomide"},{"annotation":"Treatment.Duration","text":"2 weeks"},{"annotation":"Effect","text":"short-of-breath"},{"annotation":"Effect","text":"hemoptysis"},{"annotation":"Effect","text":"severe weakness"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"leflunomide"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"leflunomide"},{"annotation":"Treatment.Duration","text":"2 weeks"},{"annotation":"Effect","text":"short-of-breath"},{"annotation":"Effect","text":"hemoptysis"},{"annotation":"Effect","text":"severe weakness"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"leflunomide"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"leflunomide"},{"annotation":"Treatment.Duration","text":"2 weeks"},{"annotation":"Effect","text":"short-of-breath"},{"annotation":"Effect","text":"hemoptysis"},{"annotation":"Effect","text":"severe weakness"}]}]}
{"id":"12659609_1","context":"Toxicity related to chloroquine treatment of resistant vivax malaria.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"related"},{"annotation":"Effect","text":"toxicity"},{"annotation":"Treatment","text":"chloroquine treatment of resistant vivax malaria"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Disorder","text":"resistant vivax malaria"},{"annotation":"Treatment.Disorder","text":"malaria"},{"annotation":"Treatment.Target_disorder","text":"resistant vivax malaria"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"toxicity does not exist"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"related"},{"annotation":"Effect","text":"toxicity"},{"annotation":"Treatment","text":"chloroquine treatment of resistant vivax malaria"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Disorder","text":"resistant vivax malaria"},{"annotation":"Treatment.Disorder","text":"malaria"},{"annotation":"Treatment.Target_disorder","text":"resistant vivax malaria"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"toxicity does not exist"}]}]}
{"id":"8250714_3","context":"Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"neurologic deterioration"},{"annotation":"Effect","text":"following nitrous oxide anesthesia"},{"annotation":"Treatment","text":"patients with vitamin B12 deficiency"},{"annotation":"Treatment.Disorder","text":"vitamin B12 deficiency"},{"annotation":"Treatment.Drug","text":"nitrous oxide"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"patients with vitamin B12 deficiency are not sensitive to neurologic deterioration following nitrous oxide anesthesia"}]}]}
{"id":"15072497_2","context":"However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presenting with PD"},{"annotation":"Effect","text":"Parkinson's disease (PD)"},{"annotation":"Treatment","text":"high dose colchicine treatment for familiar mediterranean fever (FMF)"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Treatment.Disease","text":"familiar mediterranean fever (FMF)"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Disorder","text":"familiar mediterranean fever (FMF)"},{"annotation":"Treatment.Drug","text":"colchicine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presenting with PD"},{"annotation":"Effect","text":"Parkinson's disease (PD)"},{"annotation":"Treatment","text":"high dose colchicine treatment for familiar mediterranean fever (FMF)"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Treatment.Disease","text":"familiar mediterranean fever (FMF)"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Disorder","text":"familiar mediterranean fever (FMF)"},{"annotation":"Treatment.Drug","text":"colchicine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presenting with PD"},{"annotation":"Effect","text":"Parkinson's disease (PD)"},{"annotation":"Treatment","text":"high dose colchicine treatment for familiar mediterranean fever (FMF)"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Treatment.Disease","text":"familiar mediterranean fever (FMF)"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Disorder","text":"familiar mediterranean fever (FMF)"},{"annotation":"Treatment.Drug","text":"colchicine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presenting with PD"},{"annotation":"Effect","text":"Parkinson's disease (PD)"},{"annotation":"Treatment","text":"high dose colchicine treatment for familiar mediterranean fever (FMF)"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Treatment.Disease","text":"familiar mediterranean fever (FMF)"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Disorder","text":"familiar mediterranean fever (FMF)"},{"annotation":"Treatment.Drug","text":"colchicine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presenting with PD"},{"annotation":"Effect","text":"Parkinson's disease (PD)"},{"annotation":"Treatment","text":"high dose colchicine treatment for familiar mediterranean fever (FMF)"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Treatment.Disease","text":"familiar mediterranean fever (FMF)"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Disorder","text":"familiar mediterranean fever (FMF)"},{"annotation":"Treatment.Drug","text":"colchicine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presenting with PD"}]}]}
{"id":"12786839_3","context":"We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"infectious mononucleosis-like syndrome"},{"annotation":"Treatment","text":"salazosulfapyridine (SASP)"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"infectious mononucleosis-like syndrome"},{"annotation":"Treatment","text":"salazosulfapyridine (SASP)"}]}]}
{"id":"1655228_2","context":"Myocardial ischemia associated with high-dose carmustine infusion.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"myocardial ischemia"},{"annotation":"Treatment","text":"high-dose carmustine infusion"},{"annotation":"Treatment.Drug","text":"carmustine"},{"annotation":"Treatment.Dosage","text":"high-dose"},{"annotation":"Treatment.Frequency","text":"infusion"},{"annotation":"Treatment.Route","text":"infusion"},{"annotation":"Treatment.Duration","text":"during"},{"annotation":"Treatment.Disorder","text":"myocardial ischemia"},{"annotation":"Treatment.Drug","text":"carmustine"},{"annotation":"Attribute","text":"negated"},{"annotation":"negated","text":"the myocardial ischemia was not present at the time of the report"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"high-dose carmustine infusion"},{"annotation":"Treatment.Disorder","text":"myocardial ischemia"},{"annotation":"Treatment.Drug","text":"carmustine"},{"annotation":"Attribute","text":"speculated"},{"annotation":"speculated","text":"the myocardial ischemia may have been caused by the high-dose carmustine infusion"}]}]}
{"id":"21802143_1","context":"Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hepatic drug interaction"},{"annotation":"Treatment","text":"combination of tacrolimus and lansoprazole"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Drug","text":"lansoprazole"},{"annotation":"Treatment.Drug","text":"voriconazole"},{"annotation":"Treatment.Drug","text":"CYP2C19 and CYP3A5 heterozygous mutations"},{"annotation":"Treatment.Drug","text":"voriconazole"},{"annotation":"Treatment.Disorder","text":"hepatic drug interaction"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Drug","text":"lansoprazole"},{"annotation":"Treatment.Drug","text":"voriconazole"},{"annotation":"Treatment.Drug","text":"CYP2C19 and CYP3A5 heterozygous mutations"},{"annotation":"Subject","text":"a bone marrow transplant patient"},{"annotation":"Subject.Disorder","text":"hepatic drug interaction"},{"annotation":"Subject.Drug","text":"tacrolimus"},{"annotation":"Subject.Drug","text":"lansoprazole"},{"annotation":"Subject.Drug","text":"voriconazole"},{"annotation":"Subject.Drug","text":"CYP2C19 and CYP3A5 heterozygous mutations"}]}]}
{"id":"12507063_2","context":"Gabapentin withdrawal presenting as status epilepticus.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withdrawal"},{"annotation":"Effect","text":"status epilepticus"},{"annotation":"Treatment","text":"gabapentin"},{"annotation":"Treatment.Disorder","text":"status epilepticus"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"status epilepticus does not exist"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withdrawal"},{"annotation":"Effect","text":"seizure"},{"annotation":"Treatment","text":"gabapentin"},{"annotation":"Treatment.Disorder","text":"seizure"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"seizure does not exist"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withdrawal"},{"annotation":"Effect","text":"seizure"},{"annotation":"Treatment","text":"gabapentin"},{"annotation":"Treatment.Disorder","text":"seizure"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"seizure does not exist"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withdrawal"},{"annotation":"Effect","text":"seizure"},{"annotation":"Treatment","text":"gabapentin"},{"annotation":"Treatment.Disorder","text":"seizure"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"seizure does not exist"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withdrawal"},{"annotation":"Effect","text":"seizure"},{"annotation":"Treatment","text":"gabapentin"},{"annotation":"Treatment.Disorder","text":"seizure"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"seizure does not exist"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withdrawal"},{"annotation":"Effect","text":"seizure"},{"annotation":"Treatment","text":"gabapentin"},{"annotation":"Treatment.Disorder","text":"seizure"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"seizure does not exist"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withdrawal"},{"annotation":"Effect","text":"seizure"},{"annotation":"Treatment","text":"gabapentin"},{"annotation":"Treatment.Disorder","text":"seizure"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"seizure does not exist"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withdrawal"},{"annotation":"Effect","text":"seizure"},{"annotation":"Treatment","text":"gabapentin"},{"annotation":"Treatment.Disorder","text":"seizure"},{"annotation":"Treatment.Drug","text":""}]}]}
{"id":"7056119_1","context":"Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"amiodarone"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Drug","text":"quinidine"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"arrhythmia"},{"annotation":"Effect","text":"torsade de pointes"}]}]}
{"id":"17619811_3","context":"Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"postulated"},{"annotation":"Treatment","text":"colchicine"},{"annotation":"Treatment.Disorder","text":"rhabdomyolysis"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes.severity","text":"severe"},{"annotation":"Treatment.Drug","text":"colchicine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"colchicine"},{"annotation":"Treatment.Disorder","text":"rhabdomyolysis"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not"},{"annotation":"Treatment.Drug","text":"colchicine"}]}]}
{"id":"4075534_2","context":"Spindle coma in benzodiazepine toxicity: case report.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"benzodiazepine toxicity"},{"annotation":"Treatment.Drug","text":"benzodiazepine"},{"annotation":"Treatment.Dosage","text":"toxicity"},{"annotation":"Effect","text":"spindle coma"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"benzodiazepine toxicity"},{"annotation":"Treatment.Drug","text":"benzodiazepine"},{"annotation":"Treatment.Dosage","text":"toxicity"},{"annotation":"Effect","text":"spindle coma"}]}]}
{"id":"2483959_1","context":"A typical case of dextran-40 associated acute renal failure is presented.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Effect","text":"acute renal failure"},{"annotation":"Treatment","text":"dextran-40"},{"annotation":"Treatment.Drug","text":"dextran-40"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Age","text":"unknown"},{"annotation":"Subject.Disorder","text":"acute renal failure"},{"annotation":"Treatment.Drug","text":"dextran-40"}]}]}
{"id":"15895899_1","context":"After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"infusion"},{"annotation":"Treatment","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Effect","text":"neutropenia"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Dosage","text":"second"},{"annotation":"Treatment.Frequency","text":"infusion"},{"annotation":"Treatment.Route","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"severe transient"},{"annotation":"Treatment.Duration","text":"0.5 x 10(9)/L"}]}]}
{"id":"7712052_1","context":"Lithium for irritability in post-traumatic stress disorder.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"irritability"},{"annotation":"Treatment","text":"lithium"},{"annotation":"Treatment.Disorder","text":"post-traumatic stress disorder"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"irritability"},{"annotation":"Treatment","text":"lithium"},{"annotation":"Treatment.Disorder","text":"post-traumatic stress disorder"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"for lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"T"}]}]}
{"id":"14684937_2","context":"Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics"},{"annotation":"Treatment.Disorder","text":"psoriasis"},{"annotation":"Treatment.Drug","text":"vitamin D3 ointment (1,24(OH)2D3)"},{"annotation":"Treatment.Drug","text":"thiazide diuretics"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"vitamin D3 ointment (1,24(OH)2D3)"},{"annotation":"Treatment.Combination.Drug","text":"thiazide diuretics"},{"annotation":"Subject","text":"a case of psoriasis"},{"annotation":"Subject.Disorder","text":"psoriasis"}]}]}
{"id":"6362443_1","context":"A case of mania associated with fluoxetine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Effect","text":"mania"},{"annotation":"Treatment","text":"fluoxetine"},{"annotation":"Treatment.Drug","text":"fluoxetine"}]}]}
{"id":"7748076_3","context":"RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.","events":[{"type":"Potential_therapeutic_event","annotations":[{"annotation":"Trigger","text":"found"},{"annotation":"Treatment","text":"progestin therapy"},{"annotation":"Treatment.Disorder","text":"squamous metaplasia"},{"annotation":"Treatment.Drug","text":"progestin"},{"annotation":"Subject","text":"endometrial glands"},{"annotation":"Subject.Disorder","text":"squamous metaplasia"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"found"},{"annotation":"Treatment","text":"progestin therapy"},{"annotation":"Treatment.Disorder","text":"squamous metaplasia"},{"annotation":"Treatment.Drug","text":"progestin"},{"annotation":"Subject","text":"endometrial glands"},{"annotation":"Subject.Disorder","text":"squamous metaplasia"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"found"},{"annotation":"Treatment","text":"progestin therapy"},{"annotation":"Treatment.Disorder","text":"squamous metaplasia"},{"annotation":"Treatment.Drug","text":"progestin"},{"annotation":"Subject","text":"endometrial glands"},{"annotation":"Subject.Disorder","text":"squamous metaplasia"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"found"},{"annotation":"Treatment","text":"progestin therapy"},{"annotation":"Treatment.Disorder","text":"squamous metaplasia"},{"annotation":"Treatment.Drug","text":"progestin"},{"annotation":"Subject","text":"endometrial glands"},{"annotation":"Subject.Disorder","text":"squamous metaplasia"}]}]}
{"id":"16843118_1","context":"Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused by"},{"annotation":"Effect","text":"exanthematous pustulosis"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment.Drug","text":"positive patch test"},{"annotation":"Treatment.Drug","text":"lymphocyte transformation test"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"}]}]}
{"id":"9149614_1","context":"Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"initiation of therapy with amiodarone"},{"annotation":"Treatment","text":"amiodarone"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Disorder","text":"syncope"},{"annotation":"Treatment.Disorder","text":"polymorphous ventricular tachycardia"},{"annotation":"Treatment.Dosage","text":"11 days"},{"annotation":"Treatment.Time_elapsed","text":"after initiation of therapy with amiodarone"},{"annotation":"Treatment.Dosage","text":"11 days"},{"annotation":"Treatment.Dosage","text":"11 days"},{"annotation":"Treatment","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"amiodarone"},{"annotation":"Treat"}]}]}
{"id":"8579054_3","context":"Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"lead"},{"annotation":"Effect","text":"acute leukemia"},{"annotation":"Treatment","text":"hydroxyurea"},{"annotation":"Treatment.Disorder","text":"ET"},{"annotation":"Treatment.Drug","text":"hydroxyurea"},{"annotation":"Treatment.Duration","text":"prolonged used"},{"annotation":"Treatment.Duration","text":"acute leukemia"},{"annotation":"Subject","text":"patients with ET"},{"annotation":"Subject.Disorder","text":"ET"}]}]}
{"id":"354311_2","context":"Metastatic osteomyelitis following BCG vaccination.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"metastatic osteomyelitis"},{"annotation":"Treatment","text":"BCG vaccination"},{"annotation":"Treatment.Disorder","text":"metastatic osteomyelitis"},{"annotation":"Treatment.Drug","text":"BCG vaccination"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"metastatic osteomyelitis"},{"annotation":"Treatment","text":"BCG vaccination"},{"annotation":"Treatment.Disorder","text":"metastatic osteomyelitis"},{"annotation":"Treatment.Drug","text":"BCG vaccination"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"1414247_1","context":"Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"coma"},{"annotation":"Treatment","text":"valproic acid"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Treatment.Disorder","text":"carbamyl phosphate synthetase-1 deficiency"},{"annotation":"Treatment.Drug","text":"carbamyl phosphate synthetase-1 deficiency"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Treatment.Drug","text":"carbamyl phosphate synthetase-1 deficiency"},{"annotation":"Subject","text":"an individual"},{"annotation":"Subject.Disorder","text":"carbamyl phosphate synthetase-1 deficiency"}]}]}
{"id":"8912599_5","context":"We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Effect","text":"painful erosions"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Disorder","text":"psoriasis"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"toxicity"},{"annotation":"Treatment.Frequency","text":"presenting sign"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"methotrexate toxicity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes"}]}]}
{"id":"9413296_2","context":"Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"methysergide"},{"annotation":"Treatment.Drug","text":"methysergide"},{"annotation":"Effect","text":"retroperitoneal fibrosis"},{"annotation":"Treatment.Disorder","text":"methysergide-induced retroperitoneal fibrosis"},{"annotation":"Treatment.Drug","text":"methysergide"},{"annotation":"Treatment.Treatment_duration","text":"successful outcome"},{"annotation":"Treatment.Treatment_duration","text":"two new laboratory features"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"outcome"},{"annotation":"Treatment","text":"methysergide"},{"annotation":"Treatment.Disorder","text":"methysergide-induced retroperitoneal fibrosis"},{"annotation":"Treatment.Drug","text":"methysergide"},{"annotation":"Treatment.Treatment_duration","text":"successful outcome"},{"annotation":"Treatment.Treatment_duration","text":"two new laboratory features"}]}]}
{"id":"11099623_1","context":"We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"suffered"},{"annotation":"Effect","text":"significant morbidity"},{"annotation":"Treatment","text":"hyperbaric oxygen"},{"annotation":"Treatment.Drug","text":"hyperbaric oxygen"},{"annotation":"Treatment.Dosage","text":"after treatment"},{"annotation":"Treatment.Duration","text":"immediately after treatment"},{"annotation":"Treatment.Route","text":"hyperbaric oxygen"},{"annotation":"Treatment.Combination","text":"none"},{"annotation":"Subject","text":"2 children with cerebral palsy"},{"annotation":"Subject.Disorder","text":"cerebral palsy"}]}]}
{"id":"53128_2","context":"A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"spontaneous retropharyngeal hemorrhage"},{"annotation":"Effect","text":"hemorrhage"},{"annotation":"Treatment","text":"anticoagulants"},{"annotation":"Treatment.Disorder","text":"polycythemia vera"},{"annotation":"Treatment.Drug","text":"anticoagulants"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"polycythemia vera"}]}]}
{"id":"9671138_1","context":"CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"CD4 T-lymphocyte depletion"},{"annotation":"Effect","text":"myelosuppression"},{"annotation":"Treatment","text":"fludarabine phosphate therapy"},{"annotation":"Treatment.Disorder","text":"severe infections"},{"annotation":"Treatment.Drug","text":"fludarabine"},{"annotation":"Treatment.Dosage","text":"phosphate"},{"annotation":"Treatment.Frequency","text":"severe"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"CD4 T-lymphocyte depletion"},{"annotation":"Treatment.Disorder","text":"myelosuppression"},{"annotation":"Treatment.Disorder","text":"severe infections"},{"annotation":"Treatment.Disorder","text":"fludarabine phosphate therapy"}]}]}
{"id":"16288069_3","context":"Penicillin-induced Jarisch-Herxheimer reaction.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"penicillin"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Treatment.Disorder","text":"Jarisch-Herxheimer reaction"},{"annotation":"Effect","text":"reaction"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"penicillin"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Treatment.Disorder","text":"Jarisch-Herxheimer reaction"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"penicillin"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Treatment.Disorder","text":"Jarisch-Herxheimer reaction"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"penicillin"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Treatment.Disorder","text":"Jarisch-Herxheimer reaction"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"penicillin"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Treatment.Disorder","text":"Jarisch-Herxheimer reaction"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"penicillin"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Treatment.Disorder","text":"Jarisch-Herxheimer reaction"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"penicillin"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Treatment.Disorder","text":"Jarisch-Herxheimer reaction"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"penicillin"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Treatment.Disorder","text":"Jarisch-Herxheimer reaction"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"penicillin"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Treatment.Disorder","text":"Jarisch-Herxheimer reaction"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Attribute"}]}]}
{"id":"9550246_4","context":"The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"suggestion"},{"annotation":"Treatment","text":"risperidone"},{"annotation":"Treatment.Disorder","text":"schizophrenia"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"risperidone does not increase affect"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"difficulty managing the increase"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"anxiety"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"affect"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"difficulty managing the increase"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"anxiety"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"affect"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"difficulty managing the increase"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"anxiety"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"affect"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"difficulty managing the increase"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"anxiety"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"affect"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"difficulty managing the increase"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"anxiety"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"affect"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"difficulty managing the increase"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"anxiety"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"affect"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"difficulty managing the increase"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"anxiety"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"affect"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"difficulty managing the increase"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"anxiety"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"affect"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"difficulty managing the increase"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"anxiety"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"affect"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"difficulty managing the increase"},{}]}]}
{"id":"11315123_1","context":"We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intoxication"},{"annotation":"Effect","text":"progressive renal impairment, blurred vision, QRS broadening and cardiac failure"},{"annotation":"Treatment","text":"cibenzoline intoxication"},{"annotation":"Treatment.Disorder","text":"progressive renal impairment"},{"annotation":"Treatment.Drug","text":"cibenzoline"},{"annotation":"Treatment.Dosage","text":"chronic"},{"annotation":"Treatment.Duration","text":"chronic"},{"annotation":"Treatment.Side_effect","text":"blurred vision, QRS broadening and cardiac failure"},{"annotation":"Treatment.Side_effect","text":"progressive renal impairment"},{"annotation":"Treatment.Side_effect","text":"chronic cibenzoline intoxication"},{"annotation":"Treatment.Side_effect","text":"cardiac failure"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intoxication"},{"annotation":"Effect","text":"progressive renal impairment, blurred vision, QRS broadening and cardiac failure"},{"annotation":"Treatment","text":"cibenzoline intoxication"},{"annotation":"Treatment.Disorder","text":"progressive renal impairment"},{"annotation":"Treatment.Drug","text":"cibenzoline"},{"annotation":"Treatment.Dosage","text":"chronic"},{"annotation":"Treatment.Duration","text":"chronic"},{"annotation":"Treatment.Side_effect","text":"blurred vision, QRS broadening and cardiac failure"},{"annotation":"Treatment.Side_effect","text":"progressive renal impairment"},{"annotation":"Treatment.Side_effect","text":"chronic cibenzoline intoxication"},{"annotation":"Treatment.Side_effect","text":"cardiac failure"}]}]}
{"id":"1557089_1","context":"In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"exacerbation"},{"annotation":"Effect","text":"myasthenic weakness"},{"annotation":"Treatment","text":"oral verapamil"},{"annotation":"Treatment.Disorder","text":"myasthenia gravis"},{"annotation":"Treatment.Drug","text":"verapamil"},{"annotation":"Treatment.Dosage","text":"oral"},{"annotation":"Treatment.Frequency","text":"postoperative"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Subject","text":"a postoperative patient"},{"annotation":"Subject.Disorder","text":"myasthenia gravis"}]}]}
{"id":"16288069_1","context":"An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"related"},{"annotation":"Effect","text":"JHR"},{"annotation":"Treatment","text":"penicillin"},{"annotation":"Treatment.Drug","text":"penicillin"},{"annotation":"Attribute Attributes","text":"objective causality assessment suggests"},{"annotation":"Attribute Attributes","text":"probably related"}]}]}
{"id":"16490518_2","context":"RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"acquired"},{"annotation":"Effect","text":"visual field defects"},{"annotation":"Effect","text":"severe vision loss"},{"annotation":"Treatment","text":"intravitreal injection of triamcinolone"},{"annotation":"Treatment.Drug","text":"triamcinolone"},{"annotation":"Treatment.Disorder","text":"diabetic macular edema"},{"annotation":"Subject","text":"a 34-year-old man"},{"annotation":"Subject.Age","text":"34"},{"annotation":"Subject.Disorder","text":"diabetic macular edema"}]}]}
{"id":"16537817_1","context":"Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Treatment","text":"simvastatin-amiodarone"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Effect","text":"rhabdomyolysis, azotemia, and possible hepatotoxicity"},{"annotation":"Treatment","text":"simvastatin-amiodarone interaction"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Interaction","text":"and"},{"annotation":"Treatment.Interaction","text":"simvastatin-amiodarone"},{"annotation":"Treatment.Interaction","text":"interaction"},{"annotation":"Treatment","text":"simvastatin-amiodarone interaction"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Interaction","text":"and"},{"annotation":"Treatment.Interaction","text":"simvastatin-amiodarone"},{"annotation":"Treatment.Interaction","text":"interaction"},{"annotation":"Treatment","text":"simvastatin-amiodarone interaction"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Interaction","text":"and"},{"annotation":"Treatment.Interaction","text":"simvastatin-amiodarone"},{"annotation":"Treatment.Interaction","text":"interaction"},{"annotation":"Treatment","text":"simvastatin-amiodarone interaction"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Interaction","text":"and"},{"annotation":"Treatment.Interaction","text":"simvastatin-amiodarone"},{"annotation":"Treatment.Interaction","text":"interaction"},{"annotation":"Treatment","text":"simvastatin-amiodarone interaction"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Interaction","text":"and"},{"annotation":"Treatment.Interaction","text":"simvastatin-amiodarone"},{"annotation":"Treatment.Interaction","text":"interaction"},{"annotation":"Treatment","text":"simvastatin-amiodarone interaction"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Interaction","text":"and"},{"annotation":"Treatment.Interaction","text":"simvastatin-amiodarone"},{"annotation":"Treatment.Interaction","text":"interaction"},{"annotation":"Treatment","text":"simvastatin-amiodarone interaction"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Interaction","text":"and"},{"annotation":"Treatment"}]}]}
{"id":"21330680_13","context":"A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"parkinsonism"},{"annotation":"Treatment","text":"high-dosage olanzapine for bipolar disorder"},{"annotation":"Treatment.Disorder","text":"bipolar disorder"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"smoking cessation"},{"annotation":"Treatment.Drug","text":"smoking cessation"},{"annotation":"Treatment.Drug","text":"parkinsonism"},{"annotation":"Subject","text":"a 73-year-old woman"},{"annotation":"Subject.Age","text":"73"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"high-dosage"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"parkinsonism"},{"annotation":"Attribute Attributes","text":"not specified"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"parkinsonism"},{"annotation":"Treatment","text":"high-dosage olanzapine for bipolar disorder"},{"annotation":"Treatment.Disorder","text":"bipolar disorder"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"smoking cessation"},{"annotation":"Treatment.Drug","text":"smoking cessation"},{"annotation":"Treatment.Drug","text":"parkinsonism"},{"annotation":"Subject","text":"a 73-year-old woman"},{"annotation":"Subject.Age","text":"73"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"high-dosage"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"parkinsonism"},{"annotation":"Attribute Attributes","text":"not specified"}]}]}
{"id":"16515630_2","context":"Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"paclitaxel"},{"annotation":"Treatment.Drug","text":"paclitaxel"},{"annotation":"Effect","text":"pulmonary fibrosis"},{"annotation":"Treatment.Disorder","text":"paclitaxel-induced pulmonary fibrosis"},{"annotation":"Attribute","text":"negated"},{"annotation":"negated","text":"paclitaxel-induced pulmonary fibrosis is not fatal"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"paclitaxel"},{"annotation":"Treatment.Drug","text":"paclitaxel"},{"annotation":"Effect","text":"pulmonary fibrosis"},{"annotation":"Treatment.Disorder","text":"paclitaxel-induced pulmonary fibrosis"},{"annotation":"Attribute","text":"negated"},{"annotation":"negated","text":"paclitaxel-induced pulmonary fibrosis is not fatal"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"paclitaxel"},{"annotation":"Treatment.Drug","text":"paclitaxel"},{"annotation":"Effect","text":"pulmonary fibrosis"},{"annotation":"Treatment.Disorder","text":"paclitaxel-induced pulmonary fibrosis"},{"annotation":"Attribute","text":"negated"},{"annotation":"negated","text":"paclitaxel-induced pulmonary fibrosis is not fatal"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"paclitaxel"},{"annotation":"Treatment.Drug","text":"paclitaxel"},{"annotation":"Effect","text":"pulmonary fibrosis"},{"annotation":"Treatment.Disorder","text":"paclitaxel-induced pulmonary fibrosis"},{"annotation":"Attribute","text":"negated"},{"annotation":"negated","text":"paclitaxel-induced pulmonary fibrosis is not fatal"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"paclitaxel"},{"annotation":"Treatment.Drug","text":"paclitaxel"},{"annotation":"Effect","text":"pulmonary fibrosis"},{"annotation":"Treatment.Disorder","text":"paclitaxel-induced pulmonary fibrosis"},{"annotation":"Attribute","text":"negated"},{"annotation":"negated","text":"paclitaxel-induced pulmonary fibrosis is not fatal"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"paclitaxel"},{"annotation":"Treatment.Drug","text":"paclitaxel"},{"annotation":"Effect","text":"pulmonary fibrosis"},{"annotation":"Treatment.Disorder","text":"paclitaxel-induced pulmonary fibrosis"},{"annotation":"Attribute","text":"negated"},{"annotation":"negated","text":"paclitaxel-induced pulmonary fibrosis is not fatal"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{}]}]}
{"id":"23970584_1","context":"Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"DRESS syndrome"},{"annotation":"Treatment","text":"raltegravir"},{"annotation":"Treatment.Drug","text":"raltegravir"},{"annotation":"Treatment.Disorder","text":"DRESS syndrome"},{"annotation":"Treatment.Drug","text":"eosinophilia and systemic symptoms"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"implications for clinical practice and patient safety"},{"annotation":"Effect","text":"implications for clinical practice and patient safety"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"}]}]}
{"id":"19131789_1","context":"A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotransferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"manifested"},{"annotation":"Effect","text":"renal toxicity"},{"annotation":"Treatment","text":"infusion of high-dose methotrexate (MTX)"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dose","text":"12 g/m2"},{"annotation":"Treatment.Time_elapsed","text":"2 hours"},{"annotation":"Treatment.Disorder","text":"acute renal failure"},{"annotation":"Treatment.Disorder","text":"hyperkalemia"},{"annotation":"Subject","text":"a 10-year-old boy with osteosarcoma and normal renal function"},{"annotation":"Subject.Disorder","text":"acute renal failure"},{"annotation":"Subject.Disorder","text":"hyperkalemia"},{"annotation":"Subject.Age","text":"10 years"},{"annotation":"Subject.Gender","text":"male"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Disorder","text":"methotrexate toxicity"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dose","text":"12 g/m2"},{"annotation":"Treatment.Time_elapsed","text":"2 hours"},{"annotation":"Treatment.Disorder","text":"acute renal failure"},{"annotation":"Treatment.Disorder","text":"hyperkalemia"},{"annotation":"Treatment.Disorder","text":"methotrexate toxicity"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dose","text":"12 g/m2"},{"annotation":"Treatment.Time_elapsed","text":"2 hours"},{"annotation":"Treatment.Disorder","text":"acute renal failure"},{"annotation":"Treatment.Disorder","text":"hyperkalemia"},{"annotation":"Treatment.Disorder","text":"methotrexate toxicity"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dose","text":"12 g/m2"},{"annotation":"Treatment.Time_elapsed","text":"2 hours"},{"annotation":"Treatment.Disorder","text":"acute renal failure"},{"annotation":"Treatment.Disorder","text":"hyperkalemia"},{"annotation":"Treatment.Disorder","text":"methotrexate toxicity"},{"annotation":"Treatment.Drug","text":""}]}]}
{"id":"2012922_1","context":"Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"trazodone"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Effect","text":"hypomanic symptoms"},{"annotation":"Treatment.Disorder","text":"depression"},{"annotation":"Treatment.Disorder","text":"depressed patients"},{"annotation":"Treatment.Dosage","text":"transient"},{"annotation":"Treatment.Duration","text":"symptoms"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Dosage","text":"induced"},{"annotation":"Treatment.Dosage","text":"hypomanic symptoms"},{"annotation":"Treatment.Frequency","text":"occurred"},{"annotation":"Treatment.Route","text":"in three"},{"annotation":"Subject","text":"three depressed patients"},{"annotation":"Subject.Disorder","text":"depressed patients"},{"annotation":"Treatment.Disorder","text":"depression"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"trazodone"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Effect","text":"hypomanic symptoms"},{"annotation":"Treatment.Disorder","text":"depression"},{"annotation":"Treatment.Disorder","text":"depressed patients"},{"annotation":"Treatment.Dosage","text":"transient"},{"annotation":"Treatment.Duration","text":"symptoms"},{"annotation":"Treatment.Drug","text":"trazodine"},{"annotation":"Treatment.Dosage","text":"induced"},{"annotation":"Treatment.Dosage","text":"hypomanic symptoms"},{"annotation":"Treatment.Frequency","text":"occurred"},{"annotation":"Treatment.Route","text":"in three"},{"annotation":"Subject","text":"three depressed patients"},{"annotation":"Subject.Disorder","text":"depressed patients"},{"annotation":"Treatment.Disorder","text":"depression"}]}]}
{"id":"9886213_4","context":"We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"myositis"},{"annotation":"Treatment","text":"praziquantel therapy"},{"annotation":"Treatment.Disorder","text":"disseminated muscular cysticercosis"},{"annotation":"Treatment.Drug","text":"praziquantel"},{"annotation":"Treatment.Drug","text":"cysticercosis"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"praziquantel"},{"annotation":"Treatment.Combination.Drug","text":"cysticercosis"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"disseminated muscular cysticercosis"}]}]}
{"id":"1888256_2","context":"Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Patients who have unexplained high temperatures during diltiazem therapy"},{"annotation":"Treatment","text":"diltiazem"},{"annotation":"Treatment.Disorder","text":"fever"},{"annotation":"Treatment.Drug","text":"diltiazem"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"se"}]}]}
{"id":"9443627_1","context":"Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"reversed"},{"annotation":"Effect","text":"neurotoxicity"},{"annotation":"Treatment","text":"ifosfamide"},{"annotation":"Treatment.Disorder","text":"ifosfamide-related neurotoxicity"},{"annotation":"Treatment.Therapy","text":"hemodialysis"}]}]}
{"id":"18076602_2","context":"Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"appeared"},{"annotation":"Effect","text":"purpuric skin lesions"},{"annotation":"Treatment","text":"amphotericin B"},{"annotation":"Treatment.Drug","text":"amphotericin B"},{"annotation":"Treatment.Duration","text":"55th day"},{"annotation":"Treatment.Dosage","text":"amphotericin B"},{"annotation":"Treatment.Frequency","text":"daily"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Time_elapsed","text":"55th day"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"},{"annotation":"Treatment.Time_elapsed","text":"from treatment start"}]}]}
{"id":"6199475_2","context":"Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatin, vinblastine, and bleomycin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"hemianopsia and encephalopathy"},{"annotation":"Treatment","text":"cisplatinum, vinblastine, and bleomycin"},{"annotation":"Treatment.Disorder","text":"testicular carcinoma"},{"annotation":"Treatment.Drug","text":"cisplatinum"},{"annotation":"Treatment.Drug","text":"vinblastine"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Duration","text":"transient"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":""}]}]}
{"id":"3410226_2","context":"We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"porphyria cutanea tarda"},{"annotation":"Treatment","text":"cisplatin and cyclophosphamide"},{"annotation":"Treatment.Disorder","text":"ovarian carcinoma"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Subject","text":"a 46-yr-old woman"},{"annotation":"Subject.Disorder","text":"ovarian carcinoma"}]}]}
{"id":"440873_2","context":"In one child, a second course of carbamazepine resulted in a return of the dystonia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"returned"},{"annotation":"Effect","text":"dystonia"},{"annotation":"Treatment","text":"second course of carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"}]}]}
{"id":"8726608_1","context":"Does acyclovir increase serum lithium levels?","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Does"},{"annotation":"Treatment","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Disorder","text":"serum lithium levels"},{"annotation":"Treatment.Combination.Trigger","text":"increase"},{"annotation":"Treatment.Combination.Drug","text":"acyclovir"},{"annotation":"Treatment.Combination.Drug","text":"lithium"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"negated"},{}]}]}
{"id": "2241449_2","context": "Sulfadiazine crystalluria revisited.","events": [{"type": "Adverse_event","annotations": [{"annotation": "Trigger","text": "crystalluria"},{"annotation": "Treatment","text": "sulfadiazine"},{"annotation": "Treatment.Drug","text": "sulfadiazine"},{"annotation": "Effect","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "sulfadiazine"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{"annotation": "Treatment.Drug","text": "crystalluria"},{}]}]}
{"id":"16472339_1","context":"Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"cerebral vasospasm"},{"annotation":"Treatment","text":"sumatriptan"},{"annotation":"Treatment.Disorder","text":"subarachnoid haemorrhage"},{"annotation":"Treatment.Diagnosis","text":"migraine"},{"annotation":"Treatment.Drug","text":"sumatriptan"},{"annotation":"Treatment.Dosage","text":"dose"},{"annotation":"Treatment.Frequency","text":"single dose"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"induced cerebral vasospasm is not a consequence of sumatriptan administration"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.severity","text":"high"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"}]}]}
{"id":"9550246_2","context":"Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"development"},{"annotation":"Treatment","text":"risperidone"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Effect","text":"intolerable affect"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Treatment.Disorder","text":"schizophrenia"},{"annotation":"Subject","text":"six outpatients"},{"annotation":"Subject.Disorder","text":"schizophrenia"},{"annotation":"Treatment.Duration","text":"ten weeks"},{"annotation":"Treatment.Drug","text":"risperidone"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"development"},{"annotation":"Treatment","text":"risperidone"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Effect","text":"intolerable affect"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Treatment.Disorder","text":"schizophrenia"},{"annotation":"Subject","text":"six outpatients"},{"annotation":"Subject.Disorder","text":"schizophrenia"},{"annotation":"Treatment.Duration","text":"ten weeks"},{"annotation":"Treatment.Drug","text":"risperidone"}]}]}
{"id":"10332990_1","context":"Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"during acute infusion of epoprostenol"},{"annotation":"Treatment","text":"epoprostenol"},{"annotation":"Treatment.Drug","text":"epoprostenol"},{"annotation":"Effect","text":"pulmonary edema"},{"annotation":"Treatment","text":"acute infusion of epoprostenol"},{"annotation":"Treatment.Disorder","text":"pulmonary hypertension and limited scleroderma"},{"annotation":"Treatment.Drug","text":"epoprostenol"},{"annotation":"Treatment.Drug","text":"scleroderma"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"pulmonary hypertension and limited scleroderma"}]}]}
{"id":"3003260_3","context":"Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"recent reports"},{"annotation":"Treatment","text":"Decadron (dexamethasone)"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Treatment.Drug","text":"Decadron (dexamethasone)"},{"annotation":"Treatment.Disorder","text":"cisplatin-induced vomiting"},{"annotation":"Treatment.Effect","text":"antiemetic effect"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"not"},{"annotation":"Treatment","text":"Decadron (dexamethasone)"},{"annotation":"Treatment.Drug","text":"Decadron (dexamethasone)"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Treatment.Disorder","text":"cisplatin-induced vomiting"},{"annotation":"Treatment.Effect","text":"antiemetic effect"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"}]}]}
{"id":"16087771_1","context":"Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"fibrosis"},{"annotation":"Treatment","text":"long-term treatment with pergolide"},{"annotation":"Treatment.Disorder","text":"Parkinson Disease"},{"annotation":"Treatment.Drug","text":"pergolide"},{"annotation":"Treatment.Drug","text":"dopamine agonist"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Disorder","text":"Parkinson Disease"},{"annotation":"Treatment.Drug","text":"pergolide"},{"annotation":"Treatment.Drug","text":"dopamine agonist"}]}]}
{"id":"556126_1","context":"An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"lost vision"},{"annotation":"Treatment","text":"Bromocryptine"},{"annotation":"Treatment.Disorder","text":"amenorrhea-galactorrhea syndrome"},{"annotation":"Treatment.Drug","text":"Bromocryptine"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"pregnancy"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"lost vision"},{"annotation":"Treatment","text":"Bromocryptine"},{"annotation":"Treatment.Disorder","text":"amenorrhea-galactorrhea syndrome"},{"annotation":"Treatment.Drug","text":"Bromocryptine"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"pregnancy"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"lost vision"},{"annotation":"Treatment","text":"Bromocryptine"},{"annotation":"Treatment.Disorder","text":"amenorrhea-galactorrhea syndrome"},{"annotation":"Treatment.Drug","text":"Bromocryptine"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"pregnancy"}]}]}
{"id":"8430717_2","context":"CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"neurotoxicity"},{"annotation":"Treatment","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Dosage","text":"peak serum concentrations"},{"annotation":"Treatment.Time_elapsed","text":"24 to 48 hours"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes"}]}]}
{"id":"8850251_5","context":"Two cases of mequitazine-induced photosensitivity reactions.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"photosensitivity reactions"},{"annotation":"Treatment","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"photosensitivity reactions"},{"annotation":"Treatment","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"}]}]}
{"id":"9704170_3","context":"Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"clozapine treatment"},{"annotation":"Treatment.Disorder","text":"decreased calcium-dependent potassium permeability of cell membranes"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Dosage","text":"clozapine treatment"},{"annotation":"Treatment.Frequency","text":"clozapine treatment"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"after clozapine treatment"},{"annotation":"Treatment.Duration","text":"clozapine treatment"},{"annotation":"Treatment.Disorder","text":"decreased calcium-dependent potassium permeability of cell membranes"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"clozapine treatment"},{"annotation":"Treatment.Disorder","text":"decreased calcium-dependent potassium permeability of cell membranes"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Dosage","text":"clozapine treatment"},{"annotation":"Treatment.Frequency","text":"clozapine treatment"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"after clozapine treatment"},{"annotation":"Treatment.Duration","text":"clozapine treatment"},{"annotation":"Treatment.Disorder","text":"decreased calcium-dependent potassium permeability of cell membranes"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"response"},{"annotation":"Effect","text":"response"},{"annotation":"Treatment","text":"clozapine treatment"},{"annotation":"Treatment.Disorder","text":"decreased calcium-dependent potassium permeability of cell membranes"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"9737132_1","context":"A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"intramuscular pentazocine injections"},{"annotation":"Treatment.Drug","text":"pentazocine"},{"annotation":"Treatment.Route","text":"intramuscular"},{"annotation":"Treatment.Duration","text":"4-year history"},{"annotation":"Treatment.Duration","text":"4 years"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Side_effect","text":"stiffness and weakness of the lower extremities"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"stiffness and weakness of the lower extremities"},{"annotation":"Treatment","text":"intramuscular pentazocine injections"},{"annotation":"Treatment.Drug","text":"pentazocine"},{"annotation":"Treatment.Route","text":"intramuscular"},{"annotation":"Treatment.Duration","text":"4-year history"},{"annotation":"Treatment.Duration","text":"4 years"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Side_effect","text":"stiffness and weakness of the lower extremities"}]}]}
{"id":"10592946_5","context":"The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"massive ingestion of caffeine-containing beverages"},{"annotation":"Treatment","text":"water intoxication"},{"annotation":"Treatment.Disorder","text":"severe rhabdomyolysis"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"water intoxication"}]}]}
{"id":"9533061_3","context":"CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"watery stools and abdominal cramping"},{"annotation":"Treatment","text":"clindamycin vaginal cream"},{"annotation":"Treatment.Disorder","text":"bacterial vaginosis"},{"annotation":"Subject","text":"a 25-year-old postpartum white woman"},{"annotation":"Subject.Age","text":"25"},{"annotation":"Subject.Gender","text":"white"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"white"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Dosage","text":"vaginal cream"},{"annotation":"Treatment.Frequency","text":"on day 6"},{"annotation":"Treatment.Route","text":"vaginal"},{"annotation":"Treatment.Time_elapsed","text":"after therapy was started"},{"annotation":"Treatment.Duration","text":"6 days"},{"annotation":"Treatment.Disorder","text":"bacterial vaginosis"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"11236070_1","context":"Dose-dependent olanzapine-associated leukopenia: three case reports.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"dose-dependent"},{"annotation":"Effect","text":"leukopenia"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":""}]}]}
{"id":"10682234_8","context":"He became completely premorbid 2 weeks after administration of levodopa.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"premorbidity"},{"annotation":"Treatment","text":"levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Duration","text":"2 weeks"},{"annotation":"Treatment.Disorder","text":"premorbidity"},{"annotation":"Subject","text":"he"},{"annotation":"Subject.Age","text":"2 weeks"},{"annotation":"Subject.Disorder","text":"premorbidity"}]}]}
{"id":"19112808_2","context":"The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"darifenacin"},{"annotation":"Treatment.Drug","text":"darifenacin"},{"annotation":"Effect","text":"interstitial granulomatous dermatitis"},{"annotation":"Treatment.Drug","text":"darifenacin"},{"annotation":"Treatment.Disorder","text":"interstitial granulomatous dermatitis"}]}]}
{"id":"7056119_6","context":"Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"amiodarone"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"200 mg/day"},{"annotation":"Treatment.Duration","text":"six months"},{"annotation":"Treatment.Frequency","text":"six days per week"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Disorder","text":"AVT"},{"annotation":"Treatment.Disorder","text":"not specified"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"amiodarone"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"200 mg/day"},{"annotation":"Treatment.Duration","text":"six months"},{"annotation":"Treatment.Frequency","text":"six days per week"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Disorder","text":"AVT"},{"annotation":"Treatment.Disorder","text":"not specified"}]}]}
{"id":"3003260_1","context":"A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea"},{"annotation":"Treatment.Drug","text":"Decadron"},{"annotation":"Treatment.Drug","text":"cisplatin-associated nausea"},{"annotation":"Treatment.Drug","text":"five-drug antiemetic regimen"},{"annotation":"Treatment.Drug","text":"Decadron"},{"annotation":"Treatment.Drug","text":"cisplatin-associated nausea"},{"annotation":"Treatment.Drug","text":"five-drug antiemetic regimen"},{"annotation":"Treatment.Drug","text":"Decadron"},{"annotation":"Effect","text":"visual impairment"},{"annotation":"Treatment.Drug","text":"bilateral posterior subcapsular cataracts"},{"annotation":"Treatment","text":"intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea"},{"annotation":"Treatment.Drug","text":"Decadron"},{"annotation":"Treatment","text":"cisplatin-associated nausea"},{"annotation":"Treatment.Drug","text":"five-drug antiemetic regimen"},{"annotation":"Treatment","text":"Decadron"},{"annotation":"Treatment","text":"cisplatin-associated nausea"},{"annotation":"Treatment","text":"five-drug antiemetic regimen"},{"annotation":"Treatment","text":"Decadron"},{"annotation":"Treatment","text":"cisplatin-associated nausea"},{"annotation":"Treatment","text":"five-drug antiemetic regimen"},{"annotation":"Treatment","text":"Decadron"},{"annotation":"Treatment","text":"cisplatin-associated nausea"},{"annotation":"Treatment","text":"five-drug antiemetic regimen"},{"annotation":"Treatment","text":"Decadron"},{"annotation":"Treatment","text":"cisplatin-associated nausea"},{"annotation":"Treatment","text":"five-drug antiemetic regimen"},{"annotation":"Treatment","text":"Decadron"},{"annotation":"Treatment","text":"cisplatin-associated nausea"},{"annotation":"Treatment","text":"five-drug antiemetic regimen"},{"annotation":"Treatment","text":"Decadron"},{"annotation":"Treatment","text":"cisplatin-associated nausea"},{"annotation":"Treatment","text":"five-drug antiemetic regimen"},{"annotation":"Treatment","text":"Decadron"},{"annotation":"Treatment","text":"cisplatin-associated nausea"},{"annotation":"Treatment","text":"five-drug antiemetic regimen"},{"annotation":"Treatment","text":"Decadron"},{"annotation":"Treatment","text":"cisplatin-associated nausea"},{"annotation":"Treatment","text":"five-drug antiemetic regimen"},{"annotation":"Treatment"}]}]}
{"id":"10492493_3","context":"OBJECTIVE: To report a case of angioedema associated with losartan administration.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"angioedema"},{"annotation":"Treatment","text":"losartan"},{"annotation":"Treatment.Drug","text":"losartan"}]}]}
{"id":"16341621_2","context":"The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"reaction"},{"annotation":"Effect","text":"urethral prolapse"},{"annotation":"Treatment","text":"transurethral injection of calcium hydroxylapatite"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Time_elapsed","text":"3 months"},{"annotation":"Treatment.Route","text":"transurethral injection"},{"annotation":"Treatment.Route","text":"calcium hydroxylapatite"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"urethral prolapse"}]}]}
{"id":"15595320_1","context":"Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"disorder"},{"annotation":"Treatment","text":"methotrexate and rofecoxib"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"rofecoxib"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"methotrexate"},{"annotation":"Treatment.Combination.Drug","text":"rofecoxib"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"rheumatoid arthritis"},{"annotation":"Attribute","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"disorder"},{"annotation":"Treatment","text":"methotrexate and rofecoxib"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"rofecoxib"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"methotrexate"},{"annotation":"Treatment.Combination.Drug","text":"rofecoxib"},{"annotation":"Attribute","text":"speculated"}]}]}
{"id":"18755414_4","context":"On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"promoted"},{"annotation":"Treatment","text":"aspirin"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Disorder","text":"spontaneous hemorrhage from meningioma"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"mening"}]}]}
{"id":"20925534_13","context":"The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"increased"},{"annotation":"Effect","text":"diarrhea"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Event type","text":"Adverse_event"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute"}]}]}
{"id":"1469187_1","context":"Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intoxication"},{"annotation":"Effect","text":"severe"},{"annotation":"Treatment","text":"Fab fragments of anti-digitalis antibodies"},{"annotation":"Treatment.Drug","text":"digitoxin"},{"annotation":"Treatment.Drug","text":"Fab fragments"},{"annotation":"Treatment.Disorder","text":"severe digitoxin intoxication"},{"annotation":"Treatment.Drug","text":"digitoxin"},{"annotation":"Treatment.Drug","text":"Fab fragments"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"severe digitoxin intoxication"}]}]}
{"id":"3410226_1","context":"Development of porphyria cutanea tarda after treatment with cyclophosphamide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"porphyria cutanea tarda"},{"annotation":"Treatment","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Disorder","text":"porphyria cutanea tarda"}]}]}
{"id":"3242521_2","context":"We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"seizures"},{"annotation":"Treatment","text":"intraventricular administration of nafcillin"},{"annotation":"Treatment.Drug","text":"nafcillin"},{"annotation":"Treatment.Route","text":"intraventricular"},{"annotation":"Treatment.Time_elapsed","text":"premature infant"},{"annotation":"Treatment.Duration","text":"nafcillin"},{"annotation":"Treatment.Disorder","text":"seizures"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"electroencephalographic monitoring of patients receiving intraventricular antibiotics"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"premature infant"},{"annotation":"Effect","text":"seizures"},{"annotation":"Treatment","text":"intraventricular administration of nafcillin"},{"annotation":"Treatment.Drug","text":"nafcillin"},{"annotation":"Treatment.Route","text":"intraventricular"},{"annotation":"Treatment.Time_elapsed","text":"premature infant"},{"annotation":"Treatment.Duration","text":"nafcillin"},{"annotation":"Treatment.Disorder","text":"seizures"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"electroencephalographic monitoring of patients receiving intraventricular antibiotics"}]}]}
{"id":"12022905_4","context":"OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"priapism"},{"annotation":"Treatment","text":"zuclopenthixol"},{"annotation":"Treatment.Drug","text":"zuclopenthixol"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{}]}]}
{"id":"16685112_1","context":"CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"radiation recall"},{"annotation":"Effect","text":"dermatitis and myositis"},{"annotation":"Treatment","text":"gemcitabine monotherapy"},{"annotation":"Treatment.Disorder","text":"pancreatic cancer"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Duration","text":"five months"},{"annotation":"Treatment.Duration","text":"after completing chemoradiation"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"gemcitabine"},{"annotation":"Treatment.Combination.Drug","text":"radiation"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"pancreatic cancer"}]}]}
{"id":"6427463_1","context":"Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"stroke-like syndrome"},{"annotation":"Treatment","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"gold sodium thiomalate"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"vasomotor reaction"},{"annotation":"Treatment"}]}]}
{"id":"9870779_3","context":"MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hepatic injury and liver enzyme elevations"},{"annotation":"Treatment","text":"leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"leukemia"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treat"}]}]}
{"id":"15522120_9","context":"An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"fluoxetine"},{"annotation":"Treatment.Drug","text":"fluoxetine"},{"annotation":"Effect","text":"ADR"},{"annotation":"Treatment","text":"discontinued"},{"annotation":"Treatment.Disorder","text":"ADR"},{"annotation":"Treatment.Drug","text":"fluoxetine"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":""}]}]}
{"id":"18203308_2","context":"New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"onset"},{"annotation":"Effect","text":"Crohn's disease"},{"annotation":"Treatment","text":"etanercept"},{"annotation":"Treatment.Disorder","text":"active ankylosing spondylitis"},{"annotation":"Treatment.Drug","text":"etanercept"}]}]}
{"id":"18523232_3","context":"Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"pulse itraconazole treatment for onychomycosis"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"onychomycosis"}]}]}
{"id":"3824704_1","context":"Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intravesical formalin instillation"},{"annotation":"Effect","text":"fatal outcome"},{"annotation":"Treatment","text":"intravesical formalin instillation"},{"annotation":"Treatment.Drug","text":"formaldehyde"},{"annotation":"Treatment.Disorder","text":"renal tuberculosis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"16101941_3","context":"Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused"},{"annotation":"Treatment","text":"anti-emetic drug"},{"annotation":"Treatment.Drug","text":"anti-emetic drug"},{"annotation":"Treatment.Combination.Trigger","text":"but"},{"annotation":"Treatment.Combination.Drug","text":"clemastine fumarate"},{"annotation":"Treatment.Combination.Drug","text":"clemastine fumarate"},{"annotation":"Treatment.Combination.Trigger","text":"is suggested by"},{"annotation":"Treatment.Combination.Drug","text":"clemastine fumarate"},{"annotation":"Treatment.Combination.Drug","text":"clemastine fumarate"},{"annotation":"Effect","text":"anaphylactic reaction"},{"annotation":"Treatment","text":"clemastine fumarate"},{"annotation":"Treatment.Drug","text":"clemastine fumarate"},{"annotation":"Treatment.Combination.Trigger","text":"anaphylactic reaction"},{"annotation":"Treatment.Combination.Drug","text":"clemastine fumarate"},{"annotation":"Treatment.Combination.Drug","text":"clemastine fumarate"},{"annotation":"Subject","text":"both reactions"},{"annotation":"Subject.Disorder","text":"anaphylactic reaction"}]}]}
{"id":"16357738_2","context":"Reversible posterior leukoencephalopy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"leukoencephalopy"},{"annotation":"Treatment","text":"cyclosporine"},{"annotation":"Treatment.Disorder","text":"systemic lupus erythematosus with thrombocytopenia"},{"annotation":"Treatment.Drug","text":"cyclosporine"},{"annotation":"Subject","text":"systemic lupus erythematosus with thrombocytopenia"},{"annotation":"Subject.Disorder","text":"systemic lupus erythematosus with thrombocytopenia"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"reversible"},{"annotation":"Treatment","text":"cyclosporine"},{"annotation":"Treatment.Disorder","text":"systemic lupus erythematosus with thrombocytopenia"},{"annotation":"Treatment.Drug","text":"cyclosporine"},{"annotation":"Treatment.Drug","text":"cyclosporine"}]}]}
{"id":"20925534_14","context":"Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"prophylactic use of a PPI"},{"annotation":"Effect","text":"reduced rate of upper gastrointestinal bleeding"},{"annotation":"Treatment","text":"aspirin and clopidogrel"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"clopidogrel"},{"annotation":"Treatment.Drug","text":"PPI"},{"annotation":"Treatment.Disorder","text":"upper gastrointestinal bleeding"},{"annotation":"Treatment.Drug","text":"PPI"}]}]}
{"id":"11295724_3","context":"Clofazimine enteropathy in a pediatric bone marrow transplant recipient.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"enteropathy"},{"annotation":"Effect","text":"clofazimine enteropathy"},{"annotation":"Treatment","text":"clofazimine"},{"annotation":"Treatment.Disorder","text":"pediatric bone marrow transplant recipient"},{"annotation":"Treatment.Drug","text":"clofazimine"},{"annotation":"Subject","text":"pediatric bone marrow transplant recipient"},{"annotation":"Subject.Disorder","text":"pediatric bone marrow transplant recipient"}]}]}
{"id":"11696132_2","context":"Anisocoria from transdermal scopolamine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"from"},{"annotation":"Treatment","text":"transdermal scopolamine"},{"annotation":"Treatment.Drug","text":"scopolamine"},{"annotation":"Effect","text":"anisocoria"}]}]}
{"id":"12659609_4","context":"His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"resolved"},{"annotation":"Effect","text":"toxicity"},{"annotation":"Treatment","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Dosage","text":"symptoms consistent with"},{"annotation":"Treatment.Frequency","text":"chloroquine toxicity"},{"annotation":"Subject","text":"he"},{"annotation":"Subject.Age","text":"resolved"},{"annotation":"Subject.Disorder","text":"chloroquine toxicity"}]}]}
{"id":"6199475_1","context":"A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"hemianopsia"},{"annotation":"Effect","text":"encephalopathy"},{"annotation":"Effect","text":"partial nondominant parietal lobe syndrome"},{"annotation":"Treatment","text":"cisplatinum, vinblastine, and bleomycin"},{"annotation":"Treatment.Disorder","text":"testicular carcinoma"},{"annotation":"Treatment.Drug","text":"cisplatinum"},{"annotation":"Treatment.Drug","text":"vinblastine"},{"annotation":"Treatment.Drug","text":"bleomycin"}]}]}
{"id":"12410494_2","context":"We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"statin and protease inhibitor"},{"annotation":"Treatment.Drug","text":"statin"},{"annotation":"Treatment.Drug","text":"protease inhibitor"},{"annotation":"Treatment.Drug_interaction","text":"drug-drug interaction"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"statin and protease inhibitor"},{"annotation":"Treatment.Disorder","text":"rhabdomyolysis"},{"annotation":"Treatment.Drug","text":"statin"},{"annotation":"Treatment.Drug","text":"protease inhibitor"},{"annotation":"Treatment.Drug_interaction","text":"drug-drug interaction"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"rhabdomyolysis"},{"annotation":"Subject.Age","text":"a patient"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"statin and protease inhibitor"},{"annotation":"Treatment.Drug","text":"statin"},{"annotation":"Treatment.Drug","text":"protease inhibitor"},{"annotation":"Treatment.Drug_interaction","text":"drug-drug interaction"},{"annotation":"Effect","text":"death"},{"annotation":"Treatment","text":"statin and protease inhibitor"},{"annotation":"Treatment.Disorder","text":"death"},{"annotation":"Treatment.Drug","text":"statin"},{"annotation":"Treatment.Drug","text":"protease inhibitor"},{"annotation":"Treatment.Drug_interaction","text":"drug-drug interaction"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"death"},{"annotation":"Subject.Age","text":"a patient"}]}]}
{"id":"15595320_2","context":"Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"polyclonal B cell lymphoproliferative disorder"},{"annotation":"Treatment","text":"MTX"},{"annotation":"Treatment.Disorder","text":"RA"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Combination","text":"second line agent"},{"annotation":"Treatment.Combination","text":"RA"},{"annotation":"Treatment.Combination","text":"MTX"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.Severity","text":"low"},{"annotation":"Attribute.Negated","text":"not negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"polyclonal B cell lymphoproliferative disorder"},{"annotation":"Treatment","text":"MTX"},{"annotation":"Treatment.Disorder","text":"RA"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Combination","text":"second line agent"},{"annotation":"Treatment.Combination","text":"RA"},{"annotation":"Treatment.Combination","text":"MTX"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.Severity","text":"low"},{"annotation":"Attribute.Negated","text":"not negated"}]}]}
{"id":"18505911_2","context":"To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"warfarin resistance"},{"annotation":"Treatment","text":"azathioprine"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Disorder","text":"warfarin resistance"},{"annotation":"Treatment.Drug","text":"azathioprine"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"azathioprine"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"warfarin resistance"}]}]}
{"id":"16515630_4","context":"Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"complication"},{"annotation":"Effect","text":"pulmonary fibrosis"},{"annotation":"Treatment","text":"paclitaxel therapy"},{"annotation":"Treatment.Disorder","text":"pulmonary fibrosis"},{"annotation":"Treatment.Drug","text":"paclitaxel"},{"annotation":"Treatment.Drug","text":"corticosteroids"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"complication may occur despite treatments with corticosteroids"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"complication"},{"annotation":"Treatment","text":"paclitaxel therapy"},{"annotation":"Treatment.Disorder","text":"pulmonary fibrosis"},{"annotation":"Treatment.Drug","text":"paclitaxel"},{"annotation":"Treatment.Drug","text":"corticosteroids"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"complication may occur despite treatments with corticosteroids"}]}]}
{"id":"2830062_2","context":"Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.","events":[{"type":"Potential_therapeutic_event","annotations":[{"annotation":"Trigger","text":"treated"},{"annotation":"Treatment","text":"2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD)"},{"annotation":"Treatment.Disorder","text":"adrenal carcinoma"},{"annotation":"Treatment.Drug","text":"2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD)"},{"annotation":"Treatment.Adjuvant","text":"adjuvant therapy"},{"annotation":"Treatment.Duration","text":"studied"}]}]}
{"id":"8430717_3","context":"METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"overdose"},{"annotation":"Treatment","text":"cyclovir"},{"annotation":"Treatment.Drug","text":"cyclovir"},{"annotation":"Effect","text":"coma and nonoliguric renal failure"},{"annotation":"Treatment.Drug","text":"cyclovir"},{"annotation":"Treatment.Dosage","text":"overdose"},{"annotation":"Treatment.Frequency","text":"repeated"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"cyclovir overdose"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Age","text":"unknown"},{"annotation":"Subject.Gender","text":"unknown"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Subject.Disorder","text":"cyclovir overdose"},{"annotation":"Treatment","text":"cyclovir overdose"},{"annotation":"Treatment.Drug","text":"cyclovir"},{"annotation":"Treatment.Dosage","text":"overdose"},{"annotation":"Treatment.Frequency","text":"repeated"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"cyclovir overdose"},{"annotation":"Treatment","text":"cyclovir overdose"},{"annotation":"Treatment.Drug","text":"cyclovir"},{"annotation":"Treatment.Dosage","text":"overdose"},{"annotation":"Treatment.Frequency","text":"repeated"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"cyclovir overdose"},{"annotation":"Treatment","text":"cyclovir overdose"},{"annotation":"Treatment.Drug","text":"cyclovir"},{"annotation":"Treatment.Dosage","text":"overdose"},{"annotation":"Treatment.Frequency","text":"repeated"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"cyclovir overdose"},{"annotation":"Treatment","text":"cyclovir overdose"},{"annotation":"Treatment.Drug","text":"cyclovir"},{"annotation":"Treatment.Dosage","text":"overdose"},{"annotation":"Treatment.Frequency","text":"repeated"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"cyclovir overdose"},{"annotation":"Treatment","text":"cyclovir overdose"},{"annotation":"Treatment.Drug","text":"cyclovir"},{"annotation":"Treatment.Dosage","text":""}]}]}
{"id":"354311_1","context":"An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Effect","text":"osteomyelitis"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Subject","text":"an 8-year-old girl"},{"annotation":"Subject.Age","text":"8 years old"},{"annotation":"Subject.Disorder","text":"osteomyelitis"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Duration","text":"7 months"},{"annotation":"Treatment.Duration","text":"7 months"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Drug","text":"BCG"}]}]}
{"id":"1469187_3","context":"Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Effect","text":"toxicity"},{"annotation":"Treatment","text":"cardiac DGTX toxicity (total AV-block)"},{"annotation":"Treatment.Drug","text":"DGTX"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Dosage","text":"FAB"},{"annotation":"Treatment.Drug","text":"DGTX"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"FAB"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"DGTX"},{"annotation":"Treatment.Drug","text":"FAB"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"DGTX"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"FAB"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"DGTX"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"FAB"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"DGTX"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"FAB"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"DGTX"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"FAB"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"DGTX"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"FAB"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"DGTX"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"FAB"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"DGTX"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"FAB"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"DGTX"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"FAB"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"DGTX"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"FAB"},{"annotation":"Treatment.Dosage","text":"insufficient"},{"annotation":"Treatment.Drug","text":"DGTX"},{"annotation":"Treatment.Dosage"}]}]}
{"id":"7369302_1","context":"Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"amblyopia"},{"annotation":"Effect","text":"pupil abnormalities"},{"annotation":"Treatment","text":"quinine"},{"annotation":"Treatment.Drug","text":"quinine"},{"annotation":"Treatment.Disorder","text":"amblyopia"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"visual-evoked potential"},{"annotation":"Effect","text":"abnormalities"},{"annotation":"Treatment","text":"quinine"},{"annotation":"Treatment.Drug","text":"quinine"},{"annotation":"Treatment.Disorder","text":"amblyopia"}]}]}
{"id":"1275625_4","context":"A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"resulted from"},{"annotation":"Effect","text":"severe hypocalcemia"},{"annotation":"Treatment","text":"therapeutic use of magnesium sulfate"},{"annotation":"Treatment.Drug","text":"magnesium sulfate"},{"annotation":"Treatment.Disorder","text":"toxemia of pregnancy"},{"annotation":"Treatment.Disorder","text":"severe hypocalcemia"},{"annotation":"Subject","text":"in which"},{"annotation":"Subject.Disorder","text":"severe hypocalcemia"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.severity","text":"high"},{"annotation":"Attribute.negated","text":"severe hypocalcemia is not negated"},{"annotation":"Attribute.negated","text":"magnesium sulfate is not negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute.severity","text":"severe hypocalcemia is speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"low plasma PTH concentration is not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"plasma PTH concentration is not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"low plasma PTH concentration is not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"plasma PTH concentration is not negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"resulted from"},{"annotation":"Effect","text":"severe hypocalcemia"},{"annotation":"Treatment","text":"therapeutic use of magnesium sulfate"},{"annotation":"Treatment.Drug","text":"magnesium sulfate"},{"annotation":"Treatment.Disorder","text":"toxemia of pregnancy"},{"annotation":"Treatment.Disorder","text":"severe hypocalcemia"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.severity","text":"high"},{"annotation":"Attribute.negated","text":"severe hypocalcemia is not negated"},{"annotation":"Attribute.negated","text":"magnesium sulfate is not negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute.severity","text":"severe hypocalcemia is speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"low plasma PTH concentration is not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"plasma PTH concentration is not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"low plasma PTH concentration is not negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"plasma PTH concentration is not negated"}]}]}
{"id":"8124920_1","context":"Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"concurrent"},{"annotation":"Treatment","text":"low-dose methotrexate therapy during rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"low-dose"},{"annotation":"Effect","text":"megaloblastic anaemia and pneumonitis"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"low-dose"},{"annotation":"Treatment.Duration","text":"during rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"for ADE, the adverse effect does not exist; or for PTE, the therapy is ineffective"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.severity","text":"severe"},{"annotation":"Event_type","text":"Adverse_event"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"concurrent"},{"annotation":"Treatment","text":"low-dose methotrexate therapy during rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"low-dose"},{"annotation":"Effect","text":"megaloblastic anaemia and pneumonitis"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"low-dose"},{"annotation":"Treatment.Duration","text":"during rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"for ADE, the adverse effect does not exist; or for PTE, the therapy is ineffective"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.severity","text":"severe"},{"annotation":"Event_type","text":"Adverse_event"}]}]}
{"id":"15061230_3","context":"Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"risk"},{"annotation":"Effect","text":"osteonecrosis"},{"annotation":"Treatment","text":"dexamethasone"},{"annotation":"Treatment.Drug","text":"antiemetic drug"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug."}]}]}
{"id":"16317298_5","context":"We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"gastrointestinal bleeding"},{"annotation":"Treatment","text":"radiation-recall related to gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Disease","text":"pancreatic cancer"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"},{"annotation":"Treatment.Therapy","text":"radiation-recall"},{"annotation":"Treatment.Therapy","text":"gemcitabine"}]}]}
{"id":"12836099_2","context":"We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"SJS"},{"annotation":"Treatment","text":"oral prednisolone"},{"annotation":"Treatment.Drug","text":"prednisolone"},{"annotation":"Treatment.Duration","text":"6 weeks"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Subject","text":"a 14-year-old male"},{"annotation":"Subject.Disorder","text":"nephrotic syndrome"}]}]}
{"id":"6865827_1","context":"A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"propylthiouracil"},{"annotation":"Treatment.Drug","text":"propylthiouracil"},{"annotation":"Effect","text":"agranulocytosis"},{"annotation":"Treatment.Disorder","text":"thyrotoxicosis"},{"annotation":"Subject","text":"a 45-year-old woman"},{"annotation":"Subject.Age","text":"45"},{"annotation":"Subject.Gender","text":"woman"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"thyrotoxicosis"},{"annotation":"Treatment.Drug","text":"propylthiouracil"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"thyrotoxicosis"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"severity","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"speculated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated","text":"not specified"},{"annotation":"negated"}]}]}
{"id":"3136101_3","context":"We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"cessation of prolonged ACTH therapy"},{"annotation":"Effect","text":"hyperkalemia"},{"annotation":"Treatment","text":"prolonged ACTH therapy"},{"annotation":"Treatment.Disorder","text":"prolonged ACTH therapy"},{"annotation":"Treatment.Side_effect","text":"hyperkalemia"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":""}]}]}
{"id":"6401771_1","context":"Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"complicating"},{"annotation":"Effect","text":"haemolytic-uraemic syndrome"},{"annotation":"Treatment","text":"mitomycin C and 5-fluorouracil therapy for gastric carcinoma"},{"annotation":"Treatment.Disorder","text":"gastric carcinoma"},{"annotation":"Treatment.Drug","text":"mitomycin C"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"mitomycin C and 5-fluorouracil"},{"annotation":"Subject","text":"gastric carcinoma patient"},{"annotation":"Subject.Disorder","text":"gastric carcinoma"}]}]}
{"id":"25842648_6","context":"Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"adverse interaction"},{"annotation":"Treatment","text":"SSRI and fentanyl"},{"annotation":"Treatment.Disorder","text":"serotonin syndrome"},{"annotation":"Treatment.Drug","text":"SSRI"},{"annotation":"Treatment.Drug","text":"fentanyl"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":""}]}]}
{"id":"6794018_1","context":"Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented with hypoglycaemic coma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"cholestasis and cutaneous bullae"},{"annotation":"Treatment","text":"glibenclamide therapy"},{"annotation":"Treatment.Disorder","text":"diabetes"},{"annotation":"Treatment.Drug","text":"glibenclamide"},{"annotation":"Treatment.Drug","text":"hypoglycaemic coma"},{"annotation":"Subject","text":"a 61-year-old diabetic patient"},{"annotation":"Subject.Disorder","text":"diabetes"},{"annotation":"Subject.Age","text":"61 years old"}]}]}
{"id":"22677303_10","context":"In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"warfarin activity"},{"annotation":"Effect","text":"enhanced"},{"annotation":"Treatment","text":"cloxacillin"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Time_elapsed","text":"temporal relationship"},{"annotation":"Treatment.Time_elapsed","text":"cloxacillin administration"},{"annotation":"Treatment.Time_elapsed","text":"INR increase"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Drug","text":"cloxacillin"},{"annotation":"Treatment.Drug","text":"enhanced warfarin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{"annotation":"Treatment.Drug","text":"warfarin activity"},{"annotation":"Treatment.Drug","text":"cloxacillin activity"},{}]}]}
{"id":"7783891_2","context":"Cardiac arrest following use of sumatriptan.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following use of"},{"annotation":"Treatment","text":"sumatriptan"},{"annotation":"Treatment.Drug","text":"sumatriptan"},{"annotation":"Effect","text":"cardiac arrest"},{"annotation":"Treatment.Drug","text":"sumatriptan"}]}]}
{"id":"1422497_4","context":"We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"coincident"},{"annotation":"Effect","text":"encephalopathy"},{"annotation":"Treatment","text":"continuous bladder irrigations with alum"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Dosage","text":"elevated"},{"annotation":"Treatment.Duration","text":"continuous"},{"annotation":"Subject","text":"four cases of encephalopathy"},{"annotation":"Subject.Disorder","text":"encephalopathy"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Dosage","text":"elevated"},{"annotation":"Treatment.Duration","text":"continuous"},{"annotation":"Subject","text":"one patient"},{"annotation":"Subject.Disorder","text":"seizures"},{"annotation":"Treatment","text":"continuous bladder irrigations with alum"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Dosage","text":"elevated"},{"annotation":"Treatment.Duration","text":"continuous"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Dosage","text":"elevated"},{"annotation":"Treatment.Duration","text":"continuous"},{"annotation":"Treatment","text":"continuous bladder irrigations with alum"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Dosage","text":"elevated"},{"annotation":"Treatment.Duration","text":"continuous"},{"annotation":"Treatment","text":"continuous bladder irrigations with alum"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Dosage","text":"elevated"},{"annotation":"Treatment.Duration","text":"continuous"},{"annotation":"Treatment","text":"continuous bladder irrigations with alum"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Dosage","text":"elevated"},{"annotation":"Treatment.Duration","text":"continuous"},{"annotation":"Treatment","text":"continuous bladder irrigations with alum"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Dosage","text":"elevated"},{"annotation":"Treatment.Duration","text":"continuous"},{"annotation":"Treatment","text":"continuous bladder irrigations with alum"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Dosage","text":"elevated"},{"annotation":"Treatment.Duration","text":"continuous"},{"annotation":"Treatment","text":"continuous bladder irrigations with alum"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Dosage","text":"elevated"},{"annotation":"Treatment.Duration","text":"continuous"},{"annotation":"Treatment","text":"continuous bladder irrigations with alum"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Dosage","text":"elevated"},{"annotation":"Treatment.Duration","text":"continuous"},{}]}]}
{"id":"6671350_5","context":"Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"cephalosporin or moxalactam antibiotics"},{"annotation":"Treatment.Disorder","text":"azotemic patients"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Drug","text":"moxalactam"},{"annotation":"Treatment.Drug","text":"azotemic"},{"annotation":"Treatment.Drug","text":"patients"},{"annotation":"Treatment.Drug","text":"coagulopathy"},{"annotation":"Subject","text":"nine azotemic patients"},{"annotation":"Subject.Disorder","text":"azotemic"}]}]}
{"id":"8442800_10","context":"This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"suggests"},{"annotation":"Effect","text":"poor prognosis may not be warranted"},{"annotation":"Treatment","text":"exposure to disulfiram in the first trimester"},{"annotation":"Treatment.Disorder","text":"fetal exposure to disulfiram"},{"annotation":"Treatment.Drug","text":"disulfiram"},{"annotation":"Treatment.Dosage","text":"first trimester"},{"annotation":"Treatment.Frequency","text":"exposure"},{"annotation":"Treatment.Route","text":"fetal exposure"},{"annotation":"Treatment.Time_elapsed","text":"first trimester"},{"annotation":"Treatment.Duration","text":"first trimester"},{"annotation":"Treatment.Disorder","text":"fetal exposure to disulfiram"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"suggests"},{"annotation":"Effect","text":"poor prognosis may not be warranted"},{"annotation":"Treatment","text":"exposure to disulfiram in the first trimester"},{"annotation":"Treatment.Disorder","text":"fetal exposure to disulfiram"},{"annotation":"Treatment.Drug","text":"disulfiram"},{"annotation":"Treatment.Dosage","text":"first trimester"},{"annotation":"Treatment.Frequency","text":"exposure"},{"annotation":"Treatment.Route","text":"fetal exposure"},{"annotation":"Treatment.Time_elapsed","text":"first trimester"},{"annotation":"Treatment.Duration","text":"first trimester"},{"annotation":"Treatment.Disorder","text":"fetal exposure to disulfiram"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"10592946_6","context":"We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"injured"},{"annotation":"Treatment","text":"caffeine toxicity"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Disorder","text":"muscle cells"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Treatment","text":"potassium depletion"},{"annotation":"Treatment.Disorder","text":"hyponatremia"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Disorder","text":"muscle cells"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"potassium"},{"annotation":"Treatment.Drug","text":"caffeine"},{}]}]}
{"id":"18837734_2","context":"The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"eruption"},{"annotation":"Treatment","text":"erlotinib"},{"annotation":"Treatment.Drug","text":"erlotinib"},{"annotation":"Treatment.Disorder","text":"rosaceiform eruption"},{"annotation":"Treatment.Drug","text":"Demodex folliculorum mites"},{"annotation":"Treatment.Drug","text":"Demodex folliculorum mites"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Subject","text":"an 81-year-old-man"},{"annotation":"Subject.Age","text":"81"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"1 patient"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"rosaceiform eruption"},{"annotation":"Treatment","text":"erlotinib"},{"annotation":"Treatment.Drug","text":"erlotinib"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"rosaceiform eruption"}]}]}
{"id":"11295724_1","context":"An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"clofazimine treatment for graft-versus-host disease"},{"annotation":"Treatment.Disorder","text":"graft-versus-host disease"},{"annotation":"Treatment.Drug","text":"clofazimine"},{"annotation":"Effect","text":"enteropathy"},{"annotation":"Treatment.Duration","text":"2 years"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"graft-versus-host disease"},{"annotation":"Treatment.Drug","text":"clofazimine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"graft-versus-host disease"},{"annotation":"Treatment.Drug","text":"clofazimine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"graft-versus-host disease"},{"annotation":"Treatment.Drug","text":"clofazimine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"graft-versus-host disease"},{"annotation":"Treatment.Drug","text":"clofazimine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"graft-versus-host disease"},{"annotation":"Treatment.Drug","text":"clofazimine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"graft-versus-host disease"},{"annotation":"Treatment.Drug","text":"clofazimine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.F"}]}]}
{"id":"3174043_3","context":"The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"experience"},{"annotation":"Effect","text":"visual symptoms"},{"annotation":"Treatment","text":"oral niacin"},{"annotation":"Treatment.Drug","text":"niacin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes"}]}]}
{"id":"14697943_2","context":"Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"syndrome"},{"annotation":"Effect","text":"reflex sympathetic dystrophy syndrome"},{"annotation":"Treatment","text":"immunosuppression with tacrolimus"},{"annotation":"Treatment.Disorder","text":"renal transplanted patients"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Drug","text":"immunosuppression"},{"annotation":"Subject","text":"renal transplanted patients"},{"annotation":"Subject.Disorder","text":"renal transplanted patients"}]}]}
{"id":"17387702_2","context":"We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presented"},{"annotation":"Effect","text":"renal failure"},{"annotation":"Treatment","text":"high-dose methotrexate (HDMTX)"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"mediastinal T-cell lymphoma"},{"annotation":"Treatment.Drug","text":"high-dose methotrexate (HDMTX)"},{"annotation":"Treatment.Dosage","text":"second cycle"},{"annotation":"Treatment.Frequency","text":"second cycle"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"renal failure"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"high-dose"},{"annotation":"Treatment.Frequency","text":"second cycle"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"renal failure"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"high-dose"},{"annotation":"Treatment.Frequency","text":"second cycle"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"renal failure"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"high-dose"},{"annotation":"Treatment.Frequency","text":"second cycle"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"renal failure"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"high-dose"},{"annotation":"Treatment.Frequency","text":"second cycle"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"renal failure"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"high-dose"},{"annotation":"Treatment.Frequency","text":"second cycle"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"renal failure"},{"annotation":"Treat"}]}]}
{"id":"11236070_3","context":"We report three cases of patients who developed leukopenia during olanzapine treatment.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"leukopenia"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"olanzapine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"leukopenia"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"olanzapine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"leukopenia"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"olanzapine"}]}]}
{"id":"17921794_2","context":"Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"onset"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"combined use of simvastatin and colchicine"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"colchicine"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Age","text":"rapid"},{"annotation":"Subject.Gender","text":"onset"},{"annotation":"Subject.Population","text":"a patient"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment","text":"combined use of simvastatin and colchicine"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"colchicine"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"rapid onset of muscle weakness (rhabdomyolysis)"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"combined use of simvastatin and colchicine"},{"annotation":"Treatment.Disorder","text":"rapid onset of muscle weakness (rhabdomyolysis)"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"4063627_1","context":"A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"selective IgA deficiency"},{"annotation":"Treatment","text":"fenclofenac"},{"annotation":"Treatment.Disorder","text":"seropositive rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"fenclofenac"},{"annotation":"Treatment.Disorder","text":"selective IgA deficiency"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"fenclofenac"},{"annotation":"Treatment.Disorder","text":"seropositive rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"fenclofenac"},{"annotation":"Treatment.Disorder","text":"selective IgA deficiency"}]}]}
{"id":"15461766_1","context":"In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"harlequin color change"},{"annotation":"Effect","text":"demonstrated"},{"annotation":"Treatment","text":"systemic prostaglandin E1"},{"annotation":"Treatment.Drug","text":"prostaglandin E1"},{"annotation":"Treatment.Dosage","text":"related to the dose of systemic prostaglandin E1"},{"annotation":"Treatment.Dosage","text":"course"},{"annotation":"Treatment.Drug","text":"systemic prostaglandin E1"},{"annotation":"Treatment.Dosage","text":"related"},{"annotation":"Subject","text":"two newborns with congenital heart anomalies"},{"annotation":"Subject.Disorder","text":"congenital heart anomalies"}]}]}
{"id":"8442800_4","context":"Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"described"},{"annotation":"Treatment","text":"disulfiram"},{"annotation":"Treatment.Drug","text":"disulfiram"},{"annotation":"Treatment.Drug","text":"in the first trimester of their pregnancies"},{"annotation":"Treatment.Drug","text":"during pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"},{"annotation":"Treatment.Drug","text":"in the first trimester of pregnancy"}]}]}
{"id":"15895899_3","context":"These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"triggered"},{"annotation":"Effect","text":"autoimmune agranulocytosis"},{"annotation":"Treatment","text":"infliximab"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"autoimmune agranulocytosis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.attribute","text":"production of granulocyte and neutrophil autoantibodies"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"resultant"},{"annotation":"Effect","text":"autoimmune agranulocytosis"},{"annotation":"Treatment","text":"infliximab"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"autoimmune agranulocytosis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.attribute","text":"production of granulocyte and neutrophil autoantibodies"}]}]}
{"id":"12477460_4","context":"Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"arising"},{"annotation":"Treatment","text":"tamoxifen therapy for breast cancer"},{"annotation":"Treatment.Drug","text":"tamoxifen"},{"annotation":"Disorder","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Disorder","text":"endometriotic cyst"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment.Disorder","text":"breast cancer"},{"annotation":"Subject","text":"a postmenopausal woman"},{"annotation":"Subject.Age","text":"postmenopausal"},{"annotation":"Subject.Disorder","text":"endometriotic cyst"},{"annotation":"Treatment","text":"tamoxifen therapy for breast cancer"},{"annotation":"Treatment.Drug","text":"tamoxifen"},{"annotation":"Treatment.Drug","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment.Disorder","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment.Disorder","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{"annotation":"Treatment","text":"breast cancer"},{"annotation":"Treatment","text":"ovarian endometrioid adenocarcinoma"},{}]}]}
{"id":"17123120_1","context":"Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"HUS (hemolytic uremic syndrome)"},{"annotation":"Treatment","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Drug","text":"HUS"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"acute renal failure"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"HUS (hemolytic uremic syndrome)"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"acute renal failure"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"HUS (hemolytic uremic syndrome)"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"HUS (hemolytic uremic syndrome)"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"HUS (hemolytic uremic syndrome)"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route"}]}]}
{"id":"17090724_2","context":"OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"overdose of amphotericin B"},{"annotation":"Effect","text":"cardiac arrhythmia"},{"annotation":"Treatment","text":"amphotericin B"},{"annotation":"Treatment.Drug","text":"amphotericin B"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"3542612_2","context":"We report a case of a bullous lichenoid eruption due to the intake of captopril.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intake"},{"annotation":"Effect","text":"bullous lichenoid eruption"},{"annotation":"Treatment","text":"captopril"},{"annotation":"Treatment.Drug","text":"captopril"}]}]}
{"id":"2830062_4","context":"The hypoadrenalism was overcome by increasing steroid replacement therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"overcome"},{"annotation":"Effect","text":"hypoadrenalism"},{"annotation":"Treatment","text":"steroid replacement therapy"},{"annotation":"Treatment.Drug","text":"steroid"},{"annotation":"Treatment.Duration","text":"increasing steroid replacement therapy"}]}]}
{"id":"16265343_1","context":"DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"cardiomyopathy"},{"annotation":"Treatment","text":"interferon alpha-2b"},{"annotation":"Treatment.Drug","text":"interferon alpha-2b"},{"annotation":"Treatment.Disorder","text":"cardiomyopathy"},{"annotation":"Treatment.Drug","text":"interferon alpha-2b"}]},{"type":"Adverse_event","annotations":[{"annotation":"Negated","text":"not"}]},{"type":"Adverse_event","annotations":[{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"},{"annotation":"Negated","text":"not"}]}]}
{"id":"8610807_1","context":"Choroidal hemorrhage associated with systemic tissue plasminogen activator.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"systemic tissue plasminogen activator"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Effect","text":"choroidal hemorrhage"},{"annotation":"Treatment.Disorder","text":"systemic tissue plasminogen activator"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"the occurrence of the (side) effect"}]}]}
{"id":"17665812_1","context":"Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"eosinophilia"},{"annotation":"Treatment","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Disorder","text":"chronic schizophrenia"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Disorder","text":"suicidal tendencies"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Switch","text":"switch"},{"annotation":"Treatment.Disorder","text":"chronic schizophrenia"},{"annotation":"Treatment.Disorder","text":"suicidal tendencies"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Switch","text":"switch"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Switch","text":"switch"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Switch","text":"switch"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Switch","text":"switch"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Switch","text":"switch"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Switch","text":"switch"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Switch","text":"switch"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Switch","text":"switch"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Switch","text":"switch"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Switch","text":"switch"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Switch","text":"switch"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Switch","text":"switch"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Switch"}]}]}
{"id":"18675768_1","context":"Adverse effects of propafenone after long-term therapy with the addition of citalopram.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"after long-term therapy with the addition of citalopram"},{"annotation":"Effect","text":"adverse effects"},{"annotation":"Treatment","text":"propafenone"},{"annotation":"Treatment.Drug","text":"propafenone"},{"annotation":"Treatment.Duration","text":"long-term therapy"},{"annotation":"Treatment.Combination.Trigger","text":"with the addition of citalopram"},{"annotation":"Treatment.Combination.Drug","text":"citalopram"},{"annotation":"Treatment.Combination.Drug","text":"propafenone"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"none"}]}]}
{"id":"7081289_2","context":"The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"exposure"},{"annotation":"Effect","text":"hepatic dysfunction"},{"annotation":"Treatment","text":"cimetidine"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":"Treatment.Effect","text":"hepatic dysfunction"},{"annotation":"Subject","text":"an adult"},{"annotation":"Subject.Disorder","text":"none"},{"annotation":"Treatment","text":"exposure"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":"Treatment.Effect","text":"hepatic dysfunction"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":"Treatment.Effect","text":"hepatic dysfunction"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":"Treatment.Effect","text":"hepatic dysfunction"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":"Treatment.Effect","text":"hepatic dysfunction"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":"Treatment.Effect","text":"hepatic dysfunction"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":"Treatment.Effect","text":"hepatic dysfunction"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":"Treatment.Effect","text":"hepatic dysfunction"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":"Treatment.Effect","text":"hepatic dysfunction"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":"Treatment.Effect","text":"hepatic dysfunction"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":"Treatment.Effect","text":"hepatic dysfunction"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":"Treatment.Effect","text":"hepatic dysfunction"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Effect","text":"macrophage migration impairment"},{"annotation":""}]}]}
{"id":"16609346_3","context":"We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"within 2 weeks of starting treatment with a statin drug"},{"annotation":"Treatment","text":"statin drug"},{"annotation":"Treatment.Drug","text":"statin"},{"annotation":"Effect","text":"myasthenia gravis"},{"annotation":"Treatment.Drug","text":"statin"},{"annotation":"Treatment.Disorder","text":"myasthenia gravis"},{"annotation":"Subject","text":"4 patients"},{"annotation":"Subject.Population","text":"4 patients"},{"annotation":"Subject.Disorder","text":"myasthenia gravis"}]}]}
{"id":"15927910_1","context":"After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"decreased"},{"annotation":"Effect","text":"heart rate"},{"annotation":"Treatment","text":"pentamidine"},{"annotation":"Treatment.Drug","text":"pentamidine"},{"annotation":"Treatment.Dosage","text":"third dose"},{"annotation":"Treatment.Frequency","text":"every third dose"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"after third dose"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"unknown"}]}]}
{"id":"7056119_2","context":"A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"atypical ventricular tachycardia (AVT, torsade de pointes)"},{"annotation":"Treatment","text":"amiodarone"},{"annotation":"Treatment","text":"disopyramide"},{"annotation":"Treatment","text":"quinidine"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"quinidine"},{"annotation":"Treatment.Combination.Trigger","text":"alone"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"disopyramide"},{"annotation":"Treatment.Combination.Drug","text":"quinidine"}]}]}
{"id":"18505911_9","context":"Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"resistance"},{"annotation":"Treatment","text":"warfarin"},{"annotation":"Treatment.Drug","text":"azathioprine"},{"annotation":"Treatment.Disorder","text":"warfarin resistance"},{"annotation":"Treatment.Probability","text":"probable"},{"annotation":"Treatment.Probability","text":"possible"},{"annotation":"Attribute","text":"Naranjo probability scale"},{"annotation":"Attribute","text":"Drug Interaction Probability Scale"}]}]}
{"id":"8442800_2","context":"Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"deter"},{"annotation":"Effect","text":"alcohol consumption"},{"annotation":"Treatment","text":"disulfiram"},{"annotation":"Treatment.Disorder","text":"alcohol abuse"},{"annotation":"Treatment.Drug","text":"disulfiram"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"15507779_2","context":"Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"used"},{"annotation":"Treatment","text":"nevirapine"},{"annotation":"Treatment.Disorder","text":"HIV-infected patients"},{"annotation":"Treatment.Disorder","text":"post-exposure prophylaxis"},{"annotation":"Treatment.Drug","text":"non-nucleoside reverse transcriptase inhibitor"}]}]}
{"id":"8391300_2","context":"Vasospasm associated with ergotamine is a well-known phenomenon.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"vasospasm"},{"annotation":"Treatment","text":"ergotamine"},{"annotation":"Treatment.Drug","text":"ergotamine"},{"annotation":"Treatment.Disorder","text":"vasospasm"},{"annotation":"Treatment.Drug","text":"ergotamine"}]}]}
{"id":"3359700_1","context":"After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"severe loss of glomerular filtration rate and effective renal plasma flow"},{"annotation":"Treatment","text":"six-week course of low-dose cyclosporine A"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Disorder","text":"severe loss of glomerular filtration rate and effective renal plasma flow"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Drug","text":"cyclosporine A"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Duration","text":"six weeks"},{"annotation":"Treatment.Drug","text":"cy"}]}]}
{"id":"21630612_4","context":"We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"simvastatin"},{"annotation":"Treatment.Disorder","text":"chronic statin therapy"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"chronic statin therapy"}]}]}
{"id":"23115227_3","context":"In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"recurrent"},{"annotation":"Treatment","text":"TRIO study regimen"},{"annotation":"Treatment.Disorder","text":"HIV infection"},{"annotation":"Treatment.Disorder","text":"recurrent deep vein thrombosis"},{"annotation":"Treatment.Drug","text":"TRIO study regimen"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Drug","text":"TRIO study regimen"},{"annotation":"Treatment.Disorder","text":"HIV infection"},{"annotation":"Treatment.Disorder","text":"recurrent deep vein thrombosis"},{"annotation":"Subject","text":"a 50-year-old transgender female"},{"annotation":"Subject.Age","text":"50 years old"},{"annotation":"Subject.Gender","text":"transgender female"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"HIV infection"},{"annotation":"Treatment","text":"TRIO study regimen"},{"annotation":"Treatment.Drug","text":"TRIO study regimen"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"HIV infection"},{"annotation":"Treatment.Disorder","text":"recurrent deep vein thrombosis"},{"annotation":"Effect","text":"not specified"}]}]}
{"id":"10870095_7","context":"In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"zafirlukast"},{"annotation":"Treatment.Disorder","text":"impaired clearance of S-warfarin"},{"annotation":"Treatment.Drug","text":"S-warfarin"},{"annotation":"Treatment.Drug","text":"anti-thrombotic effects"},{"annotation":"Treatment.Disorder","text":"clinically relevant plasma concentrations"},{"annotation":"Treatment.Drug","text":"zafirlukast"},{"annotation":"Treatment.Drug","text":"CYP2C9"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug"}]}]}
{"id":"18755414_6","context":"Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intratumoral hemorrhage"},{"annotation":"Effect","text":"hemorrhage"},{"annotation":"Treatment","text":"aspirin"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Disorder","text":"meningioma"},{"annotation":"Treatment.Drug","text":"asymptomatic"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":""}]}]}
{"id":"18751717_3","context":"CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"fundus picture"},{"annotation":"Treatment","text":"IVTA injection"},{"annotation":"Treatment.Disorder","text":"ASPPC"},{"annotation":"Treatment.Drug","text":"IVTA"},{"annotation":"Treatment.Route","text":"IV"},{"annotation":"Treatment.Time_elapsed","text":"after IVTA injection"},{"annotation":"Treatment.Duration","text":"not applicable"},{"annotation":"Effect","text":"ASPPC"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute.Attribute","text":"typical"},{"annotation":"Attribute.Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute","text":"typical"},{"annotation":"Attribute"}]}]}
{"id":"9149614_3","context":"The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.","events":[{"type":"Potential_therapeutic_event","annotations":[{"annotation":"Trigger","text":"proarrhythmic action"},{"annotation":"Treatment","text":"amiodarone"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Disorder","text":"proarrhythmia"},{"annotation":"Treatment.Drug","text":"intravenous magnesium sulfate therapy"},{"annotation":"Treatment.Drug","text":"magnesium sulfate"},{"annotation":"Treatment.Effect","text":"proarrhythmia"},{"annotation":"Treatment.Disorder","text":"proarrhythmia"},{"annotation":"Treatment.Drug","text":"intravenous magnesium sulfate therapy"},{"annotation":"Treatment.Drug","text":"magnesium sulfate"}]}]}
{"id":"21658326_4","context":"We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"severe, atypical ASRs"},{"annotation":"Treatment","text":"NMSC treatment with imiquimod"},{"annotation":"Treatment.Drug","text":"imiquimod"},{"annotation":"Treatment.Disorder","text":"psoriasis"},{"annotation":"Treatment.Combination","text":"NMSC treatment with imiquimod and infliximab administration for psoriasis"},{"annotation":"Treatment.Combination.Trigger","text":"in the context of"},{"annotation":"Treatment.Combination.Drug","text":"infiximab administration for psoriasis"},{"annotation":"Treatment.Combination.Drug","text":"imiquimod"},{"annotation":"Treatment.Combination.Drug","text":"infliximab"},{"annotation":"Attribute","text":"non-fortuitous association"},{"annotation":"Attribute.speculated","text":"speculated"},{"annotation":"Attribute.severity","text":"severe"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"severe, atypical ASRs"},{"annotation":"Treatment","text":"NMSC treatment with imiquimod"},{"annotation":"Treatment.Drug","text":"imiquimod"},{"annotation":"Treatment.Disorder","text":"psoriasis"},{"annotation":"Treatment.Combination","text":"NMSC treatment with imiquimab administration for psoriasis"},{"annotation":"Treatment.Combination.Trigger","text":"in the context of"},{"annotation":"Treatment.Combination.Drug","text":"infiximab administration for psoriasis"},{"annotation":"Treatment.Combination.Drug","text":"imiquimab"},{"annotation":"Treatment.Combination.Drug","text":"infliximab"},{"annotation":"Attribute","text":"non-fortuitous association"},{"annotation":"Attribute.speculated","text":"speculated"},{"annotation":"Attribute.severity","text":"severe"}]}]}
{"id":"3964363_1","context":"A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"overdose"},{"annotation":"Treatment","text":"propranolol"},{"annotation":"Treatment.Drug","text":"propranolol"},{"annotation":"Effect","text":"esophageal spasm"},{"annotation":"Treatment","text":"orogastric lavage tube"},{"annotation":"Treatment.Drug","text":"glucagon"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{}]}]}
{"id":"4063627_2","context":"Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"selective IgA deficiency"},{"annotation":"Treatment","text":"fenclofenac"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"fenclofenac"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"}]},{"type":"Attribute Attributes","annotations":[{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"}]}]}
{"id":"10082597_2","context":"Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"naproxen"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Effect","text":"dimorphic clinical pattern"},{"annotation":"Treatment.Drug","text":"PCT-like presentation"},{"annotation":"Treatment.Drug","text":"erythropoietic protoporphyria"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Subject","text":"pediatric population"},{"annotation":"Subject.Population","text":"pediatric"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Treatment.Disorder","text":"dimorphic clinical pattern"},{"annotation":"Treatment.Disorder","text":"PCT-like presentation"},{"annotation":"Treatment.Disorder","text":"erythropoietic protoporphyria"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Treatment.Disorder","text":"dimorphic clinical pattern"},{"annotation":"Treatment.Disorder","text":"PCT-like presentation"},{"annotation":"Treatment.Disorder","text":"erythropoietic protoporphyria"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Treatment.Disorder","text":"dimorphic clinical pattern"},{"annotation":"Treatment.Disorder","text":"PCT-like presentation"},{"annotation":"Treatment.Disorder","text":"erythropoietic protoporphyria"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Treatment.Disorder","text":"dimorphic clinical pattern"},{"annotation":"Treatment.Disorder","text":"PCT-like presentation"},{"annotation":"Treatment.Disorder","text":"erythropoietic protoporphyria"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Treatment.Disorder","text":"dimorphic clinical pattern"},{"annotation":"Treatment.Disorder","text":"PCT-like presentation"},{"annotation":"Treatment.Disorder","text":"erythropoietic protoporphyria"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Treatment.Disorder","text":"dimorphic clinical pattern"},{"annotation":"Treatment.Disorder","text":"PCT-like presentation"},{"annotation":"Treatment.Disorder","text":"erythropoietic protoporphyria"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Treatment.Disorder","text":"dimorphic clinical pattern"},{"annotation":"Treatment.Disorder","text":"PCT-like presentation"},{"annotation":"Treatment.Disorder","text":"erythropoietic protoporphyria"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Treatment.Disorder","text":"dimorphic clinical pattern"},{"annotation":"Treatment.Disorder","text":"PCT-like presentation"},{"annotation":"Treatment.Disorder","text":"ery"}]}]}
{"id":"10870095_2","context":"Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"used to treat"},{"annotation":"Treatment","text":"zafirlukast"},{"annotation":"Treatment.Disorder","text":"allergic and exercise-induced asthma"},{"annotation":"Treatment.Drug","text":"zafirlukast"}]}]}
{"id":"18364401_3","context":"Rapidly developing hyperglycemia during treatment with olanzapine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developing"},{"annotation":"Effect","text":"hyperglycemia"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"rapidly developing"},{"annotation":"Treatment.Duration","text":"during treatment"},{"annotation":"Treatment.Disorder","text":"hyperglycemia"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"rapidly developing"},{"annotation":"Treatment.Duration","text":"during treatment"}]}]}
{"id":"10579985_1","context":"The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"diagnosed"},{"annotation":"Effect","text":"B-cell non-Hodgkin's lymphoma"},{"annotation":"Treatment","text":"infliximab"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Subject","text":"a 61-year-old man"},{"annotation":"Subject.Disorder","text":"fistulizing CD"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Treatment.Drug","text":"inflix"}]}]}
{"id":"7761316_2","context":"Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"Fanconi syndrome"},{"annotation":"Treatment","text":"ifosfamide"},{"annotation":"Treatment.Disorder","text":"pediatric oncology"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"}]}]}
{"id":"10225085_3","context":"We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"methemoglobinemia"},{"annotation":"Treatment","text":"axillary block with bupivacaine and additional injection of lidocaine in the operative field"},{"annotation":"Treatment.Drug","text":"bupivacaine"},{"annotation":"Treatment.Drug","text":"lidocaine"},{"annotation":"Treatment.Disorder","text":"chronic renal failure and ischemic heart disease"},{"annotation":"Treatment.Drug","text":"bupivacaine"},{"annotation":"Treatment.Drug","text":"lidocaine"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"chronic renal failure and ischemic heart disease"}]}]}
{"id":"19884751_1","context":"Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"type 5 Bartter-like syndrome with severe hypocalcemia"},{"annotation":"Treatment","text":"amikacin"},{"annotation":"Treatment.Drug","text":"amikacin"},{"annotation":"Treatment.Disorder","text":"type 5 Bartter-like syndrome"},{"annotation":"Treatment.Disorder","text":"severe hypocalcemia"}]}]}
{"id":"15368548_2","context":"L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"pancreatitis"},{"annotation":"Treatment","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Disorder","text":"severe necrotizing pancreatitis"},{"annotation":"Treatment.Drug","text":"percutaneous drainage"},{"annotation":"Treatment.Drug","text":"pancreatitis"},{"annotation":"Treatment.Effect","text":"successfully treated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"response"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment.Disorder","text":"severe necrotizing pancreatitis"},{"annotation":"Treatment.Drug","text":"percutaneous drainage"}]}]}
{"id":"4014301_4","context":"This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"cardiac failure"},{"annotation":"Treatment","text":"insulin"},{"annotation":"Treatment.Drug","text":"insulin"},{"annotation":"Treatment.Disorder","text":"without underlying heart disease"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"without underlying heart disease"}]}]}
{"id":"11352235_4","context":"OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"leflunomide"},{"annotation":"Disorder","text":"rheumatoid arthritis"},{"annotation":"Effect","text":"weight loss"},{"annotation":"Treatment.Frequency","text":"frequency"},{"annotation":"Treatment.Duration","text":"duration"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment","text":"leflunomide"}]}]}
{"id":"11804071_1","context":"INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"leading cause of drug eruptions in the above group of drugs"},{"annotation":"Treatment","text":"INH"},{"annotation":"Treatment.Drug","text":"INH"},{"annotation":"Treatment.Drug","text":"above group of drugs"},{"annotation":"Treatment.Disorder","text":"drug eruptions"},{"annotation":"Treatment.Drug","text":"INH"},{"annotation":"Treatment.Drug","text":"above group of drugs"},{"annotation":"Treatment.Disorder","text":"drug eruptions"}]}]}
{"id":"19266307_1","context":"Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"perforation"},{"annotation":"Treatment","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug","text":"instillation"},{"annotation":"Treatment.Drug","text":"epirubicin"},{"annotation":"Treatment.Drug"}]}]}
{"id":"11724089_5","context":"Ofloxacin: a probable cause of toxic epidermal necrolysis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"toxic epidermal necrolysis"},{"annotation":"Treatment","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"spec"}]}]}
{"id":"16515630_1","context":"Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused by"},{"annotation":"Treatment","text":"paclitaxel toxicity"},{"annotation":"Treatment.Drug","text":"paclitaxel"},{"annotation":"Effect","text":"fatal lung fibrosis"},{"annotation":"Treatment.Drug","text":"carboplatin"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment.Disorder","text":"ovarian cancer"},{"annotation":"Treatment.Drug","text":"paclitaxel"},{"annotation":"Treatment","text":"carboplatin"},{"annotation":"Subject","text":"a 62-year-old woman"},{"annotation":"Treatment.Combination","text":"six cycles"},{"annotation":"Treatment.Combination","text":"paclitaxel and carboplatin"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment.Combination","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced ovarian cancer"},{"annotation":"Treatment","text":"combination chemotherapy"},{"annotation":"Treatment","text":"advanced o"}]}]}
{"id":"9704170_1","context":"A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"clozapine"},{"annotation":"Treatment.Disorder","text":"drug-resistant schizophrenia"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Duration","text":"nineteenth week"},{"annotation":"Subject","text":"a 21-year-old patient"},{"annotation":"Subject.Age","text":"21 years"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"effect"},{"annotation":"Effect","text":"response"},{"annotation":"Treatment","text":"clozapine"},{"annotation":"Treatment.Disorder","text":"drug-resistant schizophrenia"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Duration","text":"nineteenth week"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"for ADE, the adverse effect does not exist"}]}]}
{"id":"20349794_1","context":"Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"SIADH"},{"annotation":"Treatment","text":"cisplatin"},{"annotation":"Treatment.Disorder","text":"neuroendocrine tumor of the cervix"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"cisplatin-induced SIADH"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"SIADH"},{"annotation":"Treatment","text":"cisplatin"},{"annotation":"Treatment.Disorder","text":"neuroendocrine tumor of the cervix"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"cisplatin-induced SIADH"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.speculated","text":"not specified"}]}]}
{"id":"6610943_1","context":"Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"myoglobinuria and acute renal failure"},{"annotation":"Treatment","text":"intravenous vasopressin infusion"},{"annotation":"Treatment.Disorder","text":"myoglobinuria and acute renal failure"},{"annotation":"Treatment.Drug","text":"vasopressin"},{"annotation":"Treatment.Dosage","text":"intravenous"},{"annotation":"Treatment.Frequency","text":"infusion"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Time_elapsed","text":"after administration"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"myoglobinuria and acute renal failure"},{"annotation":"Treatment.Drug","text":"vasopressin"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"myoglobinuria and acute renal failure"},{"annotation":"Treatment","text":"intravenous vasopressin infusion"},{"annotation":"Treatment.Disorder","text":"myoglobinuria and acute renal failure"},{"annotation":"Treatment.Drug","text":"vasopressin"},{"annotation":"Treatment.Dosage","text":"intravenous"},{"annotation":"Treatment.Frequency","text":"infusion"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Time_elapsed","text":"after administration"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"myoglobinuria and acute renal failure"},{"annotation":"Treatment.Drug","text":"vasopressin"}]}]}
{"id":"18371508_2","context":"We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"ARDS"},{"annotation":"Treatment","text":"pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C"},{"annotation":"Treatment.Disorder","text":"hepatitis C"},{"annotation":"Treatment.Drug","text":"pegylated interferon alpha-2a (pegIFNalpha-2a)"},{"annotation":"Treatment.Drug","text":"ribavirin"},{"annotation":"Treatment.Disorder","text":"fulminant ARDS"},{"annotation":"Treatment.Disorder","text":"sepsis"},{"annotation":"Treatment.Disorder","text":"multiorgan failure"},{"annotation":"Treatment.Drug","text":"pegylated interferon alpha-2a (pegIFNalpha-2a)"},{"annotation":"Treatment.Drug","text":"ribavirin"}]}]}
{"id":"681921_1","context":"Catatonia associated with disulfiram therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"catatonia"},{"annotation":"Treatment","text":"disulfiram therapy"},{"annotation":"Treatment.Drug","text":"disulfiram"},{"annotation":"Treatment.Disorder","text":"catatonia"}]}]}
{"id":"21658326_5","context":"To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"suggested"},{"annotation":"Treatment","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"imiquimod"},{"annotation":"Treatment.Disorder","text":"exaggerated ASRs"},{"annotation":"Treatment.Disorder","text":"developing susceptibility"},{"annotation":"negated","text":"has ever been suggested"}]}]}
{"id":"10492493_2","context":"Losartan-induced angioedema.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"angioedema"},{"annotation":"Treatment","text":"losartan"},{"annotation":"Treatment.Drug","text":"losartan"},{"annotation":"Treatment.Disorder","text":"angioedema"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"angioedema"},{"annotation":"Treatment","text":"losartan"},{"annotation":"Treatment.Drug","text":"losartan"},{"annotation":"Treatment.Disorder","text":"angioedema"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"angioedema"},{"annotation":"Treatment","text":"losartan"},{"annotation":"Treatment.Drug","text":"losartan"},{"annotation":"Treatment.Disorder","text":"angioedema"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"angioedema"},{"annotation":"Treatment","text":"losartan"},{"annotation":"Treatment.Drug","text":"losartan"},{"annotation":"Treatment.Disorder","text":"angioedema"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"angioedema"},{"annotation":"Treatment","text":"losartan"},{"annotation":"Treatment.Drug","text":"losartan"},{"annotation":"Treatment.Disorder","text":"angioedema"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"angioedema"},{"annotation":"Treatment","text":"losartan"},{"annotation":"Treatment.Drug","text":"losartan"},{"annotation":"Treatment.Disorder","text":"angioedema"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"angioedema"},{"annotation":"Treatment","text":"losartan"},{"annotation":"Treatment.Drug","text":"losartan"},{"annotation":"Treatment.Disorder","text":"angioedema"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"angioedema"},{"annotation":"Treatment","text":"losartan"},{"annotation":"Treatment.Drug","text":"losartan"},{"annotation":"Treatment.Disorder","text":"angioedema"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"angioedema"},{"annotation":"Treatment","text":"losartan"},{"annotation":"Treatment.Drug","text":"losartan"},{"annotation":"Treatment.Disorder","text":"angioedema"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event"}]}
{"id":"8850251_1","context":"However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"photosensitivity reaction"},{"annotation":"Treatment","text":"mequitazine or other phenothiazine-derivative drugs"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"phenothiazine-derivative drugs"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"photosensitivity reaction"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"photosensitivity reaction"},{"annotation":"Treatment","text":"mequitazine or other phenothiazine-derivative drugs"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"phenothiazine-derivative drugs"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"photosensitivity reaction"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"photosensitivity reaction"},{"annotation":"Treatment","text":"mequitazine or other phenothiazine-derivative drugs"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"phenothiazine-derivative drugs"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"photosensitivity reaction"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"photosensitivity reaction"},{"annotation":"Treatment","text":"mequitazine or other phenothiazine-derivative drugs"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"phenothiazine-derivative drugs"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"photosensitivity reaction"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"photosensitivity reaction"},{"annotation":"Treatment","text":"mequitazine or other phenothiazine-derivative drugs"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"phenothiazine-derivative drugs"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"photosensitivity reaction"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"photosensitivity reaction"},{"annotation":"Treatment","text":"mequitazine or other phenothiazine-derivative drugs"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"phenothiazine-derivative drugs"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"photosensitivity reaction"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"photosensitivity reaction"},{}]}]}
{"id":"18262450_10","context":"Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"oxycodone-gabapentin"},{"annotation":"Treatment.Disorder","text":"pain relief"},{"annotation":"Treatment.Drug","text":"oxycodone"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Treatment.Combination.Trigger","text":"also"},{"annotation":"Treatment.Combination.Drug","text":"oxycodone"},{"annotation":"Treatment.Combination.Drug","text":"gabapentin"},{"annotation":"Treatment.Combination.Drug","text":"oxycodone"},{"annotation":"Treatment.Combination.Drug","text":"gabapentin"},{"annotation":"Treatment.Duration","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"pain relief"},{"annotation":"Treatment.Effect","text":"significantly improved"},{"annotation":"Treatment.Effect","text":"p"}]}]}
{"id":"11147747_1","context":"In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"incontinence"},{"annotation":"Treatment","text":"lithium carbonate and beta-blockers"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"lithium carbonate"},{"annotation":"Treatment.Drug","text":"beta-blockers"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"incontinence"},{"annotation":"Treatment","text":"lithium carbonate and beta-blockers"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"lithium carbonate"},{"annotation":"Treatment.Drug","text":"beta-blockers"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"incontinence"},{"annotation":"Treatment","text":"none"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"15286697_2","context":"Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"bis-chloronitrosourea (BCNU) therapy"},{"annotation":"Treatment.Drug","text":"bis-chloronitrosourea (BCNU)"},{"annotation":"Treatment.Disorder","text":"pulmonary fibrosis"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Drug","text":"therapy"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"severe complication"},{"annotation":"Effect","text":"pulmonary fibrosis"},{"annotation":"Treatment","text":"bis-chloronitrosourea (BCNU) therapy"},{"annotation":"Treatment.Drug","text":"bis-chloronitrosourea (BCNU)"},{"annotation":"Treatment.Drug","text":"therapy"}]}]}
{"id":"15286697_5","context":"We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"administered"},{"annotation":"Effect","text":"pulmonary fibrosis"},{"annotation":"Treatment","text":"high-dose BCNU (600 mg/m2)"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"600 mg/m2"},{"annotation":"Treatment.Duration","text":"81 days"},{"annotation":"Treatment.Disorder","text":"diffuse large B-cell lymphoma"},{"annotation":"Subject","text":"a 26-year-old female"},{"annotation":"Subject.Disorder","text":"diffuse large B-cell lymphoma"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"600 mg/m2"},{"annotation":"Treatment.Duration","text":"81 days"},{"annotation":"Treatment.Disorder","text":"diffuse large B-cell lymphoma"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"600 mg/m2"},{"annotation":"Treatment.Duration","text":"81 days"},{"annotation":"Treatment.Disorder","text":"diffuse large B-cell lymphoma"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"600 mg/m2"},{"annotation":"Treatment.Duration","text":"81 days"},{"annotation":"Treatment.Disorder","text":"diffuse large B-cell lymphoma"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"600 mg/m2"},{"annotation":"Treatment.Duration","text":"81 days"},{"annotation":"Treatment.Disorder","text":"diffuse large B-cell lymphoma"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"600 mg/m2"},{"annotation":"Treatment.Duration","text":"81 days"},{"annotation":"Treatment.Disorder","text":"diffuse large B-cell lymphoma"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"600 mg/m2"},{"annotation":"Treatment.Duration","text":"81 days"},{"annotation":"Treatment.Disorder","text":"diffuse large B-cell lymphoma"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"600 mg/m2"},{"annotation":"Treatment.Duration","text":"81 days"},{"annotation":"Treatment.Disorder","text":"diffuse large B-cell lymphoma"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"600 mg/m2"},{"annotation":"Treatment.Duration","text":"81 days"},{"annotation":"Treatment.Disorder","text":"diffuse large"}]}]}
{"id":"6865827_2","context":"The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"occurrence"},{"annotation":"Effect","text":"agranulocytosis"},{"annotation":"Treatment","text":"methimazole"},{"annotation":"Treatment.Disorder","text":"agranulocytosis"},{"annotation":"Treatment.Drug","text":"methimazole"},{"annotation":"Treatment.Drug","text":"propylthiouracil"},{"annotation":"Treatment.Duration","text":"10 weeks"},{"annotation":"Treatment.Combination.Trigger","text":"but"},{"annotation":"Treatment.Combination.Drug","text":"methimazole"},{"annotation":"Treatment.Combination.Drug","text":"propylthiouracil"},{"annotation":"Subject","text":"the patient"},{"annotation":"Subject.Disorder","text":"agranulocytosis"},{"annotation":"Treatment.Disorder","text":"agranulocytosis"}]}]}
{"id":"18675768_6","context":"Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"starting"},{"annotation":"Effect","text":"chest tightness and dizziness"},{"annotation":"Treatment","text":"citalopram"},{"annotation":"Treatment.Drug","text":"citalopram"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"episodes"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"three months"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"starting"},{"annotation":"Effect","text":"chest tightness and dizziness"},{"annotation":"Treatment","text":"citalopram"},{"annotation":"Treatment.Drug","text":"citalopram"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"episodes"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"three months"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"}]}]}
{"id":"3171334_2","context":"Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Effect","text":"visual loss"},{"annotation":"Treatment","text":"vincristine"},{"annotation":"Treatment.Disorder","text":"severe visual loss"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"very likely"}]},{"type":"Adverse_event","annotations":[{"annotation":"Effect","text":"visual loss"},{"annotation":"Treatment","text":"vincristine"},{"annotation":"Treatment.Disorder","text":"severe visual loss"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"very likely"}]}]}
{"id":"18042092_3","context":"This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"glatiramer acetate"},{"annotation":"Treatment.Drug","text":"glatiramer acetate"},{"annotation":"Treatment.Route","text":"subcutaneous"},{"annotation":"Treatment.Route","text":"intramuscular"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Disorder","text":"ECM"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"}]}]}
{"id":"15522120_4","context":"SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"SSRI-drugs"},{"annotation":"Effect","text":"pruritus and other dermal side effects"},{"annotation":"Treatment","text":"SSRI-drugs"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"SSRI-drugs"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.Attribute","text":"none"},{"annotation":"Attribute.Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{"annotation":"Attribute","text":"none"},{}]}]}
{"id":"22552763_1","context":"Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid"},{"annotation":"Treatment","text":"dabigatran etexilate"},{"annotation":"Treatment.Disorder","text":"total hip and total knee arthroplasty"},{"annotation":"Treatment.Drug","text":"dabigatran etexilate"},{"annotation":"Treatment.Drug","text":"non-steroidal anti-inflammatory drugs or acetylsalicylic acid"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"dabigatran etexilate"},{"annotation":"Treatment.Combination.Drug","text":"non-steroidal anti-inflammatory drugs or acetylsalicylic acid"},{"annotation":"Effect","text":"no increased risk of bleeding"},{"annotation":"Treatment.Duration","text":"total hip and total knee arthroplasty"}]}]}
{"id":"16393774_7","context":"Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"onset"},{"annotation":"Treatment","text":"IFN-beta"},{"annotation":"Treatment.Disorder","text":"inflammatory arthritis"},{"annotation":"Treatment.Disorder","text":"MS"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"onset"},{"annotation":"Effect","text":"inflammatory arthritis"},{"annotation":"Treatment","text":"IFN-beta"},{"annotation":"Treatment.Disorder","text":"MS"}]}]}
{"id":"7056119_5","context":"Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"arrhythmia"},{"annotation":"Treatment","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"isoproterenol"},{"annotation":"Treatment.Time_elapsed","text":"24 hours"},{"annotation":"Treatment.Time_elapsed","text":"two years"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Disorder","text":"arrhythmia"},{"annotation":"Treatment.Drug","text":"isoproterenol"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{"annotation":"Treatment.Drug","text":"disopyramide"},{}]}]}
{"id":"9865241_3","context":"The patient was initially treated with hydration and furosemide but developed congestive heart failure.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"congestive heart failure"},{"annotation":"Treatment","text":"hydration and furosemide"},{"annotation":"Treatment.Drug","text":"furosemide"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"congestive heart failure"},{"annotation":"Subject","text":"the patient"},{"annotation":"Subject.Age","text":"unknown"},{"annotation":"Subject.Gender","text":"unknown"},{"annotation":"Subject.Population","text":"unknown"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Treatment.Disorder","text":"hydration and furosemide"}]}]}
{"id":"21729965_4","context":"We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"tubal pregnancies"},{"annotation":"Treatment","text":"antiretroviral therapy"},{"annotation":"Treatment.Disorder","text":"HIV-positive"},{"annotation":"Treatment.Drug","text":"Implanon"},{"annotation":"Subject","text":"an HIV-positive woman"},{"annotation":"Subject.Age","text":"HIV-positive"},{"annotation":"Subject.Gender","text":"woman"},{"annotation":"Subject.Population","text":"an HIV-positive woman"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"HIV-positive"},{"annotation":"Treatment.Drug","text":"Implanon"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"tubal pregnancies"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"tubal pregnancies"},{"annotation":"Treatment","text":"antiretroviral therapy"},{"annotation":"Treatment.Disorder","text":"HIV-positive"},{"annotation":"Treatment.Drug","text":"Implanon"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"15595320_4","context":"We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"hypothesis"},{"annotation":"Treatment","text":"COX-2 inhibitor"},{"annotation":"Treatment.Drug","text":"COX-2 inhibitor"},{"annotation":"Treatment.Disorder","text":"MTX-induced hematopoietic toxicity and immunosuppression"},{"annotation":"Treatment.Disorder","text":"EBV-associated lymphoproliferative disease"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"high"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"MTX"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Disorder","text":"hematopoietic toxicity and immunosuppression"},{"annotation":"Treatment.Disorder","text":"MTX-induced hematopoietic toxicity and immunosuppression"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"COX-2 inhibitor"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"high"}]}]}
{"id":"19212144_2","context":"Temsirolimus-induced glomerulopathy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"glomerulopathy"},{"annotation":"Treatment","text":"temsirolimus"},{"annotation":"Treatment.Drug","text":"temsirolimus"}]}]}
{"id":"11485141_4","context":"OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"bullous dermatosis"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Disorder","text":"linear immunoglobulin (Ig) A bullous dermatosis (LABD)"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treat"}]}]}
{"id":"7949255_2","context":"This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"hemiparesis"},{"annotation":"Effect","text":"dysarthria"},{"annotation":"Effect","text":"altered consciousness"},{"annotation":"Treatment","text":"second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue"},{"annotation":"Treatment.Drug","text":"HD-MTX"},{"annotation":"Treatment.Drug","text":"leucovorin"},{"annotation":"Treatment.Duration","text":"5 days"},{"annotation":"Treatment.Dosage","text":"8 gm/m2 by 6 h continuous infusion"},{"annotation":"Subject","text":"this patient"},{"annotation":"Subject.Disorder","text":"none"}]}]}
{"id":"16685007_5","context":"Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"dependent"},{"annotation":"Treatment","text":"oral steroid"},{"annotation":"Treatment.Drug","text":"prednisone"},{"annotation":"Treatment.Disorder","text":"asthma"},{"annotation":"Subject","text":"adult and adolescent patients"},{"annotation":"Subject.Age","text":"> or = 12 years old"},{"annotation":"Subject.Population","text":"n = 141"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"asthma"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"dependent"},{"annotation":"Treatment","text":"oral steroid"},{"annotation":"Treatment.Drug","text":"prednisone"},{"annotation":"Treatment.Disorder","text":"asthma"},{"annotation":"Subject","text":"adult and adolescent patients"},{"annotation":"Subject.Age","text":"> or = 12 years old"},{"annotation":"Subject.Population","text":"n = 141"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"asthma"}]}]}
{"id":"17090724_1","context":"DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"produce significant cardiac toxicity"},{"annotation":"Effect","text":"ventricular arrhythmias and bradycardia"},{"annotation":"Treatment","text":"Amphotericin B deoxycholate"},{"annotation":"Treatment.Drug","text":"Amphotericin B deoxycholate"},{"annotation":"Treatment.Dosage","text":"overdoses"},{"annotation":"Treatment.Disorder","text":"preexisting cardiac disease"},{"annotation":"Treatment.Disorder","text":"conventional dosages and infusion rates"}]}]}
{"id":"11510798_2","context":"Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates"},{"annotation":"Treatment","text":"oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma"},{"annotation":"Treatment.Drug","text":"oxaliplatinum"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Disorder","text":"unresectable rectum carcinoma"},{"annotation":"Subject","text":"a male 60 yrs of age"},{"annotation":"Subject.Age","text":"60 yrs"},{"annotation":"Subject.Gender","text":"male"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Drug","text":"oxaliplatinum"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Disorder","text":"unresectable rectum carcinoma"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"unresectable rectum carcinoma"},{"annotation":"negated","text":"not specified"},{"annotation":"severity","text":"not specified"},{"annotation":"event_type","text":"Adverse_event"},{"annotation":"event_type","text":"Potential_therapeutic_effect"}]}]}
{"id":"18580694_2","context":"Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"tardive seizures"},{"annotation":"Treatment","text":"piperacillin and cefotiam"},{"annotation":"Treatment.Drug","text":"piperacillin"},{"annotation":"Treatment.Drug","text":"cefotiam"},{"annotation":"Treatment.Disorder","text":"tardive seizures"},{"annotation":"Treatment.Drug","text":"piperacillin"},{"annotation":"Treatment.Drug","text":"cefotiam"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"piperacillin"},{"annotation":"Treatment.Combination.Drug","text":"cefotiam"},{"annotation":"Treatment.Combination.Drug","text":"piperacillin"},{"annotation":"Treatment.Combination.Drug","text":"cefotiam"},{"annotation":"Treatment.Disorder","text":"tardive seizures"},{"annotation":"Treatment.Drug","text":"piperacillin"},{"annotation":"Treatment.Drug","text":"cefotiam"},{"annotation":"Treatment.Disorder","text":"tardive seizures"},{"annotation":"Treatment.Drug","text":"piperacillin"},{"annotation":"Treatment.Drug","text":"cefotiam"},{"annotation":"Treatment.Disorder","text":"tardive seizures"},{"annotation":"Treatment.Drug","text":"piperacillin"},{"annotation":"Treatment.Drug","text":"cefotiam"},{"annotation":"Treatment.Disorder","text":"tardive seizures"},{"annotation":"Treatment.Drug","text":"piperacillin"},{"annotation":"Treatment.Drug","text":"cefotiam"},{"annotation":"Treatment.Disorder","text":"tardive seizures"},{"annotation":"Treatment.Drug","text":"piperacillin"},{"annotation":"Treatment.Drug","text":"cefotiam"},{"annotation":"Treatment.Disorder","text":"tardive seizures"},{"annotation":"Treatment.Drug","text":"piperacillin"},{"annotation":"Treatment.Drug","text":"cefotiam"},{"annotation":"Treatment.Disorder","text":"tardive seizures"},{"annotation":"Treatment.Drug","text":"piperacillin"},{"annotation":"Treatment.Drug","text":"cefotiam"},{"annotation":"Treatment.Disorder","text":"tardive seizures"},{"annotation":"Treatment.Drug","text":"piperacillin"},{"annotation":"Treatment.Drug","text":"cefotiam"},{"annotation":"Treatment.Disorder","text":"tardive seizures"},{"annotation":"Treatment.Drug","text":"piperacillin"},{"annotation":"Treatment.Drug","text":"cefotiam"},{"annotation":"Treatment.Disorder","text":"tardive seizures"},{"annotation":"Treatment.Drug","text":"piperacillin"},{"annotation":"Treatment.Drug","text":"cefotiam"},{"annotation":"Treatment.Disorder","text":"tardive seizures"},{"annotation":"Treatment.Drug","text":"piperacillin"},{"annotation":"Treatment.Drug","text":"cefot"}]}]}
{"id":"6873616_1","context":"A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"jaundice"},{"annotation":"Treatment","text":"thiabendazole therapy"},{"annotation":"Treatment.Drug","text":"thiabendazole"},{"annotation":"Treatment.Disease","text":"jaundice"},{"annotation":"Treatment.Disease","text":"sicca complex"},{"annotation":"Subject","text":"a 55-yr-old man"},{"annotation":"Subject.Age","text":"55-yr-old"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"none"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"prolonged"},{"annotation":"Treatment","text":"thiabendazole therapy"},{"annotation":"Treatment.Disorder","text":"jaundice"},{"annotation":"Treatment.Drug","text":"thiabendazole"},{"annotation":"Treatment.Disease","text":"sicca complex"},{"annotation":"Treatment.Disease","text":"jaundice"},{"annotation":"Treatment.Disease","text":"sicca complex"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"jaundice"},{"annotation":"Treatment.Drug","text":"thiabendazole"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes"}]}]}
{"id":"17182354_3","context":"Methylphenidate (Ritalin)-associated cataract and glaucoma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Effect","text":"cataract and glaucoma"},{"annotation":"Treatment","text":"methylphenidate (Ritalin)"},{"annotation":"Treatment.Drug","text":"methylphenidate"},{"annotation":"Treatment.Drug","text":"Ritalin"},{"annotation":"Treatment.Drug","text":"cataract"},{"annotation":"Treatment.Drug","text":"glaucoma"},{"annotation":"Treatment.Drug","text":"Ritalin"}]}]}
{"id":"12410494_1","context":"Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"implicated"},{"annotation":"Effect","text":"rhabdomyolysis and death"},{"annotation":"Treatment","text":"simvastatin-nelfinavir interaction"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Drug","text":"nelfinavir"},{"annotation":"Treatment.Disorder","text":"rhabdomyolysis and death"},{"annotation":"Treatment.Interaction","text":"simvastatin-nelfinavir interaction"},{"annotation":"Treatment.Interaction.Trigger","text":"and"},{"annotation":"Treatment.Interaction.Drug","text":"simvastatin"},{"annotation":"Treatment.Interaction.Drug","text":"nelfinavir"},{"annotation":"Treatment.Interaction.Disorder","text":"rhabdomyolysis and death"},{"annotation":"Treatment.Interaction.Disorder","text":"rhabdomyolysis and death"}]}]}
{"id":"17955169_2","context":"Uncontrolled headache induced by oxcarbazepine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"oxcarbazepine"},{"annotation":"Treatment.Drug","text":"oxcarbazepine"},{"annotation":"Effect","text":"headache"},{"annotation":"Treatment.Drug","text":"oxcarbazepine"},{"annotation":"Treatment.Dosage","text":"uncontrolled"},{"annotation":"Treatment.Frequency","text":"induced"},{"annotation":"Treatment.Route","text":"oxcarbazepine"},{"annotation":"Treatment.Time_elapsed","text":"oxcarbazepine"},{"annotation":"Treatment.Duration","text":"oxcarbazepine"},{"annotation":"Treatment.Disorder","text":"oxcarbazepine"},{"annotation":"Treatment.Drug","text":"oxcarbazepine"},{"annotation":"Treatment.Dosage","text":"uncontrolled"},{"annotation":"Treatment.Frequency","text":"induced"},{"annotation":"Treatment.Route","text":"oxcarbazepine"},{"annotation":"Treatment.Time_elapsed","text":"oxcarbazepine"},{"annotation":"Treatment.Duration","text":"oxcarbazepine"},{"annotation":"Treatment.Disorder","text":"oxcarbazepine"},{"annotation":"Treatment.Drug","text":"oxcarbazepine"},{"annotation":"Treatment.Dosage","text":"uncontrolled"},{"annotation":"Treatment.Frequency","text":"induced"},{"annotation":"Treatment.Route","text":"oxcarbazepine"},{"annotation":"Treatment.Time_elapsed","text":"oxcarbazepine"},{"annotation":"Treatment.Duration","text":"oxcarbazepine"},{"annotation":"Treatment.Disorder","text":"oxcarbazepine"},{"annotation":"Treatment.Drug","text":"oxcarbazepine"},{"annotation":"Treatment.Dosage","text":"uncontrolled"},{"annotation":"Treatment.Frequency","text":"induced"},{"annotation":"Treatment.Route","text":"oxcarbazepine"},{"annotation":"Treatment.Time_elapsed","text":"oxcarbazepine"},{"annotation":"Treatment.Duration","text":"oxcarbazepine"},{"annotation":"Treatment.Disorder","text":"oxcarbazepine"},{"annotation":"Treatment.Drug","text":"oxcarbazepine"},{"annotation":"Treatment.Dosage","text":"uncontrolled"},{"annotation":"Treatment.Frequency","text":"induced"},{"annotation":"Treatment.Route","text":"oxcarbazepine"},{"annotation":"Treatment.Time_elapsed","text":"oxcarbazepine"},{"annotation":"Treatment.Duration","text":"oxcarbazepine"},{"annotation":"Treatment.Disorder","text":"oxcarbazepine"},{"annotation":"Treatment.Drug","text":"oxcarbazepine"},{"annotation":"Treatment.Dosage","text":"uncontrolled"},{"annotation":"Treatment.Frequency","text":"induced"},{"annotation":"Treatment.Route","text":"oxcarbazepine"},{"annotation":"Treatment.Time_elapsed","text":"oxcarbazepine"},{"annotation":"Treatment.Duration","text":"oxcarbazepine"},{"annotation":"Treatment.Disorder","text":"oxcarbazepine"},{"annotation":"Treatment.Drug","text":"ox"}]}]}
{"id":"14697943_3","context":"We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"in kidney transplant recipients treated with tacrolimus"},{"annotation":"Treatment","text":"tacrolimus"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Effect","text":"RSDS"},{"annotation":"Treatment.Disorder","text":"kidney transplant recipients"},{"annotation":"Treatment.Drug","text":"RSDS"},{"annotation":"Treatment.Drug","text":"tacrolimus"}]}]}
{"id":"7949255_3","context":"Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"high-dose methotrexate chemotherapy"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"osteogenic sarcoma"},{"annotation":"Effect","text":"neurological disturbances"},{"annotation":"Treatment.Disorder","text":"osteogenic sarcoma"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"high-dose"},{"annotation":"Treatment.Duration","text":"chemotherapy"},{"annotation":"Treatment.Side_effect","text":"transient neurological disturbances"},{"annotation":"Treatment.Treatment_type","text":"chemotherapy"},{"annotation":"Treatment.Treatment_type","text":"osteogenic sarcoma"},{"annotation":"Treatment.Treatment_type","text":"methotrexate"},{"annotation":"Treatment.Treatment_type","text":"transient neurological disturbances"},{"annotation":"Treatment.Treatment_type","text":"methotrexate"},{"annotation":"Treatment.Treatment_type","text":"transient neurological disturbances"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"high-dose methotrexate chemotherapy"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"osteogenic sarcoma"},{"annotation":"Effect","text":"neurological disturbances"},{"annotation":"Treatment.Disorder","text":"osteogenic sarcoma"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"high-dose"},{"annotation":"Treatment.Duration","text":"chemotherapy"},{"annotation":"Treatment.Side_effect","text":"transient neurological disturbances"},{"annotation":"Treatment.Treatment_type","text":"chemotherapy"},{"annotation":"Treatment.Treatment_type","text":"osteogenic sarcoma"},{"annotation":"Treatment.Treatment_type","text":"methotrexate"},{"annotation":"Treatment.Treatment_type","text":"transient neurological disturbances"},{"annotation":"Treatment.Treatment_type","text":"methotrexate"},{"annotation":"Treatment.Treatment_type","text":"transient neurological disturbances"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"high-dose methotrexate chemotherapy"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"osteogenic sarcoma"},{"annotation":"Effect","text":"neurological disturbances"},{"annotation":"Treatment.Disorder","text":"osteogenic sarcoma"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"high-dose"},{"annotation":"Treatment.Duration","text":"chemother"}]}]}
{"id":"22372628_1","context":"Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"adjunctive lacosamide"},{"annotation":"Treatment.Disorder","text":"uncontrolled partial-onset seizures"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Outcome","text":"efficacy and safety"},{"annotation":"Treatment.Drug","text":"lacosamide"},{"annotation":"Treatment.Dosage","text":"adjunctive"},{"annotation":"Treatment.Duration","text":"extension trial"},{"annotation":"Treatment.Trial_type","text":"Phase III open-label extension trial"},{"annotation":"Subject","text":"patients with uncontrolled partial-onset seizures"},{"annotation":"Subject.Population","text":"patients"},{"annotation":"Subject.Disorder","text":"uncontrolled partial-onset seizures"}]}]}
{"id":"8404753_2","context":"A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"development of tics"},{"annotation":"Effect","text":"tics"},{"annotation":"Treatment","text":"carbamazepine (CBZ) therapy"},{"annotation":"Treatment.Disorder","text":"movement disorders"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"CBZ"},{"annotation":"Treatment.Association","text":"in adults and children"},{"annotation":"Treatment.Association","text":"with underlying Tourette's syndrome or other movement disorders"}]}]}
{"id":"21515865_4","context":"On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.","events":[{"type":"Potential_therapeutic_event","annotations":[{"annotation":"Trigger","text":"On the day before this visit"},{"annotation":"Treatment","text":"BCG bladder instillations"},{"annotation":"Treatment.Drug","text":"BCG"},{"annotation":"Treatment.Duration","text":"six serial weekly"},{"annotation":"Treatment.Disorder","text":"bladder cancer"},{"annotation":"Treatment.Drug","text":"BCG"}]}]}
{"id":"7056119_3","context":"Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"quinidine"},{"annotation":"Treatment.Drug","text":"quinidine"},{"annotation":"Treatment.Dosage","text":"1.2 g/day"},{"annotation":"Treatment.Duration","text":"17 years"},{"annotation":"Treatment.Disorder","text":"closed mitral valvotomy"},{"annotation":"Treatment.Drug","text":"quinidine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Effect","text":"unknown"}]}]}
{"id":"3720318_2","context":"We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"pulmonary edema"},{"annotation":"Treatment","text":"intrabiliary infusion of monooctanoin"},{"annotation":"Treatment.Drug","text":"monooctanoin"},{"annotation":"Treatment.Dosage","text":""},{"annotation":"Treatment.Dosage","text":""},{"annotation":"Treatment.Frequency","text":""},{"annotation":"Treatment.Route","text":""},{"annotation":"Treatment.Time_elapsed","text":""},{"annotation":"Treatment.Duration","text":""},{"annotation":"Treatment.Disorder","text":"noncardiogenic pulmonary edema"},{"annotation":"Treatment.Drug","text":"monooctanoin"},{"annotation":"Treatment.Dosage","text":""},{"annotation":"Treatment.Dosage","text":""},{"annotation":"Treatment.Frequency","text":""},{"annotation":"Treatment.Route","text":""},{"annotation":"Treatment.Time_elapsed","text":""},{"annotation":"Treatment.Duration","text":""},{"annotation":"Treatment.Disorder","text":"noncardiogenic pulmonary edema"},{"annotation":"Treatment.Drug","text":"monooctanoin"},{"annotation":"Treatment.Dosage","text":""},{"annotation":"Treatment.Dosage","text":""},{"annotation":"Treatment.Frequency","text":""},{"annotation":"Treatment.Route","text":""},{"annotation":"Treatment.Time_elapsed","text":""},{"annotation":"Treatment.Duration","text":""},{"annotation":"Treatment.Disorder","text":"noncardiogenic pulmonary edema"},{"annotation":"Treatment.Drug","text":"monooctanoin"},{"annotation":"Treatment.Dosage","text":""},{"annotation":"Treatment.Dosage","text":""},{"annotation":"Treatment.Frequency","text":""},{"annotation":"Treatment.Route","text":""},{"annotation":"Treatment.Time_elapsed","text":""},{"annotation":"Treatment.Duration","text":""},{"annotation":"Treatment.Disorder","text":"noncardiogenic pulmonary edema"},{"annotation":"Treatment.Drug","text":"monooctanoin"},{"annotation":"Treatment.Dosage","text":""},{"annotation":"Treatment.Dosage","text":""},{"annotation":"Treatment.Frequency","text":""},{"annotation":"Treatment.Route","text":""},{"annotation":"Treatment.Time_elapsed","text":""},{"annotation":"Treatment.Duration","text":""},{"annotation":"Treatment.Disorder","text":"noncardiogenic pulmonary edema"},{"annotation":"Treatment.Drug","text":"monooctanoin"},{"annotation":"Treatment.Dosage","text":""},{"annotation":"Treatment.Dosage","text":""},{"annotation":"Treatment.Frequency","text":""},{"annotation":"Treatment.Route","text":""},{"annotation":"Treatment.Time_elapsed","text":""},{"annotation":"Treatment.Duration","text":""},{"annotation":"Treatment.Disorder","text":"noncardiogenic pulmonary edema"},{"annotation":"Treatment.Drug","text":"monooctanoin"},{"annotation":"Treatment.Dosage"}]}]}
{"id":"12166705_2","context":"Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurrence"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{"annotation":"Treatment","text":"mitomycin-C"},{"annotation":"Treatment.Drug","text":"mitomycin-C"},{"annotation":"Treatment.Dosage","text":"dose related"},{"annotation":"Treatment.Dosage","text":"serious"},{"annotation":"Treatment.Frequency","text":"occurrence"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"malignancies"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurrence"},{"annotation":"Effect","text":"hemolytic uremic syndrome"},{"annotation":"Treatment","text":"mitomycin-C"},{"annotation":"Treatment.Drug","text":"mitomycin-C"},{"annotation":"Treatment.Dosage","text":"dose related"},{"annotation":"Treatment.Dosage","text":"serious"},{"annotation":"Treatment.Frequency","text":"occurrence"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"malignancies"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"}]}]}
{"id":"1414247_2","context":"Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"coma"},{"annotation":"Treatment","text":"valproic acid"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Treatment.Disorder","text":"coma"},{"annotation":"Subject","text":"an adult patient"},{"annotation":"Subject.Disorder","text":"coma"},{"annotation":"Subject.Age","text":"adult"},{"annotation":"Subject.Gender","text":"unknown"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Subject.Population","text":"1 patient"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"coma"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute.severity","text":"unknown"},{"annotation":"Attribute.attribute","text":"unknown"}]}]}
{"id":"7355327_4","context":"Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"bronchospasm"},{"annotation":"Treatment","text":"propranolol"},{"annotation":"Treatment.Disorder","text":"hypertension"},{"annotation":"Treatment.Drug","text":"propranolol"},{"annotation":"Subject","text":"three patients"},{"annotation":"Subject.Disorder","text":"none"},{"annotation":"Subject.Disorder","text":"no history of asthma or allergy"}]}]}
{"id":"10573314_2","context":"To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"prolonged"},{"annotation":"Effect","text":"INRs"},{"annotation":"Treatment","text":"warfarin therapy"},{"annotation":"Treatment.Drug","text":"tolterodine"},{"annotation":"Treatment.Combination.Trigger","text":"addition of"},{"annotation":"Treatment.Combination.Drug","text":"tolterodine"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Subject","text":"two cases"},{"annotation":"Subject.Disorder","text":"warfarin therapy"}]}]}
{"id":"8850251_2","context":"In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"observed"},{"annotation":"Effect","text":"erythema"},{"annotation":"Treatment","text":"photopatch test"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"UV exposure"},{"annotation":"Treatment.Drug","text":"chlorpromazine"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"mequitazine"},{"annotation":"Treatment.Combination.Drug","text":"UV exposure"},{"annotation":"Subject","text":"an immediate erythematous macule"},{"annotation":"Subject.Disorder","text":"mequitazine photoallergy"}]}]}
{"id":"879939_1","context":"Acetazolamide-accelerated anticonvulsant osteomalacia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"accelerated"},{"annotation":"Effect","text":"osteomalacia"},{"annotation":"Treatment","text":"acetazolamide"},{"annotation":"Treatment.Disorder","text":"anticonvulsant osteomalacia"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Treatment.Drug","text":"anticonvulsant"}]}]}
{"id":"129501_2","context":"Both patients suddenly became hypotensive after injection of chymopapain into a disk.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"injection of chymopapain"},{"annotation":"Effect","text":"hypotension"},{"annotation":"Treatment","text":"injection of chymopapain"},{"annotation":"Treatment.Drug","text":"chymopapain"},{"annotation":"Treatment.Dosage","text":"dose of chymopapain"},{"annotation":"Treatment.Route","text":"injection"},{"annotation":"Treatment.Time_elapsed","text":"after injection of chymopapain"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"unknown"}]}]}
{"id":"17182354_2","context":"Large dose of methylphenidate may cause cataract and glaucoma.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"cause"},{"annotation":"Effect","text":"cataract and glaucoma"},{"annotation":"Treatment","text":"large dose of methylphenidate"},{"annotation":"Treatment.Drug","text":"methylphenidate"},{"annotation":"Treatment.Dosage","text":"large dose"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"cataract and glaucoma"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not present any textual cues showing cataract and glaucoma do not exist"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"cause"},{"annotation":"Effect","text":"cataract and glaucoma"},{"annotation":"Treatment","text":"large dose of methylphenidate"},{"annotation":"Treatment.Drug","text":"methylphenidate"},{"annotation":"Treatment.Dosage","text":"large dose"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"cataract and glaucoma"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not present any textual cues showing cataract and glaucoma do not exist"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"cause"},{"annotation":"Effect","text":"cataract and glaucoma"},{"annotation":"Treatment","text":"large dose of methylphenidate"},{"annotation":"Treatment.Drug","text":"methylphenidate"},{"annotation":"Treatment.Dosage","text":"large dose"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"cataract and glaucoma"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not present any textual cues showing cataract and glaucoma do not exist"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"cause"},{"annotation":"Effect","text":"cataract and glaucoma"},{"annotation":"Treatment","text":"large dose of methylphenidate"},{"annotation":"Treatment.Drug","text":"methylphenidate"},{"annotation":"Treatment.Dosage","text":"large dose"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"cataract and glaucoma"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not present any textual cues showing cataract and glaucoma do not exist"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"cause"},{"annotation":"Effect","text":"cataract and glaucoma"},{"annotation":"Treatment","text":"large dose of methylphenidate"},{"annotation":"Treatment.Drug","text":"methylphenidate"},{"annotation":"Treatment.Dosage","text":"large dose"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"cataract and glaucoma"},{}]}]}
{"id":"7369302_3","context":"Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"total blindness"},{"annotation":"Treatment","text":"quinine sulfate for leg cramps"},{"annotation":"Treatment.Drug","text":"quinine sulfate"},{"annotation":"Treatment.Drug","text":"leg cramps"},{"annotation":"Treatment.Side_effect","text":"total blindness"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":""}]}]}
{"id":"8404753_1","context":"Carbamazepine-induced tics.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"tics"},{"annotation":"Treatment","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Disorder","text":"none"}]}]}
{"id":"1655228_3","context":"Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"BCNU infusion"},{"annotation":"Treatment","text":"BCNU"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Effect","text":"myocardial ischemia"},{"annotation":"Subject","text":"three patients"},{"annotation":"Subject.Disorder","text":"myocardial ischemia"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"infusion"},{"annotation":"Treatment.Frequency","text":"during and immediately after"},{"annotation":"Treatment.Route","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"immediately after"},{"annotation":"Treatment.Duration","text":"during and immediately after"},{"annotation":"Treatment.Disorder","text":"myocardial ischemia"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"infusion"},{"annotation":"Treatment.Frequency","text":"during and immediately after"},{"annotation":"Treatment.Route","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"immediately after"},{"annotation":"Treatment.Duration","text":"during and immediately after"},{"annotation":"Treatment.Disorder","text":"myocardial ischemia"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"infusion"},{"annotation":"Treatment.Frequency","text":"during and immediately after"},{"annotation":"Treatment.Route","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"immediately after"},{"annotation":"Treatment.Duration","text":"during and immediately after"},{"annotation":"Treatment.Disorder","text":"myocardial ischemia"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"infusion"},{"annotation":"Treatment.Frequency","text":"during and immediately after"},{"annotation":"Treatment.Route","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"immediately after"},{"annotation":"Treatment.Duration","text":"during and immediately after"},{"annotation":"Treatment.Disorder","text":"myocardial ischemia"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"infusion"},{"annotation":"Treatment.Frequency","text":"during and immediately after"},{"annotation":"Treatment.Route","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"immediately after"},{"annotation":"Treatment.Duration","text":"during and immediately after"},{"annotation":"Treatment.Disorder","text":"myocardial ischemia"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Dosage","text":"infusion"},{"annotation":"Treatment.Frequency","text":"during and immediately after"},{"annotation":"Treatment.Route","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"immediately after"},{"annotation":"Treatment.Duration","text":"during and immediately after"},{"annotation":"Treatment"}]}]}
{"id":"25298587_1","context":"A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"ranolazine"},{"annotation":"Treatment","text":"clarithromycin"},{"annotation":"Treatment.Drug","text":"ranolazine"},{"annotation":"Treatment.Drug","text":"clarithromycin"},{"annotation":"Treatment.Drug","text":"interaction"},{"annotation":"Effect","text":"neurological adverse effect"},{"annotation":"Treatment","text":"ranolazine"},{"annotation":"Treatment.Drug","text":"clarithromycin"},{"annotation":"Treatment.Interaction","text":"drug interaction"},{"annotation":"Subject","text":"ranolazine"},{"annotation":"Subject.Drug","text":"ranolazine"},{"annotation":"Subject.Drug","text":"clarithromycin"},{"annotation":"Treatment.Interaction","text":"drug interaction"},{"annotation":"Treatment.Interaction","text":"ranolazine"},{"annotation":"Treatment.Interaction","text":"clarithromycin"}]}]}
{"id":"16046172_3","context":"Septic knee arthritis after intra-articular hyaluronate injection.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"after"},{"annotation":"Effect","text":"septic knee arthritis"},{"annotation":"Treatment","text":"intra-articular hyaluronate injection"},{"annotation":"Treatment.Drug","text":"hyaluronate"},{"annotation":"Treatment.Drug","text":"injection"},{"annotation":"Treatment.Disorder","text":"knee arthritis"},{"annotation":"Treatment.Drug","text":"septic"}]}]}
{"id":"17921794_3","context":"The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"rapid onset of muscle weakness"},{"annotation":"Treatment","text":"colchicine and statin"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Treatment.Drug","text":"statin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"colchicine"},{"annotation":"Treatment.Combination.Drug","text":"statin"},{"annotation":"Subject","text":"patients"},{"annotation":"Subject.Disorder","text":"muscle weakness"}]}]}
{"id":"15588385_3","context":"Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.","events":[{"type":"Potential_therapeutic_event","annotations":[{"annotation":"Trigger","text":"Successful treatment"},{"annotation":"Treatment","text":"amiodarone"},{"annotation":"Treatment.Disorder","text":"hyperthyroidism"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Drug","text":"propylthiouracil"},{"annotation":"Treatment.Drug","text":"acute hepatic failure"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"propylthiouracil-induced acute hepatic failure"}]}]}
{"id":"21330680_1","context":"Olanzapine-induced parkinsonism associated with smoking cessation.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"parkinsonism"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment","text":"smoking cessation"},{"annotation":"Treatment.Drug","text":"nicotine"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"smoking cessation"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"nicotine"}]}]}
{"id":"20465622_4","context":"CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"worsening"},{"annotation":"Effect","text":"aphthous ulcers"},{"annotation":"Treatment","text":"immunosuppressive therapy"},{"annotation":"Treatment.Disorder","text":"Budd-Chiari syndrome"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Drug","text":"sirolimus"},{"annotation":"Treatment.Combination.Trigger","text":"after"},{"annotation":"Treatment.Combination.Drug","text":"sirolimus"},{"annotation":"Treatment.Combination.Drug","text":"tacrolimus"},{"annotation":"Subject","text":"an 11-year old male"},{"annotation":"Subject.Disorder","text":"Budd-Chiari syndrome"}]}]}
{"id": "10190739_2","context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.","events": [{"type": "Adverse_event","annotations": [{"annotation": "Trigger","text": "took riluzole"},{"annotation": "Treatment","text": "riluzole"},{"annotation": "Treatment.Drug","text": "riluzole"},{"annotation": "Effect","text": "acute hepatitis"},{"annotation": "Treatment.Dosage","text": "100 mg daily"},{"annotation": "Treatment.Duration","text": "7 and 4 weeks, respectively"},{"annotation": "Treatment.Disorder","text": "acute hepatitis"},{"annotation": "Subject","text": "two patients"},{"annotation": "Subject.Age","text": "not specified"},{"annotation": "Subject.Gender","text": "not specified"},{"annotation": "Subject.Population","text": "two patients"},{"annotation": "Subject.Race","text": "not specified"},{"annotation": "Treatment.Route","text": "oral"},{"annotation": "Treatment.Time_elapsed","text": "not specified"},{"annotation": "Treatment.Duration","text": "7 and 4 weeks, respectively"},{"annotation": "Treatment.Disorder","text": "acute hepatitis"}]},{"type": "Adverse_event","annotations": [{"annotation": "Trigger","text": "took riluzole"},{"annotation": "Treatment","text": "riluzole"},{"annotation": "Treatment.Drug","text": "riluzole"},{"annotation": "Effect","text": "acute hepatitis"},{"annotation": "Treatment.Dosage","text": "100 mg daily"},{"annotation": "Treatment.Duration","text": "7 weeks"},{"annotation": "Treatment.Disorder","text": "acute hepatitis"},{"annotation": "Subject","text": "two patients"},{"annotation": "Subject.Age","text": "not specified"},{"annotation": "Subject.Gender","text": "not specified"},{"annotation": "Subject.Population","text": "two patients"},{"annotation": "Subject.Race","text": "not specified"},{"annotation": "Treatment.Route","text": "oral"},{"annotation": "Treatment.Time_elapsed","text": "not specified"},{"annotation": "Treatment.Duration","text": "7 weeks"},{"annotation": "Treatment.Disorder","text": "acute hepatitis"}]}]}
{"id":"20628041_1","context":"An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Treatment","text":"levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"enteral nutrition"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"levodopa"},{"annotation":"Treatment.Combination.Drug","text":"enteral nutrition"},{"annotation":"Treatment.Combination.Drug","text":"enteral nutrition"},{"annotation":"Effect","text":"neuroleptic malignant-like syndrome and prolonged ICU stay"},{"annotation":"Treatment","text":"enteral nutrition"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Duration","text":"prolonged ICU stay"},{"annotation":"Treatment.Disorder","text":"neuroleptic malignant-like syndrome"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Treatment","text":"levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"enteral nutrition"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"levodopa"},{"annotation":"Treatment.Combination.Drug","text":"enteral nutrition"},{"annotation":"Treatment.Combination.Drug","text":"enteral nutrition"},{"annotation":"Effect","text":"prolonged ICU stay"},{"annotation":"Treatment","text":"enteral nutrition"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Duration","text":"prolonged ICU stay"},{"annotation":"Treatment.Disorder","text":"neuroleptic malignant-like syndrome"}]}]}
{"id":"10573314_14","context":"Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"drug interaction"},{"annotation":"Treatment","text":"tolterodine therapy"},{"annotation":"Treatment.Drug","text":"tolterodine"},{"annotation":"Treatment.Disorder","text":"warfarin therapy"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"Until further data are available"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{}]}]}
{"id":"15522120_13","context":"The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"spread"},{"annotation":"Effect","text":"itch"},{"annotation":"Treatment","text":"clemastine"},{"annotation":"Treatment.Drug","text":"clemastine"},{"annotation":"Effect","text":"disappeared"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"treatment"},{"annotation":"Treatment","text":"clemastine"},{"annotation":"Treatment.Disorder","text":"itch"},{"annotation":"Treatment.Drug","text":"clemastine"}]}]}
{"id":"8391300_3","context":"In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"causing"},{"annotation":"Effect","text":"lower extremity ischemia"},{"annotation":"Treatment","text":"normal doses"},{"annotation":"Treatment.Drug","text":"erythromycin"},{"annotation":"Treatment.Drug","text":"ergotamine"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"erythromycin"},{"annotation":"Treatment.Combination.Drug","text":"ergotamine"},{"annotation":"Subject","text":"a 36-year-old woman"},{"annotation":"Subject.Age","text":"36"},{"annotation":"Subject.Disorder","text":"lower extremity ischemia"}]}]}
{"id":"16978752_2","context":"Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occur"},{"annotation":"Effect","text":"neutropenia and agranulocytosis"},{"annotation":"Treatment","text":"phenothiazines and clozapine"},{"annotation":"Treatment.Drug","text":"phenothiazines"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Disorder","text":"neutropenia and agranulocytosis"},{"annotation":"Treatment.Drug","text":"phenothiazines"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"unknown"}]}]}
{"id":"1695794_4","context":"She had been taking rifampin prior to admission for acid-fast bacilli.","events":[{"type":"Potential_therapeutic_event","annotations":[{"annotation":"Trigger","text":"acid-fast bacilli"},{"annotation":"Treatment","text":"rifampin"},{"annotation":"Treatment.Disorder","text":"acid-fast bacilli"},{"annotation":"Treatment.Drug","text":"rifampin"}]}]}
{"id":"6572542_3","context":"The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"CCNU"},{"annotation":"Treatment.Disorder","text":"pulmonary fibrosis"},{"annotation":"Treatment.Drug","text":"CCNU"},{"annotation":"Treatment.Drug","text":"responsibility"},{"annotation":"Effect","text":"likely"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"pathogenesis"},{"annotation":"Treatment","text":"CCNU"},{"annotation":"Treatment.Drug","text":"CCNU"},{"annotation":"Treatment.Drug","text":"responsibility"},{"annotation":"Effect","text":"likely"}]}]}
{"id":"15863610_1","context":"Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"malignant"},{"annotation":"Treatment","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Disorder","text":"malignant mixed mullerian tumor of the uterus"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"malignant mixed mullerian tumor of the uterus"}]}]}
{"id":"15516308_1","context":"Fatal overdoses associated with quetiapine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"overdoses"},{"annotation":"Effect","text":"fatal"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"overdoses"},{"annotation":"Effect","text":"fatal"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"16685112_3","context":"Gemcitabine-induced rectus abdominus radiation recall.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"radiation recall"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Disorder","text":"rectus abdominus"},{"annotation":"Treatment.Drug","text":"gemcitabine"}]}]}
{"id":"19754002_2","context":"We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presented"},{"annotation":"Effect","text":"skin rash"},{"annotation":"Treatment","text":"combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin"},{"annotation":"Treatment.Disorder","text":"severely depressed"},{"annotation":"Treatment.Drug","text":"antidepressants"},{"annotation":"Treatment.Drug","text":"atypical antipsychotic drugs"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Drug","text":"pravastatin"},{"annotation":"Subject","text":"a 55-year-old woman"},{"annotation":"Subject.Age","text":"55"},{"annotation":"Subject.Disorder","text":"severely depressed"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"Not specified"}]}]}
{"id":"15588385_4","context":"We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"fulminant hepatitis"},{"annotation":"Treatment","text":"PTU"},{"annotation":"Treatment.Disorder","text":"Basedow-Graves' disease"},{"annotation":"Treatment.Drug","text":"PTU"},{"annotation":"Treatment.Drug","text":"hepatitis"},{"annotation":"Treatment.Duration","text":"20 years"},{"annotation":"Treatment.Duration","text":"PTU-induced"},{"annotation":"Treatment.Duration","text":"fulminant hepatitis"},{"annotation":"Treatment.Duration","text":"acute hepatic failure"},{"annotation":"Treatment.Duration","text":"grade III hepatic encephalopathy"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":"PTU-induced fulminant hepatitis"},{"annotation":"Attribute","text":""}]}]}
{"id":"11283125_2","context":"The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX)"},{"annotation":"Treatment","text":"high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX)"},{"annotation":"Treatment.Disorder","text":"increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma"},{"annotation":"Treatment.Combination","text":"added to HD IV methotrexate (MTX)"},{"annotation":"Treatment.Combination.Drug","text":"high-dose (HD) intravenous (IV) cytarabine (Ara-C)"},{"annotation":"Treatment.Combination.Drug","text":"high-dose (HD) intravenous (IV) methotrexate (MTX)"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"high-dose (HD) intravenous (IV) cytarabine (Ara-C)"},{"annotation":"Treatment.Combination.Drug","text":"high-dose (HD) intravenous (IV) methotrexate (MTX)"},{"annotation":"Treatment.Combination.Trigger","text":"added to HD IV methotrexate (MTX)"},{"annotation":"Treatment.Combination.Drug","text":"high-dose (HD) intravenous (IV) cytarabine (Ara-C)"},{"annotation":"Treatment.Combination.Drug","text":"high-dose (HD) intravenous (IV) methotrexate (MTX)"},{"annotation":"Treatment.Combination.Trigger","text":"to reduce the incidence of CNS and systemic relapses"},{"annotation":"Treatment.Combination.Drug","text":"CNS and systemic relapses"},{"annotation":"Treatment.Combination.Drug","text":"CNS and systemic relapses"},{"annotation":"Treatment.Combination.Trigger","text":"in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphob"}]}]}
{"id":"6113770_2","context":"The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"postulate"},{"annotation":"Effect","text":"toxicity"},{"annotation":"Treatment","text":"combined lithium-neuroleptic"},{"annotation":"Treatment.Combination.Trigger","text":"occurrence"},{"annotation":"Treatment.Combination.Drug","text":"lithium"},{"annotation":"Treatment.Combination.Drug","text":"neuroleptic"},{"annotation":"Treatment.Combination.Drug","text":"phenothiazines"},{"annotation":"Treatment.Combination.Drug","text":"thioridazine"},{"annotation":"Treatment.Combination.Drug","text":"phenothiazines"},{"annotation":"Treatment.Combination.Drug","text":"lithium"},{"annotation":"Treatment.Combination.Drug","text":"neuroleptic"},{"annotation":"Treatment.Combination.Drug","text":"phenothiazines"},{"annotation":"Treatment.Combination.Drug","text":"thioridazine"},{"annotation":"Treatment.Disorder","text":"lithium-neuroleptic toxicity"},{"annotation":"Treatment.Disorder","text":"extrapyramidal syndrome"},{"annotation":"Treatment.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Disorder","text":"phenothiazine toxicity"},{"annotation":"Treatment.Disorder","text":"thioridazine toxicity"},{"annotation":"Treatment.Disorder","text":"extrapyramidal syndrome"},{"annotation":"Treatment.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Disorder","text":"phenothiazine toxicity"},{"annotation":"Treatment.Disorder","text":"thioridazine toxicity"},{"annotation":"Treatment.Disorder","text":"extrapyramidal syndrome"},{"annotation":"Treatment.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Disorder","text":"phenothiazine toxicity"},{"annotation":"Treatment.Disorder","text":"thioridazine toxicity"},{"annotation":"Treatment.Disorder","text":"extrapyramidal syndrome"},{"annotation":"Treatment.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Disorder","text":"phenothiazine toxicity"},{"annotation":"Treatment.Disorder","text":"thioridazine toxicity"},{"annotation":"Treatment.Disorder","text":"extrapyramidal syndrome"},{"annotation":"Treatment.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Disorder","text":"phenothiazine toxicity"},{"annotation":"Treatment.Disorder","text":"thioridazine toxicity"},{"annotation":"Treatment.Disorder","text":"extrapyramidal syndrome"},{"annotation":"Treatment.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Disorder","text":"phenothiazine toxicity"},{"annotation":"Treatment.Disorder","text":"thioridazine toxicity"},{"annotation":"Treatment.Disorder","text":"extrapyramidal syndrome"},{"annotation":"Treatment.Disorder","text":""}]}]}
{"id":"1711090_1","context":"Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma."}]},{"type":"Treatment","annotations":[{"annotation":"Treatment","text":"Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma."}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma."}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma."}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma."}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma."}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma."}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma."}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma."}]}]}
{"id":"6693840_2","context":"Gynecomastia associated with theophylline.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Effect","text":"gynecomastia"},{"annotation":"Treatment","text":"theophylline"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Subject","text":"associated with theophylline"}]}]}
{"id":"16393774_1","context":"Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"arthritis and bursitis"},{"annotation":"Effect","text":"arthritis and bursitis"},{"annotation":"Treatment","text":"interferon-beta"},{"annotation":"Treatment.Disorder","text":"multiple sclerosis"},{"annotation":"Treatment.Drug","text":"interferon-beta"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute"}]}]}
{"id":"1888256_3","context":"To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"fever"},{"annotation":"Treatment","text":"diltiazem hydrochloride"},{"annotation":"Treatment.Drug","text":"diltiazem"},{"annotation":"Treatment.Disorder","text":"drug-induced fever"},{"annotation":"Treatment.Drug","text":"calcium channel blocker"},{"annotation":"Treatment.Drug","text":"diltiazem hydrochloride"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not reported"}]}]}
{"id":"11155197_1","context":"Case studies in heparin-induced thrombocytopenia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"thrombocytopenia"},{"annotation":"Treatment","text":"heparin"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"thrombocytopenia"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"thrombosis"},{"annotation":"Treatment","text":"heparin"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"thrombosis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"thrombosis"},{"annotation":"Treatment","text":"heparin"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"thrombosis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"thrombosis"},{"annotation":"Treatment","text":"heparin"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"thrombosis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"thrombosis"},{"annotation":"Treatment","text":"heparin"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"thrombosis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"thrombosis"},{"annotation":"Treatment","text":"heparin"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"thrombosis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"thrombosis"},{"annotation":"Treatment","text":"heparin"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"thrombosis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"thrombosis"},{"annotation":"Treatment","text":"heparin"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"T"}]}]}
{"id":"8316494_2","context":"We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"underwent"},{"annotation":"Treatment","text":"clofazimine"},{"annotation":"Treatment.Drug","text":"clofazimine"},{"annotation":"Effect","text":"severe abdominal pain"},{"annotation":"Subject","text":"a 41 yr old leprosy patient"},{"annotation":"Subject.Disorder","text":"leprosy"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"laparotomy"},{"annotation":"Treatment","text":"clofazimine"},{"annotation":"Treatment.Drug","text":"clofazimine"},{"annotation":"Effect","text":"abdominal pain"},{"annotation":"Subject","text":"a 41 yr old leprosy patient"},{"annotation":"Subject.Disorder","text":"leprosy"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"laparotomy"},{"annotation":"Treatment","text":"clofazimine"},{"annotation":"Treatment.Disorder","text":"leprosy"},{"annotation":"Treatment.Drug","text":"clofazimine"},{"annotation":"Treatment.Duration","text":"10 yrs"},{"annotation":"Treatment.Effect","text":"severe abdominal pain"}]}]}
{"id":"15061230_2","context":"Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurs"},{"annotation":"Effect","text":"osteonecrosis"},{"annotation":"Treatment","text":"antiemetic treatment with dexamethasone"},{"annotation":"Treatment.Drug","text":"dexamethasone"},{"annotation":"Treatment.Drug","text":"antiemetic"},{"annotation":"Treatment.Disorder","text":"osteonecrosis"},{"annotation":"Treatment.Disorder","text":"serious complication"},{"annotation":"negated","text":"not negated"},{"annotation":"negated","text":"serious complication"},{"annotation":"negated","text":"this"},{"annotation":"negated","text":"serious complication"},{"annotation":"negated","text":"should be incorporated"},{"annotation":"negated","text":"in the current guidelines"},{"annotation":"negated","text":"incorporated"},{"annotation":"negated","text":"this"},{"annotation":"negated","text":"serious complication"},{"annotation":"negated","text":"should be incorporated"},{"annotation":"negated","text":"in the current guidelines"},{"annotation":"negated","text":"incorporated"},{"annotation":"negated","text":"this"},{"annotation":"negated","text":"serious complication"},{"annotation":"negated","text":"should be incorporated"},{"annotation":"negated","text":"in the current guidelines"},{"annotation":"negated","text":"incorporated"},{"annotation":"negated","text":"this"},{"annotation":"negated","text":"serious complication"},{"annotation":"negated","text":"should be incorporated"},{"annotation":"negated","text":"in the current guidelines"},{"annotation":"negated","text":"incorporated"},{"annotation":"negated","text":"this"},{"annotation":"negated","text":"serious complication"},{"annotation":"negated","text":"should be incorporated"},{"annotation":"negated","text":"in the current guidelines"},{"annotation":"negated","text":"incorporated"},{"annotation":"negated","text":"this"},{"annotation":"negated","text":"serious complication"},{"annotation":"negated","text":"should be incorporated"},{"annotation":"negated","text":"in the current guidelines"},{"annotation":"negated","text":"incorporated"},{"annotation":"negated","text":"this"},{"annotation":"negated","text":"serious complication"},{"annotation":"negated","text":"should be incorporated"},{"annotation":"negated","text":"in the current guidelines"},{"annotation":"negated","text":"incorporated"},{"annotation":"negated","text":"this"},{"annotation":"negated","text":"serious complication"},{"annotation":"negated","text":"should be incorporated"},{"annotation":"negated","text":"in the current guidelines"},{"annotation":"negated","text":"incorporated"},{"annotation":"negated","text":"this"},{"annotation":"negated","text":"serious complication"},{"annotation":"negated","text":"should be incorporated"},{"annotation":"negated","text":"in the current guidelines"},{"annotation":"negated","text":"incorporated"},{"annotation":"negated","text":"this"},{"annotation":"negated","text":"serious complication"},{"annotation":"negated","text":"should be incorporated"},{"annotation":"negated","text":"in the current guidelines"},{"annotation":"negated","text":"incorporated"},{"annotation":"negated","text":"this"},{"annotation":"negated","text":"serious complication"},{"annotation":"negated","text":"should be incorporated"},{}]}]}
{"id":"15663666_3","context":"We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"development"},{"annotation":"Effect","text":"scrotal ulcer"},{"annotation":"Treatment","text":"ATRA"},{"annotation":"Treatment.Drug","text":"ATRA"},{"annotation":"Treatment.Dosage","text":"40 mg orally twice daily"},{"annotation":"Treatment.Duration","text":"10 days"},{"annotation":"Subject","text":"a patient with acute promyleocytic leukemia (APL)"},{"annotation":"Subject.Disorder","text":"acute promyleocytic leukemia (APL)"},{"annotation":"Treatment.Disorder","text":"acute promyleocytic leukemia (APL)"},{"annotation":"Treatment.Drug","text":"ATRA"},{"annotation":"Treatment.Dosage","text":"ATRA"},{"annotation":"Treatment.Duration","text":"10 days"},{"annotation":"Treatment.Disorder","text":"acute promyleocytic leukemia (APL)"},{"annotation":"Treatment.Drug","text":"ATRA"},{"annotation":"Treatment.Dosage","text":"ATRA"},{"annotation":"Treatment.Duration","text":"10 days"},{"annotation":"Treatment.Disorder","text":"acute promyleocytic leukemia (APL)"},{"annotation":"Treatment.Drug","text":"ATRA"},{"annotation":"Treatment.Dosage","text":"ATRA"},{"annotation":"Treatment.Duration","text":"10 days"},{"annotation":"Treatment.Disorder","text":"acute promyleocytic leukemia (APL)"},{"annotation":"Treatment.Drug","text":"ATRA"},{"annotation":"Treatment.Dosage","text":"ATRA"},{"annotation":"Treatment.Duration","text":"10 days"},{"annotation":"Treatment.Disorder","text":"acute promyleocytic leukemia (APL)"},{"annotation":"Treatment.Drug","text":"ATRA"},{"annotation":"Treatment.Dosage","text":"ATRA"},{"annotation":"Treatment.Duration","text":"10 days"},{"annotation":"Treatment.Disorder","text":"acute promyleocytic leukemia (APL)"},{"annotation":"Treatment.Drug","text":"ATRA"},{"annotation":"Treatment.Dosage","text":"ATRA"},{"annotation":"Treatment.Duration","text":"10 days"},{"annotation":"Treatment.Disorder","text":"acute promyleocytic leukemia (APL)"},{"annotation":"Treatment.Drug","text":"ATRA"},{"annotation":"Treatment.Dosage","text":"ATRA"},{"annotation":"Treatment.Duration","text":"10 days"},{"annotation":"Treatment.Disorder","text":"acute promyleocytic leukemia (APL)"},{"annotation":"Treatment.Drug","text":"ATRA"},{"annotation":"Treatment.Dosage","text":"ATRA"},{"annotation":"Treatment.Duration","text":"10 days"},{"annotation":"Treatment.Disorder","text":"acute promyleocytic leukemia ("}]}]}
{"id":"14684937_1","context":"After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"initiation"},{"annotation":"Treatment","text":"topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions"},{"annotation":"Treatment.Drug","text":"tacalcitol"},{"annotation":"Treatment.Dosage","text":"10 g/day"},{"annotation":"Treatment.Route","text":"topical"},{"annotation":"Treatment.Duration","text":"gradually"},{"annotation":"Treatment.Disorder","text":"skin lesions"},{"annotation":"Effect","text":"increased serum level of calcium and urinary excretion of calcium"}]}]}
{"id":"11485141_6","context":"Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"implicated"},{"annotation":"Effect","text":"LABD"},{"annotation":"Treatment","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Disorder","text":"LABD"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LABD)"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LABD)"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LABD)"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LABD)"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LABD)"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LABD)"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LABD)"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LABD)"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LABD)"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LABD)"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LABD)"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LABD)"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LABD)"},{"annotation":"Treatment.Drug","text":"other agents"},{"annotation":"Treatment.Disorder","text":"Lethal Antibiotic-Bacterial Drug Interaction (LAB"}]}]}
{"id":"15623719_1","context":"Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"declined"},{"annotation":"Effect","text":"vision declined"},{"annotation":"Treatment","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{}]}]}
{"id":"10682234_3","context":"Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"end of interferon treatment"},{"annotation":"Effect","text":"inability to sit still for ten seconds and walked around constantly"},{"annotation":"Treatment","text":"interferon"},{"annotation":"Treatment.Drug","text":"interferon"},{"annotation":"Treatment.Time_elapsed","text":"eight days after the end of interferon treatment"},{"annotation":"Treatment.Duration","text":"eight days"},{"annotation":"Treatment.Disorder","text":"inability to sit still for ten seconds and walked around constantly"},{"annotation":"Treatment.Drug","text":"interferon"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"15895899_2","context":"Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"agranulocytosis"},{"annotation":"Treatment","text":"treatment with infliximab"},{"annotation":"Treatment.Disorder","text":"enteropathic spondyloarthropathy"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{}]}]}
{"id":"19555801_1","context":"Aripiprazole-induced hiccups: a case report.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hiccups"},{"annotation":"Treatment","text":"aripiprazole"},{"annotation":"Treatment.Drug","text":"aripiprazole"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Response"},{"annotation":"Treatment","text":"none"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Possible"},{"annotation":"Treatment","text":"none"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Possible"},{"annotation":"Treatment","text":"none"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Possible"},{"annotation":"Treatment","text":"none"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Possible"},{"annotation":"Treatment","text":"none"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Possible"},{"annotation":"Treatment","text":"none"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Possible"},{"annotation":"Treatment","text":"none"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Possible"},{"annotation":"Treatment","text":"none"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Possible"},{"annotation":"Treatment","text":"none"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Possible"},{"annotation":"Treatment","text":"none"}]}]}
{"id":"16728538_3","context":"The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"normalized"},{"annotation":"Effect","text":"hepatic enzyme disturbances"},{"annotation":"Treatment","text":"discontinuation of pegvisomant"},{"annotation":"Treatment.Drug","text":"pegvisomant"},{"annotation":"Treatment.Duration","text":"after discontinuation"},{"annotation":"Subject","text":"an acromegalic patient"},{"annotation":"Subject.Disorder","text":"acromegalic"}]}]}
{"id":"9777751_4","context":"We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"AA"},{"annotation":"Treatment","text":"methimazole (MMI)"},{"annotation":"Treatment.Drug","text":"methimazole"},{"annotation":"Treatment.Duration","text":"third exposure"},{"annotation":"Subject","text":"58-year-old female patient with Graves' disease"},{"annotation":"Subject.Disorder","text":"Graves' disease"}]}]}
{"id":"16685112_2","context":"CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"radiation recall"},{"annotation":"Treatment","text":"gemcitabine-based radiation therapy"},{"annotation":"Treatment.Disorder","text":"rectus abdominus muscles"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Radiation","text":"radiation"},{"annotation":"Subject","text":"rectus abdominus muscles"},{"annotation":"Subject.Disorder","text":"rectus abdominus muscles"}]}]}
{"id":"16046172_2","context":"One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"knee arthritis"},{"annotation":"Effect","text":"infection"},{"annotation":"Treatment","text":"intraarticular injections of sodium hyaluronate and corticosteroids"},{"annotation":"Treatment.Drug","text":"sodium hyaluronate"},{"annotation":"Treatment.Drug","text":"corticosteroids"},{"annotation":"Treatment.Disorder","text":"knee arthritis"},{"annotation":"Treatment.Drug","text":"Staphylococcus aureus"}]}]}
{"id":"6731466_5","context":"Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Effect","text":"renal cortical necrosis"},{"annotation":"Treatment","text":"zomepirac"},{"annotation":"Treatment.Drug","text":"zomepirac"},{"annotation":"Treatment.Disorder","text":"renal cortical necrosis"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":""}]}]}
{"id":"6427463_2","context":"Vasomotor reactions after gold sodium thiomalate are well recognized.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"vasomotor reactions"},{"annotation":"Effect","text":"reactions"},{"annotation":"Treatment","text":"gold sodium thiomalate"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"gold sodium thiomalate"},{"annotation":"Treatment.Dosage","text":"none"},{"annotation":"Treatment.Frequency","text":"none"},{"annotation":"Treatment.Route","text":"none"},{"annotation":"Treatment.Time_elapsed","text":"none"},{"annotation":"Treatment.Duration","text":"none"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"21515865_1","context":"Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Effect","text":"bleeding"},{"annotation":"Treatment","text":"bacille Calmette-Guerin treatment for bladder cancer"},{"annotation":"Treatment.Disorder","text":"bleeding"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"warfarin"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Effect","text":"bleeding"},{"annotation":"Treatment","text":"bacille Calmette-Guerin treatment for bladder cancer"},{"annotation":"Treatment.Disorder","text":"bleeding"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"warfarin"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Effect","text":"bleeding"},{"annotation":"Treatment","text":"bacille Calmette-Guerin treatment for bladder cancer"},{"annotation":"Treatment.Disorder","text":"bleeding"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"warfarin"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Effect","text":"bleeding"},{"annotation":"Treatment","text":"bacille Calmette-Guerin treatment for bladder cancer"},{"annotation":"Treatment.Disorder","text":"bleeding"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"warfarin"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Effect","text":"bleeding"},{"annotation":"Treatment","text":"bacille Calmette-Guerin treatment for bladder cancer"},{"annotation":"Treatment.Disorder","text":"bleeding"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"warfarin"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Effect","text":"bleeding"},{"annotation":"Treatment","text":"bacille Calmette-Guerin treatment for bladder cancer"},{"annotation":"Treatment.Disorder","text":"bleeding"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"warfarin"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Effect","text":"ble"}]}]}
{"id":"15571949_1","context":"In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"thrombosis"},{"annotation":"Treatment","text":"intensive chemotherapy containing busulfan"},{"annotation":"Treatment.Disorder","text":"severe hepatic veno-occlusive disease (HVOD)"},{"annotation":"Treatment.Drug","text":"busulfan"},{"annotation":"Treatment.Time_elapsed","text":"2-45 days"},{"annotation":"Subject","text":"four patients"},{"annotation":"Subject.Disorder","text":"severe hepatic veno-occlusive disease (HVOD)"},{"annotation":"Treatment.Drug","text":"busulfan"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"thrombosis"},{"annotation":"Treatment","text":"intensive chemotherapy containing busulfan"},{"annotation":"Treatment.Disorder","text":"severe hepatic veno-occlusive disease (HVOD)"},{"annotation":"Treatment.Drug","text":"busulfan"},{"annotation":"Treatment.Time_elapsed","text":"2-45 days"},{"annotation":"Subject","text":"four patients"},{"annotation":"Subject.Disorder","text":"severe hepatic veno-occlusive disease (HVOD)"},{"annotation":"Treatment.Drug","text":"busulfan"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"thrombosis"},{"annotation":"Treatment","text":"intensive chemotherapy containing busulfan"},{"annotation":"Treatment.Disorder","text":"severe hepatic veno-occlusive disease (HVOD)"},{"annotation":"Treatment.Drug","text":"busulfan"},{"annotation":"Treatment.Time_elapsed","text":"2-45 days"},{"annotation":"Subject","text":"four patients"},{"annotation":"Subject.Disorder","text":"severe hepatic veno-occlusive disease (HVOD)"},{"annotation":"Treatment.Drug","text":"busulfan"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"thrombosis"},{"annotation":"Treatment","text":"intensive chemotherapy containing busulfan"},{"annotation":"Treatment.Disorder","text":"severe hepatic veno-occlusive disease (HVOD)"},{"annotation":"Treatment.Drug","text":"busulfan"},{"annotation":"Treatment.Time_elapsed","text":"2-45 days"},{"annotation":"Subject","text":"four patients"},{"annotation":"Subject.Disorder","text":"severe hepatic veno-occlusive disease (HVOD)"},{"annotation":"Treatment.Drug","text":"busulfan"}]}]}
{"id":"7139589_1","context":"An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"intramuscular L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Duration","text":"16 weeks"},{"annotation":"Treatment.Disorder","text":"acute pancreatitis and pseudocyst of the pancreas"},{"annotation":"Treatment.Disorder","text":"L-asparaginase treatment"},{"annotation":"Effect","text":"acute pancreatitis and pseudocyst of the pancreas"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Duration","text":"16 weeks"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"intramuscular L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Duration","text":"16 weeks"},{"annotation":"Treatment.Disorder","text":"acute pancreatitis and pseudocyst of the pancreas"},{"annotation":"Treatment.Disorder","text":"L-asparaginase treatment"},{"annotation":"Effect","text":"acute pancreatitis and pseudocyst of the pancreas"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Duration","text":"16 weeks"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"intramuscular L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Duration","text":"16 weeks"},{"annotation":"Treatment.Disorder","text":"acute pancreatitis and pseudocyst of the pancreas"},{"annotation":"Treatment.Disorder","text":"L-asparaginase treatment"},{"annotation":"Effect","text":"acute pancreatitis and pseudocyst of the pancreas"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Duration","text":"16 weeks"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"intramuscular L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Duration","text":"16 weeks"},{"annotation":"Treatment.Disorder","text":"acute pancreatitis and pseudocyst of the pancreas"},{"annotation":"Treatment.Disorder","text":"L-asparaginase treatment"},{"annotation":"Effect","text":"acute pancreatitis and pseudocyst of the pancreas"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Duration","text":"16 weeks"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"intramuscular L"}]}]}
{"id":"22047557_1","context":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Potentiator"},{"annotation":"Treatment","text":"CFTR potentiator"},{"annotation":"Treatment.Disorder","text":"cystic fibrosis"},{"annotation":"Treatment.Drug","text":"CFTR potentiator"},{"annotation":"Treatment.Mutation","text":"G551D"},{"annotation":"Treatment.Drug","text":"potentiator"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"cystic fibrosis"},{"annotation":"Attribute Attributes","text":"not specified"}]}]}
{"id":"17205927_1","context":"Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"overdose"},{"annotation":"Treatment","text":"quinapril"},{"annotation":"Treatment.Drug","text":"quinapril"},{"annotation":"Treatment.Disorder","text":"prolonged hypotension"},{"annotation":"Treatment.Disorder","text":"transient renal impairment"},{"annotation":"Treatment.Drug","text":"ACE-inhibitor"},{"annotation":"Treatment.Drug","text":"overdose"},{"annotation":"Treatment.Drug","text":"quinapril"}]}]}
{"id":"9725786_1","context":"We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developing"},{"annotation":"Effect","text":"Nocardia Asteroides brain abscess"},{"annotation":"Treatment","text":"cyclosporine and prednisone"},{"annotation":"Treatment.Disorder","text":"renal transplant recipient"},{"annotation":"Treatment.Drug","text":"cyclosporine"},{"annotation":"Treatment.Drug","text":"prednisone"},{"annotation":"Subject","text":"renal transplant recipient"},{"annotation":"Subject.Disorder","text":"renal transplant recipient"}]}]}
{"id":"15588385_2","context":"After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"amiodarone"},{"annotation":"Treatment.Disorder","text":"hyperthyroidism"},{"annotation":"Treatment.Disorder","text":"PTU-induced fulminant hepatitis"},{"annotation":"Treatment.Duration","text":"control"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"PTU-induced fulminant hepatitis"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"PTU"},{"annotation":"Treatment.Disorder","text":"PTU-induced fulminant hepatitis"},{"annotation":"Treatment.Drug","text":"PTU"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Duration","text":"control"}]}]}
{"id":"12042592_1","context":"After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Overwhelming sepsis"},{"annotation":"Treatment","text":"metamizole use"},{"annotation":"Treatment.Disorder","text":"overwhelming sepsis"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Att"}]}]}
{"id":"9671138_3","context":"We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"RSV infection"},{"annotation":"Effect","text":"infection"},{"annotation":"Treatment","text":"fludarabine phosphate"},{"annotation":"Treatment.Disorder","text":"refractory CLL"},{"annotation":"Treatment.Drug","text":"fludarabine"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"for ADE, the adverse effect does not exist; or for PTE, the therapy is ineffective."}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"RSV infection"},{"annotation":"Treatment","text":"fludarabine phosphate"},{"annotation":"Treatment.Disorder","text":"refractory CLL"},{"annotation":"Treatment.Drug","text":"fludarabine"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"for PTE events"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute.severity","text":"for PTE events"},{"annotation":"Event type","text":"Potential_therapeutic_effect"}]}]}
{"id":"10812579_1","context":"A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presented"},{"annotation":"Effect","text":"nonconvulsive status epilepticus"},{"annotation":"Treatment","text":"continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment.Disorder","text":"nonconvulsive status epilepticus"},{"annotation":"Treatment.Disorder","text":"back pain"},{"annotation":"Treatment.Drug","text":"malignant lymphoma"},{"annotation":"Treatment.Disorder","text":"vertebral metastasis"},{"annotation":"Subject","text":"a 77-year-old woman"},{"annotation":"Subject.Age","text":"77"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"no history of epilepsy"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presented"},{"annotation":"Effect","text":"nonconvulsive status epilepticus"},{"annotation":"Treatment","text":"continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment.Disorder","text":"nonconvulsive status epilepticus"},{"annotation":"Treatment.Disorder","text":"back pain"},{"annotation":"Treatment.Drug","text":"malignant lymphoma"},{"annotation":"Treatment.Disorder","text":"vertebral metastasis"},{"annotation":"Subject","text":"a 77-year-old woman"},{"annotation":"Subject.Age","text":"77"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"no history of epilepsy"}]}]}
{"id":"16685007_2","context":"Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"reduced"},{"annotation":"Treatment","text":"replacing"},{"annotation":"Treatment.Drug","text":"oral corticosteroids"},{"annotation":"Treatment.Drug","text":"inhaled corticosteroids"},{"annotation":"Treatment.Disorder","text":"systemic adverse events (AEs)"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"oral corticosteroids"},{"annotation":"Treatment.Drug","text":"oral corticosteroids"},{"annotation":"Effect","text":"systemic adverse events (AEs)"}]}]}
{"id":"15072497_1","context":"Development of Peyronie's disease during long-term colchicine treatment.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"development"},{"annotation":"Effect","text":"Peyronie's disease"},{"annotation":"Treatment","text":"long-term colchicine treatment"},{"annotation":"Treatment.Disorder","text":"Peyronie's disease"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage","text":"colchicine"},{"annotation":"Treatment.Route","text":"oral"},{}]}]}
{"id":"9007910_6","context":"The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"5-FU"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Effect","text":"neurologic symptoms"},{"annotation":"Treatment","text":"thymidine"},{"annotation":"Treatment.Disorder","text":"DPD-deficient patients with severe acute 5-FU reactions"},{"annotation":"Treatment.Disorder","text":"5-FU reactions"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"thymidine"},{"annotation":"Treatment.Drug","text":"thymidine"},{"annotation":"Effect","text":"reversed severe 5-FU-induced neurologic symptoms"},{"annotation":"Treatment","text":"supportive care"},{"annotation":"Treatment.Disorder","text":"DPD-deficient patients with severe acute 5-FU reactions"},{"annotation":"Treatment.Disorder","text":"5-FU reactions"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"5-FU"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment","text":"thymidine"},{"annotation":"Treatment.Disorder","text":"DPD-deficient patients with severe acute 5-FU reactions"},{"annotation":"Treatment.Disorder","text":"5-FU reactions"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"5-FU"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment","text":"thymidine"},{"annotation":"Treatment.Disorder","text":"DPD-deficient patients with severe acute 5-FU reactions"},{"annotation":"Treatment.Disorder","text":"5-FU reactions"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"5-FU"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment","text":"thymidine"},{"annotation":"Treatment.Disorder","text":"DPD-deficient patients with severe acute 5-FU reactions"},{"annotation":"Treatment.Disorder","text":"5-FU reactions"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"5-FU"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment","text":"thymidine"},{"annotation":"Treatment.Disorder","text":"DPD-deficient patients with severe acute 5-FU reactions"},{"annotation":"Treatment.Disorder","text":"5-FU reactions"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{}]}]}
{"id":"16599252_1","context":"Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"zafirlukast"},{"annotation":"Treatment.Drug","text":"zafirlukast"},{"annotation":"Treatment.Disorder","text":"aspirin-induced asthma"},{"annotation":"Effect","text":"adverse reaction"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not present"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"zafirlukast"},{"annotation":"Treatment.Drug","text":"zafirlukast"},{"annotation":"Treatment.Disorder","text":"aspirin-induced asthma"},{"annotation":"Effect","text":"adverse reaction"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.speculated","text":"unknown"}]}]}
{"id":"6788011_4","context":"The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"nephrotic syndrome"},{"annotation":"Treatment","text":"therapy with gold for rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Dosage","text":"therapy"},{"annotation":"Treatment.Duration","text":"for rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Dosage","text":"therapy"},{"annotation":"Treatment.Duration","text":"for rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Dosage","text":"therapy"},{"annotation":"Treatment.Duration","text":"for rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Dosage","text":"therapy"},{"annotation":"Treatment.Duration","text":"for rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Dosage","text":"therapy"},{"annotation":"Treatment.Duration","text":"for rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Dosage","text":"therapy"},{"annotation":"Treatment.Duration","text":"for rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Dosage","text":"therapy"},{"annotation":"Treatment.Duration","text":"for rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Dosage","text":"therapy"},{"annotation":"Treatment.Duration","text":"for rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Dosage","text":"therapy"},{"annotation":"Treatment.Duration","text":"for rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Dosage","text":"therapy"},{"annotation":"Treatment.Duration","text":"for rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Dosage","text":"therapy"},{"annotation":"Treatment.Duration","text":""}]}]}
{"id":"6731466_6","context":"This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"complications"},{"annotation":"Treatment","text":"nonsteroidal anti-inflammatory agents"},{"annotation":"Treatment.Drug","text":"zomepirac"},{"annotation":"Treatment.Disorder","text":"renal complications"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"This observation does not add any new information about the previously reported renal complications of nonsteroidal anti-inflammatory agents."}]}]}
{"id":"12488741_1","context":"Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"resolved"},{"annotation":"Effect","text":"abnormalities"},{"annotation":"Treatment","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"resolved"},{"annotation":"Effect","text":"abnormalities"},{"annotation":"Treatment","text":"metronidazole"},{"annotation":"Treatment.Drug","text":"metronidazole"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"}]}]}
{"id":"20202988_8","context":"In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"started"},{"annotation":"Treatment","text":"raltegravir-based HIV therapy"},{"annotation":"Treatment.Disorder","text":"HIV"},{"annotation":"Treatment.Drug","text":"raltegravir"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Dosage","text":"1 or 2 mg"},{"annotation":"Treatment.Frequency","text":"twice daily"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Combination.Trigger","text":"while"},{"annotation":"Treatment.Combination.Drug","text":"raltegravir"},{"annotation":"Treatment.Combination.Drug","text":"tacrolimus"},{"annotation":"Treatment.Combination.Drug","text":"OLTX"},{"annotation":"Treatment.Combination.Drug","text":"Crohn's disease"},{"annotation":"Treatment.Combination.Drug","text":"HIV"},{"annotation":"Treatment.Combination.Drug","text":"tacrolimus"},{"annotation":"Treatment.Combination.Drug","text":"OLTX"},{"annotation":"Treatment.Combination.Drug","text":"Crohn's disease"},{"annotation":"Treatment.Combination.Drug","text":"raltegravir"},{"annotation":"Treatment.Combination.Drug","text":"tacrolimus"},{"annotation":"Treatment.Combination.Drug","text":"OLTX"},{"annotation":"Treatment.Combination.Drug","text":"Crohn's disease"},{"annotation":"Treatment.Combination.Drug","text":"HIV"},{"annotation":"Treatment.Combination.Drug","text":"raltegravir"},{"annotation":"Treatment.Combination.Drug","text":"tacrolimus"},{"annotation":"Treatment.Combination.Drug","text":"OLTX"},{"annotation":"Treatment.Combination.Drug","text":"Crohn's disease"},{"annotation":"Treatment.Combination.Drug","text":"HIV"},{"annotation":"Treatment.Combination.Drug","text":"raltegravir"},{"annotation":"Treatment.Combination.Drug","text":"tacrolimus"},{"annotation":"Treatment.Combination.Drug","text":"OLTX"},{"annotation":"Treatment.Combination.Drug","text":"Crohn's disease"},{"annotation":"Treatment.Combination.Drug","text":"raltegravir"},{"annotation":"Treatment.Combination.Drug","text":"tacrolimus"},{"annotation":"Treatment.Combination.Drug","text":"OLTX"},{"annotation":"Treatment.Combination.Drug","text":"Crohn's disease"},{"annotation":"Treatment.Combination.Drug","text":"HIV"},{"annotation":"Treatment.Combination.Drug","text":"raltegravir"},{"annotation":"Treatment.Combination.Drug","text":"tacrolimus"},{"annotation":"Treatment.Combination.Drug","text":"OLTX"},{"annotation":"Treatment.Combination.Drug","text":"C"}]}]}
{"id":"16265343_2","context":"Reversible cardiomyopathy caused by administration of interferon alpha.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused by"},{"annotation":"Effect","text":"cardiomyopathy"},{"annotation":"Treatment","text":"interferon alpha"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Duration","text":"reversible"}]}]}
{"id":"8696525_1","context":"Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Effect","text":"anterior uveitis"},{"annotation":"Treatment","text":"metipranolol"},{"annotation":"Treatment.Drug","text":"metipranolol"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{}]}]}
{"id":"12851279_13","context":"There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Effect","text":"bleeding"},{"annotation":"Treatment","text":"tifacogin"},{"annotation":"Treatment.Drug","text":"tifacogin"},{"annotation":"Treatment.Duration","text":"duration"},{"annotation":"Treatment.Combination.Trigger","text":"in both cohorts"},{"annotation":"Treatment.Combination.Drug","text":"tifacogin"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Trigger","text":"for high INR"},{"annotation":"Treatment.Combination.Drug","text":"tifacogin"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Trigger","text":"for low INR"},{"annotation":"Treatment.Combination.Drug","text":"tifacogin"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Trigger","text":"in both cohorts"},{"annotation":"Treatment.Combination.Drug","text":"tifacogin"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Trigger","text":"for high INR"},{"annotation":"Treatment.Combination.Drug","text":"tifacogin"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Trigger","text":"for low INR"},{"annotation":"Treatment.Combination.Drug","text":"tifacogin"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Trigger","text":"in both cohorts"},{"annotation":"Treatment.Combination.Drug","text":"tifacogin"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Trigger","text":"for high INR"},{"annotation":"Treatment.Combination.Drug","text":"tifacogin"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination.Trigger","text":"for low INR"},{"annotation":"Treatment.Combination.Drug","text":"tifacogin"},{"annotation":"Treatment.Combination.Drug","text":"placebo"},{"annotation":"Treatment.Combination"}]}]}
{"id":"3318771_1","context":"We also describe a case of timolol-induced ocular pemphigoid.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"ocular pemphigoid"},{"annotation":"Treatment","text":"timolol"},{"annotation":"Treatment.Drug","text":"timolol"},{"annotation":"Treatment.Disorder","text":"ocular pemphigoid"}]}]}
{"id":"17016002_1","context":"A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"dyspnea"},{"annotation":"Treatment","text":"antihistaminic agent (homochlorcyclizine hydrochloride)"},{"annotation":"Treatment.Drug","text":"homochlorcyclizine hydrochloride"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Effect","text":"dyspnea"},{"annotation":"Treatment.Disorder","text":"itching"},{"annotation":"Treatment.Drug","text":"antihistaminic agent"},{"annotation":"Subject","text":"a 70-year-old man"},{"annotation":"Subject.Age","text":"70"},{"annotation":"Subject.Disorder","text":"itching"},{"annotation":"Treatment.Drug","text":"homochlorcyclizine hydrochloride"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Effect","text":"dyspnea"},{"annotation":"Treatment.Disorder","text":"itching"},{"annotation":"Treatment.Drug","text":"antihistaminic agent"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Effect","text":"dyspnea"},{"annotation":"Treatment.Disorder","text":"itching"},{"annotation":"Treatment.Drug","text":"antihistaminic agent"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Effect","text":"dyspnea"},{"annotation":"Treatment.Disorder","text":"itching"},{"annotation":"Treatment.Drug","text":"antihistaminic agent"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Effect","text":"dyspnea"},{"annotation":"Treatment.Disorder","text":"itching"},{"annotation":"Treatment.Drug","text":"antihistaminic agent"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Effect","text":"dyspnea"},{"annotation":"Treatment.Disorder","text":"itching"},{"annotation":"Treatment.Drug","text":"antihistaminic agent"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Effect","text":"dyspnea"},{"annotation":"Treatment.Disorder","text":"itching"},{"annotation":"Treatment.Drug","text":"antihistaminic agent"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Effect","text":"dyspnea"},{"annotation":"Treatment.Disorder","text":"itching"},{"annotation":"Treatment.Drug","text":"antihistaminic agent"},{}]}]}
{"id":"10212021_1","context":"Methadone withdrawal when starting an antiretroviral regimen including nevirapine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withdrawal"},{"annotation":"Effect","text":"methadone withdrawal"},{"annotation":"Treatment","text":"methadone"},{"annotation":"Treatment.Drug","text":"antiretroviral regimen including nevirapine"},{"annotation":"Treatment.Disorder","text":"methadone withdrawal"},{"annotation":"Treatment.Drug","text":"antiretroviral regimen including nevirapine"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"antiretroviral regimen including nevirapine"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"methadone withdrawal"}]}]}
{"id":"9253492_4","context":"The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused"},{"annotation":"Effect","text":"oligohidrosis"},{"annotation":"Treatment","text":"zonisamide"},{"annotation":"Treatment.Drug","text":"zonisamide"},{"annotation":"Treatment.Drug","text":"oligohidrosis"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"reversible"},{"annotation":"Attribute Attributes","text":"reversible"},{"annotation":"Attribute Attributes","text":"regained"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused"},{"annotation":"Effect","text":"oligohidrosis"},{"annotation":"Treatment","text":"zonisamide"},{"annotation":"Treatment.Drug","text":"zonisamide"},{"annotation":"Treatment.Drug","text":"oligohidrosis"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"reversible"},{"annotation":"Attribute Attributes","text":"regained"},{"annotation":"Attribute Attributes","text":"within 2 weeks of cessation of drug administration"}]}]}
{"id":"16317298_4","context":"Radiation recall related to gemcitabine has been reported in lung and breast cancer.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"radiation recall"},{"annotation":"Effect","text":"recall"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Disorder","text":"lung and breast cancer"},{"annotation":"Treatment.Drug","text":"gemcitabine"}]}]}
{"id":"10435399_1","context":"It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"carries"},{"annotation":"Treatment","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Effect","text":"neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocytosis"},{"annotation":"Treatment.Disorder","text":"clozapine-induced neutropenia and agranulocyt"}]}]}
{"id":"17827338_2","context":"Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"under investigation"},{"annotation":"Treatment","text":"vicriviroc (SCH 417690)"},{"annotation":"Treatment.Disorder","text":"human immunodeficiency virus infection"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"9253492_2","context":"Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"zonisamide"},{"annotation":"Treatment.Drug","text":"zonisamide"},{"annotation":"Effect","text":"oligohidrosis and neurological symptoms"},{"annotation":"Treatment.Disorder","text":"elevation of body temperature"},{"annotation":"Treatment.Disorder","text":"children receiving zonisamide"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"11147747_3","context":"This concerns 2 male patients who experienced incontinence while taking venlafaxine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"experienced"},{"annotation":"Treatment","text":"venlafaxine"},{"annotation":"Treatment.Drug","text":"venlafaxine"},{"annotation":"Effect","text":"incontinence"},{"annotation":"Subject","text":"2 male patients"},{"annotation":"Subject.Disorder","text":"none"}]}]}
{"id":"1087773_2","context":"Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"polyarthritis"},{"annotation":"Treatment","text":"ethambutol and rifampicin"},{"annotation":"Treatment.Drug","text":"ethambutol"},{"annotation":"Treatment.Drug","text":"rifampicin"},{"annotation":"Treatment.Disorder","text":"polyarthritis"},{"annotation":"Treatment.Disorder","text":"hepatitis"},{"annotation":"Treatment.Disorder","text":"anti-native DNA antibodies"},{"annotation":"Treatment.Drug","text":"ethambutol"},{"annotation":"Treatment.Drug","text":"rifampicin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"ethambutol"},{"annotation":"Treatment.Combination.Drug","text":"rifampicin"},{"annotation":"Treatment.Combination.Drug","text":"ethambutol"},{"annotation":"Treatment.Combination.Drug","text":"rifampicin"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"polyarthritis"},{"annotation":"Subject.Disorder","text":"hepatitis"},{"annotation":"Subject.Disorder","text":"anti-native DNA antibodies"},{"annotation":"Subject.Disorder","text":"hepatitis"},{"annotation":"Subject.Disorder","text":"anti-native DNA antibodies"},{"annotation":"Treatment","text":"ethambutol and rifampicin"},{"annotation":"Treatment.Drug","text":"ethambutol"},{"annotation":"Treatment.Drug","text":"rifampicin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"ethambutol"},{"annotation":"Treatment.Combination.Drug","text":"rifampicin"},{"annotation":"Treatment.Combination.Drug","text":"ethambutol"},{"annotation":"Treatment.Combination.Drug","text":"rifampicin"},{"annotation":"Treatment.Combination.Drug","text":"ethambutol"},{"annotation":"Treatment.Combination.Drug","text":"rifampicin"},{"annotation":"Treatment.Combination.Drug","text":"ethambutol"},{"annotation":"Treatment.Combination.Drug","text":"rifampicin"},{"annotation":"Treatment.Disorder","text":"polyarthritis"},{"annotation":"Treatment.Disorder","text":"hepatitis"},{"annotation":"Treatment.Disorder","text":"anti-native DNA antibodies"},{"annotation":"Treatment.Drug","text":"ethambutol"},{"annotation":"Treatment.Drug","text":"rifampicin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"ethambutol"},{"annotation":"Treatment.Combination.Drug","text":"rifampicin"},{"annotation":"Treatment.Combination.Drug","text":"ethambutol"},{"annotation":"Treatment.Combination.Drug","text":"rifampicin"},{"annotation":"Treatment.Combination.Drug","text":"ethambutol"},{"annotation":"Treatment.Combination.Drug","text":"rifampicin"},{"annotation":""}]}]}
{"id":"15507779_4","context":"We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"leukopenia"},{"annotation":"Treatment.Drug","text":"skin toxicity"},{"annotation":"Treatment.Drug","text":"hepatic toxicity"},{"annotation":"Treatment.Drug","text":"more severe leukopenia"},{"annotation":"Effect","text":"mild leukopenia"},{"annotation":"Subject","text":"an HIV-infected woman"},{"annotation":"Subject.Disorder","text":"HIV-infected"}]}]}
{"id":"18364401_2","context":"OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Treatment","text":"treatment with olanzapine"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Effect","text":"hyperglycemia"},{"annotation":"Treatment.Duration","text":"3 days"},{"annotation":"Subject","text":"geriatric patient"},{"annotation":"Subject.Age","text":"geriatric patient"},{"annotation":"Subject.Disorder","text":"hyperglycemia"},{"annotation":"Treatment.Disorder","text":"treatment with olanzapine"}]}]}
{"id":"12851279_15","context":"Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"tifacogin administration"},{"annotation":"Treatment.Drug","text":"tifacogin"},{"annotation":"Effect","text":"risk of bleeding"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"risk of bleeding"},{"annotation":"Treatment","text":"tifacogin administration"},{"annotation":"Treatment.Disorder","text":"irrespective of baseline INR"},{"annotation":"Treatment.Drug","text":"tifacogin"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"6618859_1","context":"Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"gynecomastia"},{"annotation":"Treatment","text":"oral fluoresone 750 mg daily"},{"annotation":"Treatment.Drug","text":"fluoresone"},{"annotation":"Treatment.Drug","text":"phenobarbital"},{"annotation":"Treatment.Drug","text":"phenytoin"},{"annotation":"Treatment.Duration","text":"months"},{"annotation":"Treatment.Combination.Trigger","text":"after the addition of"},{"annotation":"Treatment.Combination.Drug","text":"fluoresone"},{"annotation":"Treatment.Combination.Drug","text":"phenobarbital"},{"annotation":"Treatment.Combination.Drug","text":"phenytoin"},{"annotation":"Subject","text":"two epileptic patients"},{"annotation":"Subject.Disorder","text":"epileptic"}]}]}
{"id":"6113770_1","context":"The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"toxicity"},{"annotation":"Effect","text":"hyperpyrexia"},{"annotation":"Effect","text":"severe rigidity"},{"annotation":"Effect","text":"mutism"},{"annotation":"Effect","text":"irreversible tardive dyskinesia"},{"annotation":"Treatment","text":"combined lithium and haloperidol"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Drug","text":"haloperidol"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"lithium"},{"annotation":"Treatment.Combination.Drug","text":"haloperidol"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Age","text":"unknown"},{"annotation":"Subject.Gender","text":"unknown"},{"annotation":"Subject.Population","text":"1 patient"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Subject.Disorder","text":"combined lithium and haloperidol toxicity"},{"annotation":"Treatment.Disorder","text":"combined lithium and haloperidol toxicity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues showing the event is negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"no textual cues"}]}]}
{"id":"17665812_3","context":"Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"due"},{"annotation":"Treatment","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Disorder","text":"agranulocytosis"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"T"}]}]}
{"id":"7139589_4","context":"Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"reported"},{"annotation":"Effect","text":"pseudocyst of the pancreas"},{"annotation":"Treatment","text":"intravenous L-asparaginase"},{"annotation":"Treatment.Disorder","text":"pseudocyst of the pancreas"},{"annotation":"Treatment.Drug","text":"intravenous L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Subject","text":"three individuals"},{"annotation":"Subject.Disorder","text":"pseudocyst of the pancreas"}]}]}
{"id":"17182354_4","context":"We report a case of Ritalin-associated cataract and glaucoma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Effect","text":"cataract and glaucoma"},{"annotation":"Treatment","text":"Ritalin"},{"annotation":"Treatment.Drug","text":"Ritalin"},{"annotation":"Treatment.Disorder","text":"cataract and glaucoma"}]}]}
{"id":"19884751_3","context":"We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary to short-term therapy with Amikacin"},{"annotation":"Treatment","text":"Amikacin"},{"annotation":"Treatment.Disorder","text":"renal tubular dysfunction"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Effect","text":"severe"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Treatment.Drug","text":"Am"}]}]}
{"id":"1655228_1","context":"Cardiac toxicity related to BCNU has not been described well.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"related to BCNU"},{"annotation":"Effect","text":"cardiac toxicity"},{"annotation":"Treatment","text":"BCNU"},{"annotation":"Treatment.Disorder","text":"cardiac toxicity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{}]}]}
{"id":"12891225_2","context":"Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"enhances"},{"annotation":"Treatment","text":"prevention of chemotherapy-induced nausea and vomiting"},{"annotation":"Treatment.Disorder","text":"chemotherapy-induced nausea and vomiting"},{"annotation":"Treatment.Drug","text":"aprepitant"},{"annotation":"Treatment.Drug","text":"corticosteroid"},{"annotation":"Treatment.Drug","text":"5-hydroxytryptamine(3) (5-HT(3)) antagonist"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"corticosteroid"},{"annotation":"Treatment.Combination.Drug","text":"5-hydroxytryptamine(3) (5-HT(3)) antagonist"},{"annotation":"Subject","text":"patients"},{"annotation":"Subject.Disorder","text":"chemotherapy-induced nausea and vomiting"}]}]}
{"id":"17123120_2","context":"Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"HUS"},{"annotation":"Treatment","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"ARF"},{"annotation":"Treatment.Disorder","text":"HUS"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Disorder","text":"ARF"},{"annotation":"Treatment.Disorder","text":"HUS"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Disorder","text":"ARF"},{"annotation":"Treatment.Disorder","text":"HUS"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Disorder","text":"ARF"},{"annotation":"Treatment.Disorder","text":"HUS"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Disorder","text":"ARF"},{"annotation":"Treatment.Disorder","text":"HUS"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Disorder","text":"ARF"},{"annotation":"Treatment.Disorder","text":"HUS"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Disorder","text":"ARF"},{"annotation":"Treatment.Disorder","text":"HUS"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Disorder","text":"ARF"},{"annotation":"Treatment.Disorder","text":"HUS"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Disorder","text":"ARF"},{"annotation":"Treatment.Disorder","text":"HUS"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Disorder","text":"ARF"},{"annotation":"Treatment.Disorder","text":"HUS"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Disorder","text":"ARF"},{"annotation":"Treatment.Disorder","text":"HUS"},{"annotation":"Treatment.Drug","text":"tacrolimus"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Dis"}]}]}
{"id":"15927910_3","context":"Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"in patients receiving pentamidine"},{"annotation":"Effect","text":"cardiotoxicity"},{"annotation":"Treatment","text":"pentamidine"},{"annotation":"Treatment.Duration","text":"throughout the duration of therapy"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"}]}]}
{"id":"14684937_3","context":"The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hypercalcemia"},{"annotation":"Treatment","text":"vitamin D3 ointment and thiazide"},{"annotation":"Treatment.Disorder","text":"hypercalcemia"},{"annotation":"Treatment.Drug","text":"vitamin D3 ointment"},{"annotation":"Treatment.Drug","text":"thiazide"},{"annotation":"Subject","text":"the present case"},{"annotation":"Subject.Disorder","text":"hypercalcemia"}]}]}
{"id":"11352235_1","context":"CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"potential"},{"annotation":"Effect","text":"significant weight loss"},{"annotation":"Treatment","text":"leflunomide"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"potential"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.speculated","text":"not explicitly remarked"}]}]}
{"id":"7071645_2","context":"We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"nephrotic syndrome"},{"annotation":"Treatment","text":"rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"membranous nephropathy"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Drug","text":"penicillamine"},{"annotation":"negated","text":"not related to gold or penicillamine therapy"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"described"},{"annotation":"Effect","text":"man with classic rheumatoid arthritis"},{"annotation":"Treatment","text":"rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"membranous nephropathy"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Drug","text":"penicillamine"},{"annotation":"negated","text":"not related to gold or penicillamine therapy"}]}]}
{"id":"24531907_1","context":"Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"Pharmacokinetics"},{"annotation":"Treatment","text":"etravirine"},{"annotation":"Treatment.Drug","text":"etravirine"},{"annotation":"Treatment.Drug","text":"rifampin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"etravirine"},{"annotation":"Treatment.Combination.Drug","text":"rifampin"},{"annotation":"Subject","text":"HIV-infected patients"},{"annotation":"Subject.Disorder","text":"HIV-infected"}]}]}
{"id":"9352164_5","context":"We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"AZ"},{"annotation":"Treatment.Drug","text":"AZ"},{"annotation":"Treatment.Dosage","text":"excessive dose"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Effect","text":"hemorrhagic gastritis"},{"annotation":"Treatment.Disorder","text":"gastric mucosal barrier destruction"},{"annotation":"Treatment.Disorder","text":"thrombocytopenia due to bone marrow disorder"},{"annotation":"Treatment.Disorder","text":"bone marrow disorder"},{"annotation":"Treatment.Disorder","text":"hemorrhagic gastritis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"AZ"},{"annotation":"Treatment.Drug","text":"AZ"},{"annotation":"Treatment.Dosage","text":"excessive dose"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Effect","text":"hemorrhagic gastritis"},{"annotation":"Treatment.Disorder","text":"gastric mucosal barrier destruction"},{"annotation":"Treatment.Disorder","text":"thrombocytopenia due to bone marrow disorder"},{"annotation":"Treatment.Disorder","text":"bone marrow disorder"},{"annotation":"Treatment.Disorder","text":"hemorrhagic gastritis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"AZ"},{"annotation":"Treatment.Drug","text":"AZ"},{"annotation":"Treatment.Dosage","text":"excessive dose"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Effect","text":"hemorrhagic gastritis"},{"annotation":"Treatment.Disorder","text":"gastric mucosal barrier destruction"},{"annotation":"Treatment.Disorder","text":"thrombocytopenia due to bone marrow disorder"},{"annotation":"Treatment.Disorder","text":"bone marrow disorder"},{"annotation":"Treatment.Disorder","text":"hemorrhagic gastritis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"AZ"},{"annotation":"Treatment.Drug","text":"AZ"},{"annotation":"Treatment.Dosage","text":"excessive dose"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":""}]}]}
{"id":"8430717_1","context":"Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"neurotoxicity"},{"annotation":"Treatment","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Dosage","text":"overdose"},{"annotation":"Treatment.Dosage","text":"concentration-side effect relationship"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Age","text":"adult"},{"annotation":"Subject.Gender","text":"male"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Dosage","text":"overdose"},{"annotation":"Treatment.Dosage","text":"concentration-side effect relationship"},{"annotation":"Treatment.Dosage","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes"}]}]}
{"id":"1680596_2","context":"Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"after"},{"annotation":"Effect","text":"skin reaction"},{"annotation":"Treatment","text":"sulphasalazine therapy"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"sulphasalazine"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"the adverse effect does not exist"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"in"},{"annotation":"Effect","text":"psoriasis-like skin reaction"},{"annotation":"Treatment","text":"sulphasalazine therapy"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"sulphasalazine"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"the adverse effect does not exist"}]}]}
{"id":"10579985_4","context":"We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"diagnosed"},{"annotation":"Treatment","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Effect","text":"lymphoma"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Subject","text":"2 patients with Crohn's disease"},{"annotation":"Subject.Disorder","text":"Crohn's disease"},{"annotation":"Treatment","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment."}]}]}
{"id":"17275666_2","context":"Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"treatment"},{"annotation":"Treatment","text":"valproic acid"},{"annotation":"Treatment.Disorder","text":"idiopathic generalized epilepsies"},{"annotation":"Treatment.Disorder","text":"juvenile absence epilepsy"},{"annotation":"Treatment.Effect","text":"effective"},{"annotation":"Treatment.Effect","text":"commonly used"}]}]}
{"id":"14561622_3","context":"We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intrathecal methotrexate"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"intrathecal"},{"annotation":"Treatment.Route","text":"intrathecal"},{"annotation":"Effect","text":"left arm weakness and aphasia"},{"annotation":"Treatment.Disorder","text":"intrathecal methotrexate neurotoxicity"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"intrathecal methotrexate neurotoxicity"}]}]}
{"id":"22677303_11","context":"According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated ","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"warfarin-cloxacillin interaction"},{"annotation":"Effect","text":"increased INR value"},{"annotation":"Treatment","text":"warfarin"},{"annotation":"Treatment.Drug","text":"cloxacillin"},{"annotation":"Treatment.Interaction","text":"warfarin-cloxacillin interaction"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Disorder","text":"warfarin-induced bleeding"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Disorder","text":"hemorrhage"},{"annotation":"Treatment.Disorder","text":"thrombosis"},{"annotation":"Treatment.Disorder","text":"warfarin-induced bleeding"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Disorder","text":"hemorrhage"},{"annotation":"Treatment.Disorder","text":"thrombosis"},{"annotation":"Treatment.Disorder","text":"warfarin-induced bleeding"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Disorder","text":"hemorrhage"},{"annotation":"Treatment.Disorder","text":"thrombosis"},{"annotation":"Treatment.Disorder","text":"warfarin-induced bleeding"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Disorder","text":"hemorrhage"},{"annotation":"Treatment.Disorder","text":"thrombosis"},{"annotation":"Treatment.Disorder","text":"warfarin-induced bleeding"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Disorder","text":"hemorrhage"},{"annotation":"Treatment.Disorder","text":"thrombosis"},{"annotation":"Treatment.Disorder","text":"warfarin-induced bleeding"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Disorder","text":"hemorrhage"},{"annotation":"Treatment.Disorder","text":"thrombosis"},{"annotation":"Treatment.Disorder","text":"warfarin-induced bleeding"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Disorder","text":"hemorrhage"},{"annotation":"Treatment.Disorder","text":"thrombosis"},{"annotation":"Treatment.Disorder","text":"warfarin-induced bleeding"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Disorder","text":"hemorrhage"},{"annotation":"Treatment.Disorder","text":"thrombosis"},{"annotation":"Treatment.Disorder","text":"warfarin-induced bleeding"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Disorder","text":"hemorrhage"},{}]}]}
{"id":"16393774_4","context":"We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"inflammatory musculoskeletal manifestations"},{"annotation":"Treatment","text":"IFN-beta therapy"},{"annotation":"Treatment.Disorder","text":"relapsing-remitting multiple sclerosis (RRMS)"},{"annotation":"Treatment.Drug","text":"IFN-beta"},{"annotation":"Subject","text":"two female patients"},{"annotation":"Subject.Gender","text":"female"},{"annotation":"Subject.Population","text":"two patients"},{"annotation":"Subject.Disorder","text":"relapsing-remitting multiple sclerosis (RRMS)"},{"annotation":"Treatment.Drug","text":"IFN-beta"}]}]}
{"id":"440873_1","context":"Dystonia associated with carbamazepine administration: experience in brain-damaged children.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"dystonia"},{"annotation":"Treatment","text":"carbamazepine administration"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Disorder","text":"brain-damaged children"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Disorder","text":"brain-damaged children"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Disorder","text":"brain-damaged children"},{"annotation":"Subject","text":"brain-damaged children"},{"annotation":"Subject.Disorder","text":"brain-damaged children"}]}]}
{"id":"20925534_10","context":"In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"gastrointestinal event"},{"annotation":"Event rate","text":"1.1% with omeprazole and 2.9% with placebo at 180 days"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Disorder","text":"gastrointestinal event"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Treatment.Duration","text":"180 days"},{"annotation":"Treatment.Hazard ratio","text":"0.34 (95% confidence interval [CI], 0.18 to 0.63; P<0.001)"},{"annotation":"Treatment.Effect","text":"gastrointestinal event"},{"annotation":"Treatment.Patient_population","text":"51 patients"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"gastrointestinal event"},{"annotation":"Event rate","text":"1.1% with omeprazole and 2.9% with placebo at 180 days"},{"annotation":"Treatment","text":"placebo"},{"annotation":"Treatment.Disorder","text":"gastrointestinal event"},{"annotation":"Treatment.Drug","text":"placebo"},{"annotation":"Treatment.Duration","text":"180 days"},{"annotation":"Treatment.Hazard ratio","text":"0.34 (95% confidence interval [CI], 0.18 to 0.63; P<0.001)"},{"annotation":"Treatment.Effect","text":"gastrointestinal event"},{"annotation":"Treatment.Patient_population","text":"51 patients"}]}]}
{"id":"9865241_1","context":"CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"significant hypercalcemia"},{"annotation":"Treatment","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"acute vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Duration","text":"for significant hypercalcemia"},{"annotation":"Effect","text":"reduced hypercalcemia"},{"annotation":"Treatment.Dosage","text":"pamidronate"},{"annotation":"Treatment.Frequency","text":"pamidronate"},{"annotation":"Treatment.Route","text":"pamidronate"},{"annotation":"Treatment.Time_elapsed","text":"reduced hypercalcemia"},{"annotation":"Treatment.Duration","text":"for significant hypercalcemia"},{"annotation":"Treatment.Disorder","text":"acute vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Dosage","text":"pamidronate"},{"annotation":"Treatment.Frequency","text":"pamidronate"},{"annotation":"Treatment.Route","text":"pamidronate"},{"annotation":"Treatment.Time_elapsed","text":"reduced hypercalcemia"},{"annotation":"Treatment.Duration","text":"for significant hypercalcemia"},{"annotation":"Treatment.Disorder","text":"acute vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Dosage","text":"pamidronate"},{"annotation":"Treatment.Frequency","text":"pamidronate"},{"annotation":"Treatment.Route","text":"pamidronate"},{"annotation":"Treatment.Time_elapsed","text":"reduced hypercalcemia"},{"annotation":"Treatment.Duration","text":"for significant hypercalcemia"},{"annotation":"Treatment.Disorder","text":"acute vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Dosage","text":"pamidronate"},{"annotation":"Treatment.Frequency","text":"pamidronate"},{"annotation":"Treatment.Route","text":"pamidronate"},{"annotation":"Treatment.Time_elapsed","text":"reduced hypercalcemia"},{"annotation":"Treatment.Duration","text":"for significant hypercalcemia"},{"annotation":"Treatment.Disorder","text":"acute vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Dosage","text":"pamidronate"},{"annotation":"Treatment.Frequency","text":"pamidronate"},{"annotation":"Treatment.Route","text":"pamidronate"},{"annotation":"Treatment.Time_elapsed","text":"reduced hypercalcemia"},{"annotation":"Treatment.Duration","text":"for significant hypercalcemia"},{"annotation":"Treatment.Disorder","text":"acute vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Dosage","text":"pamidronate"}]}]}
{"id":"20925534_1","context":"Clopidogrel with or without omeprazole in coronary artery disease.","events":[{"type":"Potential_therapeutic_event","annotations":[{"annotation":"Trigger","text":"with or without"},{"annotation":"Treatment","text":"clopidogrel"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment","text":"coronary artery disease"},{"annotation":"Treatment.Disorder","text":"coronary artery disease"},{"annotation":"Treatment.Drug","text":"clopidogrel"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"clopidogrel"},{"annotation":"Treatment.Combination.Drug","text":"omeprazole"},{"annotation":"Subject","text":"coronary artery disease"},{"annotation":"Subject.Disorder","text":"coronary artery disease"}]}]}
{"id":"11001600_1","context":"The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"risperidone"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Effect","text":"dystonia"},{"annotation":"Treatment.Drug","text":"dystonia"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Treatment.Disorder","text":"dementia"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Treatment.Drug","text":"dystonia"},{"annotation":"Subject","text":"patients with dementia"},{"annotation":"Subject.Disorder","text":"dementia"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"neg"}]}]}
{"id":"18580694_1","context":"In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"prolonged"},{"annotation":"Treatment","text":"ECT seizure"},{"annotation":"Treatment.Drug","text":"ciprofloxacin"},{"annotation":"Treatment.Disorder","text":"prolonged ECT seizure"},{"annotation":"Treatment.Drug","text":"beta-lactam antibiotics"},{"annotation":"Attribute","text":"epileptogenic property"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"related to"},{"annotation":"Treatment","text":"ciprofloxacin"},{"annotation":"Treatment.Drug","text":"ciprofloxacin"},{"annotation":"Treatment.Drug","text":"beta-lactam antibiotics"},{"annotation":"Attribute","text":"epileptogenic property"},{"annotation":"Attribute","text":"similar action"}]}]}
{"id":"10592946_2","context":"After abstinence from oolong tea his delirium resolved.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"After abstinence"},{"annotation":"Treatment","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Duration","text":"abstinence"},{"annotation":"Effect","text":"delirium resolved"},{"annotation":"Treatment.Disorder","text":"delirium"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"delirium resolved"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"After abstinence"},{"annotation":"Treatment","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Duration","text":"abstinence"},{"annotation":"Effect","text":"delirium resolved"},{"annotation":"Treatment.Disorder","text":"delirium"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"delirium resolved"}]}]}
{"id":"16901609_1","context":"Anaphylaxis to intrathecal diamorphine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"intrathecal diamorphine"},{"annotation":"Treatment.Drug","text":"intrathecal diamorphine"},{"annotation":"Effect","text":"anaphylaxis"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"anaphylaxis"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"}]}]}
{"id":"8726608_3","context":"This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"resulted"},{"annotation":"Effect","text":"increased serum lithium concentrations"},{"annotation":"Treatment","text":"intravenous acyclovir"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Dosage","text":"10 mg/kg"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Disorder","text":"lithium concentrations"},{"annotation":"Treatment.Disorder","text":"serum lithium concentrations"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"suggests"},{"annotation":"Treatment","text":"acyclovir"},{"annotation":"Treatment.Disorder","text":"lithium concentrations"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Dosage","text":"10 mg/kg"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Disorder","text":"serum lithium concentrations"},{"annotation":"Treatment.Disorder","text":"lithium concentrations"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"suggests"},{"annotation":"Treatment","text":"acyclovir"},{"annotation":"Treatment.Disorder","text":"lithium concentrations"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Dosage","text":"10 mg/kg"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Disorder","text":"serum lithium concentrations"},{"annotation":"Treatment.Disorder","text":"lithium concentrations"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"suggests"},{"annotation":"Treatment","text":"acyclovir"},{"annotation":"Treatment.Disorder","text":"lithium concentrations"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Dosage","text":"10 mg/kg"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Disorder","text":"serum lithium concentrations"},{"annotation":"Treatment.Disorder","text":"lithium concentrations"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"suggests"},{"annotation":"Treatment","text":"acyclovir"},{"annotation":"Treatment.Disorder","text":"lithium concentrations"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Dosage","text":"10 mg/kg"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Disorder","text":"serum lithium concentrations"},{"annotation":"Treatment.Disorder","text":"lithium concentrations"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"suggests"},{"annotation":"Treatment","text":"acyclovir"},{"annotation":"Treatment.Disorder","text":"l"}]}]}
{"id":"15522120_12","context":"After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"after eating"},{"annotation":"Effect","text":"intense itching sensation"},{"annotation":"Treatment","text":"sertraline"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Time_elapsed","text":"after approximately two weeks"},{"annotation":"Treatment.Food","text":"chocolate cake"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"for ADE, the adverse effect does not exist; or for PTE, the therapy is ineffective."}]}]}
{"id":"8589490_2","context":"Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"known"},{"annotation":"Effect","text":"pigmentary aberrations"},{"annotation":"Treatment","text":"cytostatic chemotherapeutic agents"}]}]}
{"id":"7485371_1","context":"CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"CONCLUSION"},{"annotation":"Treatment","text":"Atovaquone"},{"annotation":"Treatment.Disorder","text":"vortex keratopathy involving the corneal epithelium"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"Atovaquone"},{"annotation":"Treatment","text":"Atovaquone"},{"annotation":"Treatment.Drug","text":"Atovaquone"},{"annotation":"Effect","text":"vortex keratopathy involving the corneal epithelium"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"}]}]}
{"id":"10812579_2","context":"A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"seizure"},{"annotation":"Treatment","text":"injection of naloxone"},{"annotation":"Treatment.Drug","text":"naloxone"},{"annotation":"Treatment.Dosage","text":"a few minutes after"},{"annotation":"Treatment.Frequency","text":"a single dose"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"seizure"},{"annotation":"Treatment","text":"injection of morphine antagonist naloxone"},{"annotation":"Treatment.Drug","text":"naloxone"},{"annotation":"Treatment.Dosage","text":"a few minutes after"},{"annotation":"Treatment.Frequency","text":"a single dose"}]}]}
{"id":"7748076_1","context":"CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.","events":[{"type":"Conclusion","annotations":[{"annotation":"Treatment","text":"progestin therapy"},{"annotation":"Treatment.Disorder","text":"squamous metaplasia"},{"annotation":"Effect","text":"appears to be a consequence"},{"annotation":"Treatment","text":"progestin therapy"}]}]}
{"id":"6610943_4","context":"This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"association"},{"annotation":"Treatment","text":"vasopressin-treated gastrointestinal hemorrhage"},{"annotation":"Treatment.Disorder","text":"gastrointestinal hemorrhage"},{"annotation":"Treatment.Drug","text":"vasopressin"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.severity","text":"low severity"},{"annotation":"Attribute.speculated","text":"not speculated"},{"annotation":"Subject","text":"the patient"},{"annotation":"Subject.Population","text":"1 patient"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Subject.Age","text":"unknown"},{"annotation":"Subject.Disorder","text":"gastrointestinal hemorrhage"},{"annotation":"Treatment","text":"vasopressin-treated gastrointestinal hemorrhage"},{"annotation":"Treatment.Drug","text":"vasopressin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Effect","text":"association"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.severity","text":"low severity"},{"annotation":"Attribute.speculated","text":"not speculated"},{"annotation":"Treatment","text":"vasopressin-treated gastrointestinal hemorrhage"},{"annotation":"Treatment.Drug","text":"vasopressin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Effect","text":"association"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.severity","text":"low severity"},{"annotation":"Attribute.speculated","text":"not speculated"},{"annotation":"Treatment","text":"vasopressin-treated gastrointestinal hemorrhage"},{"annotation":"Treatment.Drug","text":"vasopressin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Effect","text":"association"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.severity","text":"low severity"},{"annotation":"Attribute.speculated","text":"not speculated"},{"annotation":"Treatment","text":"vasopressin-treated gastrointestinal hemorrhage"},{"annotation":"Treatment.Drug","text":"vasopressin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":""}]}]}
{"id":"6693840_4","context":"The gynecomastia regressed when the theophylline was discontinued.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"regressed"},{"annotation":"Effect","text":"gynecomastia"},{"annotation":"Treatment","text":"theophylline"},{"annotation":"Treatment.Disorder","text":"gynecomastia"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"discontinued"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"discontinued"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"regressed"},{"annotation":"Treatment","text":"theophylline"},{"annotation":"Treatment.Disorder","text":"gynecomastia"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"discontinued"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"discontinued"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"discontinued"}]}]}
{"id":"3277077_1","context":"Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused"},{"annotation":"Effect","text":"renal hypophosphatemia"},{"annotation":"Treatment","text":"erroneous intake of 1 g doxycycline"},{"annotation":"Treatment.Drug","text":"doxycycline"},{"annotation":"Treatment.Dosage","text":"1 g"},{"annotation":"Treatment.Dosage","text":"doxycycline"},{"annotation":"Treatment.Dosage","text":"doxycycline"},{"annotation":"Treatment.Dosage","text":"doxycycline"},{"annotation":"Subject","text":"this patient"},{"annotation":"Subject.Disorder","text":"renal hypophosphatemia"}]}]}
{"id":"2297635_1","context":"Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Effect","text":"visual loss and loss of consciousness"},{"annotation":"Treatment","text":"MTX and Ara-C"},{"annotation":"Treatment.Disorder","text":"meningeal tumor"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"Ara-C"},{"annotation":"Treatment.Duration","text":"3 weeks"},{"annotation":"Subject","text":"the patient"},{"annotation":"Subject.Disorder","text":"meningeal tumor"}]},{"type":"Adverse_event","annotations":[{"annotation":"Effect","text":"death"},{"annotation":"Treatment","text":"MTX and Ara-C"},{"annotation":"Treatment.Disorder","text":"meningeal tumor"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Drug","text":"Ara-C"},{"annotation":"Treatment.Duration","text":"3 weeks"},{"annotation":"Subject","text":"the patient"},{"annotation":"Subject.Disorder","text":"meningeal tumor"}]}]}
{"id":"1087773_1","context":"After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"polyarthritis"},{"annotation":"Effect","text":"rash"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol"},{"annotation":"Treatment.Drug","text":"rifampicin"},{"annotation":"Treatment.Drug","text":"ethambutol"},{"annotation":"Treatment.Duration","text":"seven months"},{"annotation":"Treatment.Disorder","text":"suspected tuberculosis"},{"annotation":"Attribute Attributes","text":"positive antinuclear factor"},{"annotation":"Attribute Attributes","text":"anti-native DNA antibodies"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"polyarthritis"},{"annotation":"Effect","text":"rash"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol"},{"annotation":"Treatment.Drug","text":"rifampicin"},{"annotation":"Treatment.Drug","text":"ethambutol"},{"annotation":"Treatment.Duration","text":"seven months"},{"annotation":"Treatment.Disorder","text":"suspected tuberculosis"},{"annotation":"Attribute Attributes","text":"positive antinuclear factor"},{"annotation":"Attribute Attributes","text":"anti-native DNA antibodies"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"}]}]}
{"id":"16609346_1","context":"A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"suggested"},{"annotation":"Effect","text":"myasthenic syndrome"},{"annotation":"Treatment","text":"statin treatment"},{"annotation":"Treatment.Disorder","text":"myasthenic syndrome"},{"annotation":"Treatment.Drug","text":"statin"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"statin"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"statin"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.Drug","text":"treatment"},{"annotation":"Treatment.D"}]}]}
{"id":"21658326_2","context":"Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Effect","text":"acceptance"},{"annotation":"Treatment","text":"topical imiquimod and TNF-alpha inhibitors"},{"annotation":"Treatment.Disorder","text":"non-melanoma skin cancer"},{"annotation":"Treatment.Disorder","text":"moderate to severe psoriasis"},{"annotation":"Treatment.Drug","text":"imiquimod"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"topical"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"topical"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"non-melanoma skin cancer"},{"annotation":"Treatment.Drug","text":"moderate to severe psoriasis"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"topical"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"topical"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{"annotation":"Treatment.Drug","text":"TNF-alpha inhibitors"},{}]}]}
{"id":"6731466_1","context":"Focal renal cortical necrosis associated with zomepirac.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"zomepirac"},{"annotation":"Treatment.Drug","text":"zomepirac"},{"annotation":"Effect","text":"necrosis"},{"annotation":"Treatment.Disorder","text":"renal cortical necrosis"},{"annotation":"Treatment.Drug","text":"zomepirac"}]}]}
{"id":"8850251_6","context":"We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"photosensitivity reaction"},{"annotation":"Treatment","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Disorder","text":"dermatologic problems"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment"}]}]}
{"id":"20349794_4","context":"Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"episodes"},{"annotation":"Treatment","text":"cisplatin"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Effect","text":"SIADH"},{"annotation":"Treatment.Substitution","text":"substituted"},{"annotation":"Treatment.Substitution","text":"with carboplatin"},{"annotation":"Treatment.Drug","text":"carboplatin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"no further episodes of SIADH"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"episodes"},{"annotation":"Treatment","text":"cisplatin"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Effect","text":"SIADH"},{"annotation":"Treatment.Substitution","text":"substituted"},{"annotation":"Treatment.Substitution","text":"with carboplatin"},{"annotation":"Treatment.Drug","text":"carboplatin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"no further episodes of SIADH"}]}]}
{"id":"16490518_3","context":"Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"glaucoma"},{"annotation":"Treatment","text":"intravitreal injection of triamcinolone acetonide"},{"annotation":"Treatment.Drug","text":"triamcinolone acetonide"},{"annotation":"Treatment.Disorder","text":"steroid-induced glaucoma"},{"annotation":"Treatment.Drug","text":"triamcinolone"},{"annotation":"Treatment.Route","text":"intravitreal"},{"annotation":"Treatment.Time_elapsed","text":"severe"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"steroid-induced glaucoma"}]}]}
{"id":"16160485_1","context":"CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"progression"},{"annotation":"Treatment","text":"rituximab"},{"annotation":"Treatment.Disorder","text":"nodular lymphocyte-predominant Hodgkin's lymphoma"},{"annotation":"Treatment.Drug","text":"rituximab"},{"annotation":"Effect","text":"CD20-negative T-cell-rich B-cell lymphoma"},{"annotation":"Treatment.Drug","text":"rituximab"},{"annotation":"Treatment.Disorder","text":"nodular lymphocyte-predominant Hodgkin's lymphoma"},{"annotation":"Treatment.Drug","text":"rituximab"},{"annotation":"Effect","text":"CD20-negative T-cell-rich B-cell lymphoma"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Subject","text":"a nodular lymphocyte-predominant Hodgkin's lymphoma patient"},{"annotation":"Subject.Disorder","text":"nodular lymphocyte-predominant Hodgkin's lymphoma"},{"annotation":"Treatment","text":"rituximab"},{"annotation":"Treatment.Drug","text":"rituximab"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment.Drug","text":"rituximab"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular analysis using laser capture microdissection"},{"annotation":"Treatment","text":"molecular"}]}]}
{"id":"10717401_2","context":"We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presented with"},{"annotation":"Effect","text":"transient ischemic attacks and seizure"},{"annotation":"Treatment","text":"consolidation treatment with L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Disease","text":"acute lymphoblastic leukemia"},{"annotation":"Subject","text":"an adult patient"},{"annotation":"Subject.Disorder","text":"acute lymphoblastic leukemia"}]}]}
{"id":"16317298_1","context":"Gemcitabine-related radiation recall in a patient with pancreatic cancer.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"related"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Disorder","text":"pancreatic cancer"},{"annotation":"Treatment.Radiation","text":"radiation recall"},{"annotation":"Treatment.Radiation","text":"radiation"},{"annotation":"Treatment.Radiation","text":"radiation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":""}]}]}
{"id":"8404753_7","context":"After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"development"},{"annotation":"Treatment","text":"CBZ"},{"annotation":"Treatment.Drug","text":"CBZ"},{"annotation":"Effect","text":"tics"},{"annotation":"Treatment.Dosage","text":"same or higher dose"},{"annotation":"Treatment.Duration","text":"< or = 6 months"},{"annotation":"Treatment.Dosage","text":"same or higher dose"},{"annotation":"Treatment.Duration","text":"< or = 6 months"},{"annotation":"Subject","text":"2"},{"annotation":"Subject.Disorder","text":"tics"}]}]}
{"id":"16978752_4","context":"Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurring"},{"annotation":"Effect","text":"severe neutropenia"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"severe neutropenia"},{"annotation":"Treatment.Side_effect","text":"severe neutropenia"},{"annotation":"Treatment.Disorder","text":"neutropenia"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"attribute","text":"severity"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute"}]}]}
{"id":"18203308_4","context":"We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"new onset of CD"},{"annotation":"Effect","text":"CD"},{"annotation":"Treatment","text":"etanercept"},{"annotation":"Treatment.Disorder","text":"active AS"},{"annotation":"Treatment.Drug","text":"etanercept"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{}]}]}
{"id":"11510798_5","context":"It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"aforementioned pathological manifestations"},{"annotation":"Effect","text":"were due to chemotherapy"},{"annotation":"Treatment","text":"oxaliplatinum and 5-fluorouracil regimens"},{"annotation":"Treatment.Disorder","text":"pulmonary adverse reaction"},{"annotation":"Treatment.Drug","text":"oxaliplatinum"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens"},{"annotation":"Treatment","text":"oxaliplatinum and 5-fluorouracil regimens"},{"annotation":"Treatment.Disorder","text":"pulmonary adverse reaction"},{"annotation":"Treatment.Drug","text":"oxaliplatinum"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"}]}]}
{"id":"17619811_2","context":"A case of colchicine-induced rhabdomyolysis is reported.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"colchicine"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"}]},{"type":"Attribute Attributes","annotations":[{"annotation":"attribute negated","text":"negated"},{"annotation":"attribute severity","text":"high severity"}]}]}
{"id":"7056119_4","context":"Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"recurrence of paroxysmal atrial fibrillation"},{"annotation":"Treatment","text":"drug was increased to 1.4 g/day"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Effect","text":"AVT with syncope"},{"annotation":"Treatment","text":"promptly responded to atropine"},{"annotation":"Treatment.Drug","text":"atropine"},{"annotation":"Treatment.Duration","text":"24 hours"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Subject","text":"paroxysmal atrial fibrillation"},{"annotation":"Subject.Disorder","text":"paroxysmal atrial fibrillation"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"AVT with syncope"},{"annotation":"Treatment","text":"promptly responded to atropine"},{"annotation":"Treatment.Drug","text":"atropine"},{"annotation":"Treatment.Duration","text":"24 hours"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"T"}]}]}
{"id":"17167851_2","context":"Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"emerged"},{"annotation":"Effect","text":"severe hepatotoxic reactions"},{"annotation":"Treatment","text":"CPA administration"},{"annotation":"Treatment.Drug","text":"CPA"},{"annotation":"Subject","text":"three male patients"},{"annotation":"Subject.Age","text":"78-83 years"},{"annotation":"Subject.Population","text":"three male patients"},{"annotation":"Treatment.Time_elapsed","text":"after CPA administration"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"severe hepatotoxic reactions"},{"annotation":"Treatment.Drug","text":"CPA"}]}]}
{"id": "172214_2", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "events": [{"type": "Adverse_event", "annotations": [{"annotation": "Trigger", "text": "temporally related to"}, {"annotation": "Effect", "text": "exacerbations of heart failure"}, {"annotation": "Treatment", "text": "antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559)"}, {"annotation": "Treatment.Disorder", "text": "heart failure"}, {"annotation": "Treatment.Drug", "text": "actinomycin-D (NSC-3053)"}, {"annotation": "Treatment.Drug", "text": "mithramycin (NSC-24559)"}, {"annotation": "Treatment.Combination.Trigger", "text": "and"}, {"annotation": "Treatment.Combination.Drug", "text": "actinomycin-D (NSC-3053)"}, {"annotation": "Treatment.Combination.Drug", "text": "mithramycin (NSC-24559)"}, {"annotation": "Subject", "text": "heart failure"}, {"annotation": "Subject.Disorder", "text": "heart failure"}]}]}
{"id":"18347524_1","context":"Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"after"},{"annotation":"Effect","text":"hemorrhage"},{"annotation":"Treatment","text":"leflunomide therapy"},{"annotation":"Treatment.Drug","text":"leflunomide"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Subject","text":"a patient with rheumatoid arthritis"},{"annotation":"Subject.Disorder","text":"rheumatoid arthritis"}]}]}
{"id":"15836666_2","context":"We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"secondary adrenocortical insufficiency"},{"annotation":"Treatment","text":"transdermal fentanyl"},{"annotation":"Treatment.Drug","text":"fentanyl"},{"annotation":"Treatment.Disease","text":"sciatic pain syndrome"},{"annotation":"Treatment.Duration","text":"chronic"},{"annotation":"Treatment.Dosage","text":"transdermal fentanyl"},{"annotation":"Treatment.Frequency","text":"transdermal fentanyl"},{"annotation":"Treatment.Route","text":"transdermal"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Duration","text":"sciatic pain syndrome"},{"annotation":"Treatment.Disorder","text":"secondary adrenocortical insufficiency"},{"annotation":"Treatment.Drug","text":"fentanyl"},{"annotation":"Treatment.Dosage","text":"transdermal fentanyl"},{"annotation":"Treatment.Frequency","text":"transdermal fentanyl"},{"annotation":"Treatment.Route","text":"transdermal"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Duration","text":"sciatic pain syndrome"},{"annotation":"Treatment.Disorder","text":"secondary adrenocortical insufficiency"},{"annotation":"Treatment.Drug","text":"fentanyl"},{"annotation":"Treatment.Dosage","text":"transdermal fentanyl"},{"annotation":"Treatment.Frequency","text":"transdermal fentanyl"},{"annotation":"Treatment.Route","text":"transdermal"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Duration","text":"sciatic pain syndrome"},{"annotation":"Treatment.Disorder","text":"secondary adrenocortical insufficiency"},{"annotation":"Treatment.Drug","text":"fentanyl"},{"annotation":"Treatment.Dosage","text":"transdermal fentanyl"},{"annotation":"Treatment.Frequency","text":"transdermal fentanyl"},{"annotation":"Treatment.Route","text":"transdermal"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Duration","text":"sciatic pain syndrome"},{"annotation":"Treatment.Disorder","text":"secondary adrenocortical insufficiency"},{"annotation":"Treatment.Drug","text":"fentanyl"},{"annotation":"Treatment.Dosage","text":"transdermal fentanyl"},{"annotation":"Treatment.Frequency","text":"transdermal fentanyl"},{"annotation":"Treatment.Route","text":"transdermal"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Duration","text":"sciatic pain syndrome"},{"annotation":"Treatment.Disorder","text":"secondary adrenocortical insufficiency"},{"annotation":"Treatment.Drug","text":"fentanyl"},{"annotation":"Treatment.Dosage","text":"transdermal fentanyl"},{"annotation":"Treatment.Frequency"}]}]}
{"id":"6440806_1","context":"A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"fever, cough, dyspnea"},{"annotation":"Treatment","text":"sodium aurothiomalate"},{"annotation":"Treatment.Drug","text":"sodium aurothiomalate"},{"annotation":"Treatment.Duration","text":"8 weeks"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Subject","text":"a 52-year-old, white female"},{"annotation":"Subject.Age","text":"52"},{"annotation":"Subject.Gender","text":"white female"},{"annotation":"Subject.Population","text":"one patient"},{"annotation":"Subject.Race","text":"white"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"8 weeks"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"response"},{"annotation":"Treatment","text":"sodium aurothiomalate"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"sodium aurothiomalate"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.speculated","text":"not specified"}]}]}
{"id":"12786839_1","context":"In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"high fever, skin rash, liver dysfunction and atypical lymphocytosis"},{"annotation":"Treatment","text":"initiating treatment with SASP"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Time_elapsed","text":"3 weeks"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"high fever, skin rash, liver dysfunction and atypical lymphocytosis"},{"annotation":"Treatment","text":"initiating treatment with SASP"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Time_elapsed","text":"3 weeks"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"}]}]}
{"id":"12659609_2","context":"OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"toxicity"},{"annotation":"Effect","text":"severe chloroquine toxicity"},{"annotation":"Treatment","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Disorder","text":"chloroquine-resistant Plasmodium vivax"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Drug"}]}]}
{"id":"15857283_4","context":"RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"previous use of rifabutin"},{"annotation":"Effect","text":"corneal endothelial deposits"},{"annotation":"Treatment","text":"rifabutin"},{"annotation":"Treatment.Drug","text":"rifabutin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"The adverse effect of corneal endothelial deposits does not exist."}]}]}
{"id":"3136101_2","context":"Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"hyperkalemia"},{"annotation":"Treatment","text":"cessation of prolonged ACTH therapy"},{"annotation":"Treatment.Disorder","text":"infantile spasms"},{"annotation":"Treatment.Drug","text":"ACTH"},{"annotation":"Treatment.Duration","text":"prolonged"},{"annotation":"Treatment.Duration","text":"shortly after"},{"annotation":"Subject","text":"two infants"},{"annotation":"Subject.Age","text":"infants"},{"annotation":"Subject.Disorder","text":"infantile spasms"}]}]}
{"id":"19318596_2","context":"In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.","events":[{"type":"Potential_therapeutic_event","annotations":[{"annotation":"Trigger","text":"CIPS was considered"},{"annotation":"Treatment","text":"cyclosporine"},{"annotation":"Treatment.Disorder","text":"CIPS"},{"annotation":"Treatment.Drug","text":"cyclosporine"},{"annotation":"Attribute","text":"probably associated"},{"annotation":"Attribute.Attribute","text":"with cyclosporine"},{"annotation":"Attribute.Probability_scale","text":"Naranjo probability scale"},{"annotation":"Attribute.Probability_value","text":"probably associated"}]}]}
{"id":"18751717_1","context":"Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Treatment","text":"intravitreal triamcinolone acetonide injection"},{"annotation":"Treatment.Drug","text":"triamcinolone acetonide"},{"annotation":"Treatment.Dosage","text":"intravitreal"},{"annotation":"Treatment.Route","text":"injection"},{"annotation":"Treatment.Duration","text":"acute"},{"annotation":"Treatment.Disorder","text":"syphilitic posterior placoid chorioretinitis"},{"annotation":"Effect","text":"chorioretinitis"}]}]}
{"id":"7139589_2","context":"Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"delayed"},{"annotation":"Effect","text":"pseudocyst"},{"annotation":"Treatment","text":"intramuscular L-asparaginase"},{"annotation":"Treatment.Disorder","text":"pancreatitis"},{"annotation":"Treatment.Drug","text":"L-asparaginase"}]}]}
{"id":"7783891_3","context":"I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"receiving"},{"annotation":"Treatment","text":"subcutaneous sumatriptan"},{"annotation":"Treatment.Drug","text":"sumatriptan"},{"annotation":"Effect","text":"cardiac arrest"},{"annotation":"Treatment","text":"migraine"},{"annotation":"Treatment.Disorder","text":"occult coronary artery disease"},{"annotation":"Subject","text":"a 35-year-old woman"},{"annotation":"Subject.Disorder","text":"occult coronary artery disease"},{"annotation":"Treatment","text":"migraine"},{"annotation":"Treatment.Disorder","text":"migraine"},{"annotation":"Treatment","text":"sumatriptan"},{"annotation":"Treatment.Drug","text":"sumatriptan"},{"annotation":"Treatment","text":"migraine"},{"annotation":"Treatment.Disorder","text":"migraine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"cardiac arrest"},{"annotation":"Treatment","text":"subcutaneous sumatriptan"},{"annotation":"Treatment.Drug","text":"sumatriptan"},{"annotation":"Effect","text":"cardiac arrest"},{"annotation":"Treatment","text":"migraine"},{"annotation":"Treatment.Disorder","text":"occult coronary artery disease"},{"annotation":"Subject","text":"a 35-year-old woman"},{"annotation":"Subject.Disorder","text":"occult coronary artery disease"},{"annotation":"Treatment","text":"migraine"},{"annotation":"Treatment.Disorder","text":"migraine"},{"annotation":"Treatment","text":"sumatriptan"},{"annotation":"Treatment.Drug","text":"sumatriptan"},{"annotation":"Treatment","text":"migraine"},{"annotation":"Treatment.Disorder","text":"migraine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"cardiac arrest"},{"annotation":"Treatment","text":"subcutaneous sumatriptan"},{"annotation":"Treatment.Drug","text":"sumatriptan"},{"annotation":"Effect","text":"cardiac arrest"},{"annotation":"Treatment","text":"migraine"},{"annotation":"Treatment.Disorder","text":"occult coronary artery disease"},{"annotation":"Subject","text":"a 35-year-old woman"},{"annotation":"Subject.Disorder","text":"occult coronary artery disease"},{"annotation":"Treatment","text":"migraine"},{"annotation":"Treatment.Disorder","text":"migraine"},{"annotation":"Treatment","text":"sumatriptan"},{"annotation":"Treatment.Drug","text":"sumatriptan"},{"annotation":"Treatment","text":"migraine"},{"annotation":"Treatment.Disorder","text":"migraine"}]}]}
{"id":"10332990_2","context":"Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"epoprostenol (prostacyclin)"},{"annotation":"Treatment.Disorder","text":"primary pulmonary hypertension"},{"annotation":"Treatment.Disorder","text":"scleroderma"},{"annotation":"Treatment.Drug","text":"epoprostenol (prostacyclin)"}]}]}
{"id":"11724089_4","context":"OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"toxic epidermal necrolysis"},{"annotation":"Treatment","text":"oral ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Disorder","text":"epididymitis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"fatal outcome"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"toxic epidermal necrolysis"},{"annotation":"Treatment","text":"oral ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Disorder","text":"epididymitis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"fatal outcome"}]}]}
{"id":"12869178_1","context":"Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"late-onset heparin-induced thrombocytopenia"},{"annotation":"Effect","text":"massive pulmonary embolism"},{"annotation":"Treatment","text":"coronary artery bypass graft surgery"},{"annotation":"Treatment.Disorder","text":"late-onset heparin-induced thrombocytopenia"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Treatment.Drug","text":"lepirudin"},{"annotation":"Treatment.Dosage","text":"successful treatment"},{"annotation":"Treatment.Frequency","text":"following"},{"annotation":"Treatment.Route","text":"coronary artery bypass graft surgery"},{"annotation":"Treatment.Time_elapsed","text":"late-onset heparin-induced thrombocytopenia"},{"annotation":"Treatment.Duration","text":"following"},{"annotation":"Treatment.Disorder","text":"massive pulmonary embolism"}]}]}
{"id":"11283125_1","context":"Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"during"},{"annotation":"Treatment","text":"interval therapy of a Berlin-Frankfurt-Munster-based protocol"},{"annotation":"Treatment.Drug","text":"high-dose cytarabine"},{"annotation":"Treatment.Disorder","text":"acute lymphoblastic leukemia and lymphoblastic lymphoma"},{"annotation":"Treatment.Drug","text":"cytarabine"},{"annotation":"Treatment.Duration","text":"interval therapy"},{"annotation":"Treatment.Dose","text":"high-dose"},{"annotation":"Treatment.Frequency","text":"interval therapy"},{"annotation":"Treatment.Route","text":"interval therapy"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"cytarabine"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Drug","text":"interval therapy"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug"}]}]}
{"id":"11450788_4","context":"We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"didanosine"},{"annotation":"Treatment.Drug","text":"didanosine"},{"annotation":"Effect","text":"fulminant hepatic failure"},{"annotation":"Treatment.Drug","text":"masquerading"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"masquerading as"},{"annotation":"Effect","text":"surgical abdomen"},{"annotation":"Treatment","text":"didanosine"},{"annotation":"Treatment.Drug","text":"didanosine"},{"annotation":"Treatment.Drug","text":"masquerading"}]}]}
{"id":"16537817_10","context":"An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"related"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Effect","text":"renal failure"},{"annotation":"Effect","text":"hepatotoxicity"},{"annotation":"Treatment","text":"amiodarone-simvastatin interaction"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiod"}]}]}
{"id":"11105373_2","context":"Nail staining from hydroquinone cream.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"staining"},{"annotation":"Effect","text":"nail staining"},{"annotation":"Treatment","text":"hydroquinone cream"},{"annotation":"Treatment.Drug","text":"hydroquinone"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"}]}]}
{"id":"748238_2","context":"The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"development"},{"annotation":"Effect","text":"IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma"},{"annotation":"Treatment","text":"diphenylhydantoin (DILANTIN) therapy"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin (DILANTIN)"},{"annotation":"Treatment.Duration","text":"20 years"},{"annotation":"Subject","text":"an epilepsy patient"},{"annotation":"Subject.Disorder","text":"epilepsy"},{"annotation":"Treatment.Duration","text":"20 years"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin (DILANTIN)"},{"annotation":"Treatment.Duration","text":"20 years"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin (DILANTIN)"},{"annotation":"Treatment.Duration","text":"20 years"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin (DILANTIN)"},{"annotation":"Treatment.Duration","text":"20 years"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin (DILANTIN)"},{"annotation":"Treatment.Duration","text":"20 years"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin (DILANTIN)"},{"annotation":"Treatment.Duration","text":"20 years"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin (DILANTIN)"},{"annotation":"Treatment.Duration","text":"20 years"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin (DILANTIN)"},{"annotation":"Treatment.Duration","text":"20 years"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin (DILANTIN)"},{"annotation":"Treatment.Duration","text":"20 years"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin (DILANTIN)"},{"annotation":"Treatment.Duration","text":"20 years"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin (DILANTIN)"},{"annotation":"Treatment.Duration","text":"20 years"},{"annotation":"Treatment.Disorder","text":"ep"}]}]}
{"id":"10698143_2","context":"Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Effect","text":"GI upset"},{"annotation":"Effect","text":"dizziness"},{"annotation":"Effect","text":"mild sedation"},{"annotation":"Treatment","text":"ibuprofen overdose"},{"annotation":"Treatment.Drug","text":"ibuprofen"}]}]}
{"id":"20628041_5","context":"His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.","events":[{"type":"Treatment","annotations":[{"annotation":"Treatment.Drug","text":"pramipexole"},{"annotation":"Treatment.Drug","text":"entacapone"},{"annotation":"Treatment.Drug","text":"immediate-release levodopa/carbidopa 100 mg/25 mg"},{"annotation":"Treatment.Drug","text":"1.5 tablets"},{"annotation":"Treatment.Drug","text":"4 times daily"},{"annotation":"Treatment.Route","text":"nasogastric tube"}]},{"type":"Treatment","annotations":[{"annotation":"Treatment.Drug","text":"pramipexole"},{"annotation":"Treatment.Drug","text":"entacapone"},{"annotation":"Treatment.Drug","text":"immediate-release levodopa/carbidopa 100 mg/25 mg"},{"annotation":"Treatment.Drug","text":"1.5 tablets"},{"annotation":"Treatment.Drug","text":"4 times daily"},{"annotation":"Treatment.Route","text":"nasogastric tube"}]},{"type":"Treatment","annotations":[{"annotation":"Treatment.Drug","text":"pramipexole"},{"annotation":"Treatment.Drug","text":"entacapone"},{"annotation":"Treatment.Drug","text":"immediate-release levodopa/carbidopa 100 mg/25 mg"},{"annotation":"Treatment.Drug","text":"1.5 tablets"},{"annotation":"Treatment.Drug","text":"4 times daily"},{"annotation":"Treatment.Route","text":"nasogastric tube"}]},{"type":"Treatment","annotations":[{"annotation":"Treatment.Drug","text":"pramipexole"},{"annotation":"Treatment.Drug","text":"entacapone"},{"annotation":"Treatment.Drug","text":"immediate-release levodopa/carbidopa 100 mg/25 mg"},{"annotation":"Treatment.Drug","text":"1.5 tablets"},{"annotation":"Treatment.Drug","text":"4 times daily"},{"annotation":"Treatment.Route","text":"nasogastric tube"}]},{"type":"Treatment","annotations":[{"annotation":"Treatment.Drug","text":"pramipexole"},{"annotation":"Treatment.Drug","text":"entacapone"},{"annotation":"Treatment.Drug","text":"immediate-release levodopa/carbidopa 100 mg/25 mg"},{"annotation":"Treatment.Drug","text":"1.5 tablets"},{"annotation":"Treatment.Drug","text":"4 times daily"},{"annotation":"Treatment.Route","text":"nasogastric tube"}]},{"type":"Treatment","annotations":[{"annotation":"Treatment.Drug","text":"pramipexole"},{"annotation":"Treatment.Drug","text":"entacapone"},{"annotation":"Treatment.Drug","text":"immediate-release levodopa/carbidopa 100 mg/25 mg"},{"annotation":"Treatment"}]}]}
{"id":"18675768_15","context":"CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"propafenone"},{"annotation":"Treatment.Drug","text":"citalopram"},{"annotation":"Treatment.Drug","text":"propafenone"},{"annotation":"Treatment.Drug","text":"citalopram"},{"annotation":"Treatment.Interaction","text":"interaction between propafenone and citalopram"},{"annotation":"Treatment.Adverse_effect","text":"adverse effects (eg, dizziness, falls)"},{"annotation":"Treatment.Adverse_effect","text":"mimicked coronary artery disease"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"propafenone"},{"annotation":"Treatment.Disorder","text":"coronary artery disease"},{"annotation":"Treatment.Drug","text":"propafenone"},{"annotation":"Treatment.Drug","text":"citalopram"},{"annotation":"Treatment.Interaction","text":"interaction between propafenone and citalopram"}]}]}
{"id":"14614357_2","context":"We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presented"},{"annotation":"Effect","text":"overanticoagulation"},{"annotation":"Treatment","text":"acenocoumarol"},{"annotation":"Treatment.Disorder","text":"thromboembolic episode"},{"annotation":"Treatment.Drug","text":"acenocoumarol"},{"annotation":"Treatment.Dosage","text":"early"},{"annotation":"Treatment.Duration","text":"overanticoagulation"},{"annotation":"Subject","text":"a young healthy woman"},{"annotation":"Subject.Disorder","text":"thromboembolic episode"}]}]}
{"id":"3708949_2","context":"A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"acute changes"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"parenteral amiodarone administration"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"parenteral"},{"annotation":"Treatment.Frequency","text":"acute changes"},{"annotation":"Treatment.Route","text":"parenteral"},{"annotation":"Treatment.Time_elapsed","text":"after parenteral amiodarone administration"},{"annotation":"Treatment.Duration","text":"acute changes"},{"annotation":"Treatment.Disorder","text":"acute hepatitis"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Age","text":"acute changes"},{"annotation":"Subject.Disorder","text":"acute hepatitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"acute changes"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"parenteral amiodarone administration"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"parenteral"},{"annotation":"Treatment.Frequency","text":"acute changes"},{"annotation":"Treatment.Route","text":"parenteral"},{"annotation":"Treatment.Time_elapsed","text":"after parenteral amiodarone administration"},{"annotation":"Treatment.Duration","text":"acute changes"},{"annotation":"Treatment.Disorder","text":"acute hepatitis"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Age","text":"acute changes"},{"annotation":"Subject.Disorder","text":"acute hepatitis"}]}]}
{"id":"18364401_4","context":"Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Effect","text":"hyperglycemia"},{"annotation":"Treatment.Duration","text":"2 days"},{"annotation":"Treatment.Dosage","text":"2.5 mg twice daily"},{"annotation":"Treatment.Dosage","text":"olanzapine"},{"annotation":"Treatment.Duration","text":"2 days"},{"annotation":"Treatment.Disorder","text":"hyperglycemia"},{"annotation":"Treatment.Disorder","text":"fasting blood glucose"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"resolved"},{"annotation":"Treatment","text":"olanzapine was stopped"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Disorder","text":"hyperglycemia"},{"annotation":"Treatment.Duration","text":"2 days"},{"annotation":"Treatment.Dosage","text":"2.5 mg twice daily"},{"annotation":"Treatment.Dosage","text":"olanzapine"},{"annotation":"Treatment.Duration","text":"2 days"},{"annotation":"Treatment.Disorder","text":"hyperglycemia"},{"annotation":"Treatment.Disorder","text":"fasting blood glucose"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"recurred"},{"annotation":"Treatment","text":"olanzapine was rechallenged"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Effect","text":"hyperglycemia"},{"annotation":"Treatment.Duration","text":"2 days"},{"annotation":"Treatment.Dosage","text":"2.5 mg twice daily"},{"annotation":"Treatment.Dosage","text":"olanzapine"},{"annotation":"Treatment.Duration","text":"2 days"},{"annotation":"Treatment.Disorder","text":"hyperglycemia"},{"annotation":"Treatment.Disorder","text":"fasting blood glucose"}]}]}
{"id":"8151270_1","context":"Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"fulminant"},{"annotation":"Treatment","text":"didanosine therapy"},{"annotation":"Treatment.Disorder","text":"HIV-infected"},{"annotation":"Treatment.Drug","text":"didanosine"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment.Drug","text":"lactate acidosis"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Subject","text":"HIV-infected patients"},{"annotation":"Subject.Disorder","text":"HIV-infected"}]}]}
{"id":"18425523_4","context":"Persistent ocular hypertension following intravitreal ranibizumab.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"hypertension"},{"annotation":"Treatment","text":"intravitreal ranibizumab"},{"annotation":"Treatment.Drug","text":"ranibizumab"},{"annotation":"Treatment.Dosage","text":"intravitreal"},{"annotation":"Treatment.Frequency","text":"ranibizumab"},{"annotation":"Treatment.Route","text":"intravitreal"},{"annotation":"Treatment.Time_elapsed","text":"persistent"},{"annotation":"Treatment.Duration","text":"following"},{"annotation":"Treatment.Disorder","text":"hypertension"},{"annotation":"Attribute","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"hypertension"},{"annotation":"Treatment","text":"intravitreal ranibizumab"},{"annotation":"Treatment.Drug","text":"ranibizumab"},{"annotation":"Treatment.Dosage","text":"intravitreal"},{"annotation":"Treatment.Frequency","text":"ranibizumab"},{"annotation":"Treatment.Route","text":"intravitreal"},{"annotation":"Treatment.Time_elapsed","text":"persistent"},{"annotation":"Treatment.Duration","text":"following"},{"annotation":"Treatment.Disorder","text":"hypertension"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"14968106_4","context":"STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intrathecal administration of doxorubicin"},{"annotation":"Treatment","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Effect","text":"toxic myelopathy"},{"annotation":"Treatment.Disorder","text":"intrathecal administration of doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Route","text":"intrathecal"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"toxic myelopathy"},{"annotation":"Subject","text":"a 31-year-old woman"},{"annotation":"Subject.Age","text":"31"},{"annotation":"Subject.Gender","text":"unknown"},{"annotation":"Subject.Population","text":"unknown"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"intrathecal"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"toxic myelopathy"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Event type","text":"Adverse_event"}]}]}
{"id":"18166746_4","context":"The patient had a background of obsessive compulsive disorder treated with paroxetine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"paroxetine"},{"annotation":"Effect","text":"obsessive compulsive disorder"},{"annotation":"Treatment.Disorder","text":"obsessive compulsive disorder"},{"annotation":"Treatment.Drug","text":"paroxetine"}]}]}
{"id":"9704170_2","context":"Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"speculated"},{"annotation":"Treatment","text":"clozapine"},{"annotation":"Treatment.Disorder","text":"patients with defective calcium-activated K+ channels"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"minor"},{"annotation":"Attribute.negated","text":"not explicitly remarked"},{"annotation":"Subject","text":"patients with defective calcium-activated K+ channels"},{"annotation":"Subject.Disorder","text":"patients with defective calcium-activated K+ channels"}]}]}
{"id":"11485141_2","context":"CONCLUSIONS: We report the first case of gemcitabine-induced LABD.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Effect","text":"LABD"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Effect","text":"LABD"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Effect","text":"LABD"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Effect","text":"LABD"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Effect","text":"LABD"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Effect","text":"LABD"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Effect","text":"LABD"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Effect","text":"LABD"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Effect","text":"LABD"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Effect","text":"LABD"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Effect","text":"LABD"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Effect","text":"LABD"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":""}]}]}
{"id":"10752888_1","context":"Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"lung disease"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Treatment.Duration","text":"resolution of apparently irreversible CT abnormalities"},{"annotation":"Treatment.Duration","text":"2 cases"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"lung disease"},{"annotation":"Effect","text":"resolution"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Treatment.Duration","text":"resolution of apparently irreversible CT abnormalities"},{"annotation":"Treatment.Duration","text":"2 cases"}]}]}
{"id":"2012922_2","context":"Trazodone-induced transient hypomanic symptoms and their management.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hypomanic symptoms"},{"annotation":"Treatment","text":"trazodone"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Dosage","text":"dosage"},{"annotation":"Treatment.Duration","text":"transient"},{"annotation":"Treatment.Effect","text":"symptoms"},{"annotation":"Treatment.Effect","text":"management"},{"annotation":"Treatment.Disorder","text":"hypomanic symptoms"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Dosage","text":"dosage"},{"annotation":"Treatment.Duration","text":"transient"},{"annotation":"Treatment.Effect","text":"symptoms"},{"annotation":"Treatment.Effect","text":"management"},{"annotation":"Treatment.Disorder","text":"hypomanic symptoms"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Dosage","text":"dosage"},{"annotation":"Treatment.Duration","text":"transient"},{"annotation":"Treatment.Effect","text":"symptoms"},{"annotation":"Treatment.Effect","text":"management"},{"annotation":"Treatment.Disorder","text":"hypomanic symptoms"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Dosage","text":"dosage"},{"annotation":"Treatment.Duration","text":"transient"},{"annotation":"Treatment.Effect","text":"symptoms"},{"annotation":"Treatment.Effect","text":"management"},{"annotation":"Treatment.Disorder","text":"hypomanic symptoms"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Dosage","text":"dosage"},{"annotation":"Treatment.Duration","text":"transient"},{"annotation":"Treatment.Effect","text":"symptoms"},{"annotation":"Treatment.Effect","text":"management"},{"annotation":"Treatment.Disorder","text":"hypomanic symptoms"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Dosage","text":"dosage"},{"annotation":"Treatment.Duration","text":"transient"},{"annotation":"Treatment.Effect","text":"symptoms"},{"annotation":"Treatment.Effect","text":"management"},{"annotation":"Treatment.Disorder","text":"hypomanic symptoms"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Dosage","text":"dosage"},{"annotation":"Treatment.Duration","text":"transient"},{"annotation":"Treatment.Effect","text":"symptoms"},{"annotation":"Treatment.Effect","text":"management"},{"annotation":"Treatment.Disorder","text":"hypomanic symptoms"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Dosage","text":"dosage"},{"annotation":"Treatment.Duration","text":"transient"},{"annotation":"Treatment.Effect","text":"symptoms"},{"annotation":"Treatment.Effect","text":"management"},{"annotation":"Treatment.Disorder","text":"hypomanic symptoms"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Dosage","text":"dosage"},{"annotation":""}]}]}
{"id":"2219619_1","context":"Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"after"},{"annotation":"Effect","text":"aluminum toxicity"},{"annotation":"Treatment","text":"continuous intravesical alum irrigation for hemorrhagic cystitis"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Disorder","text":"hemorrhagic cystitis"},{"annotation":"Treatment.Drug","text":"alum"},{"annotation":"Treatment.Drug","text":"irrigation"},{"annotation":"Treatment.Drug","text":"continuous"},{"annotation":"Treatment.Drug","text":"intravesical"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"hemorrhagic cystitis"}]}]}
{"id":"18076602_1","context":"Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"vasculitis"},{"annotation":"Treatment","text":"amphotericin B"},{"annotation":"Treatment.Drug","text":"amphotericin B"},{"annotation":"Treatment.Dosage","text":"cutaneous leucocytoclastic vasculitis"},{"annotation":"Treatment.Frequency","text":"case report"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Population","text":"patient"},{"annotation":"Treatment.Route","text":"cutaneous"},{"annotation":"Treatment.Time_elapsed","text":"vasculitis"},{"annotation":"Treatment.Duration","text":"case report"},{"annotation":"Treatment.Disorder","text":"vasculitis"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":""}]}]}
{"id":"8726608_5","context":"When measured, the serum lithium level had increased 4-fold during acyclovir therapy.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"measured"},{"annotation":"Treatment","text":"acyclovir therapy"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Dosage","text":"4-fold increase"},{"annotation":"Treatment.Duration","text":"during acyclovir therapy"},{"annotation":"Effect","text":"increased serum lithium level"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"acyclovir therapy"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Dosage","text":"4-fold increase"},{"annotation":"Treatment.Duration","text":"during acyclovir therapy"},{"annotation":"Effect","text":"increased serum lithium level"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not a toxic increase"}]}]}
{"id":"17504225_3","context":"In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"evidence"},{"annotation":"Treatment","text":"pharmacokinetic interaction"},{"annotation":"Treatment.Drug","text":"clarithromycin"},{"annotation":"Treatment.Drug","text":"sirolimus"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influenzae"},{"annotation":"Treatment.Disorder","text":"kidney transplant"},{"annotation":"Treatment.Disorder","text":"pulmonary infection sustained by Hemophilus Influen"}]}]}
{"id":"12847760_1","context":"A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developing"},{"annotation":"Effect","text":"reversal reaction"},{"annotation":"Treatment","text":"dapsone and rifampin therapy"},{"annotation":"Treatment.Drug","text":"dapsone"},{"annotation":"Treatment.Drug","text":"rifampin"},{"annotation":"Subject","text":"a 25-year-old man with a history of mid-borderline (BB) Hansen's disease"},{"annotation":"Subject.Disorder","text":"Hansen's disease"}]}]}
{"id":"15516308_15","context":"In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"overdose"},{"annotation":"Effect","text":"death"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"other drugs"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"quetiapine"},{"annotation":"Treatment.Combination.Drug","text":"other drugs"},{"annotation":"Subject","text":"all cases"},{"annotation":"Subject.Disorder","text":"not specified"}]}]}
{"id":"17275666_4","context":"Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"seizure"},{"annotation":"Treatment","text":"antiepileptic drugs"},{"annotation":"Treatment.Disorder","text":"seizures"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"exacerbate"},{"annotation":"Effect","text":"seizure"},{"annotation":"Treatment","text":"antiepileptic drugs"},{"annotation":"Treatment.Disorder","text":"seizures"}]}]}
{"id":"16192734_3","context":"We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"ritodrine-hydrochloride"},{"annotation":"Treatment.Drug","text":"ritodrine"},{"annotation":"Treatment.Disorder","text":"myotonic dystrophy"},{"annotation":"Treatment.Drug","text":"pregnancy"},{"annotation":"Treatment.Drug","text":"ritodrine-hydrochloride"},{"annotation":"Treatment.Drug","text":"hydrochloride"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"rhabdomyolysis"},{"annotation":"Treatment.Drug","text":"ritodrine-hydrochloride"},{"annotation":"Treatment.Drug","text":"hydrochloride"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"rhabdomyolysis"},{"annotation":"Treatment.Drug","text":"ritodrine-hydrochloride"},{"annotation":"Treatment.Drug","text":"hydrochloride"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"rhabdomyolysis"},{"annotation":"Treatment.Drug","text":"ritodrine-hydrochloride"},{"annotation":"Treatment.Drug","text":"hydrochloride"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"rhabdomyolysis"},{"annotation":"Treatment.Drug","text":"ritodrine-hydrochloride"},{"annotation":"Treatment.Drug","text":"hydrochloride"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"rhabdomyolysis"},{"annotation":"Treatment.Drug","text":"ritodrine-hydrochloride"},{"annotation":"Treatment.Drug","text":"hydrochloride"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"rhabdomyolysis"},{"annotation":"Treatment.Drug","text":"ritodrine-hydrochloride"},{"annotation":"Treatment.Drug","text":"hydrochloride"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"rhabdomyolysis"},{"annotation":"Treatment.Drug","text":"ritodrine-hydrochloride"},{"annotation":"Treatment.Drug","text":"hydrochloride"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"rhabdomyolysis"},{"annotation":"Treatment.Drug","text":"ritodrine-hydrochloride"},{"annotation":"Treatment.Drug","text":"hydrochloride"},{"annotation":"Treatment.Drug","text":"induced"},{"annotation":"Treatment.Drug","text":"rhabdomyolysis"},{"annotation":"Treatment."}]}]}
{"id":"7748076_2","context":"OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurring"},{"annotation":"Effect","text":"squamous metaplasia"},{"annotation":"Treatment","text":"progestin therapy of hyperplasia"},{"annotation":"Treatment.Disorder","text":"hyperplasia"},{"annotation":"Treatment.Drug","text":"progestin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"finding"},{"annotation":"Treatment","text":"progestin therapy of hyperplasia"},{"annotation":"Treatment.Disorder","text":"hyperplasia"},{"annotation":"Treatment.Drug","text":"progestin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"}]}]}
{"id":"9007910_8","context":"IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"5-FU therapy"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"DPD-deficiency"},{"annotation":"Treatment.Disorder","text":"cancer"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Risk","text":"potentially lethal risks"},{"annotation":"Treatment.Risk","text":"traumatic psychosocial stresses"},{"annotation":"Treatment.Effect","text":"clinically present"},{"annotation":"Treatment.Effect","text":"develop timely interventions and alternative plans of care"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":""}]}]}
{"id":"8912599_2","context":"Methotrexate is an effective but potentially toxic treatment for psoriasis.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"psoriasis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"potentially toxic"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"psoriasis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"18203308_3","context":"Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Treatment","text":"etanercept therapy"},{"annotation":"Treatment.Drug","text":"etanercept"},{"annotation":"Effect","text":"active CD"},{"annotation":"Treatment.Duration","text":"11 months"},{"annotation":"Treatment.Duration","text":"12 months"},{"annotation":"Treatment.Duration","text":"26 months"},{"annotation":"Treatment.Disorder","text":"active CD"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"active CD"}]}]}
{"id":"53128_3","context":"This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"progressed"},{"annotation":"Effect","text":"tracheal compression with stridor"},{"annotation":"Treatment","text":"aspirin"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Dosage","text":"some"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Dosage","text":"for relief of neck pain"},{"annotation":"Treatment.Dosage","text":"aspirin"},{"annotation":"Treatment.Dosage","text":"for relief of neck pain"},{"annotation":"Subject","text":"he"},{"annotation":"Subject.Age","text":"after he"},{"annotation":"Subject.Disorder","text":"tracheal compression with stridor"},{"annotation":"Subject.Disorder","text":"tracheal compression with stridor"},{"annotation":"Subject.Disorder","text":"tracheal compression with stridor"},{"annotation":"Subject.Disorder","text":"tracheal compression with stridor"},{"annotation":"Subject.Disorder","text":"tracheal compression with stridor"},{"annotation":"Subject.Disorder","text":"tracheal compression with stridor"}]}]}
{"id":"9533061_2","context":"OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"colitis"},{"annotation":"Treatment","text":"clindamycin phosphate vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Disorder","text":"Clostridium difficile-induced colitis"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate vaginal cream"},{"annotation":"Treatment.Toxin","text":"positive"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"Treatment.Drug","text":"vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"Treatment.Drug","text":"vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"Treatment.Drug","text":"vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"Treatment.Drug","text":"vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"Treatment.Drug","text":"vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"Treatment.Drug","text":"vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"Treatment.Drug","text":"vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"Treatment.Drug","text":"vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"Treatment.Drug","text":"vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"Treatment.Drug","text":"vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"Treatment.Drug","text":"vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"Treatment.Drug","text":"vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Drug","text":"phosphate"},{"annotation":"T"}]}]}
{"id":"20234160_1","context":"Severe vancomycin-induced anaphylactic reaction.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Effect","text":"anaphylactic reaction"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"negated","text":"not"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Attributes","text":"not"},{"annotation":"Attribute Att"}]}]}
{"id":"8876616_2","context":"We report the case of a 74-year-old female patient who received the antidepressant amitriptyline because of a major depression.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"major depression"},{"annotation":"Treatment","text":"antidepressant amitriptyline"},{"annotation":"Treatment.Drug","text":"amitriptyline"},{"annotation":"Treatment.Disorder","text":"major depression"},{"annotation":"Subject","text":"a 74-year-old female patient"},{"annotation":"Subject.Disorder","text":"major depression"}]}]}
{"id":"16192734_2","context":"Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"recognized"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"tolytic therapy with ritodrine hydrochloride"},{"annotation":"Treatment.Drug","text":"ritodrine"},{"annotation":"Treatment.Disorder","text":"pregnancy-related complication"},{"annotation":"Treatment.Disorder","text":"rhabdomyolysis"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"complication"},{"annotation":"Treatment","text":"tolytic therapy with ritodrine hydrochloride"},{"annotation":"Treatment.Disorder","text":"pregnancy-related complication"},{"annotation":"Treatment.Drug","text":"ritodrine"}]}]}
{"id":"18628507_5","context":"Voriconazole (VRC) has not previously been reported to cause angio-oedema.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"cause"},{"annotation":"Treatment","text":"voriconazole"},{"annotation":"Treatment.Drug","text":"voriconazole"},{"annotation":"Effect","text":"angio-oedema"},{"annotation":"Treatment.Drug","text":"voriconazole"},{"annotation":"Treatment.Disorder","text":"angio-oedema"},{"annotation":"Treatment.Drug","text":"voriconazole"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"voriconazole has not previously been reported to cause angio-oedema"}]}]}
{"id":"12477460_3","context":"CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"tamoxifen"},{"annotation":"Treatment.Disorder","text":"endometriosis"},{"annotation":"Treatment.Drug","text":"tamoxifen"},{"annotation":"Effect","text":"malignant transformation"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"10573314_5","context":"One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"episode of prostatitis"},{"annotation":"Treatment","text":"levofloxacin"},{"annotation":"Treatment.Drug","text":"levofloxacin"},{"annotation":"Treatment.Disorder","text":"prostatitis"},{"annotation":"Treatment.Drug","text":"tolterodine"},{"annotation":"Treatment.Drug","text":"tolterodine"},{"annotation":"Treatment.Combination.Trigger","text":"immediately prior to"},{"annotation":"Treatment.Combination.Drug","text":"tolterodine"},{"annotation":"Treatment.Combination.Drug","text":"levofloxacin"},{"annotation":"Subject","text":"one patient"},{"annotation":"Subject.Disorder","text":"prostatitis"}]}]}
{"id":"16393774_5","context":"The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"IFN-beta"},{"annotation":"Treatment.Drug","text":"IFN-beta"},{"annotation":"Effect","text":"monoarthritis"},{"annotation":"Treatment.Duration","text":"14 months"},{"annotation":"Treatment.Duration","text":"persisted"},{"annotation":"Treatment","text":"discontinuation"},{"annotation":"Effect","text":"resolved"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"IFN-beta"},{"annotation":"Treatment.Drug","text":"IFN-beta"},{"annotation":"Treatment.Disorder","text":"monoarthritis"},{"annotation":"Treatment.Duration","text":"14 months"},{"annotation":"Treatment.Duration","text":"persisted"},{"annotation":"Treatment","text":"discontinuation"},{"annotation":"Effect","text":"resolved"}]}]}
{"id":"10682234_9","context":"The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"refractory akathisia"},{"annotation":"Effect","text":"akathisia"},{"annotation":"Treatment","text":"interferon-alpha"},{"annotation":"Treatment.Disorder","text":"akathisia"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Duration","text":"refractory"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Duration","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"levod"}]}]}
{"id":"18837734_1","context":"Rosaceiform eruption induced by erlotinib.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"eruption"},{"annotation":"Treatment","text":"erlotinib"},{"annotation":"Treatment.Drug","text":"erlotinib"},{"annotation":"Treatment.Disorder","text":"rosaceiform eruption"},{"annotation":"Treatment.Drug","text":"erlotinib"}]}]}
{"id":"6697887_2","context":"The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"incidence"},{"annotation":"Treatment","text":"oral-verapamil-induced hypotension"},{"annotation":"Treatment.Drug","text":"verapamil"},{"annotation":"Treatment.Combination.Trigger","text":"in the presence of concomitant beta-adrenergic blockade by the oral route"},{"annotation":"Treatment.Combination.Drug","text":"verapamil"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"Treatment.Combination.Drug","text":"beta-adrenergic blocker"},{"annotation":"T"}]}]}
{"id":"8726608_4","context":"Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"concurrently"},{"annotation":"Treatment","text":"intravenous acyclovir"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Combination","text":"concurrently with intravenous acyclovir"},{"annotation":"Treatment.Combination","text":"lithium"},{"annotation":"Treatment.Combination","text":"intravenous acyclovir"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"monitoring"},{"annotation":"Attribute","text":"measurement"},{"annotation":"Attribute","text":"serum lithium levels"},{"annotation":"Attribute","text":"every second or third day"},{"annotation":"Attribute","text":"closely"},{"annotation":"Attribute","text":"monitoring"},{"annotation":"Attribute","text":"signs of lithium toxicity"},{"annotation":"Attribute","text":"lithium toxicity"},{"annotation":"Attribute","text":"serum lithium levels"},{"annotation":"Attribute","text":"every second or third day"},{"annotation":"Attribute","text":"closely"},{"annotation":"Attribute","text":"monitoring"},{"annotation":"Attribute","text":"signs of lithium toxicity"},{"annotation":"Attribute","text":"lithium toxicity"},{"annotation":"Attribute","text":"serum lithium levels"},{"annotation":"Attribute","text":"every second or third day"},{"annotation":"Attribute","text":"closely"},{"annotation":"Attribute","text":"monitoring"},{"annotation":"Attribute","text":"signs of lithium toxicity"},{"annotation":"Attribute","text":"lithium toxicity"},{"annotation":"Attribute","text":"serum lithium levels"},{"annotation":"Attribute","text":"every second or third day"},{"annotation":"Attribute","text":"closely"},{"annotation":"Attribute","text":"monitoring"},{"annotation":"Attribute","text":"signs of lithium toxicity"},{"annotation":"Attribute","text":"lithium toxicity"},{"annotation":"Attribute","text":"serum lithium levels"},{"annotation":"Attribute","text":"every second or third day"},{"annotation":"Attribute","text":"closely"},{"annotation":"Attribute","text":"monitoring"},{"annotation":"Attribute","text":"signs of lithium toxicity"},{"annotation":"Attribute","text":"lithium toxicity"},{"annotation":"Attribute","text":"serum lithium levels"},{"annotation":"Attribute","text":"every second or third day"},{"annotation":"Attribute","text":"closely"},{"annotation":"Attribute","text":"monitoring"},{"annotation":"Attribute","text":"signs of lithium toxicity"},{"annotation":"Attribute","text":"lithium toxicity"},{"annotation":"Attribute","text":"serum lithium levels"},{"annotation":"Attribute","text":"every second or third day"},{"annotation":"Attribute","text":"closely"},{"annotation":"Attribute","text":"monitoring"},{"annotation":"Attribute","text":"signs of lithium toxicity"},{"annotation":"Attribute","text":"lithium toxicity"},{"annotation":"Attribute","text":"serum lithium levels"},{"annotation":"Attribute","text":"every second or third day"},{"annotation":"Attribute","text":"closely"},{"annotation":"Attribute","text":"monitoring"},{"annotation":"Attribute","text":"signs of lithium toxicity"},{"annotation":"Attribute","text":"lithium toxicity"},{"annotation":"Attribute","text":"serum lithium levels"},{}]}]}
{"id":"11283125_9","context":"Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"failed"},{"annotation":"Effect","text":"CNS relapse"},{"annotation":"Treatment","text":"HD Ara-C added to HD MTX"},{"annotation":"Treatment.Drug","text":"HD Ara-C"},{"annotation":"Treatment.Drug","text":"HD MTX"},{"annotation":"Treatment.Dose_schedule","text":"dose schedule used in this protocol"},{"annotation":"Treatment.Combination","text":"added to HD MTX"},{"annotation":"Treatment.Combination","text":"HD Ara-C"},{"annotation":"Treatment.Combination","text":"HD MTX"},{"annotation":"Treatment.Combination","text":"and"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"to improve"},{"annotation":"Treatment.Combination","text":"overall DFS"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"to decrease"},{"annotation":"Treatment.Combination","text":"incidence of CNS relapse"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"to further decrease"},{"annotation":"Treatment.Combination","text":"incidence of CNS relapse"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"to improve"},{"annotation":"Treatment.Combination","text":"overall DFS"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"to decrease"},{"annotation":"Treatment.Combination","text":"incidence of CNS relapse"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"to improve"},{"annotation":"Treatment.Combination","text":"overall DFS"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"to decrease"},{"annotation":"Treatment.Combination","text":"incidence of CNS relapse"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"to improve"},{"annotation":"Treatment.Combination","text":"overall DFS"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"to decrease"},{"annotation":"Treatment.Combination","text":"incidence of CNS relapse"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"to improve"},{"annotation":"Treatment.Combination","text":"overall DFS"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"failed"},{"annotation":"Treatment.Combination","text":"to decrease"},{"annotation":"Treatment.Combination","text":"incidence of CNS relapse"},{"annotation":"Treatment.Combination","text":"failed"},{}]}]}
{"id":"3732375_1","context":"Theophylline intoxication following viloxazine induced decrease in clearance.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"intoxication"},{"annotation":"Treatment","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment","text":"viloxazine induced decrease in clearance"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment","text":"viloxazine induced decrease in clearance"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment","text":"viloxazine induced decrease in clearance"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment","text":"viloxazine induced decrease in clearance"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment","text":"viloxazine induced decrease in clearance"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment","text":"viloxazine induced decrease in clearance"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment","text":"viloxazine induced decrease in clearance"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment","text":"viloxazine induced decrease in clearance"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Drug","text":"theophylline"},{"annotation":"Treatment","text":"viloxazine induced decrease in clearance"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"T"}]}]}
{"id":"11197767_3","context":"Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"encystment"},{"annotation":"Treatment","text":"cercarial"},{"annotation":"Treatment.Drug","text":"zinc"},{"annotation":"Treatment.Drug","text":"other metals"},{"annotation":"Treatment.Dosage","text":"25000 microg/l or higher"},{"annotation":"Treatment.Dosage","text":"lower concentrations"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":"Treatment.Dosage","text":"other metals"},{"annotation":"Treatment.Dosage","text":"cercarial"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":"Treatment.Dosage","text":"other metals"},{"annotation":"Treatment.Dosage","text":"cercarial"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":"Treatment.Dosage","text":"other metals"},{"annotation":"Treatment.Dosage","text":"cercarial"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":"Treatment.Dosage","text":"other metals"},{"annotation":"Treatment.Dosage","text":"cercarial"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":"Treatment.Dosage","text":"other metals"},{"annotation":"Treatment.Dosage","text":"cercarial"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":"Treatment.Dosage","text":"other metals"},{"annotation":"Treatment.Dosage","text":"cercarial"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":"Treatment.Dosage","text":"other metals"},{"annotation":"Treatment.Dosage","text":"cercarial"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":"Treatment.Dosage","text":"other metals"},{"annotation":"Treatment.Dosage","text":"cercarial"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":"Treatment.Dosage","text":"other metals"},{"annotation":"Treatment.Dosage","text":"cercarial"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":"Treatment.Dosage","text":"other metals"},{"annotation":"Treatment.Dosage","text":"cercarial"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":"Treatment.Dosage","text":"other metals"},{"annotation":"Treatment.Dosage","text":"cercarial"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":"Treatment.Dosage","text":"other metals"},{"annotation":"Treatment.Dosage","text":"cercarial"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":"Treatment.Dosage","text":"other metals"},{"annotation":"Treatment.Dosage","text":"cercarial"},{"annotation":"Treatment.Dosage","text":"zinc"},{"annotation":""}]}]}
{"id":"12504711_3","context":"PURPOSE: We report an unusual paradoxical effect of brimonidine.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Type","text":"Potential_therapeutic_effect"},{"annotation":"Annotation","text":"purpose"},{"annotation":"Annotation","text":"report"},{"annotation":"Effect","text":"paradoxical effect"},{"annotation":"Treatment","text":"brimonidine"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"brimonidine"}]}]}
{"id":"17387702_1","context":"Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"renal failure"},{"annotation":"Effect","text":"renal failure"},{"annotation":"Treatment","text":"high-dose methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"high-dose"},{"annotation":"Treatment.Duration","text":"after"},{"annotation":"Treatment.Duration","text":"high-dose methotrexate"},{"annotation":"Treatment.Duration","text":"in"},{"annotation":"Treatment.Dosage","text":"child"},{"annotation":"Treatment.Dosage","text":"homozygous for MTHFR C677T polymorphism"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"homozygous for MTHFR C677T polymorphism"},{"annotation":"Treatment.Drug","text":"renal failure"},{"annotation":"Subject","text":"child"},{"annotation":"Subject.Disorder","text":"renal failure"},{"annotation":"Subject.Disorder","text":"homozygous for MTHFR C677T polymorphism"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"homozygous for MTHFR C677T polymorphism"},{"annotation":"Treatment.Drug","text":"renal failure"},{"annotation":"Treatment.Drug","text":"homozygous for MTHFR C677T polymorphism"},{"annotation":"Treatment.Drug","text":"renal failure"},{"annotation":"Treatment.Drug","text":"homozygous for MTHFR C677T polymorphism"},{"annotation":"Treatment.Drug","text":"renal failure"},{"annotation":"Treatment.Drug","text":"homozygous for MTHFR C677T polymorphism"},{"annotation":"Treatment.Drug","text":"renal failure"},{"annotation":"Treatment.Drug","text":"homozygous for MTHFR C677T polymorphism"},{"annotation":"Treatment.Drug","text":"renal failure"},{"annotation":"Treatment.Drug","text":"homozygous for MTHFR C677T polymorphism"},{"annotation":"Treatment.Drug","text":"renal failure"},{"annotation":"Treatment.Drug","text":"homozygous for MTHFR C677T polymorphism"},{"annotation":"Treatment.Drug","text":"renal failure"},{"annotation":"Treatment.Drug","text":"homozygous for MTHFR C677T polymorphism"},{"annotation":"Treatment.Drug","text":"renal failure"},{"annotation":"Treatment.Drug","text":"homozygous for MTHFR C677T polymorphism"},{"annotation":"Treatment.Drug","text":"renal failure"},{"annotation":"Treatment.Drug","text":"homozygous for MTHFR C677T polymorphism"},{"annotation":"Treatment.Drug","text":"renal failure"},{"annotation":"Treatment.D"}]}]}
{"id":"19131789_2","context":"Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"completion of MTX infusion"},{"annotation":"Treatment","text":"high-dose leucovorin"},{"annotation":"Treatment","text":"hemodialysis"},{"annotation":"Treatment","text":"charcoal hemoperfusion"},{"annotation":"Treatment","text":"carboxypeptidase G2"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Disorder","text":"renal toxicity"},{"annotation":"Treatment.Dosage","text":"4-hour MTX infusion"},{"annotation":"Treatment.Duration","text":"2 hours"},{"annotation":"Treatment.Frequency","text":"once"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Event type","text":"Adverse_event"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute"}]}]}
{"id":"10646879_2","context":"Ten to 15% of patients treated with ifosfamide develop an encephalopathy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"develop"},{"annotation":"Treatment","text":"ifosfamide"},{"annotation":"Treatment.Disorder","text":"encephalopathy"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Dosage","text":"10%"},{"annotation":"Treatment.Frequency","text":"15%"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Effect","text":"encephalopathy"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"}]}]}
{"id":"11352235_3","context":"METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"weight loss"},{"annotation":"Treatment","text":"leflunomide"},{"annotation":"Treatment.Disorder","text":"arthritis"},{"annotation":"Effect","text":"weight loss"}]}]}
{"id":"681921_3","context":"This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"catatonic syndrome"},{"annotation":"Treatment","text":"disulfiram treatment"},{"annotation":"Treatment.Disorder","text":"catatonic syndrome"},{"annotation":"Treatment.Drug","text":"disulfiram"}]}]}
{"id":"11096051_2","context":"Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hypophosphatemia"},{"annotation":"Treatment","text":"high-flux hemodiafiltration for the treatment of vancomycin toxicity"},{"annotation":"Treatment.Disorder","text":"vancomycin toxicity"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Therapy","text":"intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate"},{"annotation":"Treatment.Disorder","text":"hypophosphatemia"},{"annotation":"Treatment.Drug","text":"phosphorus"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Therapy","text":"intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate"},{"annotation":"Treatment.Drug","text":"phosphorus"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Therapy","text":"intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate"},{"annotation":"Treatment.Drug","text":"phosphorus"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Therapy","text":"intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate"},{"annotation":"Treatment.Drug","text":"phosphorus"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Therapy","text":"intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate"},{"annotation":"Treatment.Drug","text":"phosphorus"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Therapy","text":"intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate"},{"annotation":"Treatment.Drug","text":"phosphorus"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Therapy","text":"intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate"},{"annotation":"Treatment.Drug","text":"phosphorus"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Therapy","text":"intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate"},{"annotation":"Treatment.Drug","text":"phosphorus"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Therapy","text":"intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate"},{"annotation":"Treatment.Drug","text":"phosphorus"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Therapy","text":"intravenous phosphorus therapy versus use of a phosphorus-enriched dialys"}]}]}
{"id": "18569796_4","context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.","events": [{"type": "Adverse_event","annotations": [{"annotation": "Trigger","text": "rechallenge"},{"annotation": "Treatment","text": "alendronate sodium"},{"annotation": "Treatment.Drug","text": "alendronate sodium"},{"annotation": "Effect","text": "scleritis"},{"annotation": "Treatment.Disorder","text": "scleritis"},{"annotation": "Treatment.Drug","text": "alendronate sodium"},{"annotation": "Treatment.Duration","text": "two weeks"},{"annotation": "Subject","text": "his"}]}]}
{"id": "16901609_2", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "events": [{"type": "Adverse_event", "annotations": [{"annotation": "Trigger", "text": "intrathecal diamorphine"}, {"annotation": "Effect", "text": "anaphylaxis"}, {"annotation": "Treatment", "text": "intrathecal diamorphine"}, {"annotation": "Treatment.Drug", "text": "diamorphine"}, {"annotation": "Attribute", "text": "negated"}, {"annotation": "Attribute Attributes", "text": "severity"}]}, {"type": "Potential_therapeutic_effect", "annotations": [{"annotation": "Trigger", "text": "response"}, {"annotation": "Treatment", "text": "intrathecal diamorphine"}, {"annotation": "Treatment.Disorder", "text": "anaphylaxis"}, {"annotation": "Treatment.Drug", "text": "diamorphine"}]}]}
{"id":"15811174_2","context":"Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"cerivastatin"},{"annotation":"Treatment.Disorder","text":"cerivastatin-induced rhabdomyolysis"},{"annotation":"Treatment.Drug","text":"cerivastatin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"clearance rates"},{"annotation":"Treatment","text":"cerivastatin metabolites"},{"annotation":"Treatment.Disorder","text":"cerivastatin-induced rhabdomyolysis"},{"annotation":"Treatment.Drug","text":"cerivastatin"}]}]}
{"id":"18505911_13","context":"This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"resistance"},{"annotation":"Treatment","text":"warfarin"},{"annotation":"Treatment.Drug","text":"azathioprine"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"clinically significant"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"azathioprine"},{"annotation":"Treatment.Disorder","text":"warfarin resistance"},{"annotation":"Treatment.Drug","text":"azathioprine"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"clinically significant"}]}]}
{"id":"18569796_3","context":"PURPOSE: To report a case of nodular scleritis following alendronate sodium.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"nodular scleritis"},{"annotation":"Treatment","text":"alendronate sodium"},{"annotation":"Treatment.Drug","text":"alendronate sodium"}]}]}
{"id":"12869178_2","context":"Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"diagnostic or therapeutic interventions"},{"annotation":"Treatment","text":"heparin"},{"annotation":"Effect","text":"HIT"},{"annotation":"Treatment.Disorder","text":"HIT"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"diagnostic or therapeutic interventions"},{"annotation":"Treatment","text":"heparin"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Effect","text":"HIT"},{"annotation":"Treatment.Disorder","text":"HIT"},{"annotation":"Treatment.Drug","text":"heparin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"}]}]}
{"id":"7485371_2","context":"PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"vortex keratopathy"},{"annotation":"Treatment","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Disorder","text":"vortex keratopathy"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaquone"},{"annotation":"Treatment.Drug","text":"atovaqu"}]}]}
{"id":"16216617_2","context":"While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"prominent positive U waves"},{"annotation":"Treatment","text":"phenylephrine"},{"annotation":"Treatment.Drug","text":"phenylephrine"},{"annotation":"Treatment.Dosage","text":"maximal dose"},{"annotation":"Treatment.Frequency","text":"prominent positive U waves"},{"annotation":"Treatment.Route","text":"phenylephrine"},{"annotation":"Treatment.Time_elapsed","text":"with cessation of the drug"},{"annotation":"Treatment.Duration","text":"prominent positive U waves"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Attribute","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"prominent positive U waves"},{"annotation":"Effect","text":"disappeared"},{"annotation":"Treatment","text":"phenylephrine"},{"annotation":"Treatment.Drug","text":"phenylephrine"},{"annotation":"Treatment.Dosage","text":"maximal dose"},{"annotation":"Treatment.Frequency","text":"prominent positive U waves"},{"annotation":"Treatment.Route","text":"phenylephrine"},{"annotation":"Treatment.Time_elapsed","text":"with cessation of the drug"},{"annotation":"Treatment.Duration","text":"prominent positive U waves"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"18751717_4","context":"RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"chorioretinitis"},{"annotation":"Treatment","text":"IVTA injection"},{"annotation":"Treatment.Drug","text":"IVTA"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Disorder","text":"ocular inflammation of unknown origin"},{"annotation":"Treatment.Drug","text":"IVTA"},{"annotation":"Treatment.Drug","text":"chorioretinitis"}]}]}
{"id":"1695794_5","context":"Disopyramide was started on admission for supraventricular tachycardia.","events":[{"type":"Treatment","annotations":[{"annotation":"Treatment","text":"Disopyramide"},{"annotation":"Treatment.Drug","text":"Disopyramide"},{"annotation":"Treatment.Time_elapsed","text":"on admission"},{"annotation":"Treatment.Disorder","text":"supraventricular tachycardia"}]}]}
{"id":"10759907_1","context":"A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"spinal cord lesion"},{"annotation":"Treatment","text":"zolmitriptan"},{"annotation":"Treatment.Drug","text":"zolmitriptan"},{"annotation":"Treatment.Disorder","text":"migraine without aura"},{"annotation":"Treatment.Disorder","text":"spinal cord lesion"},{"annotation":"Subject","text":"a 50-year-old woman"},{"annotation":"Subject.Age","text":"50"},{"annotation":"Subject.Disorder","text":"migraine without aura"}]}]}
{"id":"19754002_3","context":"The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"skin rash"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"pravastatin"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Disorder","text":"cutaneous skin condition"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"pravastatin"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"pravastatin"},{"annotation":"Treatment.Combination.Drug","text":"lithium"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"pravastatin"},{"annotation":"Treatment.Combination.Drug","text":"lithium"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"pravastatin"},{"annotation":"Treatment.Combination.Drug","text":"lithium"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"pravastatin"},{"annotation":"Treatment.Combination.Drug","text":"lithium"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"pravastatin"},{"annotation":"Treatment.Combination.Drug","text":"lithium"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"cutaneous skin condition"}]}]}
{"id":"7639655_2","context":"CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"complicate"},{"annotation":"Effect","text":"anterior ischemic optic neuropathy"},{"annotation":"Treatment","text":"interferon alfa"},{"annotation":"Treatment.Disorder","text":"anterior ischemic optic neuropathy"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"severe"},{"annotation":"Attribute Attributes","text":"mild"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"severe"},{"annotation":"Attribute Attributes","text":"mild"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"mild"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"severe"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"mild"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"severe"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"mild"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"severe"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"mild"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"severe"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"mild"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"severe"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"mild"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"severe"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"mild"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"severe"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"mild"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"severe"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"mild"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"severe"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"mild"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"severe"},{"annotation":"Attribute Attributes","text":"low"}]}]}
{"id":"14742791_2","context":"After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"pantoprazole"},{"annotation":"Treatment.Duration","text":"5 weeks"},{"annotation":"Effect","text":"malaise"},{"annotation":"negated","text":"general"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"low severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"pantoprazole"},{"annotation":"Treatment.Drug","text":"pantoprazole"},{"annotation":"Treatment.Duration","text":"5 weeks"},{"annotation":"Effect","text":"malaise"},{"annotation":"negated","text":"general"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"low severity"}]}]}
{"id":"9865241_5","context":"We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"acute"},{"annotation":"Effect","text":"hypercalcemia"},{"annotation":"Treatment","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"iatrogenic vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Drug","text":"vitamin D"},{"annotation":"Treatment.Duration","text":"acute"},{"annotation":"Treatment.Dosage","text":"pamidronate"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Time_elapsed","text":"acute"},{"annotation":"Treatment.Duration","text":"acute"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"hypercalcemia"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"iatrogenic vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"hypercalcemia"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"iatrogenic vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"hypercalcemia"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"iatrogenic vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"hypercalcemia"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"iatrogenic vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"hypercalcemia"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"iatrogenic vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"hypercalcemia"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"iatrogenic vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"hypercalcemia"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"iatrogenic vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"hypercalcemia"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Disorder","text":"iatrogenic vitamin D poisoning"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment."}]}]}
{"id":"11485141_1","context":"According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"cutaneous eruption"},{"annotation":"Effect","text":"cutaneous eruption"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Disorder","text":"gemcitabine treatment"},{"annotation":"Attribute","text":"Naranjo probability scale"},{"annotation":"Attribute.Type","text":"possible"},{"annotation":"Attribute.Value","text":"cutaneous eruption"}]}]}
{"id":"18166746_3","context":"Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.","events":[{"type":"Administration","annotations":[{"annotation":"Trigger","text":"administered"},{"annotation":"Treatment","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Subject","text":"a 58-yr-old woman"},{"annotation":"Subject.Age","text":"58-yr-old"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"1 patient"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Route","text":"under general anesthesia"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"parathyroidectomy"}]}]}
{"id":"7712052_3","context":"We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"complained"},{"annotation":"Treatment","text":"lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Disorder","text":"PTSD"},{"annotation":"Treatment.Symptom","text":"irritability or angry outbursts"},{"annotation":"Treatment.Symptom","text":"serious problems"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"complained"},{"annotation":"Treatment","text":"lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Disorder","text":"PTSD"},{"annotation":"Treatment.Symptom","text":"irritability or angry outbursts"},{"annotation":"Treatment.Symptom","text":"serious problems"}]}]}
{"id":"15773973_2","context":"It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"resulted in"},{"annotation":"Effect","text":"hepatic injury"},{"annotation":"Treatment","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Disorder","text":"fatal hepatic injury"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Dosage","text":"occasionally"},{"annotation":"Treatment.Dosage","text":"fatal"},{"annotation":"Treatment.Dosage","text":"hepatic injury"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"may"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"may"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"may"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"may"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"may"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"may"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"may"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"fatal hepatic injury"},{"annotation":"Treatment.Dosage","text":"resulted in"},{"annotation":"Treatment.Dosage","text":"may"},{"annotation":"Treatment.Dosage"}]}]}
{"id":"2943526_1","context":"Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"hepatic artery infusion HAI of FUdR"},{"annotation":"Treatment.Drug","text":"FUdR"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"hepatic artery infusion"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Effect","text":"neurologic toxicity"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"3136101_1","context":"Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"late"},{"annotation":"Treatment","text":"prolonged adrenocorticotropic hormone therapy for infantile spasms"},{"annotation":"Treatment.Disorder","text":"infantile spasms"},{"annotation":"Treatment.Drug","text":"adrenocorticotropic hormone"},{"annotation":"Effect","text":"hyperkalemia"},{"annotation":"Treatment.Drug","text":"adrenocorticotropic hormone"},{"annotation":"Treatment.Duration","text":"prolonged"},{"annotation":"Treatment.Duration","text":"adrenocorticotropic hormone therapy"},{"annotation":"Subject","text":"infantile spasms"},{"annotation":"Subject.Disorder","text":"infantile spasms"}]}]}
{"id":"10082597_1","context":"METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused by"},{"annotation":"Treatment","text":"naproxen and oxaprozin"},{"annotation":"Treatment.Drug","text":"naproxen"},{"annotation":"Treatment.Drug","text":"oxaprozin"},{"annotation":"Effect","text":"pseudoporphyria"},{"annotation":"Treatment.Disorder","text":"pseudoporphyria"}]}]}
{"id":"18505911_4","context":"She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.","events":[{"type":"Treatment","annotations":[{"annotation":"Drug","text":"warfarin"},{"annotation":"Dosage","text":"39 mg (5.5 mg daily)"},{"annotation":"Duration","text":"prior to beginning azathioprine therapy"},{"annotation":"Treatment.Disorder","text":"not specified"}]}]}
{"id":"9279731_1","context":"When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"severe side effects"},{"annotation":"Treatment","text":"conventional amphotericin B"},{"annotation":"Treatment.Drug","text":"conventional amphotericin B"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"disease recurrence"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes","text":"not specified"},{"annotation":"Attribute Attributes"}]}]}
{"id":"3211830_2","context":"Widespread cutaneous vasculitis associated with diltiazem.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"diltiazem"},{"annotation":"Treatment.Drug","text":"diltiazem"},{"annotation":"Effect","text":"vasculitis"},{"annotation":"Treatment.Disorder","text":"widespread cutaneous"},{"annotation":"Treatment.Drug","text":"vasculitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"diltiazem"},{"annotation":"Treatment.Drug","text":"diltiazem"},{"annotation":"Effect","text":"vasculitis"},{"annotation":"Treatment.Disorder","text":"widespread cutaneous"},{"annotation":"Treatment.Drug","text":"vasculitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"diltiazem"},{"annotation":"Treatment.Drug","text":"diltiazem"},{"annotation":"Effect","text":"vasculitis"},{"annotation":"Treatment.Disorder","text":"widespread cutaneous"},{"annotation":"Treatment.Drug","text":"vasculitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"diltiazem"},{"annotation":"Treatment.Drug","text":"diltiazem"},{"annotation":"Effect","text":"vasculitis"},{"annotation":"Treatment.Disorder","text":"widespread cutaneous"},{"annotation":"Treatment.Drug","text":"vasculitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"diltiazem"},{"annotation":"Treatment.Drug","text":"diltiazem"},{"annotation":"Effect","text":"vasculitis"},{"annotation":"Treatment.Disorder","text":"widespread cutaneous"},{"annotation":"Treatment.Drug","text":"vasculitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"diltiazem"},{"annotation":"Treatment.Drug","text":"diltiazem"},{"annotation":"Effect","text":"vasculitis"},{"annotation":"Treatment.Disorder","text":"widespread cutaneous"},{"annotation":"Treatment.Drug","text":"vasculitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"diltiazem"},{"annotation":"Treatment.Drug","text":"diltiazem"},{"annotation":"Effect","text":"vasculitis"},{"annotation":"Treatment.Disorder","text":"widespread cutaneous"},{"annotation":"Treatment.Drug","text":"vasculitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"diltiazem"},{"annotation":"Treatment.Drug","text":"diltiazem"},{"annotation":"Effect","text":"vasculitis"},{"annotation":"Treatment.Disorder","text":"widespread cutaneous"},{"annotation":"Treatment.Drug","text":"vasculitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"diltiazem"},{"annotation":"Treat"}]}]}
{"id":"9726762_2","context":"The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"hypoprothrombinemia and bleeding"},{"annotation":"Treatment","text":"warfarin"},{"annotation":"Treatment.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Duration","text":"4 weeks"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"hypoprothrombinemia"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Duration","text":"4 weeks"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"hypoprothrombinemia"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Drug","text":"gemfibrozil"},{"annotation":"Treatment.Duration","text":"4 weeks"}]}]}
{"id":"15773973_3","context":"We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"fulminant hepatic failure"},{"annotation":"Treatment","text":"oral flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.D"}]}]}
{"id":"16697705_2","context":"This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"development"},{"annotation":"Effect","text":"acute coronary syndrome"},{"annotation":"Treatment","text":"Capecitabine therapy"},{"annotation":"Treatment.Disorder","text":"acute coronary syndrome"},{"annotation":"Treatment.Drug","text":"Capecitabine"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Population","text":"a patient"}]}]}
{"id":"7212107_2","context":"These results indicate that lithium may cause biochemical hyperparathyroidism.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused"},{"annotation":"Effect","text":"hyperparathyroidism"},{"annotation":"Treatment","text":"lithium"},{"annotation":"Treatment.Disorder","text":"biochemical hyperparathyroidism"},{"annotation":"Treatment.Drug","text":"lithium"}]}]}
{"id":"10579985_2","context":"The relationship between infliximab treatment and lymphoma in Crohn's disease.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"increased risk of"},{"annotation":"Effect","text":"lymphoma"},{"annotation":"Treatment","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Treatment.Drug","text":""}]}]}
{"id":"15863610_7","context":"CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"association"},{"annotation":"Treatment","text":"raloxifene"},{"annotation":"Treatment.Disorder","text":"malignant mixed mesodermal tumor"},{"annotation":"Effect","text":"development"}]}]}
{"id":"19131789_3","context":"Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"renal toxicity"},{"annotation":"Treatment","text":"high-dose methotrexate therapy"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"high-dose"},{"annotation":"Treatment.Duration","text":"therapy"},{"annotation":"Treatment.Disorder","text":"renal toxicity"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"high-dose"},{"annotation":"Treatment.Duration","text":"therapy"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Age","text":"not specified"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"not specified"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"renal toxicity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":""}]}]}
{"id":"8467620_2","context":"The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developing"},{"annotation":"Effect","text":"lymphoproliferative diseases"},{"annotation":"Treatment","text":"methotrexate therapy"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"immunosuppression"},{"annotation":"Treatment.Drug","text":"mild"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Disorder","text":"lymphoproliferative diseases"}]}]}
{"id":"14561622_2","context":"We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary to intrathecal methotrexate"},{"annotation":"Effect","text":"cytotoxic edema"},{"annotation":"Treatment","text":"intrathecal methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Dosage","text":"intrathecal"},{"annotation":"Treatment.Route","text":"intrathecal"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"cytotoxic edema"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"clinical and radiographic findings"},{"annotation":"Attribute.negated","text":"cytotoxic edema"},{"annotation":"Attribute.negated","text":"intrathecal methotrexate"}]}]}
{"id":"16843118_2","context":"Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"causes"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment.Drug","text":"hyperhidrosis"},{"annotation":"Treatment.Drug","text":"facial flushing"},{"annotation":"Treatment.Severity","text":"serious"},{"annotation":"Treatment.Side_effect","text":"cutaneous adverse drug reactions"},{"annotation":"Treatment.Severity","text":"seldom observed"}]}]}
{"id":"20465622_1","context":"Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"aphthous stomatitis"},{"annotation":"Treatment","text":"oral calcineurin and mTOR inhibitors"},{"annotation":"Treatment.Drug","text":"oral calcineurin"},{"annotation":"Treatment.Drug","text":"oral mTOR inhibitors"},{"annotation":"Treatment.Drug","text":"oral"},{"annotation":"Treatment.Drug","text":"calcinurin"},{"annotation":"Treatment.Drug","text":"mTOR"},{"annotation":"Treatment.Drug","text":"oral"},{"annotation":"Subject","text":"patients"},{"annotation":"Subject.Disorder","text":"aphthous stomatitis"}]}]}
{"id":"17619811_1","context":"A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"starting treatment with colchicine"},{"annotation":"Effect","text":"fatigue"},{"annotation":"Effect","text":"myalgia"},{"annotation":"Effect","text":"leg weakness"},{"annotation":"Treatment","text":"colchicine"},{"annotation":"Treatment.Disorder","text":"gout arthritis"},{"annotation":"Subject","text":"a 79-year-old man"},{"annotation":"Subject.Disorder","text":"gout arthritis"},{"annotation":"Subject.Disorder","text":"ischemic heart disease"},{"annotation":"Subject.Disorder","text":"chronic atrial fibrillation"},{"annotation":"Subject.Disorder","text":"chronic renal failure"},{"annotation":"Subject.Disorder","text":"hypothyroidism"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"starting treatment with colchicine"},{"annotation":"Effect","text":"fatigue"},{"annotation":"Effect","text":"myalgia"},{"annotation":"Effect","text":"leg weakness"},{"annotation":"Treatment","text":"colchicine"},{"annotation":"Treatment.Disorder","text":"gout arthritis"},{"annotation":"Subject","text":"a 79-year-old man"},{"annotation":"Subject.Disorder","text":"gout arthritis"},{"annotation":"Subject.Disorder","text":"ischemic heart disease"},{"annotation":"Subject.Disorder","text":"chronic atrial fibrillation"},{"annotation":"Subject.Disorder","text":"chronic renal failure"},{"annotation":"Subject.Disorder","text":"hypothyroidism"}]}]}
{"id":"17275666_6","context":"This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"seizure exacerbation"},{"annotation":"Treatment","text":"intravenous valproic acid"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Treatment.Disorder","text":"juvenile absence epilepsy"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Duration","text":"documented by video-electroencephalography"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"seizure exacerbation"},{"annotation":"Treatment","text":"intravenous valproic acid"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Treatment.Disorder","text":"juvenile absence epilepsy"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Duration","text":"documented by video-electroencephalography"}]}]}
{"id":"18277922_1","context":"She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"zoster"},{"annotation":"Treatment","text":"acyclovir"},{"annotation":"Treatment.Disorder","text":"VZV antigen-positive zoster"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"VZV antigen-positive zoster"},{"annotation":"Treatment.Treatment_result","text":"VZV antigen-positive zoster"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{}]}]}
{"id":"15857283_1","context":"CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"corneal endothelial deposits"},{"annotation":"Treatment","text":"rifabutin"},{"annotation":"Treatment.Drug","text":"rifabutin"},{"annotation":"Treatment.Disorder","text":"corneal endothelial deposits"},{"annotation":"Treatment.Drug","text":"corneal endothelial deposits"},{"annotation":"Effect","text":"corneal endothelial deposits"}]}]}
{"id":"7978578_1","context":"Response of a promethazine-induced coma to flumazenil.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"promethazine"},{"annotation":"Treatment.Drug","text":"promethazine"},{ "annotation":"Effect","text":"coma"}]},{"type":"Potential_therapeutic_event","annotations":[{"annotation":"Trigger","text":"Response"},{"annotation":"Treatment","text":"flumazenil"},{"annotation":"Treatment.Disorder","text":"promethazine-induced coma"},{"annotation":"Treatment.Drug","text":"flumazenil"}]}]}
{"id":"16978752_1","context":"First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"during treatment with olanzapine (Zyprexa)"},{"annotation":"Effect","text":"neutropenia or agranulocytosis"},{"annotation":"Treatment","text":"olanzapine (Zyprexa)"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"Zyprexa"}]}]}
{"id":"8250714_2","context":"Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"neurologic degeneration"},{"annotation":"Treatment","text":"nitrous oxide anesthesia"},{"annotation":"Treatment.Drug","text":"nitrous oxide"},{"annotation":"Treatment.Disorder","text":"vitamin B12 deficiency"},{"annotation":"Treatment.Drug","text":"nitrous oxide"},{"annotation":"Treatment.Drug","text":"vitamin B12"},{"annotation":"Treatment.Combination.Trigger","text":"in patients with"},{"annotation":"Treatment.Combination.Drug","text":"nitrous oxide"},{"annotation":"Treatment.Combination.Drug","text":"vitamin B12"},{"annotation":"Subject","text":"patients with vitamin B12 deficiency"},{"annotation":"Subject.Disorder","text":"vitamin B12 deficiency"}]}]}
{"id":"1695794_3","context":"Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"previous therapy"},{"annotation":"Treatment","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Disorder","text":"arrhythmia"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"Treatment.Drug","text":"antiarrhythmics"},{"annotation":"T"}]}]}
{"id":"6239881_1","context":"Allergic contact dermatitis to compound tincture of benzoin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"contact"},{"annotation":"Effect","text":"dermatitis"},{"annotation":"Treatment","text":"compound tincture of benzoin"},{"annotation":"Treatment.Drug","text":"benzoin"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"allergic contact dermatitis"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"8610807_3","context":"PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"spontaneous choroidal hemorrhage"},{"annotation":"Treatment","text":"tissue plasminogen activator"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Effect","text":"hemorrhage"},{"annotation":"Treatment.Disorder","text":"myocardial infarction"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Subject","text":"a 67-year-old man"},{"annotation":"Subject.Age","text":"67"},{"annotation":"Subject.Disorder","text":"myocardial infarction"}]}]}
{"id":"23970584_4","context":"Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"Cushing's syndrome"},{"annotation":"Treatment","text":"triamcinolone"},{"annotation":"Treatment.Drug","text":"boosted protease inhibitor therapy"},{"annotation":"Treatment.Drug","text":"triamcinolone"},{"annotation":"Treatment.Drug","text":"boosted protease inhibitor therapy"},{"annotation":"Treatment.Drug","text":"drug-drug interaction"},{"annotation":"Treatment.Combination.Trigger","text":"between"},{"annotation":"Treatment.Combination.Drug","text":"triamcinolone"},{"annotation":"Treatment.Combination.Drug","text":"boosted protease inhibitor therapy"},{"annotation":"Subject","text":"she"},{"annotation":"Subject.Disorder","text":"Cushing's syndrome"}]}]}
{"id":"11341670_2","context":"Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"observed"},{"annotation":"Treatment","text":"proton pump inhibitors omeprazole, lansoprazole, or pantoprazole"},{"annotation":"Treatment.Drug","text":"proton pump inhibitors"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"lansoprazole"},{"annotation":"Treatment.Drug","text":"pantoprazole"},{"annotation":"Treatment.Dosage","text":"recommended standard doses"},{"annotation":"Treatment.Duration","text":"7-15 days"},{"annotation":"Treatment.Disorder","text":"peptic acid diseases"},{"annotation":"Effect","text":"phlebitis"},{"annotation":"Treatment.Drug","text":"proton pump inhibitors"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"lansoprazole"},{"annotation":"Treatment.Drug","text":"pantoprazole"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"proton pump inhibitors"},{"annotation":"Treatment.Combination.Drug","text":"omeprazole"},{"annotation":"Treatment.Combination.Drug","text":"lansoprazole"},{"annotation":"Treatment.Combination.Drug","text":"pantoprazole"},{"annotation":"Subject","text":"five female patients"},{"annotation":"Subject.Disorder","text":"peptic acid diseases"},{"annotation":"Subject.Disorder","text":"phlebitis"}]}]}
{"id":"18855892_5","context":"We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"anaphylactic/anaphylactoid reaction"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"metastatic osteosarcoma"},{"annotation":"Treatment.Drug","text":"methotrexate"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"anaphylactic/anaphylactoid reaction"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"metastatic osteosarcoma"},{"annotation":"Treatment.Drug","text":"methotrexate"}]}]}
{"id":"17823522_5","context":"It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"speculation"},{"annotation":"Treatment","text":"interferon alpha"},{"annotation":"Treatment.Disorder","text":"lichen nitidus"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.Severity","text":"unknown"}]}]}
{"id":"18569796_1","context":"CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"alendronate"},{"annotation":"Treatment.Drug","text":"alendronate"},{"annotation":"Effect","text":"nodular scleritis"},{"annotation":"Treatment.Drug","text":"rechallenge"},{"annotation":"Effect","text":"recurrence of scleritis"},{"annotation":"Treatment.Drug","text":"nodular scleritis"},{"annotation":"Treatment.Disorder","text":"nodular scleritis"},{"annotation":"Treatment.Drug","text":"alendronate"},{"annotation":"Subject","text":"an individual"},{"annotation":"Subject.Disorder","text":"nodular scleritis"}]}]}
{"id":"1469187_2","context":"A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intoxication"},{"annotation":"Effect","text":"digitoxin intoxication"},{"annotation":"Treatment","text":"prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB)"},{"annotation":"Treatment.Disorder","text":"digitoxin intoxication"},{"annotation":"Treatment.Drug","text":"digitoxin"},{"annotation":"Treatment.Drug","text":"Fab fragments of anti-digitalis antibodies (FAB)"},{"annotation":"Treatment.Route","text":"i.v.-infusions"},{"annotation":"Treatment.Duration","text":"prolonged and repeated"},{"annotation":"Treatment.Dosage","text":"35 mg DGTX"},{"annotation":"Treatment.Drug","text":"digitoxin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"for ADE, the adverse effect does not exist; or for PTE, the therapy is ineffective."}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intoxication"},{"annotation":"Effect","text":"digitoxin intoxication"},{"annotation":"Treatment","text":"prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB)"},{"annotation":"Treatment.Disorder","text":"digitoxin intoxication"},{"annotation":"Treatment.Drug","text":"digitoxin"},{"annotation":"Treatment.Drug","text":"Fab fragments of anti-digitalis antibodies (FAB)"},{"annotation":"Treatment.Route","text":"i.v.-infusions"},{"annotation":"Treatment.Duration","text":"prolonged and repeated"},{"annotation":"Treatment.Dosage","text":"35 mg DGTX"},{"annotation":"Treatment.Drug","text":"digitoxin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"for ADE, the adverse effect does not exist; or for PTE, the therapy is ineffective."}]}]}
{"id":"6788011_3","context":"Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"result"},{"annotation":"Effect","text":"damage"},{"annotation":"Treatment","text":"gold-salt therapy"},{"annotation":"Treatment.Disorder","text":"proximal tubular damage"},{"annotation":"Treatment.Drug","text":"gold-salt"},{"annotation":"Treatment.Drug","text":"renal tubular antigen"},{"annotation":"Treatment.Combination.Trigger","text":"in turn complex with autoantibody and produce an autoimmune membranous nephropathy"},{"annotation":"Treatment.Combination.Drug","text":"renal tubular antigen"},{"annotation":"Treatment.Combination.Drug","text":"autoantibody"},{"annotation":"Subject","text":"proximal tubules"},{"annotation":"Subject.Disorder","text":"proximal tubular damage"}]}]}
{"id":"20199429_1","context":"Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"dermatitis"},{"annotation":"Effect","text":"recalcitrant"},{"annotation":"Treatment","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Disorder","text":"atopic dermatitis"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"},{"annotation":"Treatment.Drug","text":"Aquaphor emollient"},{"annotation":"Treatment.Drug","text":"bisabolol"}]}]}
{"id":"16160485_2","context":"Recently, CD20-negative tumors have been described after Rituximab therapy.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"CD20-negative tumors"},{"annotation":"Treatment","text":"Rituximab therapy"},{"annotation":"Treatment.Disorder","text":"CD20-negative tumors"},{"annotation":"Treatment.Drug","text":"Rituximab"}]}]}
{"id":"10560960_1","context":"A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"agranulocytosis"},{"annotation":"Treatment","text":"methimazole"},{"annotation":"Treatment.Disorder","text":"thyrotoxicosis"},{"annotation":"Treatment.Drug","text":"methimazole"},{"annotation":"Subject","text":"a 48-year-old woman"},{"annotation":"Subject.Age","text":"48"},{"annotation":"Subject.Disorder","text":"thyrotoxicosis"},{"annotation":"Treatment.Drug","text":"methimazole"}]}]}
{"id": "10646879_1","context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.","events": [{"type": "Adverse_event","annotations": [{"annotation": "Trigger","text": "induced"},{"annotation": "Treatment","text": "ifosfamide"},{"annotation": "Treatment.Disorder","text": "encephalopathy"},{"annotation": "Effect","text": "methylene blue"},{"annotation": "Treatment.Drug","text": "methylene blue"},{"annotation": "Treatment.Dosage","text": "not specified"},{"annotation": "Treatment.Frequency","text": "not specified"},{"annotation": "Treatment.Route","text": "not specified"},{"annotation": "Treatment.Time_elapsed","text": "not specified"},{"annotation": "Treatment.Duration","text": "not specified"},{"annotation": "Treatment.Combination.Trigger","text": "in ifosfamide-induced encephalopathy"},{"annotation": "Treatment.Combination.Drug","text": "methylene blue"},{"annotation": "Treatment.Combination.Drug","text": "ifosfamide"},{"annotation": "Treatment.Combination.Drug","text": "methylene blue"},{"annotation": "Treatment.Combination.Drug","text": "ifosfamide"},{"annotation": "Treatment.Combination.Drug","text": "methylene blue"},{"annotation": "Treatment.Combination.Drug","text": "ifosfamide"},{"annotation": "Treatment.Combination.Drug","text": "methylene blue"},{"annotation": "Treatment.Combination.Drug","text": "ifosfamide"},{"annotation": "Treatment.Combination.Drug","text": "methylene blue"},{"annotation": "Treatment.Combination.Drug","text": "ifosfamide"},{"annotation": "Treatment.Combination.Drug","text": "methylene blue"},{"annotation": "Treatment.Combination.Drug","text": "ifosfamide"},{"annotation": "Treatment.Combination.Drug","text": "methylene blue"},{"annotation": "Treatment.Combination.Drug","text": "ifosfamide"},{"annotation": "Treatment.Combination.Drug","text": "methylene blue"},{"annotation": "Treatment.Combination.Drug","text": "ifosfamide"},{"annotation": "Treatment.Combination.Drug","text": "methylene blue"},{"annotation": "Treatment.Combination.Drug","text": "ifosfamide"}]}]}
{"id":"15863610_4","context":"We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"diagnosed"},{"annotation":"Treatment","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Disorder","text":"malignant mixed mesodermal tumor"},{"annotation":"Treatment.Disorder","text":"malignant mixed mesodermal tumor"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Drug","text":"raloxifene"}]}]}
{"id":"22677303_12","context":"Interactions between warfarin and cloxacillin can result in serious adverse reactions.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"Interactions between warfarin and cloxacillin"},{"annotation":"Effect","text":"serious adverse reactions"},{"annotation":"Treatment","text":"warfarin"},{"annotation":"Treatment.Drug","text":"cloxacillin"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Drug","text":"cloxacillin"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Drug","text":"cloxacillin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Drug","text":"cloxacillin"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Drug","text":"cloxacillin"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Drug","text":"cloxacillin"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Drug","text":"cloxacillin"}]}]}
{"id":"11724089_2","context":"However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Type","text":"Stevens-Johnson syndrome or toxic epidermal necrolysis"},{"annotation":"Treatment","text":"ofloxacin"},{"annotation":"Effect","text":"associated with"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Type","text":"Stevens-Johnson syndrome or toxic epidermal necrolysis"},{"annotation":"Treatment","text":"ofloxacin"},{"annotation":"Effect","text":"associated with"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Type","text":"Stevens-Johnson syndrome or toxic epidermal necrolysis"},{"annotation":"Treatment","text":"ofloxacin"},{"annotation":"Effect","text":"associated with"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Type","text":"Stevens-Johnson syndrome or toxic epidermal necrolysis"},{"annotation":"Treatment","text":"ofloxacin"},{"annotation":"Effect","text":"associated with"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Type","text":"Stevens-Johnson syndrome or toxic epidermal necrolysis"},{"annotation":"Treatment","text":"ofloxacin"},{"annotation":"Effect","text":"associated with"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Type","text":"Stevens-Johnson syndrome or toxic epidermal necrolysis"},{"annotation":"Treatment","text":"ofloxacin"},{"annotation":"Effect","text":"associated with"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Type","text":"Stevens-Johnson syndrome or toxic epidermal necrolysis"},{"annotation":"Treatment","text":"ofloxacin"},{"annotation":"Effect","text":"associated with"},{"annotation":"Treatment.Drug","text":"ofloxacin"}]}]}
{"id":"879939_5","context":"Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"accelerated"},{"annotation":"Treatment","text":"acetazolamide"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Treatment.Disorder","text":"osteomalacia"},{"annotation":"Treatment.Mechanism","text":"increased renal calcium excretion"}]}]}
{"id":"14697943_1","context":"In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"relevant"},{"annotation":"Treatment","text":"anticalcineurinic drug"},{"annotation":"Treatment.Drug","text":"CyA or tacrolimus"},{"annotation":"Treatment.Disorder","text":"RSDS"},{"annotation":"Treatment.Dosage","text":"low steroid dose"},{"annotation":"Treatment.Dosage","text":"monotherapy"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"occurrence"},{"annotation":"Effect","text":"RSDS"},{"annotation":"Treatment","text":"anticalcineurinic drug"},{"annotation":"Treatment.Drug","text":"CyA or tacrolimus"},{"annotation":"Treatment.Disorder","text":"RSDS"},{"annotation":"Treatment.Dosage","text":"low steroid dose"},{"annotation":"Treatment.Dosage","text":"monotherapy"}]}]}
{"id":"14742791_5","context":"There have been several reported cases of omeprazole-induced AIN.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Effect","text":"AIN"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger"}]}]}
{"id":"9726762_4","context":"This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"overlooked"},{"annotation":"Effect","text":"bleeding risk"},{"annotation":"Treatment","text":"warfarin"},{"annotation":"Treatment.Disorder","text":"bleeding risk"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{}]}]}
{"id":"1966850_1","context":"Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"cardiomyopathy"},{"annotation":"Treatment","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"adriamycin"},{"annotation":"Treatment.Drug","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"dialysis"},{"annotation":"Treatment.Disorder","text":"cardiomyopathy"},{"annotation":"Treatment.Disorder","text":"nephrotoxicity"},{"annotation":"Treatment.Disorder","text":"dialysis"},{"annotation":"Treatment.Drug","text":"adriamycin"},{"annotation":"Treatment.Drug","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"dialysis"},{"annotation":"Treatment.Drug","text":"cardiomyopathy"},{"annotation":"Treatment.Drug","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"dialysis"},{"annotation":"Treatment.Drug","text":"cardiomyopathy"},{"annotation":"Treatment.Drug","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"dialysis"},{"annotation":"Treatment.Drug","text":"cardiomyopathy"},{"annotation":"Treatment.Drug","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"dialysis"},{"annotation":"Treatment.Drug","text":"cardiomyopathy"},{"annotation":"Treatment.Drug","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"dialysis"},{"annotation":"Treatment.Drug","text":"cardiomyopathy"},{"annotation":"Treatment.Drug","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"dialysis"},{"annotation":"Treatment.Drug","text":"cardiomyopathy"},{"annotation":"Treatment.Drug","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"dialysis"},{"annotation":"Treatment.Drug","text":"cardiomyopathy"},{"annotation":"Treatment.Drug","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"dialysis"},{"annotation":"Treatment.Drug","text":"cardiomyopathy"},{"annotation":"Treatment.Drug","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"dialysis"},{"annotation":"Treatment.Drug","text":"cardiomyopathy"},{"annotation":"Treatment.Drug","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"dialysis"},{"annotation":"Treatment.Drug","text":"cardiomyopathy"},{"annotation":"Treatment.Drug","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"dialysis"},{"annotation":"Treatment.Drug","text":"cardiomyopathy"},{"annotation":"Treatment.Drug","text":"cis-platinum"},{"annotation":"Treatment.Drug","text":"dialysis"},{"annotation":"Treatment.Drug","text":"cardiomyopathy"},{"annotation":"Treatment.Drug","text":"cis-"}]}]}
{"id":"8145359_1","context":"An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"suffering from respiratory distress syndrome"},{"annotation":"Effect","text":"respiratory distress syndrome"},{"annotation":"Treatment","text":"methotrimeprazine meleate (Levemepromazine)"},{"annotation":"Treatment.Drug","text":"methotrimeprazine meleate (Levemepromazine)"},{"annotation":"Treatment.Dosage","text":"relatively high dose"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"respiratory distress syndrome"},{"annotation":"Subject","text":"an 11-year-old boy"},{"annotation":"Subject.Age","text":"11 years"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"1 patient"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"}]}]}
{"id":"11762672_1","context":"An adult male presented with central blindness after ingesting methanol.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"ingesting"},{"annotation":"Treatment","text":"methanol"},{"annotation":"Treatment.Drug","text":"methanol"},{"annotation":"Effect","text":"central blindness"},{"annotation":"Treatment.Drug","text":"methanol"},{"annotation":"Treatment.Drug","text":"methanol"},{"annotation":"Subject","text":"an adult male"},{"annotation":"Subject.Age","text":"adult"},{"annotation":"Subject.Gender","text":"male"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"central blindness"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"presentation"},{"annotation":"Treatment","text":"unknown"},{"annotation":"Treatment.Disorder","text":"central blindness"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Att"}]}]}
{"id":"8523340_1","context":"All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"im gold therapy"},{"annotation":"Treatment.Drug","text":"im gold"},{"annotation":"Treatment.Dosage","text":"within 20 weeks"},{"annotation":"Treatment.Side_effect","text":"mucocutaneous side effects"},{"annotation":"Treatment.Disorder","text":"RA"},{"annotation":"Subject","text":"all patients"},{"annotation":"Subject.Disorder","text":"RA"},{"annotation":"Treatment.Duration","text":"markedly improved compared to pretreatment status"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"RA had improved"},{"annotation":"Treatment","text":"im gold therapy"},{"annotation":"Treatment.Disorder","text":"RA"},{"annotation":"Treatment.Effect","text":"markedly improved compared to pretreatment status"}]}]}
{"id":"1868481_2","context":"Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presented"},{"annotation":"Treatment","text":"i.v. pulse methylprednisolone (IVPMP)"},{"annotation":"Treatment.Disorder","text":"idiopathic nephrotic syndrome and endo-extracapillary glomerulonephritis"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Dosage","text":"i.v."},{"annotation":"Treatment.Duration","text":"pulse"},{"annotation":"Treatment.Time_elapsed","text":"presented"},{"annotation":"Treatment.Time_elapsed","text":"at different times"},{"annotation":"Treatment.Side_effect","text":"seizures and transient blindness"},{"annotation":"Treatment.Side_effect","text":"episode of"},{"annotation":"Effect","text":"seizures and transient blindness"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presented"},{"annotation":"Treatment","text":"i.v. pulse methylprednisolone (IVPMP)"},{"annotation":"Treatment.Disorder","text":"idiopathic nephrotic syndrome and endo-extracapillary glomerulonephritis"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Treatment.Dosage","text":"i.v."},{"annotation":"Treatment.Duration","text":"pulse"},{"annotation":"Treatment.Time_elapsed","text":"presented"},{"annotation":"Treatment.Time_elapsed","text":"at different times"},{"annotation":"Treatment.Side_effect","text":"seizures and transient blindness"},{"annotation":"Treatment.Side_effect","text":"episode of"},{"annotation":"Effect","text":"seizures and transient blindness"}]}]}
{"id":"12836099_1","context":"Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"Stevens-Johnson syndrome"},{"annotation":"Treatment","text":"prednisolone therapy"},{"annotation":"Treatment.Drug","text":"prednisolone"},{"annotation":"Treatment.Disorder","text":"nephrotic syndrome"},{"annotation":"Treatment.Drug","text":"prednisolone"},{"annotation":"Treatment.Dosage","text":"during prednisolone therapy"},{"annotation":"Subject","text":"a boy"},{"annotation":"Subject.Disorder","text":"nephrotic syndrome"}]}]}
{"id":"18628507_4","context":"To our knowledge, this is the first report of an angio-oedema associated with VRC.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"angio-oedema"},{"annotation":"Treatment","text":"VRC"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"report"},{"annotation":"Treatment","text":"VRC"},{"annotation":"Treatment.Disorder","text":"angio-oedema"},{"annotation":"Treatment.Drug","text":"VRC"}]}]}
{"id":"4014301_1","context":"Insulin-induced cardiac failure.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"cardiac failure"},{"annotation":"Treatment","text":"insulin"},{"annotation":"Treatment.Disorder","text":"cardiac failure"},{"annotation":"Treatment.Drug","text":"insulin"}]}]}
{"id":"15522120_10","context":"The symptoms disappeared with clemastine and betametasone treatment.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"disappeared"},{"annotation":"Effect","text":"symptoms"},{"annotation":"Treatment","text":"clemastine and betametasone"},{"annotation":"Treatment.Drug","text":"clemastine"},{"annotation":"Treatment.Drug","text":"betametasone"},{"annotation":"Subject","text":"with"},{"annotation":"Subject.Age","text":"clemastine and betametasone treatment"},{"annotation":"Subject.Disorder","text":"symptoms"},{"annotation":"Treatment.Drug","text":"clemastine"},{"annotation":"Treatment.Drug","text":"betametasone"},{"annotation":"Treatment.Frequency","text":"with clemastine and betametasone treatment"},{"annotation":"Treatment.Route","text":"with clemastine and betametasone treatment"},{"annotation":"Treatment.Time_elapsed","text":"with clemastine and betametasone treatment"},{"annotation":"Treatment.Duration","text":"with clemastine and betametasone treatment"},{"annotation":"Treatment.Disorder","text":"symptoms"}]}]}
{"id":"11724089_6","context":"This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"rules out"},{"annotation":"Treatment","text":"toxic epidermal necrolysis"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Disorder","text":"drug-induced toxic epidermal necrolysis"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"implicates"},{"annotation":"Effect","text":"toxic epidermal necrolysis"},{"annotation":"Treatment","text":"ofloxacin"},{"annotation":"Treatment.Disorder","text":"drug-induced toxic epidermal necrolysis"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Disorder","text":"drug-induced toxic epidermal necrolysis"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"}]}]}
{"id":"3917429_1","context":"Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"discussed"},{"annotation":"Treatment","text":"lithium therapy"},{"annotation":"Treatment.Disorder","text":"nephrotoxicity"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute"}]}]}
{"id":"6738830_1","context":"A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"unique behavioral change"},{"annotation":"Treatment","text":"oral administration of cinepazide"},{"annotation":"Treatment.Drug","text":"cinepazide"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"parkinsonian"},{"annotation":"Treatment.Disorder","text":"cerebral vasodilator"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"unique behavioral change"},{"annotation":"Effect","text":"behavioral change"},{"annotation":"Treatment","text":"oral administration of cinepazide"},{"annotation":"Treatment.Drug","text":"cinepazide"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"parkinsonian"},{"annotation":"Treatment.Disorder","text":"cerebral vasodilator"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"unique behavioral change"},{"annotation":"Treatment","text":"oral administration of cinepazide"},{"annotation":"Treatment.Drug","text":"cinepazide"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"parkinsonian"},{"annotation":"Treatment.Disorder","text":"cerebral vasodilator"}]}]}
{"id":"440873_3","context":"The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"carbamazepine"},{"annotation":"Treatment.Disorder","text":"dystonia"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"dopamine"},{"annotation":"Treatment.Drug","text":"antagonist"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"high severity"}]}]}
{"id":"12042592_2","context":"Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"use"},{"annotation":"Treatment","text":"metamizole"},{"annotation":"Treatment.Drug","text":"metamizole"},{"annotation":"Treatment.Disorder","text":"agranulocytosis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated.text","text":"not prohibited"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"use"},{"annotation":"Treatment","text":"metamizole"},{"annotation":"Treatment.Drug","text":"metamizole"},{"annotation":"Treatment.Disorder","text":"agranulocytosis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated.text","text":"not prohibited"}]}]}
{"id":"9777751_6","context":"We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"correction"},{"annotation":"Treatment","text":"hemopoietic colony stimulating factors"},{"annotation":"Treatment.Disorder","text":"thionamide-induced hematologic adverse reactions"},{"annotation":"Treatment.Drug","text":"hemopoietic colony stimulating factors"},{"annotation":"Effect","text":"correction"}]}]}
{"id":"8696525_2","context":"Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"anterior uveitis"},{"annotation":"Treatment","text":"metripranolol"},{"annotation":"Treatment.Drug","text":"metripranolol"},{"annotation":"Treatment.Disorder","text":"open angle glaucoma"},{"annotation":"Treatment.Drug","text":"eye drops"},{"annotation":"Treatment.Dosage","text":"0.6%"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"topical"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"open angle glaucoma"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Disorder","text":"open angle glaucoma"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"anterior uveitis"},{"annotation":"Treatment","text":"metripranolol"},{"annotation":"Treatment.Drug","text":"metripranolol"},{"annotation":"Treatment.Disorder","text":"open angle glaucoma"},{"annotation":"Treatment.Drug","text":"eye drops"},{"annotation":"Treatment.Dosage","text":"0.6%"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"topical"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"open angle glaucoma"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Disorder","text":"open angle glaucoma"}]}]}
{"id":"7355327_2","context":"Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"life-threatening bronchospasm"},{"annotation":"Treatment","text":"propranolol therapy"},{"annotation":"Treatment.Disorder","text":"bronchospasm"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":""}]}]}
{"id":"11147747_2","context":"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"selective serotonin reuptake inhibitors paroxetine and sertraline"},{"annotation":"Treatment.Drug","text":"paroxetine"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Drug","text":"venlafaxine"},{"annotation":"Treatment.Disorder","text":"incontinence"},{"annotation":"Subject","text":"2 female patients"},{"annotation":"Subject.Disorder","text":"incontinence"}]}]}
{"id":"1680596_1","context":"Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"introduction"},{"annotation":"Treatment","text":"SASP therapy"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{"annotation":"Treatment.Drug","text":"SASP"},{"annotation":"Treatment.Side_effect","text":"severe and lasting psoriasis-like skin reaction"},{}]}]}
{"id":"19112808_1","context":"Interstitial granulomatous dermatitis associated with darifenacin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"interstitial granulomatous dermatitis"},{"annotation":"Treatment","text":"darifenacin"},{"annotation":"Treatment.Disorder","text":"interstitial granulomatous dermatitis"},{"annotation":"Treatment.Drug","text":"darifenacin"}]}]}
{"id":"11762672_2","context":"Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"visual impairment"},{"annotation":"Treatment","text":"methanol"},{"annotation":"Treatment.Drug","text":"fomepizole"},{"annotation":"Treatment.Drug","text":"methanol"},{"annotation":"Treatment.Drug","text":"fomepizole"},{"annotation":"Treatment.Time_elapsed","text":"severe"},{"annotation":"Treatment.Duration","text":"reversal"},{"annotation":"Treatment.Disorder","text":"methanol-induced visual impairment"},{"annotation":"Treatment.Drug","text":"fomepizole"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"no evidence of retinal toxicity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"visual impairment"},{"annotation":"Treatment","text":"methanol"},{"annotation":"Treatment.Drug","text":"fomepizole"},{"annotation":"Treatment.Drug","text":"methanol"},{"annotation":"Treatment.Drug","text":"fomepizole"},{"annotation":"Treatment.Time_elapsed","text":"severe"},{"annotation":"Treatment.Duration","text":"reversal"},{"annotation":"Treatment.Disorder","text":"methanol-induced visual impairment"},{"annotation":"Treatment.Drug","text":"fomepizole"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"no evidence of retinal toxicity"}]}]}
{"id":"20925534_3","context":"Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"believed"},{"annotation":"Treatment","text":"proton-pump inhibitors (PPIs)"},{"annotation":"Treatment.Drug","text":"proton-pump inhibitors (PPIs)"},{"annotation":"Treatment.Disorder","text":"complications"},{"annotation":"Treatment.Combination","text":"dual antiplatelet therapy"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"no randomized trial has proved this"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"complications"},{"annotation":"Treatment","text":"dual antiplatelet therapy"},{"annotation":"Treatment.Disorder","text":"complications"},{"annotation":"Treatment.Combination","text":"dual antiplatelet therapy"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"no randomized trial has proved this"}]}]}
{"id":"10592946_4","context":"The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caffeine"},{"annotation":"Effect","text":"rhabdomyolysis and delirium"},{"annotation":"Treatment","text":"caffeine"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"none"},{"annotation":"Treatment.Combination.Drug","text":"none"},{"annotation":"Subject","text":"none"},{"annotation":"Subject.Disorder","text":"none"}]}]}
{"id":"11283125_8","context":"Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Prevention"},{"annotation":"Treatment","text":"HD IV MTX and intrathecal injections of MTX"},{"annotation":"Treatment.Disorder","text":"children with increased-risk ALL or stage III and IV lymphoblastic lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Treatment_protocol","text":"BFM-based treatment protocol"},{"annotation":"Treatment.Omission","text":"cranial irradiation"},{"annotation":"Subject","text":"children"},{"annotation":"Treatment.Duration","text":"HD IV MTX and intrathecal injections of MTX"},{"annotation":"Treatment.Duration","text":"duration of treatment"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"},{"annotation":"Treatment.Disorder","text":"ALL or lymphoma"}]}]}
{"id":"17823522_1","context":"Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"lichen nitidus"},{"annotation":"Treatment","text":"interferon alpha treatment"},{"annotation":"Treatment.Disorder","text":"lichen nitidus"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Drug","text":"lichen nitidus"},{"annotation":"Treatment.Drug","text":"palms"},{"annotation":"Treatment.Drug","text":"lichen nitidus"},{"annotation":"Subject","text":"lichen nitidus"},{"annotation":"Subject.Disorder","text":"lichen nitidus"},{"annotation":"Subject.Age","text":"generalized"},{"annotation":"Subject.Race","text":"lichen nitidus"},{"annotation":"Subject.Gender","text":"lichen nitidus"},{"annotation":"Subject.Population","text":"lichen nitidus"},{"annotation":"Treatment","text":"interferon alpha treatment"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Drug","text":"lichen nitidus"},{"annotation":"Treatment.Drug","text":"palms"},{"annotation":"Treatment.Drug","text":"lichen nitidus"},{"annotation":"Treatment.Drug","text":"lichen nitidus"},{"annotation":"Treatment.Drug","text":"lichen nitidus"},{"annotation":"Treatment.Time_elapsed","text":"lichen nitidus"},{"annotation":"Treatment.Duration","text":"lichen nitidus"},{"annotation":"Treatment.Disorder","text":"lichen nitidus"},{"annotation":"Effect","text":"lichen nitidus"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":""}]}]}
{"id":"1422497_2","context":"Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"cyclophosphamide therapy"},{"annotation":"Effect","text":"hemorrhagic cystitis"},{"annotation":"Treatment","text":"cyclophosphamide therapy"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Disorder","text":"hemorrhagic cystitis"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"}]}]}
{"id":"7212107_1","context":"Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"possible"},{"annotation":"Effect","text":"hyperparathyroidism"},{"annotation":"Treatment","text":"lithium nephrotoxicity"},{"annotation":"Treatment.Disorder","text":"lithium nephrotoxicity"},{"annotation":"Treatment.Disorder","text":"hyperparathyroidism"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not all patients with lithium nephrotoxicity develop hyperparathyroidism"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"possible"},{"annotation":"Effect","text":"hyperparathyroidism"},{"annotation":"Treatment","text":"lithium nephrotoxicity"},{"annotation":"Treatment.Disorder","text":"lithium nephrotoxicity"},{"annotation":"Treatment.Disorder","text":"hyperparathyroidism"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not all patients with lithium nephrotoxicity develop hyperparathyroidism"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"possible"},{"annotation":"Effect","text":"hyperparathyroidism"},{"annotation":"Treatment","text":"lithium nephrotoxicity"},{"annotation":"Treatment.Disorder","text":"lithium nephrotoxicity"},{"annotation":"Treatment.Disorder","text":"hyperparathyroidism"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not all patients with lithium nephrotoxicity develop hyperparathyroidism"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"possible"},{"annotation":"Effect","text":"hyperparathyroidism"},{"annotation":"Treatment","text":"lithium nephrotoxicity"},{"annotation":"Treatment.Disorder","text":"lithium nephrotoxicity"},{"annotation":"Treatment.Disorder","text":"hyperparathyroidism"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not all patients with lithium nephrotoxicity develop hyperparathyroidism"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"possible"},{"annotation":"Effect","text":"hyperparathyroidism"},{"annotation":"Treatment","text":"lithium nephrotoxicity"},{"annotation":"Treatment.Disorder","text":"lithium nephrotoxicity"},{"annotation":"Treatment.Disorder","text":"hyperparathyroidism"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not all patients with lithium nephrotoxicity develop hyperparathyroidism"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"possible"},{"annotation":"Effect","text":"hyperparathyroidism"},{"annotation":"Treatment","text":"lithium nephrotoxicity"},{"annotation":"Treatment.Disorder","text":"lithium nephrotoxicity"},{"annotation":"Treatment.Disorder","text":"hyperparathyroidism"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not all patients with lithium nephrotoxicity develop hyperparathyroidism"}]}]}
{"id":"18755414_2","context":"We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"hemorrhage"},{"annotation":"Treatment","text":"internal use of low-dose aspirin"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Duration","text":"16 months"},{"annotation":"Treatment.Disease","text":"falx meningioma"},{"annotation":"Subject","text":"an asymptomatic patient"},{"annotation":"Subject.Disease","text":"falx meningioma"}]}]}
{"id":"589261_3","context":"Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"cardiac glycoside"},{"annotation":"Treatment.Drug","text":"ouabain"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Disorder","text":"electrocardiographical changes"},{"annotation":"Treatment.Drug","text":"ouabain"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"T"}]}]}
{"id":"19754002_4","context":"The allergic reaction started to develop after co-administration of pravastatin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed after"},{"annotation":"Treatment","text":"co-administration of pravastatin"},{"annotation":"Treatment.Drug","text":"pravastatin"},{"annotation":"Effect","text":"allergic reaction"},{"annotation":"Treatment.Drug","text":"pravastatin"},{"annotation":"Treatment","text":"pravastatin"}]}]}
{"id":"11202801_3","context":"We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"propose"},{"annotation":"Treatment","text":"cyclophosphamide"},{"annotation":"Treatment.Disorder","text":"hepatic angiosarcoma"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"868978_2","context":"The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"ocular motor disturbances"},{"annotation":"Effect","text":"disturbances"},{"annotation":"Treatment","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"5-FU neurotoxicity"},{"annotation":"Treatment.Disorder","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"brain stem"},{"annotation":"Treatment.Drug","text":"5-FU"},{}]}]}
{"id":"1966850_2","context":"Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"cisplatinum"},{"annotation":"Treatment","text":"chemotherapy"},{"annotation":"Treatment.Drug","text":"cisplatinum"},{"annotation":"Treatment.Drug","text":"adriamycin"},{"annotation":"Treatment.Disorder","text":"synovial sarcoma"},{"annotation":"Treatment.Disorder","text":"eight-year old boy"},{"annotation":"Treatment.Drug","text":"cisplatinum"},{"annotation":"Treatment.Drug","text":"adriamycin"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Subject","text":"an eight-year old boy"},{"annotation":"Subject.Disorder","text":"synovial sarcoma"}]}]}
{"id":"17504225_2","context":"Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"event"},{"annotation":"Effect","text":"infection"},{"annotation":"Treatment","text":"antimicrobial agents"},{"annotation":"Treatment.Disorder","text":"renal transplant recipients"},{"annotation":"Treatment.Drug","text":"antimicrobial agents"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes"}]}]}
{"id":"16685007_12","context":"Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Effect","text":"reduces the need for OCS"},{"annotation":"Treatment","text":"ciclesonide"},{"annotation":"Treatment.Drug","text":"ciclesonide"},{"annotation":"Treatment.Disorder","text":"severe, persistent asthma"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":""}]}]}
{"id":"14968106_1","context":"CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"accidental intrathecal administration of doxorubicin"},{"annotation":"Treatment","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Effect","text":"myelopathy"},{"annotation":"Treatment.Disorder","text":"severe myelopathy"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":""}]}]}
{"id":"12854039_5","context":"Multiple sclerosis-like disease secondary to alpha interferon.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary to"},{"annotation":"Effect","text":"multiple sclerosis-like disease"},{"annotation":"Treatment","text":"alpha interferon"},{"annotation":"Treatment.Disorder","text":"multiple sclerosis-like disease"},{"annotation":"Treatment.Drug","text":"alpha interferon"}]}]}
{"id":"17921794_4","context":"We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"acute weakness"},{"annotation":"Treatment","text":"simvastatin"},{"annotation":"Treatment.Disorder","text":"mild chronic renal insufficiency"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Treatment.Drug","text":"acute gouty bursitis"},{"annotation":"Treatment.Duration","text":"3 weeks"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Treatment.Duration","text":"over a year"},{"annotation":"Subject","text":"a patient with mild chronic renal insufficiency"},{"annotation":"Subject.Disorder","text":"mild chronic renal insufficiency"}]}]}
{"id":"16603845_1","context":"Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"erythema"},{"annotation":"Effect","text":"edema"},{"annotation":"Effect","text":"pain"},{"annotation":"Treatment","text":"chemotherapy and an injection of pegfilgrastim"},{"annotation":"Treatment.Drug","text":"pegfilgrastim"},{"annotation":"Treatment.Time_elapsed","text":"shortly after"},{"annotation":"Treatment.Route","text":"injection"},{"annotation":"Treatment.Dosage","text":"pegfilgrastim"},{"annotation":"Treatment.Dosage","text":"chemotherapy"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Treatment.Disorder","text":"poorly defined"},{"annotation":"Treatment.Disorder","text":"rapidly progressive"},{"annotation":"Treatment.Disorder","text":"erythema"},{"annotation":"Treatment.Disorder","text":"edema"},{"annotation":"Treatment.Disorder","text":"pain"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Age","text":"not specified"},{"annotation":"Subject.Disorder","text":"not specified"},{"annotation":"Treatment.Drug","text":"pegfilgrastim"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Treatment.Time_elapsed","text":"shortly after"},{"annotation":"Treatment.Route","text":"injection"},{"annotation":"Treatment.Dosage","text":"pegfilgrastim"},{"annotation":"Treatment.Dosage","text":"chemotherapy"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Treatment.Disorder","text":"poorly defined"},{"annotation":"Treatment.Disorder","text":"rapidly progressive"},{"annotation":"Treatment.Disorder","text":"erythema"},{"annotation":"Treatment.Disorder","text":"edema"},{"annotation":"Treatment.Disorder","text":"pain"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Age","text":"not specified"},{"annotation":"Subject.Disorder","text":"not specified"},{"annotation":"Treatment.Drug","text":"pegfilgrastim"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Treatment.Time_elapsed","text":"shortly after"},{"annotation":"Treatment.Route","text":"injection"},{"annotation":"Treatment.Dosage","text":"pegfilgrastim"},{"annotation":"Treatment.Dosage","text":"chemotherapy"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Treatment.Disorder","text":"poorly defined"},{"annotation":"Treatment.Disorder","text":"rapidly progressive"},{"annotation":"Treatment.Disorder","text":"erythema"},{"annotation":"Treatment.Disorder"}]}]}
{"id":"20628041_2","context":"To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction between enteral feeds and levodopa"},{"annotation":"Treatment","text":"levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"enteral feeds"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"levodopa"},{"annotation":"Treatment.Combination.Drug","text":"enteral feeds"},{"annotation":"Effect","text":"neuroleptic malignant-like syndrome (NMLS)"},{"annotation":"Treatment","text":"enteral feeds"},{"annotation":"Treatment.Disorder","text":"polytrauma patient with Parkinson's disease (PD)"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Drug","text":"enteral feeds"},{"annotation":"Treatment.Combination.Trigger","text":"leading to"},{"annotation":"Treatment.Combination.Drug","text":"NMLS"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute"}]}]}
{"id":"16978752_3","context":"Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"proved"},{"annotation":"Effect","text":"neutropenia"},{"annotation":"Treatment","text":"olanzapine and thiazide"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"thiazide"},{"annotation":"Treatment.Disorder","text":"schizophrenia"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"thiazide"},{"annotation":"Subject","text":"a schizophrenia patient"},{"annotation":"Subject.Disorder","text":"schizophrenia"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug","text":"thiazide"},{"annotation":"Treatment.Combination.Drug","text":"olanzapine"},{"annotation":"Treatment.Combination.Drug"}]}]}
{"id":"21658326_3","context":"While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"elicited"},{"annotation":"Treatment","text":"TNF-alpha blockers"},{"annotation":"Treatment.Drug","text":"TNF-alpha blockers"},{"annotation":"Treatment.Drug","text":"imiquimod"},{"annotation":"Treatment.Combination.Trigger","text":"while"},{"annotation":"Treatment.Combination.Drug","text":"imiquimod"},{"annotation":"Treatment.Combination.Drug","text":"TNF-alpha blockers"},{"annotation":"Treatment.Combination.Trigger","text":"associated"},{"annotation":"Subject","text":"imiquimod"},{"annotation":"Subject.Disorder","text":"ASRs"}]}]}
{"id":"6239881_2","context":"Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"contact"},{"annotation":"Treatment","text":"compound tincture of benzoin"},{"annotation":"Treatment.Drug","text":"benzoin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"allergic contact dermatitis"},{"annotation":"Effect","text":"dermatitis"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"compound tincture of benzoin"},{"annotation":"Treatment","text":"compound tincture of benzoin"},{"annotation":"Treatment.Drug","text":"benzoin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"allergic contact dermatitis"},{"annotation":"Effect","text":"dermatitis"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"8404753_3","context":"We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"initiation"},{"annotation":"Effect","text":"facial motor tics"},{"annotation":"Treatment","text":"CBZ"},{"annotation":"Treatment.Disorder","text":"complex partial seizures"},{"annotation":"Subject","text":"3 children with epilepsy"},{"annotation":"Subject.Disorder","text":"epilepsy"}]}]}
{"id":"11197767_2","context":"The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"investigated"},{"annotation":"Treatment","text":"cadmium, zinc and cadmium/zinc mixtures"},{"annotation":"Treatment.Disorder","text":"toxicity"},{"annotation":"Treatment.Drug","text":"cadmium"},{"annotation":"Treatment.Drug","text":"zinc"},{"annotation":"Treatment.Drug","text":"cadmium/zinc mixtures"},{"annotation":"Treatment.Disorder","text":"cercariae and metacercariae of Parorchis acanthus"},{"annotation":"Treatment.Drug","text":"dog whelk Nucella lapillus"},{"annotation":"Treatment.Drug","text":"Nucella lapillus"}]}]}
{"id":"18354950_3","context":"We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"syndrome of inappropriate antidiuresis"},{"annotation":"Treatment","text":"carbamazepine administration"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Disorder","text":"generalized tonic-elonic seizures"},{"annotation":"Subject","text":"a 29-year Nigerian female patient"},{"annotation":"Subject.Age","text":"29 years"},{"annotation":"Subject.Gender","text":"female"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"Nigerian"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Disorder","text":"generalized tonic-elonic seizures"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Disorder","text":"generalized tonic-elonic seizures"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Disorder","text":"generalized tonic-elonic seizures"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Disorder","text":"generalized tonic-elonic seizures"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Disorder","text":"generalized tonic-elonic seizures"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Drug","text":""}]}]}
{"id":"11310527_2","context":"A patient was treated with warfarin for atrial fibrillation.","events":[{"type":"Treatment","annotations":[{"annotation":"Treatment","text":"warfarin"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Disorder","text":"atrial fibrillation"}]}]}
{"id":"19754002_1","context":"Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"adverse skin reactions"},{"annotation":"Treatment","text":"mood stabilizer therapy and pravastatin"},{"annotation":"Treatment.Drug","text":"pravastatin"},{"annotation":"Treatment.Drug","text":"mood stabilizer therapy"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"mood stabilizer therapy"},{"annotation":"Treatment.Combination.Drug","text":"pravastatin"},{"annotation":"Treatment.Combination.Drug","text":"mood stabilizer therapy"},{"annotation":"Subject","text":"patients"},{"annotation":"Subject.Population","text":"patients"}]}]}
{"id":"1602800_1","context":"Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary"},{"annotation":"Effect","text":"leukostasis"},{"annotation":"Treatment","text":"all-trans retinoic acid"},{"annotation":"Treatment.Disorder","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Drug","text":"all-trans retinoic acid"},{"annotation":"Treatment.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Trigger","text":"in first relapse"},{"annotation":"Treatment.Combination.Drug","text":"all-trans retinoic acid"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"acute promyelocytic leukemia"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"response"},{"annotation":"Treatment","text":"all-trans retinoic acid"},{"annotation":"Treatment.Disorder","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Drug","text":"all-trans retinoic acid"},{"annotation":"Treatment.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Trigger","text":"in first relapse"},{"annotation":"Treatment.Combination.Drug","text":"all-trans retinoic acid"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukemia"},{"annotation":"Treatment.Combination.Drug","text":"acute promyelocytic leukem"}]}]}
{"id":"15811174_1","context":"A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"complained"},{"annotation":"Effect","text":"muscle weakness and muscle pain"},{"annotation":"Treatment","text":"cerivastatin"},{"annotation":"Treatment.Drug","text":"cerivastatin"},{"annotation":"Treatment.Dosage","text":"0.15 mg/day"},{"annotation":"Treatment.Duration","text":"22 days"},{"annotation":"Subject","text":"a 74-year-old hypercholestrerolaemic woman"},{"annotation":"Subject.Age","text":"74"},{"annotation":"Subject.Gender","text":"female"},{"annotation":"Subject.Disorder","text":"hypercholestrerolaemia"},{"annotation":"Treatment.Disorder","text":"hypercholestrerolaemia"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"complained"},{"annotation":"Effect","text":"muscle weakness and muscle pain"},{"annotation":"Treatment","text":"cerivastatin"},{"annotation":"Treatment.Drug","text":"cerivastatin"},{"annotation":"Treatment.Dosage","text":"0.15 mg/day"},{"annotation":"Treatment.Duration","text":"22 days"},{"annotation":"Subject","text":"a 74-year-old hypercholestrerolaemic woman"},{"annotation":"Subject.Age","text":"74"},{"annotation":"Subject.Gender","text":"female"},{"annotation":"Subject.Disorder","text":"hypercholestrerolaemia"},{"annotation":"Treatment.Disorder","text":"hypercholestrerolaemia"}]}]}
{"id":"7081289_3","context":"There have been only two reports of cimetidine-induced hepatitis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"cimetidine"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"There have been only two reports of cimetidine-induced hepatitis."}]}]}
{"id":"3732375_2","context":"A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intoxication"},{"annotation":"Effect","text":"toxicity"},{"annotation":"Treatment","text":"theophylline"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Combination.Trigger","text":"concomitant administration of viloxazine"},{"annotation":"Treatment.Combination.Drug","text":"theophylline"},{"annotation":"Treatment.Combination.Drug","text":"viloxazine"},{"annotation":"Treatment.Combination.Effect","text":"decreased clearance"},{"annotation":"Treatment.Combination.Effect","text":"toxicity"},{"annotation":"Treatment.Combination.Effect","text":"intoxication"},{"annotation":"Treatment.Disorder","text":"theophylline intoxication"},{"annotation":"Treatment.Disorder","text":"toxicity"},{"annotation":"Treatment.Disorder","text":"intoxication"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"theophylline intoxication"},{"annotation":"Subject.Disorder","text":"toxicity"},{"annotation":"Subject.Disorder","text":"intoxication"},{"annotation":"Subject.Disorder","text":"theophylline toxicity"},{"annotation":"Treatment","text":"theophylline"},{"annotation":"Treatment.Drug","text":"viloxazine"},{"annotation":"Treatment.Combination.Trigger","text":"concomitant administration of viloxazine"},{"annotation":"Treatment.Combination.Drug","text":"theophylline"},{"annotation":"Treatment.Combination.Drug","text":"viloxazine"},{"annotation":"Treatment.Combination.Effect","text":"decreased clearance"},{"annotation":"Treatment.Combination.Effect","text":"toxicity"},{"annotation":"Treatment.Combination.Effect","text":"intoxication"},{"annotation":"Treatment.Combination.Effect","text":"intoxication"},{"annotation":"Treatment.Combination.Effect","text":"toxicity"},{"annotation":"Treatment.Combination.Effect","text":"intoxication"},{"annotation":"Treatment.Combination.Effect","text":"toxicity"},{"annotation":"Treatment.Combination.Effect","text":"intoxication"},{"annotation":"Treatment.Combination.Effect","text":"toxicity"},{"annotation":"Treatment.Combination.Effect","text":"intoxication"},{"annotation":"Treatment.Combination.Effect","text":"toxicity"},{"annotation":"Treatment.Combination.Effect","text":"intoxication"},{"annotation":"Treatment.Combination.Effect","text":"toxicity"},{"annotation":"Treatment.Combination.Effect","text":"intoxication"},{"annotation":"Treatment.Combination.Effect","text":"toxicity"},{"annotation":"Treatment.Combination.Effect","text":"intoxication"},{"annotation":"Treatment.Combination.Effect","text":"toxicity"},{"annotation":"Treatment.Combination.Effect","text":"intoxication"},{"annotation":"Treatment.Combination.Effect","text":"toxicity"},{"annotation":"Treatment.Combination.Effect","text":"intoxication"},{"annotation":"Treatment.Combination.Effect","text":"toxicity"},{"annotation":"Treatment.Combination.Effect","text":"intoxication"},{"annotation":""}]}]}
{"id":"7639655_1","context":"Anterior ischemic optic neuropathy secondary to interferon alfa.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary to interferon alfa"},{"annotation":"Effect","text":"anterior ischemic optic neuropathy"},{"annotation":"Treatment","text":"interferon alfa"},{"annotation":"Treatment.Drug","text":"interferon alfa"}]}]}
{"id":"12854039_6","context":"PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred as an adverse effect of"},{"annotation":"Treatment","text":"recombinant and natural interferon alpha administration"},{"annotation":"Treatment.Drug","text":"recombinant and natural interferon alpha"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Effect","text":"bilateral optic neuritis"},{"annotation":"Treatment.Disorder","text":"bilateral optic neuritis"}]}]}
{"id":"12234159_2","context":"Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused"},{"annotation":"Effect","text":"herpetiform fixed drug eruption"},{"annotation":"Treatment","text":"rofecoxib"},{"annotation":"Treatment.Disorder","text":"dysmenorrhea"},{"annotation":"Treatment.Drug","text":"rofecoxib"},{"annotation":"Treatment.Site","text":"lips"},{"annotation":"Treatment.Site","text":"dorsal hand"},{"annotation":"Treatment.Clinical_findings","text":"red-brown lesion"},{"annotation":"Treatment.Histological_findings","text":"classic findings"},{"annotation":"Treatment.Drug_class","text":"NSAID"},{"annotation":"Treatment.Drug_dosage","text":"not specified"},{"annotation":"Treatment.Drug_frequency","text":"not specified"},{"annotation":"Treatment.Drug_route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"dysmenorrhea"},{"annotation":"Treatment.Drug","text":"rofecoxib"},{"annotation":"Treatment.Disorder","text":"dysmenorrhea"},{"annotation":"Treatment.Drug","text":"rofecoxib"},{"annotation":"Treatment.Site","text":"lips"},{"annotation":"Treatment.Site","text":"dorsal hand"},{"annotation":"Treatment.Clinical_findings","text":"red-brown lesion"},{"annotation":"Treatment.Histological_findings","text":"classic findings"},{"annotation":"Treatment.Drug_class","text":"NSAID"},{"annotation":"Treatment.Drug_dosage","text":"not specified"},{"annotation":"Treatment.Drug_frequency","text":"not specified"},{"annotation":"Treatment.Drug_route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"dysmenorrhea"},{"annotation":"Treatment.Drug","text":"rofecoxib"},{"annotation":"Treatment.Disorder","text":"dysmenorrhea"},{"annotation":"Treatment.Drug","text":"rofecoxib"},{"annotation":"Treatment.Site","text":"lips"},{"annotation":"Treatment.Site","text":"dorsal hand"},{"annotation":"Treatment.Clinical_findings","text":"red-brown lesion"},{"annotation":"Treatment.Histological_findings","text":"classic findings"},{"annotation":"Treatment.Drug_class","text":"NSAID"},{"annotation":"Treatment.Drug_dosage","text":"not specified"},{"annotation":"Treatment.Drug_frequency","text":"not specified"},{"annotation":"Treatment.Drug_route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment."}]}]}
{"id":"16609346_2","context":"Statin-associated myasthenia gravis: report of 4 cases and review of the literature.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Effect","text":"myasthenia gravis"},{"annotation":"Treatment","text":"statin"},{"annotation":"Treatment.Disorder","text":"myasthenia gravis"},{"annotation":"Treatment.Drug","text":"statin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"report of 4 cases and review of the literature"},{"annotation":"Treatment","text":"statin"},{"annotation":"Treatment.Disorder","text":"myasthenia gravis"},{"annotation":"Treatment.Drug","text":"statin"}]}]}
{"id":"4075534_3","context":"Two reports of spindle coma are noted with alcohol and imipramine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"spindle coma"},{"annotation":"Treatment","text":"alcohol and imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Disorder","text":"spindle coma"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.Drug","text":"alcohol"},{"annotation":"Treatment.Drug","text":"imipramine"},{"annotation":"Treatment.D"}]}]}
{"id":"3003260_2","context":"Cataracts induced by intermittent Decadron used as an antiemetic.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"cataracts"},{"annotation":"Treatment","text":"intermittent Decadron used as an antiemetic"},{"annotation":"Treatment.Drug","text":"Decadron"},{"annotation":"Treatment.Dosage","text":"intermittent"},{"annotation":"Treatment.Frequency","text":"as an antiemetic"},{"annotation":"Treatment.Route","text":"Decadron"},{"annotation":"Treatment.Time_elapsed","text":"cataracts"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Response"},{"annotation":"Treatment","text":"Decadron"},{"annotation":"Treatment.Disorder","text":"cataracts"},{"annotation":"Treatment.Drug","text":"Decadron"}]}]}
{"id":"879939_2","context":"Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"present"},{"annotation":"Treatment","text":"long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide"},{"annotation":"Treatment.Disorder","text":"severe osteomalacia"},{"annotation":"Treatment.Drug","text":"congeners of phenytoin, phenobarbital, and acetazolamide"},{"annotation":"Treatment.Drug","text":"phenytoin"},{"annotation":"Treatment.Drug","text":"phenobarbital"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Subject","text":"two epileptic patients"},{"annotation":"Subject.Disorder","text":"epileptic"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide"},{"annotation":"Treatment","text":"severe osteomalacia"},{"annotation":"Treatment.Disorder","text":"congeners of phenytoin, phenobarbital, and acetazolamide"},{"annotation":"Treatment.Drug","text":"phenytoin"},{"annotation":"Treatment.Drug","text":"phenobarbital"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Treatment.Drug","text":"phenytoin"},{"annotation":"Treatment.Drug","text":"phenobarbital"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Treatment.Drug","text":"phenytoin"},{"annotation":"Treatment.Drug","text":"phenobarbital"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Treatment.Drug","text":"phenytoin"},{"annotation":"Treatment.Drug","text":"phenobarbital"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Treatment.Drug","text":"phenytoin"},{"annotation":"Treatment.Drug","text":"phenobarbital"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Treatment.Drug","text":"phenytoin"},{"annotation":"Treatment.Drug","text":"phenobarbital"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Treatment.Drug","text":"phenytoin"},{"annotation":"Treatment.Drug","text":"phenobarbital"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Treatment.Drug","text":"phenytoin"},{"annotation":"Treatment.Drug","text":"phenobarbital"},{"annotation":"Treatment.Drug","text":"acetazolamide"},{"annotation":"Treatment.Drug","text":"phenytoin"},{"annotation":"Treatment.Drug","text":"phenobarbital"},{"annotation":"Treatment.Drug"}]}]}
{"id":"3969689_4","context":"Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"caffeine"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"acetaminophen"},{"annotation":"Treatment.Combination.Drug","text":"caffeine"},{"annotation":"Effect","text":"hepatotoxicity"},{"annotation":"Treatment.Combination.Disorder","text":"none"},{"annotation":"Treatment.Combination.Disorder","text":"none"}]}]}
{"id":"8912599_6","context":"Erosion of psoriatic plaques: an early sign of methotrexate toxicity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erosion"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"psoriatic plaques"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"methotrexate toxicity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erosion"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"psoriatic plaques"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"methotrexate toxicity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erosion"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"psoriatic plaques"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"methotrexate toxicity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erosion"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"psoriatic plaques"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"methotrexate toxicity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erosion"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"psoriatic plaques"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"methotrexate toxicity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erosion"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"psoriatic plaques"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"methotrexate toxicity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erosion"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"psoriatic plaques"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"methotrexate toxicity"}]},{"type":"Adverse_event","annotations":[]}]}
{"id":"11696132_1","context":"After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"anisocoria"},{"annotation":"Effect","text":"related to"},{"annotation":"Treatment","text":"transdermal scopolamine patch"},{"annotation":"Treatment.Drug","text":"scopolamine"},{"annotation":"Treatment.Dosage","text":"transdermal"},{"annotation":"Treatment.Duration","text":"weaning off opioid"},{"annotation":"Treatment.Side_effect","text":"anisocoria"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Subject","text":"patient weaning off opioid"},{"annotation":"Subject.Disorder","text":"none"}]}]}
{"id":"12851279_1","context":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"severe sepsis"},{"annotation":"Treatment","text":"tifacogin"},{"annotation":"Treatment.Disorder","text":"severe sepsis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated","text":"attribute not negated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute.negated"}]}]}
{"id":"15863610_5","context":"CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"diagnosed"},{"annotation":"Effect","text":"malignant mixed mesodermal tumor"},{"annotation":"Treatment","text":"raloxifene"},{"annotation":"Treatment.Disorder","text":"malignant mixed mesodermal tumor"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Subject","text":"a 64-year-old woman"},{"annotation":"Subject.Age","text":"64"},{"annotation":"Subject.Gender","text":"woman"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"bicornuate uterus"},{"annotation":"Treatment.Drug","text":"raloxifene"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"malignant mixed mesodermal tumor"}]}]}
{"id":"16728538_1","context":"After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"combined treatment with pegvisomant and octreotide long-acting repeatable"},{"annotation":"Treatment.Disorder","text":"acromegalic"},{"annotation":"Treatment.Drug","text":"pegvisomant"},{"annotation":"Treatment.Drug","text":"octreotide"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"pegvisomant"},{"annotation":"Treatment.Combination.Drug","text":"octreotide"},{"annotation":"Subject","text":"an acromegalic patient"},{"annotation":"Subject.Disorder","text":"acromegalic"}]}]}
{"id":"22372628_2","context":"To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"lacosamide"},{"annotation":"Treatment.Dosage","text":"adjunctive therapy"},{"annotation":"Treatment.Duration","text":"5 years"},{"annotation":"Treatment.Combination","text":"one to three concomitant antiepileptic drugs (AEDs)"},{"annotation":"Treatment.Drug","text":"lacosamide"},{"annotation":"Effect","text":"partial-onset seizures"},{"annotation":"Treatment.Disorder","text":"uncontrolled partial-onset seizures"},{"annotation":"Treatment.Disorder","text":"partial-onset seizures"},{"annotation":"Treatment.Drug","text":"one to three concomitant antiepileptic drugs (AEDs)"},{"annotation":"Treatment.Drug","text":"AEDs"},{"annotation":"Treatment.Combination","text":"adjunctive therapy"},{"annotation":"Treatment.Combination","text":"one to three concomitant antiepileptic drugs (AEDs)"},{"annotation":"Treatment.Combination","text":"lacosamide"},{"annotation":"Treatment.Combination","text":"AEDs"},{"annotation":"Treatment.Combination","text":"partial-onset seizures"},{"annotation":"Treatment.Combination","text":"uncontrolled partial-onset seizures"},{"annotation":"Treatment.Combination","text":"adjunctive therapy"},{"annotation":"Treatment.Combination","text":"one to three concomitant antiepileptic drugs (AEDs)"},{"annotation":"Treatment.Combination","text":"lacosamide"},{"annotation":"Treatment.Combination","text":"AEDs"},{"annotation":"Treatment.Combination","text":"partial-onset seizures"},{"annotation":"Treatment.Combination","text":"uncontrolled partial-onset seizures"},{"annotation":"Treatment.Combination","text":"adjunctive therapy"},{"annotation":"Treatment.Combination","text":"one to three concomitant antiepileptic drugs (AEDs)"},{"annotation":"Treatment.Combination","text":"lacosamide"},{"annotation":"Treatment.Combination","text":"AEDs"},{"annotation":"Treatment.Combination","text":"partial-onset seizures"},{"annotation":"Treatment.Combination","text":"uncontrolled partial-onset seizures"},{"annotation":"Treatment.Combination","text":"adjunctive therapy"},{"annotation":"Treatment.Combination","text":"one to three concomitant antiepileptic drugs (AEDs)"},{"annotation":"Treatment.Combination","text":"lacosamide"},{"annotation":"Treatment.Combination","text":"AEDs"},{"annotation":"Treatment.Combination","text":"partial-onset seizures"},{"annotation":"Treatment.Combination","text":"uncontrolled partial-onset seizures"},{"annotation":"T"}]}]}
{"id":"7071645_3","context":"Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"remission"},{"annotation":"Effect","text":"nephrosis"},{"annotation":"Treatment","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Disorder","text":"nephrosis"},{"annotation":"Treatment.Drug","text":"hydroxychloroquine"},{"annotation":"Treatment.Duration","text":"after discontinuation"},{"annotation":"Treatment.Duration","text":"of hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"duration of hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine therapy"},{"annotation":"Treatment.Duration","text":"hydroxychloroquine"}]}]}
{"id":"18364401_1","context":"CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"rapidly developing hyperglycemia"},{"annotation":"Effect","text":"hyperglycemia"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Disorder","text":"elderly patients"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"elderly"},{"annotation":"Subject","text":"patients"},{"annotation":"Subject.Age","text":"elderly"},{"annotation":"Subject.Gender","text":"unknown"},{"annotation":"Subject.Population","text":"elderly patients"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"hyperglycemia"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute.severity","text":"unknown"},{"annotation":"Effect","text":"hyperglycemia"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"neg"}]}]}
{"id":"18661248_2","context":"We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"PRES"},{"annotation":"Treatment","text":"cyclosporine (CSA)"},{"annotation":"Treatment.Disorder","text":"collapsing focal glomeruloesclerosis (collapsing FGS)"},{"annotation":"Treatment.Disorder","text":"collapsing FGS"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withdrawal of cyclosporine (CSA)"},{"annotation":"Effect","text":"recovery"},{"annotation":"Treatment","text":"cyclosporine (CSA)"},{"annotation":"Treatment.Disorder","text":"collapsing focal glomeruloesclerosis (collapsing FGS)"},{"annotation":"Treatment.Disorder","text":"collapsing FGS"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"withdrawal of cyclosporine (CSA)"},{"annotation":"Treatment","text":"complete recovery"},{"annotation":"Treatment.Disorder","text":"collapsing focal glomeruloesclerosis (collapsing FGS)"},{"annotation":"Treatment.Drug","text":"cyclosporine (CSA)"}]}]}
{"id":"12022905_3","context":"DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"occurrence"},{"annotation":"Treatment","text":"priapism"},{"annotation":"Treatment.Drug","text":"zuclopenthixol"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"zuclopenthixol"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Effect","text":"priapism"}]}]}
{"id":"11202801_2","context":"Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurring after"},{"annotation":"Effect","text":"hepatic angiosarcoma"},{"annotation":"Treatment","text":"cyclophosphamide therapy"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"hepatic angiosarcoma"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"},{"annotation":"Treatment."}]}]}
{"id":"11283125_3","context":"After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"randomized"},{"annotation":"Treatment","text":"four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX"},{"annotation":"Treatment.Disorder","text":"children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma"},{"annotation":"Treatment.Drug","text":"HD MTX"},{"annotation":"Treatment.Drug","text":"intrathecal MTX"},{"annotation":"Treatment.Combination","text":"HD IV Ara-C"},{"annotation":"Treatment.Combination","text":"HD MTX"},{"annotation":"Treatment.Combination","text":"intrathecal MTX"},{"annotation":"Treatment.Combination","text":"HD IV Ara-C"},{"annotation":"Treatment.Combination","text":"HD MTX"},{"annotation":"Treatment.Combination","text":"intrathecal MTX"},{"annotation":"Treatment.Combination","text":"HD IV Ara-C"},{"annotation":"Treatment.Combination","text":"HD MTX"},{"annotation":"Treatment.Combination","text":"intrathecal MTX"},{"annotation":"Treatment.Combination","text":"HD IV Ara-C"},{"annotation":"Treatment.Combination","text":"HD MTX"},{"annotation":"Treatment.Combination","text":"intrathecal MTX"},{"annotation":"Treatment.Combination","text":"HD IV Ara-C"},{"annotation":"Treatment.Combination","text":"HD MTX"},{"annotation":"Treatment.Combination","text":"intrathecal MTX"},{"annotation":"Treatment.Combination","text":"HD IV Ara-C"},{"annotation":"Treatment.Combination","text":"HD MTX"},{"annotation":"Treatment.Combination","text":"intrathecal MTX"},{"annotation":"Treatment.Combination","text":"HD IV Ara-C"},{"annotation":"Treatment.Combination","text":"HD MTX"},{"annotation":"Treatment.Combination","text":"intrathecal MTX"},{"annotation":"Treatment.Combination","text":"HD IV Ara-C"},{"annotation":"Treatment.Combination","text":"HD MTX"},{"annotation":"Treatment.Combination","text":"intrathecal MTX"},{"annotation":""}]}]}
{"id":"7756684_1","context":"The dose-limiting toxicity of KW-2149 is pulmonary toxicity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"dose-limiting"},{"annotation":"Treatment","text":"KW-2149"},{"annotation":"Treatment.Drug","text":"KW-2149"},{"annotation":"Treatment.Dose","text":"dose-limiting"},{"annotation":"Treatment.Toxicity","text":"pulmonary toxicity"},{"annotation":"Treatment.Toxicity","text":"dose-limiting"},{"annotation":"Treatment.Drug","text":"KW-2149"},{"annotation":"Treatment.Toxicity","text":"dose-limiting"},{"annotation":"Treatment.Toxicity","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"KW-2149"},{"annotation":"Treatment.Dose","text":"dose-limiting"},{"annotation":"Treatment.Toxicity","text":"pulmonary toxicity"},{"annotation":"Treatment.Dose","text":"dose-limiting"},{"annotation":"Treatment.Toxicity","text":"pulmonary toxicity"},{"annotation":"Treatment.Toxicity","text":"dose-limiting"},{"annotation":"Treatment.Drug","text":"KW-2149"},{"annotation":"Treatment.Dose","text":"dose-limiting"},{"annotation":"Treatment.Toxicity","text":"pulmonary toxicity"},{"annotation":"Treatment.Toxicity","text":"dose-limiting"},{"annotation":"Treatment.Drug","text":"KW-2149"},{"annotation":"Treatment.Toxicity","text":"pulmonary toxicity"},{"annotation":"Treatment.Dose","text":"dose-limiting"},{"annotation":"Treatment.Toxicity","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"KW-2149"},{"annotation":"Treatment.Toxicity","text":"dose-limiting"},{"annotation":"Treatment.Toxicity","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"KW-2149"},{"annotation":"Treatment.Dose","text":"dose-limiting"},{"annotation":"Treatment.Toxicity","text":"pulmonary toxicity"},{"annotation":"Treatment.Toxicity","text":"dose-limiting"},{"annotation":"Treatment.Drug","text":"KW-2149"},{"annotation":"Treatment.Toxicity","text":"dose-limiting"},{"annotation":"Treatment.Toxicity","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"KW-2149"},{"annotation":"Treatment.Toxicity","text":"dose-limiting"},{"annotation":"Treatment.Toxicity","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"KW-2149"},{"annotation":"Treatment.Toxicity","text":"dose-limiting"},{"annotation":"Treatment.Toxicity","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"KW-2149"},{"annotation":"Treatment.Toxicity","text":"dose-limiting"},{"annotation":"Treatment.Toxicity","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"KW-2149"},{}]}]}
{"id":"15773973_1","context":"Flucloxacillin-induced aplastic anaemia and liver failure.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"aplastic anaemia and liver failure"},{"annotation":"Treatment","text":"flucloxacillin"},{"annotation":"Treatment.Drug","text":"flucloxacillin"},{"annotation":"Treatment.Disorder","text":"aplastic anaemia and liver failure"}]}]}
{"id":"18855892_8","context":"Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"methotrexate-induced anaphylaxis"},{"annotation":"Treatment","text":"desensitization"},{"annotation":"Treatment.Disorder","text":"anaphylaxis"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Duration","text":"desensitization"},{"annotation":"Attribute Attributes","text":"safe"},{"annotation":"Attribute Attributes","text":"procedure"},{"annotation":"Attribute Attributes","text":"in patients with cancer"}]}]}
{"id":"15286697_4","context":"We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"examined"},{"annotation":"Treatment","text":"immunohistochemistry (IHC)"},{"annotation":"Treatment.Disorder","text":"BCNU-related pulmonary fibrosis"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Drug","text":"platelet-derived growth factor-B (PDGF-B)"},{"annotation":"Treatment.Drug","text":"insulin-like growth factor I (IGF-I)"},{"annotation":"Treatment.Drug","text":"transforming growth factor-beta1 (TGF-beta1)"},{"annotation":"Treatment.Drug","text":"cyclooxygenase-2 (COX-2)"},{"annotation":"Treatment.Drug","text":"TGF-beta1"},{"annotation":"Treatment.Drug","text":"COX-2"},{"annotation":"Treatment.Disorder","text":"BCNU-related pulmonary fibrosis"},{"annotation":"Treatment.Drug","text":"BCNU"},{"annotation":"Treatment.Drug","text":"platelet-derived growth factor-B (PDGF-B)"},{"annotation":"Treatment.Drug","text":"insulin-like growth factor I (IGF-I)"},{"annotation":"Treatment.Drug","text":"transforming growth factor-beta1 (TGF-beta1)"},{"annotation":"Treatment.Drug","text":"cyclooxygenase-2 (COX-2)"},{"annotation":"Treatment.Drug","text":"TGF-beta1"},{"annotation":"Treatment.Drug","text":"COX-2"},{"annotation":"Treatment.Drug","text":"TGF-beta1"},{"annotation":"Treatment.Drug","text":"COX-2"},{"annotation":"Treatment.Drug","text":"TGF-beta1"},{"annotation":"Treatment.Drug","text":"COX-2"},{"annotation":"Treatment.Drug","text":"TGF-beta1"},{"annotation":"Treatment.Drug","text":"COX-2"},{"annotation":"Treatment.Drug","text":"TGF-beta1"},{"annotation":"Treatment.Drug","text":"COX-2"},{"annotation":"Treatment.Drug","text":"TGF-beta1"},{"annotation":"Treatment.Drug","text":"COX-2"},{"annotation":"Treatment.Drug","text":"TGF-beta1"},{"annotation":"Treatment.Drug","text":"COX-2"},{"annotation":"Treatment.Drug","text":"TGF-beta1"},{"annotation":"Treatment.Drug","text":"COX-2"},{"annotation":"Treatment.Drug","text":"TGF-beta1"},{"annotation":"Treatment.Drug"}]}]}
{"id":"2241449_1","context":"Physicians using this ","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Physicians using this"},{"annotation":"Treatment","text":"drug"},{"annotation":"Treatment.Disorder","text":"sulfonamide-induced injury"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"urinary tract"},{"annotation":"Treatment.Drug","text":"sulfonamide"},{"annotation":"Treatment.Dosage","text":"injury"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"physicians using this"},{"annotation":"Treatment.Drug","text":"drug"},{"annotation":"Treatment.Dosage","text":"injury"},{"annotation":"Treatment.Duration","text":"physicians using this"},{"annotation":"Treatment.Duration","text":"drug"}]}]}
{"id":"12504711_4","context":"RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused"},{"annotation":"Effect","text":"IOP elevation"},{"annotation":"Treatment","text":"brimonidine"},{"annotation":"Treatment.Drug","text":"brimonidine"},{"annotation":"Attribute Attributes","text":"8 (strong probability)"},{"annotation":"Attribute Attributes","text":"adverse drug reaction probability score"}]}]}
{"id":"15507779_1","context":"Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"nevirapine"},{"annotation":"Treatment.Disorder","text":"HIV carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"mild hepatotoxicity"},{"annotation":"Treatment.Drug","text":"severe leukopenia"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treatment.Drug","text":"HIV"},{"annotation":"Treatment.Drug","text":"carrier"},{"annotation":"Treatment.Drug","text":"nevirapine"},{"annotation":"Treat"}]}]}
{"id":"1711090_2","context":"The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"clinical evaluation"},{"annotation":"Treatment","text":"Lp-TAE combined with radiofrequency (RF) capacitive hyperthermia (HT)"},{"annotation":"Treatment.Disorder","text":"hepatocellular carcinoma (HCC) associated with cirrhosis of the liver"},{"annotation":"Treatment.Drug","text":"Lp-TAE"},{"annotation":"Treatment.Drug","text":"radiofrequency (RF) capacitive hyperthermia (HT)"},{"annotation":"Treatment.Duration","text":"20 patients"},{"annotation":"Treatment.Effect","text":"clinical effect and safety"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"Lp-TAE combined with radiofrequency (RF) capacitive hyperthermia (HT)"},{"annotation":"Treatment.Disorder","text":"hepatocellular carcinoma (HCC) associated with cirrhosis of the liver"},{"annotation":"Treatment.Drug","text":"Lp-TAE"},{"annotation":"Treatment.Drug","text":"radiofrequency (RF) capacitive hyperthermia (HT)"},{"annotation":"Treatment.Duration","text":"20 patients"},{"annotation":"Treatment.Effect","text":"clinical effect and safety"},{"annotation":"attribute","text":"negated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"severity"},{"annotation":"attribute","text":"attribute"}]}]}
{"id":"3806824_1","context":"Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intracavernous injection of phentolamine/papaverine"},{"annotation":"Effect","text":"fibrosis of corpus cavernosum"},{"annotation":"Treatment","text":"intracavernous injection of phentolamine/papaverine"},{"annotation":"Treatment.Drug","text":"phentolamine/papaverine"},{"annotation":"Treatment.Route","text":"intracavernous injection"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"fibrosis of corpus cavernosum"},{"annotation":"Treatment.Drug","text":"phentolamine/papaverine"},{"annotation":"Treatment.Route","text":"intracavernous injection"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intracavernous injection of phentolamine/papaverine"},{"annotation":"Effect","text":"fibrosis of corpus cavernosum"},{"annotation":"Treatment","text":"intracavernous injection of phentolamine/papaverine"},{"annotation":"Treatment.Drug","text":"phentolamine/papaverine"},{"annotation":"Treatment.Route","text":"intracavernous injection"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"fibrosis of corpus cavernosum"},{"annotation":"Treatment.Drug","text":"phentolamine/papaverine"},{"annotation":"Treatment.Route","text":"intracavernous injection"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intracavernous injection of phentolamine/papaverine"},{"annotation":"Effect","text":"fibrosis of corpus cavernosum"},{"annotation":"Treatment","text":"intracavernous injection of phentolamine/papaverine"},{"annotation":"Treatment.Drug","text":"phentolamine/papaverine"},{"annotation":"Treatment.Route","text":"intracavernous injection"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"fibrosis of corpus cavernosum"},{"annotation":"Treatment.Drug","text":"phentolamine/papaverine"},{"annotation":"Treatment.Route","text":"intracavernous injection"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intracavernous injection of phentolamine/papaverine"},{"annotation":"Effect","text":"fibrosis of corpus cavernosum"},{"annotation":"Treatment","text":"intracavernous injection of phentolamine/papaverine"},{"annotation":"Treatment.Drug","text":"phentolamine/papaverine"},{"annotation":"Treatment.Route","text":"intracavernous injection"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"fibrosis of corpus cavernosum"},{"annotation":"Treatment.Drug","text":"phentolamine/papaverine"},{"annotation":"Treatment.Route","text":"intracavernous injection"}]},{"type":"Adverse_event","annotations":[{}]}]}
{"id":"440873_4","context":"We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"dystonia"},{"annotation":"Effect","text":"opisthotonus"},{"annotation":"Treatment","text":"carbamazepine"},{"annotation":"Treatment.Disorder","text":"carbamazepine-induced dystonia"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Subject","text":"three children"},{"annotation":"Subject.Population","text":"three children"},{"annotation":"Subject.Disorder","text":"carbamazepine-induced dystonia"}]}]}
{"id":"17275666_1","context":"Juvenile absence epilepsy exacerbated by valproic acid.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"exacerbated"},{"annotation":"Effect","text":"absence epilepsy"},{"annotation":"Treatment","text":"valproic acid"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Subject","text":"juvenile absence epilepsy"},{"annotation":"Subject.Disorder","text":"juvenile absence epilepsy"}]}]}
{"id":"15516308_10","context":"These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"suicidal ingestion of drugs"},{"annotation":"Effect","text":"deaths"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"deaths were not directly caused by quetiapine"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"suicidal ingestion of drugs was not directly caused by quetiapine"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly involved in the suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly implicated in the suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly associated with suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly linked to suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly related to suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly connected to suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly implicated in suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly associated with suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly related to suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly linked to suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly connected to suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly implicated in suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly associated with suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly related to suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly linked to suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly connected to suicidal ingestion of drugs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"quetiapine was not directly implicated in suicidal ingestion of drugs"},{"annotation":"Attribute"}]}]}
{"id":"16599252_2","context":"We present a case of hypereosinophilia related to zafirlukast therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"related"},{"annotation":"Treatment","text":"zafirlukast therapy"},{"annotation":"Treatment.Drug","text":"zafirlukast"},{"annotation":"Effect","text":"hypereosinophilia"},{"annotation":"Treatment","text":"zafirlukast therapy"},{"annotation":"Treatment.Drug","text":"zafirlukast"}]}]}
{"id":"18855892_3","context":"In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"anaphylaxis"},{"annotation":"Effect","text":"death"},{"annotation":"Treatment","text":"discontinuation of treatment"},{"annotation":"Treatment.Disorder","text":"methotrexate-induced anaphylaxis"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"anaphylaxis"},{"annotation":"Subject","text":"patients"},{"annotation":"Subject.Disorder","text":"methotrexate-induced anaphylaxis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"death due to cancer progression"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"de"}]}]}
{"id":"9737132_3","context":"Pentazocine-induced fibrous myopathy and localized neuropathy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"fibrous myopathy and localized neuropathy"},{"annotation":"Treatment","text":"pentazocine"},{"annotation":"Treatment.Drug","text":"pentazocine"},{"annotation":"Treatment.Disorder","text":"fibrous myopathy and localized neuropathy"}]}]}
{"id":"11096051_1","context":"Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"management"},{"annotation":"Treatment","text":"intensive high-flux hemodiafiltration"},{"annotation":"Treatment.Disorder","text":"vancomycin toxicity"},{"annotation":"Treatment.Drug","text":"vancomycin"}]}]}
{"id":"17823522_3","context":"Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"involvement"},{"annotation":"Effect","text":"lichen nitidus"},{"annotation":"Treatment","text":"systemic treatment with interferon alpha and ribavirin"},{"annotation":"Treatment.Disorder","text":"hepatitis C"},{"annotation":"Treatment.Drug","text":"interferon alpha"},{"annotation":"Treatment.Drug","text":"ribavirin"},{"annotation":"Treatment.Drug","text":"lichen nitidus"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"hepatitis C"}]}]}
{"id":"6810714_1","context":"The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"after"},{"annotation":"Effect","text":"delirium"},{"annotation":"Effect","text":"grand mal seizure"},{"annotation":"Effect","text":"photosensitivity"},{"annotation":"Treatment","text":"propranolol"},{"annotation":"Treatment.Drug","text":"propranolol"},{"annotation":"Treatment.Drug","text":"neuroleptic regimen"},{"annotation":"Treatment.Drug","text":"propranolol"},{"annotation":"Treatment.Drug","text":"neuroleptic"},{"annotation":"Subject","text":"a woman with chronic schizophrenia"},{"annotation":"Subject.Disorder","text":"chronic schizophrenia"}]}]}
{"id":"16132305_2","context":"We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"placed on captopril"},{"annotation":"Treatment","text":"captopril for afterload reduction"},{"annotation":"Treatment.Disorder","text":"complex congenital heart disease"},{"annotation":"Treatment.Drug","text":"captopril"},{"annotation":"Treatment.Time_elapsed","text":"after cardiac surgery"},{"annotation":"Effect","text":"pulmonary infiltrates with eosinophilia"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"placed on captopril"},{"annotation":"Treatment","text":"captopril for afterload reduction"},{"annotation":"Treatment.Disorder","text":"complex congenital heart disease"},{"annotation":"Treatment.Drug","text":"captopril"},{"annotation":"Treatment.Time_elapsed","text":"after cardiac surgery"},{"annotation":"Effect","text":"pulmonary infiltrates with eosinophilia"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"}]}]}
{"id":"3084231_1","context":"Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"valproic acid"},{"annotation":"Treatment.Disorder","text":"valproic acid toxicity"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Effect","text":"CNS toxicity"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Disorder","text":"hyperammonemia"},{"annotation":"Treatment.Disorder","text":"CNS toxicity"}]}]}
{"id":"19583682_3","context":"We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"serotonin syndrome"},{"annotation":"Treatment","text":"pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin"},{"annotation":"Treatment.Disorder","text":"serotonin syndrome"},{"annotation":"Treatment.Drug","text":"selective serotonin-reuptake inhibitors (SSRI)"},{"annotation":"Treatment.Drug","text":"ciprofloxacin"},{"annotation":"Treatment.Drug","text":"serotonin"},{"annotation":"Treatment.Drug","text":"SSRI"},{"annotation":"Treatment.Drug","text":"ciprofloxacin"},{"annotation":"Treatment.Pharmacokinetic_interaction","text":"pharmacokinetic interaction"},{"annotation":"Treatment.Pharmacodynamic_interaction","text":"pharmacodynamic interaction"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"serotonin syndrome"}]}]}
{"id":"12218252_1","context":"Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"withdrawal of cyclosporin"},{"annotation":"Treatment.Drug","text":"cyclosporin"},{"annotation":"Treatment.Drug","text":"etanercept"},{"annotation":"Treatment.Disorder","text":"generalised pustular psoriasis"},{"annotation":"Treatment.Drug","text":"etanercept"},{"annotation":"Treatment.Drug","text":"cyclosporin"},{"annotation":"Treatment.Combination.Trigger","text":"withdrawal of"},{"annotation":"Treatment.Combination.Drug","text":"cyclosporin"},{"annotation":"Treatment.Combination.Drug","text":"etanercept"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"generalised pustular psoriasis"}]}]}
{"id":"10592946_1","context":"A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"consumption"},{"annotation":"Treatment","text":"oolong tea"},{"annotation":"Treatment.Disorder","text":"schizophrenia"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Effect","text":"delirious"},{"annotation":"Treatment","text":"gradually increasing quantities of oolong tea"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Drug","text":"15 L each day"},{"annotation":"Subject","text":"a 36-y-o patient"},{"annotation":"Subject.Disorder","text":"schizophrenia"},{"annotation":"Subject.Age","text":"36 y-o"},{"annotation":"Subject.Population","text":"1 patient"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Drug","text":"oolong tea"},{"annotation":"Treatment.Dosage","text":"15 L each day"},{"annotation":"Treatment.Frequency","text":"gradually increasing quantities"},{"annotation":"Treatment.Route","text":"consumption"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"schizophrenia"},{"annotation":"Effect","text":"delirious"}]}]}
{"id":"3242521_1","context":"Intraventricular nafcillin-induced seizures in a neonate.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"seizures"},{"annotation":"Treatment","text":"intraventricular nafcillin"},{"annotation":"Treatment.Drug","text":"nafcillin"},{"annotation":"Subject","text":"a neonate"},{"annotation":"Subject.Age","text":"neonate"},{"annotation":"Treatment.Drug","text":"nafcillin"},{"annotation":"Treatment.Dosage","text":"intraventricular"},{"annotation":"Treatment.Frequency","text":"seizures"},{"annotation":"Treatment.Route","text":"intraventricular"},{"annotation":"Treatment.Time_elapsed","text":"after drug administration"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"nafcillin-induced seizures"},{"annotation":"Attribute","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"response"},{"annotation":"Effect","text":"unknown"},{"annotation":"Treatment","text":"nafcillin"},{"annotation":"Treatment.Disorder","text":"nafcillin-induced seizures"},{"annotation":"Attribute","text":"speculated"}]}]}
{"id":"6671350_4","context":"Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"administered"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Effect","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":""}]}]}
{"id":"6873616_2","context":"Intrahepatic cholestasis and sicca complex after thiabendazole.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"intrahepatic cholestasis and sicca complex"},{"annotation":"Treatment","text":"thiabendazole"},{"annotation":"Treatment.Drug","text":"thiabendazole"},{"annotation":"Treatment.Disorder","text":"intrahepatic cholestasis and sicca complex"},{"annotation":"Treatment.Drug","text":"thiabendazole"},{"annotation":"Treatment.Disorder","text":"intrahepatic cholestasis and sicca complex"}]}]}
{"id":"748238_3","context":"We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"development of monoclonal gammopathy"},{"annotation":"Effect","text":"monoclonal gammopathy"},{"annotation":"Treatment","text":"diphenylhydantoin"},{"annotation":"Treatment.Drug","text":"diphenylhydantoin"},{"annotation":"Treatment.Disorder","text":"monoclonal gammopathy"},{"annotation":"Treatment.Drug","text":"serum proteins"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{}]}]}
{"id":"6671350_3","context":"Moxalactam is more likely to be associated with platelet dysfunction.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"moxalactam"},{"annotation":"Treatment.Drug","text":"moxalactam"},{"annotation":"Effect","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"platelet dysfunction"},{"annotation":"Treatment.Drug","text":"pl"}]}]}
{"id":"8151270_2","context":"This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"prompted"},{"annotation":"Effect","text":"fulminant hepatitis"},{"annotation":"Treatment","text":"ddI"},{"annotation":"Treatment.Disorder","text":"AIDS"},{"annotation":"Treatment.Drug","text":"ddI"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"ddI is not responsible for fulminant hepatitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"prompted"},{"annotation":"Effect","text":"fulminant hepatitis"},{"annotation":"Treatment","text":"ddI"},{"annotation":"Treatment.Disorder","text":"AIDS"},{"annotation":"Treatment.Drug","text":"ddI"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"ddI is not responsible for fulminant hepatitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"prompted"},{"annotation":"Effect","text":"fulminant hepatitis"},{"annotation":"Treatment","text":"ddI"},{"annotation":"Treatment.Disorder","text":"AIDS"},{"annotation":"Treatment.Drug","text":"ddI"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"ddI is not responsible for fulminant hepatitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"prompted"},{"annotation":"Effect","text":"fulminant hepatitis"},{"annotation":"Treatment","text":"ddI"},{"annotation":"Treatment.Disorder","text":"AIDS"},{"annotation":"Treatment.Drug","text":"ddI"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"ddI is not responsible for fulminant hepatitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"prompted"},{"annotation":"Effect","text":"fulminant hepatitis"},{"annotation":"Treatment","text":"ddI"},{"annotation":"Treatment.Disorder","text":"AIDS"},{"annotation":"Treatment.Drug","text":"ddI"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"ddI is not responsible for fulminant hepatitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"prompted"},{"annotation":"Effect","text":"fulminant hepatitis"},{"annotation":"Treatment","text":"ddI"},{"annotation":"Treatment.Disorder","text":"AIDS"},{"annotation":"Treatment.Drug","text":"ddI"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"ddI is not responsible for fulminant hepatitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"prompted"},{"annotation":"Effect","text":"fulminant hepatitis"},{"annotation":"Treatment","text":"ddI"},{"annotation":"Treatment.Disorder","text":"AIDS"},{"annotation":"Treatment.Drug","text":"ddI"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"ddI is not responsible for fulminant hepatitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"prompted"},{"annotation":"Effect"}]}]}
{"id":"10573314_3","context":"Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"initiation of tolterodine"},{"annotation":"Effect","text":"adverse effects"},{"annotation":"Treatment","text":"warfarin for stroke prophylaxis in association with chronic atrial fibrillation"},{"annotation":"Treatment.Disorder","text":"chronic atrial fibrillation"},{"annotation":"Treatment.Drug","text":"tolterodine"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"tolterodine"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Disorder","text":"chronic atrial fibrillation"}]}]}
{"id":"16288069_2","context":"CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presented"},{"annotation":"Effect","text":"JHR"},{"annotation":"Treatment","text":"penicillin G"},{"annotation":"Treatment.Drug","text":"penicillin G"},{"annotation":"Treatment.Disorder","text":"HIV-positive man"},{"annotation":"Treatment.Disorder","text":"AIDS-defining illness"},{"annotation":"Subject","text":"a 45-year-old HIV-positive man"},{"annotation":"Subject.Age","text":"45 years"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Drug","text":"penicillin G"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"neurosyphilis"},{"annotation":"Attribute Attributes","text":"not specified"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presented"},{"annotation":"Effect","text":"JHR"},{"annotation":"Treatment","text":"penicillin G"},{"annotation":"Treatment.Drug","text":"penicillin G"},{"annotation":"Treatment.Disorder","text":"HIV-positive man"},{"annotation":"Treatment.Disorder","text":"AIDS-defining illness"},{"annotation":"Subject","text":"a 45-year-old HIV-positive man"},{"annotation":"Subject.Age","text":"45 years"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Drug","text":"penicillin G"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"neurosyphilis"},{"annotation":"Attribute Attributes","text":"not specified"}]}]}
{"id":"16393774_6","context":"The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"IFN-beta therapy"},{"annotation":"Treatment.Disorder","text":"autoimmune thyroid disease"},{"annotation":"Treatment.Disorder","text":"refractory pre-patellar bursitis"},{"annotation":"Treatment.Duration","text":"50 months"},{"annotation":"Subject","text":"the second patient"},{"annotation":"Subject.Disorder","text":"autoimmune thyroid disease"},{"annotation":"Subject.Disorder","text":"refractory pre-patellar bursitis"}]}]}
{"id":"3156465_3","context":"We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"teratogenicity"},{"annotation":"Effect","text":"isotretinoin-induced congenital malformations"},{"annotation":"Treatment","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Disorder","text":"isotretinoin-induced congenital malformations"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Age","text":"postnatal"},{"annotation":"Subject.Disorder","text":"isotretinoin-induced congenital malformations"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Duration","text":"postnatal"},{"annotation":"Treatment.Disorder","text":"isotretinoin-induced congenital malformations"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":""}]}]}
{"id":"13680140_1","context":"Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"due to"},{"annotation":"Effect","text":"sclerotic changes"},{"annotation":"Treatment","text":"long-term oral isotretinoin therapy"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Dosage","text":"long-term"},{"annotation":"Treatment.Duration","text":"oral"},{"annotation":"Treatment.Disorder","text":"sclerotic changes"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Dosage","text":"oral"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"sclerotic changes"}]}]}
{"id":"6725214_1","context":"A case of priapism associated with trazodone is described.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with trazodone"},{"annotation":"Effect","text":"priapism"},{"annotation":"Treatment","text":"trazodone"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment","text":"priapism"},{"annotation":"Treatment","text":"associated with"},{"annotation":"Treatment","text":"trazodone"},{"annotation":"Treatment","text":"priapism"}]}]}
{"id":"16678268_1","context":"Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"pneumonia"},{"annotation":"Treatment","text":"infiximab infusion for the treatment of Crohn's disease"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"pneumonia"},{"annotation":"Treatment","text":"infiximab infusion for the treatment of Crohn's disease"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"pneumonia"},{"annotation":"Treatment","text":"infiximab infusion for the treatment of Crohn's disease"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"pneumonia"},{"annotation":"Treatment","text":"infiximab infusion for the treatment of Crohn's disease"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"pneumonia"},{"annotation":"Treatment","text":"infiximab infusion for the treatment of Crohn's disease"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"pneumonia"},{"annotation":"Treatment","text":"infiximab infusion for the treatment of Crohn's disease"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infiximab"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Adverse_event"}]}
{"id":"6693840_3","context":"No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"found"},{"annotation":"Effect","text":"gynecomastia"},{"annotation":"Treatment","text":"theophylline"},{"annotation":"Treatment.Disorder","text":"gynecomastia"},{"annotation":"Treatment.Drug","text":"theophylline"}]}]}
{"id":"16018164_5","context":"This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Effect","text":"hemorrhage"},{"annotation":"Treatment.Disorder","text":"vascular malformation"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoep"}]}]}
{"id":"6651138_1","context":"A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"acute angle-closure glaucoma"},{"annotation":"Treatment","text":"transdermal scopolamine delivery system (TRANSDERM-V)"},{"annotation":"Treatment.Drug","text":"scopolamine"},{"annotation":"Treatment.Dosage","text":"patch"},{"annotation":"Treatment.Duration","text":"four days"},{"annotation":"Treatment.Route","text":"patch"},{"annotation":"Treatment.Time_elapsed","text":"four days"},{"annotation":"Subject","text":"a 58-year-old woman"},{"annotation":"Subject.Age","text":"58 years"},{"annotation":"Subject.Gender","text":"female"},{"annotation":"Subject.Population","text":"1 woman"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Subject.Disorder","text":"unilateral acute angle-closure glaucoma"},{"annotation":"Treatment.Disorder","text":"acute angle-closure glaucoma"}]}]}
{"id":"12218252_2","context":"We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withdrawal of cyclosporin A"},{"annotation":"Effect","text":"generalised pustular exacerbation and aggravation of joint condition"},{"annotation":"Treatment","text":"cyclosporin A"},{"annotation":"Treatment.Disorder","text":"psoriasis including mutilating psoriatic arthritis"},{"annotation":"Treatment.Drug","text":"cyclosporin A"},{"annotation":"Treatment.Drug","text":"psoriasis"},{"annotation":"Subject","text":"50-year-old male patient"},{"annotation":"Subject.Age","text":"50"},{"annotation":"Subject.Disorder","text":"psoriasis including mutilating psoriatic arthritis"},{"annotation":"Treatment.Drug","text":"cyclosporin A"},{"annotation":"Treatment.Drug","text":"psoriasis"}]}]}
{"id":"8726608_2","context":"Six days after starting acyclovir she exhibited signs of lithium toxicity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"six days after starting acyclovir"},{"annotation":"Treatment","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Dosage","text":"toxicity"},{"annotation":"Treatment.Duration","text":"six days"},{"annotation":"Effect","text":"lithium toxicity"},{"annotation":"Treatment.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Dosage","text":"toxicity"},{"annotation":"Treatment.Duration","text":"six days"},{"annotation":"Subject","text":"she"},{"annotation":"Subject.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Dosage","text":"toxicity"},{"annotation":"Treatment.Duration","text":"six days"},{"annotation":"Effect","text":"lithium toxicity"},{"annotation":"Treatment.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Dosage","text":"toxicity"},{"annotation":"Treatment.Duration","text":"six days"},{"annotation":"Effect","text":"lithium toxicity"},{"annotation":"Treatment.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Dosage","text":"toxicity"},{"annotation":"Treatment.Duration","text":"six days"},{"annotation":"Effect","text":"lithium toxicity"},{"annotation":"Treatment.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Dosage","text":"toxicity"},{"annotation":"Treatment.Duration","text":"six days"},{"annotation":"Effect","text":"lithium toxicity"},{"annotation":"Treatment.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Dosage","text":"toxicity"},{"annotation":"Treatment.Duration","text":"six days"},{"annotation":"Effect","text":"lithium toxicity"},{"annotation":"Treatment.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Dosage","text":"toxicity"},{"annotation":"Treatment.Duration","text":"six days"},{"annotation":"Effect","text":"lithium toxicity"},{"annotation":"Treatment.Disorder","text":"lithium toxicity"},{"annotation":"Treatment.Drug","text":"acyclovir"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"T"}]}]}
{"id":"11197767_1","context":"Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"to"},{"annotation":"Effect","text":"encystment and in vitro excystment"},{"annotation":"Treatment","text":"cadmium and zinc"},{"annotation":"Treatment.Drug","text":"cadmium"},{"annotation":"Treatment.Drug","text":"zinc"},{"annotation":"Treatment.Drug","text":"encystment"},{"annotation":"Treatment.Drug","text":"in vitro excystment"},{"annotation":"Treatment.Drug","text":"Parorchis acanthus"},{"annotation":"Treatment.Drug","text":"Digenea"},{"annotation":"Treatment.Drug","text":"Philophthalmidae"}]}]}
{"id":"2717661_1","context":"The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Effect","text":"neurotoxicity"},{"annotation":"Treatment","text":"lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Disorder","text":"syndrome of irreversible lithium-effectuated neurotoxicity (SILENT)"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"irreversible"},{"annotation":"Treatment.Drug","text":"syndrome"},{"annotation":"Treatment.Drug","text":"effectuated"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"syndrome"},{"annotation":"Treatment.Drug","text":"effectuated"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"irreversible"},{"annotation":"Treatment.Drug","text":"syndrome"},{"annotation":"Treatment.Drug","text":"effectuated"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"irreversible"},{"annotation":"Treatment.Drug","text":"syndrome"},{"annotation":"Treatment.Drug","text":"effectuated"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"irreversible"},{"annotation":"Treatment.Drug","text":"syndrome"},{"annotation":"Treatment.Drug","text":"effectuated"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"irreversible"},{"annotation":"Treatment.Drug","text":"syndrome"},{"annotation":"Treatment.Drug","text":"effectuated"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"irreversible"},{"annotation":"Treatment.Drug","text":"syndrome"},{"annotation":"Treatment.Drug","text":"effectuated"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"irreversible"},{"annotation":"Treatment.Drug","text":"syndrome"},{"annotation":"Treatment.Drug","text":"effectuated"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"irreversible"},{"annotation":"Treatment.Drug","text":"syndrome"},{"annotation":"Treatment.Drug","text":"effectuated"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"irreversible"},{"annotation":"Treatment.Drug","text":"syndrome"},{"annotation":"Treatment.Drug","text":"effectuated"},{"annotation":"Treatment.Drug","text":"neurotoxicity"},{"annotation":"Treatment.Drug","text":"irreversible"},{"annotation":"Treatment.Drug","text":"syndrome"},{"annotation":"Treatment.Drug","text":"effectuated"},{"annotation":"Treatment.Drug","text":"neurotoxic"}]}]}
{"id":"589261_5","context":"One patient on ouabain also developed cardiomyopathy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"cardiomyopathy"},{"annotation":"Treatment","text":"ouabain"},{"annotation":"Treatment.Drug","text":"ouabain"},{"annotation":"Subject","text":"one patient"},{"annotation":"Subject.Disorder","text":"cardiomyopathy"}]}]}
{"id":"15863610_3","context":"Data suggest that tamoxifen is involved in the pathogenesis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"involved"},{"annotation":"Treatment","text":"tamoxifen"},{"annotation":"Treatment.Drug","text":"tamoxifen"},{"annotation":"Treatment.Disorder","text":"pathogenesis"}]}]}
{"id":"6794018_2","context":"Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"cholestasis and bullae"},{"annotation":"Treatment","text":"glibenclamide therapy"},{"annotation":"Treatment.Disorder","text":"intrahepatic cholestasis"},{"annotation":"Treatment.Drug","text":"glibenclamide"},{"annotation":"Treatment.Drug","text":"bullae"},{"annotation":"Treatment.Drug","text":"cutaneous"},{"annotation":"Treatment.Drug","text":"bullae"},{"annotation":"Treatment.Drug","text":"cutaneous"},{"annotation":"Treatment.Drug","text":"bullae"},{"annotation":"Treatment.Drug","text":"cutaneous"},{"annotation":"Treatment.Drug","text":"bullae"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Disorder","text":"intrahepatic cholestasis"},{"annotation":"Treatment.Drug","text":"glibenclamide"}]}]}
{"id":"18262450_1","context":"Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"enhances"},{"annotation":"Effect","text":"painful diabetic neuropathy"},{"annotation":"Treatment","text":"prolonged-release oxycodone"},{"annotation":"Treatment.Drug","text":"oxycodone"},{"annotation":"Treatment.Disorder","text":"painful diabetic neuropathy"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Treatment.Combination.Trigger","text":"existing"},{"annotation":"Treatment.Combination.Drug","text":"gabapentin"},{"annotation":"Treatment.Combination.Drug","text":"oxycodone"},{"annotation":"Subject","text":"painful diabetic neuropathy patients"},{"annotation":"Subject.Disorder","text":"painful diabetic neuropathy"}]}]}
{"id":"14742791_3","context":"OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"acute interstitial nephritis (AIN)"},{"annotation":"Treatment","text":"pantoprazole"},{"annotation":"Treatment.Disorder","text":"acute interstitial nephritis (AIN)"},{"annotation":"Treatment.Drug","text":"pantoprazole"},{"annotation":"Treatment.Duration","text":"as of November 4, 2003"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Event type","text":"Potential_therapeutic_effect"}]}]}
{"id":"19555801_2","context":"We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"hiccups"},{"annotation":"Treatment","text":"aripiprazole"},{"annotation":"Treatment.Drug","text":"atypical antipsychotic"},{"annotation":"Treatment.Disorder","text":"organic bipolar affective disorder"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"organic bipolar affective disorder"}]}]}
{"id":"10682234_2","context":"A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.","events":[{"type":"Treatment","annotations":[{"annotation":"Treatment","text":"interferon-alpha"},{"annotation":"Treatment.Drug","text":"interferon-alpha"},{"annotation":"Treatment.Dosage","text":"5 x 10(6) IU"},{"annotation":"Treatment.Frequency","text":"once a day"},{"annotation":"Treatment.Duration","text":"28 days"},{"annotation":"Treatment.Disorder","text":"chronic hepatitis B"}]},{"type":"Effect","annotations":[{"annotation":"Effect","text":"treatment response"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Attribute Attributes","annotations":[{"annotation":"negated","text":"not negated"}]}]}
{"id":"21330680_2","context":"The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"after smoking cessation"},{"annotation":"Effect","text":"parkinsonism"},{"annotation":"Treatment","text":"high-dosage olanzapine"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"cigarettes"},{"annotation":"Attribute","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"parkinsonism"},{"annotation":"Treatment","text":"high-dosage olanzapine"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"cigarettes"},{"annotation":"Attribute","text":"speculated"}]}]}
{"id":"4066620_1","context":"A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"high doses of trazodone"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Treatment.Disorder","text":"bipolar disorder"},{"annotation":"Treatment.Disorder","text":"complicated cardiovascular disease"},{"annotation":"Treatment.Disorder","text":"movement disorder"},{"annotation":"Effect","text":"movement disorder"},{"annotation":"Treatment","text":"maintenance lithium therapy"}]}]}
{"id":"19354059_1","context":"The most common complication of warfarin use is adverse bleeding.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"use"},{"annotation":"Effect","text":"adverse bleeding"},{"annotation":"Treatment","text":"warfarin"},{"annotation":"Treatment.Disorder","text":"warfarin use"}]}]}
{"id":"18166746_2","context":"To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"methylene blue infusion"},{"annotation":"Effect","text":"autonomic, neurological and neuromuscular instability"},{"annotation":"Treatment","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"}]}]}
{"id":"15571949_2","context":"PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"during chemotherapy"},{"annotation":"Effect","text":"PVT"},{"annotation":"Treatment","text":"intensive chemotherapy containing busulfan"},{"annotation":"Treatment.Drug","text":"busulfan"},{"annotation":"Treatment.Disorder","text":"HVOD"},{"annotation":"Treatment.Drug","text":"intensive chemotherapy containing busulfan"},{"annotation":"Treatment.Drug","text":"intensive chemotherapy containing busulfan"},{"annotation":"Treatment.Drug","text":"intensive chemotherapy containing busulfan"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"intensive chemotherapy containing busulfan"},{"annotation":"Treatment.Combination.Drug","text":"intensive chemotherapy containing busulfan"},{"annotation":"Treatment.Combination.Drug","text":"intensive chemotherapy containing busulfan"},{"annotation":"Subject","text":"children"},{"annotation":"Subject.Age","text":"children"},{"annotation":"Subject.Population","text":"children"},{"annotation":"Subject.Race","text":"children"},{"annotation":"Subject.Disorder","text":"HVOD"},{"annotation":"Treatment.Disorder","text":"intensive chemotherapy containing busulfan"}]}]}
{"id":"11724089_3","context":"It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"toxic epidermal necrolysis"},{"annotation":"Treatment","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"awareness"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"}]}]}
{"id":"21630612_1","context":"Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"concomitant use"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"simvastatin and amiodarone"},{"annotation":"Treatment.Drug","text":"simvastatin"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"simvastatin"},{"annotation":"Treatment.Combination.Drug","text":"amiodarone"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"none"}]}]}
{"id":"9533061_10","context":"CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"CDIC"},{"annotation":"Effect","text":"diarrhea"},{"annotation":"Treatment","text":"clindamycin phosphate vaginal cream"},{"annotation":"Treatment.Drug","text":"clindamycin"},{"annotation":"Treatment.Dosage","text":"vaginal"},{"annotation":"Treatment.Dosage","text":"phosphate"},{"annotation":"Treatment.Time_elapsed","text":"CDIC"},{"annotation":"Treatment.Duration","text":"CDIC"},{"annotation":"Treatment.Disorder","text":"CDIC"},{"annotation":"Treatment.Disorder","text":"diarrhea"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"8308951_2","context":"A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hematoma"},{"annotation":"Treatment","text":"warfarin"},{"annotation":"Treatment.Disorder","text":"warfarin-induced coagulopathy"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"warfarin-induced coagulopathy"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Drug","text":"coagulopathy"},{"annotation":"Treatment.Effect","text":"hematoma"},{"annotation":"Treatment.Effect","text":"intercerebral"},{"annotation":"Treatment.Effect","text":"cerebral"}]}]}
{"id":"3171334_3","context":"Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"vincristine"},{"annotation":"Effect","text":"visual loss"},{"annotation":"Treatment","text":"vincristine"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Dosage","text":"single dose"},{"annotation":"Treatment.Frequency","text":"single"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Time_elapsed","text":"after vincristine administration"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"spinal cord astrocytoma"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"spinal cord astrocytoma"}]}]}
{"id":"10682234_5","context":"Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"did not ameliorate"},{"annotation":"Treatment","text":"clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine"},{"annotation":"Treatment.Disorder","text":"akathisia"},{"annotation":"Treatment.Drug","text":"clonazepam"},{"annotation":"Treatment.Drug","text":"thioridazine"},{"annotation":"Treatment.Drug","text":"beta-blockers"},{"annotation":"Treatment.Drug","text":"anticholinergics"},{"annotation":"Treatment.Drug","text":"bromocriptine"}]}]}
{"id":"7761316_1","context":"Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presenting symptoms"},{"annotation":"Treatment","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Disorder","text":"relapsed Wilms' tumors"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Duration","text":"relapsed Wilms' tumors"},{"annotation":"Subject","text":"four of 44 children (9%)"},{"annotation":"Subject.Population","text":"four of 44 children (9%)"},{"annotation":"Subject.Age","text":"children"},{"annotation":"Subject.Disorder","text":"relapsed Wilms' tumors"},{"annotation":"Treatment.Disorder","text":"relapsed Wilms' tumors"},{"annotation":"Effect","text":"musculoskeletal complaints"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment.Drug","text":"cyclophosphamide"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Treatment."}]}]}
{"id":"8308951_1","context":"Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"cutaneous exposure"},{"annotation":"Effect","text":"intracerebral hemorrhage"},{"annotation":"Treatment","text":"warfarin-like anticoagulant"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Drug","text":"anticoagulant"},{"annotation":"Treatment.Route","text":"cutaneous"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"intracerebral hemorrhage"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"}]}]}
{"id":"16317298_2","context":"Gemcitabine should be added to the list of drugs known to cause radiation recall.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"radiation recall"},{"annotation":"Effect","text":"radiation recall"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Disorder","text":"radiation recall"}]}]}
{"id":"12504711_1","context":"A paradoxical ocular effect of brimonidine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"effect"},{"annotation":"Effect","text":"paradoxical ocular effect"},{"annotation":"Treatment","text":"brimonidine"},{"annotation":"Treatment.Drug","text":"brimonidine"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Att"}]}]}
{"id":"12234159_1","context":"Fixed drug eruption to rofecoxib.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"fixed drug eruption"},{"annotation":"Treatment","text":"rofecoxib"},{"annotation":"Treatment.Drug","text":"rofecoxib"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"9533061_8","context":"DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"No published clinical studies"},{"annotation":"Treatment","text":"clindamycin vaginal cream"},{"annotation":"Treatment.Disorder","text":"bacterial vaginosis"},{"annotation":"Effect","text":"C. difficile toxin not documented in stool samples of patients with diarrhea"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.Attribute","text":"not documented"},{"annotation":"Attribute.Attribute","text":"stool samples"},{"annotation":"Attribute.Attribute","text":"diarrhea"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute","text":"C. difficile toxin"},{"annotation":"Attribute.Attribute","text":"clindamycin vaginal cream"},{"annotation":"Attribute.Attribute"}]}]}
{"id":"14742791_1","context":"Acute interstitial nephritis due to pantoprazole.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"due to"},{"annotation":"Effect","text":"interstitial nephritis"},{"annotation":"Treatment","text":"pantoprazole"},{"annotation":"Treatment.Drug","text":"pantoprazole"},{"annotation":"Treatment.Disorder","text":"acute interstitial nephritis"}]}]}
{"id":"16515630_3","context":"Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"potential"},{"annotation":"Treatment","text":"taxanes such as paclitaxel"},{"annotation":"Treatment.Drug","text":"paclitaxel"},{"annotation":"Treatment.Disorder","text":"pneumonitis and lung fibrosis"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"}]}]}
{"id":"1238016_1","context":"Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"burns"},{"annotation":"Effect","text":"circumoral and pharyngeal"},{"annotation":"Treatment","text":"concentrated solution of benzalkonium (Zephiran) chloride"},{"annotation":"Treatment.Disorder","text":"candidiasis"},{"annotation":"Treatment.Drug","text":"benzalkonium (Zephiran) chloride"},{"annotation":"Treatment.Drug","text":"candidiasis"},{"annotation":"Treatment.Drug","text":"candidiasis"},{"annotation":"Treatment.Drug","text":"candidiasis"},{"annotation":"Subject","text":"infant twins"},{"annotation":"Subject.Age","text":"infant"},{"annotation":"Subject.Disorder","text":"candidiasis"},{"annotation":"Treatment.Drug","text":"benzalkonium (Zephiran) chloride"},{"annotation":"Treatment.Drug","text":"candidiasis"},{"annotation":"Treatment.Drug","text":"candidiasis"},{"annotation":"Treatment.Drug","text":"candidiasis"},{"annotation":"Treatment.Drug","text":"candidiasis"},{"annotation":"Treatment.Drug","text":"candidiasis"}]}]}
{"id":"3156465_2","context":"Isotretinoin teratogenicity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Effect","text":"teratogenicity"},{"annotation":"Treatment","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Disorder","text":"teratogenic effect"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Treatment"},{"annotation":"Treatment","text":"isotretinoin"},{"annotation":"Treatment.Disorder","text":"teratogenic effect"},{"annotation":"Treatment.Drug","text":"isotretinoin"}]}]}
{"id":"7081289_1","context":"Hepatitis following cimetidine administration.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"cimetidine"},{"annotation":"Treatment.Drug","text":"cimetidine"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"cimetidine"}]}]}
{"id":"10698143_4","context":"We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"ingestion"},{"annotation":"Treatment","text":"ibuprofen"},{"annotation":"Treatment.Drug","text":"ibuprofen"},{"annotation":"Effect","text":"depressed level of consciousness"},{"annotation":"Treatment","text":"naloxone"},{"annotation":"Treatment.Drug","text":"naloxone"},{"annotation":"Treatment.Drug","text":"ibuprofen"},{"annotation":"Treatment.Drug","text":"naloxone"},{"annotation":"Treatment.Frequency","text":"once"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"11-month-old"},{"annotation":"Treatment.Duration","text":"markedly improved"},{"annotation":"Treatment.Disorder","text":"depressed level of consciousness"},{"annotation":"Treatment.Drug","text":"naloxone"},{"annotation":"Treatment.Drug","text":"ibuprofen"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"markedly improved"},{"annotation":"Treatment","text":"naloxone"},{"annotation":"Treatment.Disorder","text":"depressed level of consciousness"},{"annotation":"Treatment.Drug","text":"naloxone"}]}]}
{"id":"17619811_5","context":"Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"diagnosis"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"colchicine"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes"}]}]}
{"id":"7526455_1","context":"A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"initiation"},{"annotation":"Treatment","text":"flecainide"},{"annotation":"Treatment.Drug","text":"flecainide"},{"annotation":"Treatment.Disorder","text":"Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia"},{"annotation":"Treatment.Drug","text":"flecainide"},{"annotation":"Treatment.Time_elapsed","text":"within 15 days"},{"annotation":"Effect","text":"encephalopathy"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"acute reversible"}]}]}
{"id":"15522120_11","context":"Since the depressive symptoms returned sertraline medication was initiated.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"returned"},{"annotation":"Effect","text":"depressive symptoms"},{"annotation":"Treatment","text":"sertraline medication"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Disorder","text":"depressive symptoms"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Disorder","text":"depression"}]}]}
{"id":"8589490_1","context":"Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hyperpigmentation"},{"annotation":"Treatment","text":"CHOP chemotherapy"},{"annotation":"Treatment.Disorder","text":"anaplastic large-cell lymphoma"},{"annotation":"Treatment.Drug","text":"CHOP chemotherapy"},{"annotation":"Treatment.Drug","text":"anaplastic large-cell lymphoma"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"CHOP chemotherapy"},{"annotation":"Treatment.Combination.Drug","text":"anaplastic large-cell lymphoma"},{"annotation":"Subject","text":"a CD30 (Ki-1)-positive anaplastic large-cell lymphoma"},{"annotation":"Subject.Disorder","text":"anaplastic large-cell lymphoma"}]}]}
{"id":"11105373_1","context":"A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"application"},{"annotation":"Treatment","text":"4% hydroquinone in sorbolene cream and 0.1% tretinoin cream"},{"annotation":"Treatment.Drug","text":"hydroquinone"},{"annotation":"Treatment.Drug","text":"tretinoin"},{"annotation":"Treatment.Dosage","text":"intermittent application for 9 months"},{"annotation":"Treatment.Drug","text":"hydroquinone"},{"annotation":"Treatment.Drug","text":"tretinoin"},{"annotation":"Treatment.Duration","text":"9 months"},{"annotation":"Subject","text":"a 33-year-old male"},{"annotation":"Subject.Disorder","text":"brown discolouration of fingernails"}]}]}
{"id":"2241449_3","context":"We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"crystalluria and renal failure"},{"annotation":"Treatment","text":"sulfadiazine"},{"annotation":"Treatment.Disorder","text":"acquired immunodeficiency syndrome"},{"annotation":"Treatment.Drug","text":"sulfadiazine"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":""}]}]}
{"id":"17016002_2","context":"Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused"},{"annotation":"Effect","text":"eosinophilic pneumonia"},{"annotation":"Treatment","text":"calcium stearate"},{"annotation":"Treatment.Drug","text":"oral antihistaminic medication"},{"annotation":"Treatment.Drug","text":"calcium stearate"},{"annotation":"Treatment.Drug","text":"oral antihistaminic medication"},{"annotation":"Treatment.Drug","text":"calcium stearate"},{"annotation":"Treatment.Drug","text":"oral antihistaminic medication"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Disorder","text":"acute eosinophilic pneumonia"}]}]}
{"id":"11563738_1","context":"The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intoxication"},{"annotation":"Effect","text":"death"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"acute"},{"annotation":"Treatment.Frequency","text":"accidental"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Subject","text":"unknown"},{"annotation":"Subject.Population","text":"unknown"},{"annotation":"Subject.Disorder","text":"unknown"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"death"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Disorder","text":"acute intoxication"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Att"}]}]}
{"id":"2719905_1","context":"Long lasting respiratory depression induced by morphine-6-glucuronide?","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"respiratory depression"},{"annotation":"Treatment","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Duration","text":"long lasting"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6-glucuronide"},{"annotation":"Treatment.Drug","text":"6-glucuronide"},{"annotation":"Treatment.Drug","text":"morphine-6"}]}]}
{"id":"623061_1","context":"A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"encephalopathy"},{"annotation":"Treatment","text":"antiemetic combination of pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Disorder","text":"toxic encephalopathy"},{"annotation":"Treatment.Drug","text":"pentobarbital"},{"annotation":"Treatment.Drug","text":"pyrilamine"},{"annotation":"Subject","text":"seven children"},{"annotation":"Subject.Age","text":"5 years of age and younger"},{"annotation":"Subject.Population","text":"seven children"},{"annotation":"Treatment.Combination.Trigger","text":"following administration of"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital"},{"annotation":"Treatment.Combination.Drug","text":"pyrilamine"},{"annotation":"Treatment.Combination.Drug","text":"pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"antiemetic combination of pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"antiemetic combination of pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":"Treatment.Combination.Drug","text":"pentobarbital and pyrilamine maleate"},{"annotation":""}]}]}
{"id":"868978_1","context":"Oculomotor disturbances associated with 5-fluorouracil chemotherapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"oculomotor disturbances"},{"annotation":"Treatment","text":"5-fluorouracil chemotherapy"},{"annotation":"Treatment.Disorder","text":"oculomotor disturbances"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"none"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"none"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"oculomotor disturbances"},{"annotation":"Treatment","text":"5-fluorouracil chemotherapy"},{"annotation":"Treatment.Disorder","text":"oculomotor disturbances"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"none"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"moderate"},{"annotation":"Attribute Attributes","text":"none"}]}]}
{"id":"18258513_1","context":"While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presented"},{"annotation":"Treatment","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Effect","text":"thoracic pain and breathing distress"},{"annotation":"Treatment.Device","text":"central catheter"},{"annotation":"Treatment.Device","text":"superior vena cava"},{"annotation":"Treatment.Device","text":"mediastinum"},{"annotation":"Treatment.Device","text":"extravasation"},{"annotation":"Treatment.Device","text":"drug"},{"annotation":"Treatment.Device","text":"perforation"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Dosage","text":"extravasation of the drug into the mediastinum"},{"annotation":"Treatment.Dosage","text":"doxorubicin"},{"annotation":"Treatment.Frequency","text":"while doxorubicin was administered"},{"annotation":"Treatment.Route","text":"central catheter"},{"annotation":"Treatment.Time_elapsed","text":"subsequent extravasation of the drug into the mediastinum"},{"annotation":"Treatment.Duration","text":"doxorubicin"},{"annotation":"Treatment.Disorder","text":"thoracic pain and breathing distress"},{"annotation":"Treatment.Disorder","text":"superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum"},{"annotation":"Treatment.Disorder","text":"extravasation of the drug into the mediastinum"},{"annotation":"Treatment.Disorder","text":"mediastinum"},{"annotation":"Treatment.Disorder","text":"doxorubicin"},{"annotation":"Treatment.Disorder","text":"superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum"},{"annotation":"Treatment.Disorder","text":"extravasation of the drug into the mediastinum"},{"annotation":"Treatment.Disorder","text":"mediastinum"},{"annotation":"Treatment.Disorder","text":"doxorubicin"},{"annotation":"Treatment.Disorder","text":"superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum"},{"annotation":"Treatment.Disorder","text":"extravasation of the drug into the mediastinum"},{"annotation":"Treatment.Disorder","text":"mediastinum"},{"annotation":"Treatment.Disorder","text":"doxorubicin"},{"annotation":"Treatment.Disorder","text":"superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum"},{"annotation":"Treatment.Disorder","text":"extravasation of the drug into the mediastinum"},{"annotation":"Treatment.Disorder","text":"mediastinum"},{"annotation":"Treatment.Disorder","text":"doxorub"}]}]}
{"id":"21802143_5","context":"An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"post-transplantation"},{"annotation":"Treatment","text":"TAC"},{"annotation":"Treatment.Drug","text":"TAC"},{"annotation":"Treatment.Disorder","text":"graft-versus-host disease (GVHD)"},{"annotation":"Treatment.Disorder","text":"anaplastic large cell lymphoma"},{"annotation":"Treatment.Disorder","text":"allogeneic bone marrow transplantation (BMT)"}]}]}
{"id":"10682234_1","context":"Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"akathisia"},{"annotation":"Treatment","text":"intravenous administration of levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Disorder","text":"interferon-alpha"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"refractory"},{"annotation":"Effect","text":"akathisia"},{"annotation":"Treatment","text":"intravenous administration of levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Disorder","text":"interferon-alpha"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"ameliorated"},{"annotation":"Effect","text":"akathisia"},{"annotation":"Treatment","text":"intravenous administration of levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Disorder","text":"interferon-alpha"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"akathisia"},{"annotation":"Treatment","text":"intravenous administration of levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Disorder","text":"interferon-alpha"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"refractory"},{"annotation":"Effect","text":"akathisia"},{"annotation":"Treatment","text":"intravenous administration of levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Disorder","text":"interferon-alpha"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"ameliorated"},{"annotation":"Effect","text":"akathisia"},{"annotation":"Treatment","text":"intravenous administration of levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Disorder","text":"interferon-alpha"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"akathisia"},{"annotation":"Treatment","text":"intravenous administration of levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Disorder","text":"interferon-alpha"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"refractory"},{"annotation":"Effect","text":"akathisia"},{"annotation":"Treatment","text":"intravenous administration of levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Disorder","text":"interferon-alpha"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"ameliorated"},{"annotation":"Effect","text":"akathisia"},{"annotation":"Treatment","text":"intravenous administration of levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Disorder","text":"interferon-alpha"}]}]}
{"id":"12567347_1","context":"Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"development"},{"annotation":"Effect","text":"cortical venous thrombosis"},{"annotation":"Treatment","text":"L-asparaginase and steroid"},{"annotation":"Treatment.Disorder","text":"lymphoblastic lymphoma"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"steroid"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"spec"}]}]}
{"id":"7783891_1","context":"Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"cause"},{"annotation":"Effect","text":"coronary artery vasospasm"},{"annotation":"Treatment","text":"sumatriptan"},{"annotation":"Treatment.Disorder","text":"coronary artery disease"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"}]}]}
{"id": "11563738_2","context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.","events": [{"type": "Adverse_event","annotations": [{"annotation": "Trigger","text": "found dead"},{"annotation": "Effect","text": "death"},{"annotation": "Treatment","text": "olanzapine"},{"annotation": "Treatment.Drug","text": "olanzapine"},{"annotation": "Treatment.Disorder","text": "schizophrenia"},{"annotation": "Subject","text": "a 25-year-old man"},{"annotation": "Subject.Age","text": "25 years"},{"annotation": "Subject.Gender","text": "not specified"},{"annotation": "Subject.Population","text": "1 man"},{"annotation": "Subject.Race","text": "not specified"},{"annotation": "Treatment.Drug","text": "olanzapine"},{"annotation": "Treatment.Dosage","text": "not specified"},{"annotation": "Treatment.Frequency","text": "not specified"},{"annotation": "Treatment.Route","text": "not specified"},{"annotation": "Treatment.Time_elapsed","text": "not specified"},{"annotation": "Treatment.Duration","text": "not specified"},{"annotation": "Treatment.Disorder","text": "schizophrenia"},{"annotation": "negated","text": "not specified"},{"annotation": "severity","text": "not specified"},{"annotation": "event_type","text": "Adverse_event"},{"annotation": "event_type","text": "Potential_therapeutic_effect"}]},{"type": "Potential_therapeutic_effect","annotations": [{"annotation": "Trigger","text": "prescribed"},{"annotation": "Treatment","text": "olanzapine"},{"annotation": "Treatment.Disorder","text": "schizophrenia"},{"annotation": "negated","text": "not specified"},{"annotation": "severity","text": "not specified"},{"annotation": "event_type","text": "Potential_therapeutic_effect"}]}]}
{"id":"7258204_1","context":"A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"oral ampicillin"},{"annotation":"Treatment.Drug","text":"ampicillin"},{"annotation":"Effect","text":"diarrhea"},{"annotation":"Treatment.Duration","text":"10-day course"},{"annotation":"Subject","text":"a 67-year-old man"},{"annotation":"Subject.Age","text":"67"},{"annotation":"Subject.Gender","text":"unknown"},{"annotation":"Subject.Population","text":"1 man"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"shortly after"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"none"},{"annotation":"Effect","text":"none"},{"annotation":"Treatment","text":"none"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"none"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"none"},{"annotation":"Treatment.Time_elapsed","text":"none"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"negated","text":"false"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"},{"annotation":"attribute","text":"none"}]}]}
{"id":"16216617_1","context":"Prominent positive U waves appearing with high-dose intravenous phenylephrine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"appearing"},{"annotation":"Effect","text":"positive U waves"},{"annotation":"Treatment","text":"high-dose intravenous phenylephrine"},{"annotation":"Treatment.Drug","text":"phenylephrine"},{"annotation":"Treatment.Side_effect","text":"positive U waves"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"high-dose intravenous phenylephrine"},{"annotation":"Treatment.Drug","text":"phenylephrine"},{"annotation":"Treatment.Side_effect","text":"positive U waves"}]}]}
{"id":"16620273_2","context":"Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"severe acidosis"},{"annotation":"Effect","text":"acidosis"},{"annotation":"Treatment","text":"metformin"},{"annotation":"Treatment.Drug","text":"metformin"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Event_type","text":"Adverse_event"},{"annotation":"Subject","text":"patients taking metformin"},{"annotation":"Subject.Disorder","text":"acidosis"}]}]}
{"id":"1868481_1","context":"Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Treatment","text":"intravenous pulse methylprednisolone"},{"annotation":"Treatment.Drug","text":"methylprednisolone"},{"annotation":"Effect","text":"seizures and transient blindness"},{"annotation":"Treatment","text":"children with primary glomerulonephritis"},{"annotation":"Treatment.Disorder","text":"primary glomerulonephritis"}]}]}
{"id":"16728538_4","context":"We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"combined treatment with octreotide and pegvisomant"},{"annotation":"Treatment.Disorder","text":"acromegalic"},{"annotation":"Treatment.Drug","text":"octreotide"},{"annotation":"Treatment.Drug","text":"pegvisomant"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"octreotide"},{"annotation":"Treatment.Combination.Drug","text":"pegvisomant"},{"annotation":"Subject","text":"a patient with acromegaly"},{"annotation":"Subject.Disorder","text":"acromegalic"}]}]}
{"id":"12851279_6","context":"The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"primary efficacy population"},{"annotation":"Treatment","text":"intravenous infusion of either tifacogin or placebo"},{"annotation":"Treatment.Disorder","text":"severe sepsis"},{"annotation":"Treatment.Disorder","text":"high INR"},{"annotation":"Treatment.Drug","text":"tifacogin"},{"annotation":"Treatment.Drug","text":"arginine citrate buffer"},{"annotation":"Treatment.Duration","text":"96 hours"},{"annotation":"Treatment.Dose","text":"0.025 mg/kg per hour"},{"annotation":"Treatment.Combination.Drug","text":"tifacogin"},{"annotation":"Treatment.Combination.Drug","text":"arginine citrate buffer"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"high INR"},{"annotation":"Treatment.Combination.Drug","text":"low INR"},{"annotation":"Subject","text":"1754 patients (> or =18 years) with severe sepsis and a high INR"},{"annotation":"Subject.Disorder","text":"severe sepsis"},{"annotation":"Subject.Disorder","text":"high INR"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"primary efficacy population"},{"annotation":"Treatment","text":"intravenous infusion of either tifacogin or placebo"},{"annotation":"Treatment.Disorder","text":"severe sepsis"},{"annotation":"Treatment.Disorder","text":"high INR"},{"annotation":"Treatment.Drug","text":"tifacogin"},{"annotation":"Treatment.Drug","text":"arginine citrate buffer"},{"annotation":"Treatment.Duration","text":"96 hours"},{"annotation":"Treatment.Dose","text":"0.025 mg/kg per hour"},{"annotation":"Treatment.Combination.Drug","text":"tifacogin"},{"annotation":"Treatment.Combination.Drug","text":"arginine citrate buffer"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"high INR"},{"annotation":"Treatment.Combination.Drug","text":"low INR"},{"annotation":"Subject","text":"1754 patients (> or =18 years) with"}]}]}
{"id":"20234160_3","context":"We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"anaphylactic reaction"},{"annotation":"Treatment","text":"vancomycin"},{"annotation":"Treatment.Disorder","text":"methicillin-resistant Staphylococcus aureus infection"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"methicillin"},{"annotation":"Treatment.Drug","text":"Staphylococcus aureus"},{"annotation":"Treatment.Drug","text":"resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Subject","text":"a 23-year-old man"},{"annotation":"Subject.Disorder","text":"methicillin-resistant Staphylococcus aureus infection"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"methicillin"},{"annotation":"Treatment.Drug","text":"Staphylococcus aureus"},{"annotation":"Treatment.Drug","text":"resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"Staphylococcus aureus"},{"annotation":"Treatment.Drug","text":"resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"},{"annotation":"Treatment.Drug","text":"methicillin-resistant"}]}]}
{"id":"19884751_2","context":"Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"took"},{"annotation":"Treatment","text":"cessation of Amikacin"},{"annotation":"Treatment.Drug","text":"Amikacin"},{"annotation":"Effect","text":"tubular dysfunction"},{"annotation":"Treatment.Duration","text":"15 days"},{"annotation":"Treatment.Disorder","text":"tubular dysfunction"}]}]}
{"id":"7139589_3","context":"L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"pancreatitis"},{"annotation":"Treatment","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Dosage","text":"during or closely following administration of the drug"},{"annotation":"Treatment.Frequency","text":"during or closely following administration of the drug"},{"annotation":"Treatment.Route","text":"during or closely following administration of the drug"},{"annotation":"Treatment.Time_elapsed","text":"during or closely following administration of the drug"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Disorder","text":"not specified"}]}]}
{"id":"15286697_3","context":"These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"These novel findings"},{"annotation":"Effect","text":"specific therapeutic targets"},{"annotation":"Treatment","text":"BCNU-associated pulmonary fibrosis"},{"annotation":"Treatment.Disorder","text":"BCNU-associated pulmonary fibrosis"}]}]}
{"id":"19212144_1","context":"A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"proteinuria"},{"annotation":"Treatment","text":"temsirolimus infusion"},{"annotation":"Treatment.Drug","text":"temsirolimus"},{"annotation":"Treatment.Duration","text":"five days"},{"annotation":"Treatment.Disorder","text":"advanced renal cell carcinoma"},{"annotation":"Subject","text":"58-year-old man"},{"annotation":"Subject.Disorder","text":"advanced renal cell carcinoma"},{"annotation":"Subject.Age","text":"58 years old"},{"annotation":"Subject.Gender","text":"male"},{"annotation":"Subject.Population","text":"1 man"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"proteinuria"},{"annotation":"Treatment","text":"temsirolimus infusion"},{"annotation":"Treatment.Drug","text":"temsirolimus"},{"annotation":"Treatment.Duration","text":"five days"},{"annotation":"Treatment.Disorder","text":"advanced renal cell carcinoma"},{"annotation":"Subject","text":"58-year-old man"},{"annotation":"Subject.Disorder","text":"advanced renal cell carcinoma"},{"annotation":"Subject.Age","text":"58 years old"},{"annotation":"Subject.Gender","text":"male"},{"annotation":"Subject.Population","text":"1 man"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"}]}]}
{"id":"9253492_1","context":"A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"presented"},{"annotation":"Effect","text":"episode resembling heat stroke"},{"annotation":"Treatment","text":"administration of zonisamide"},{"annotation":"Treatment.Drug","text":"zonisamide"},{"annotation":"Treatment.Disorder","text":"frontal lobe epilepsy"},{"annotation":"Subject","text":"a 2-year-old mentally retarded boy"},{"annotation":"Subject.Age","text":"2 years old"},{"annotation":"Subject.Gender","text":"mentally retarded boy"},{"annotation":"Subject.Disorder","text":"frontal lobe epilepsy"},{"annotation":"Treatment.Drug","text":"zonisamide"},{"annotation":"Treatment.Dosage","text":"during administration"},{"annotation":"Treatment.Route","text":"during administration"},{"annotation":"Treatment.Time_elapsed","text":"during administration"},{"annotation":"Treatment.Duration","text":"during administration"},{"annotation":"Treatment.Disorder","text":"frontal lobe epilepsy"},{"annotation":"Treatment.Drug","text":"zonisamide"},{"annotation":"Treatment.Dosage","text":"during administration"},{"annotation":"Treatment.Route","text":"during administration"},{"annotation":"Treatment.Time_elapsed","text":"during administration"},{"annotation":"Treatment.Duration","text":"during administration"},{"annotation":"Treatment.Disorder","text":"frontal lobe epilepsy"},{"annotation":"Treatment.Drug","text":"zonisamide"},{"annotation":"Treatment.Dosage","text":"during administration"},{"annotation":"Treatment.Route","text":"during administration"},{"annotation":"Treatment.Time_elapsed","text":"during administration"},{"annotation":"Treatment.Duration","text":"during administration"},{"annotation":"Treatment.Disorder","text":"frontal lobe epilepsy"},{"annotation":"Treatment.Drug","text":"zonisamide"},{"annotation":"Treatment.Dosage","text":"during administration"},{"annotation":"Treatment.Route","text":"during administration"},{"annotation":"Treatment.Time_elapsed","text":"during administration"},{"annotation":"Treatment.Duration","text":"during administration"},{"annotation":"Treatment.Disorder","text":"frontal lobe epilepsy"},{"annotation":"Treatment.Drug","text":"zonisamide"},{"annotation":"Treatment.Dosage","text":"during administration"},{"annotation":"Treatment.Route","text":"during administration"},{"annotation":"Treatment.Time_elapsed","text":"during administration"},{"annotation":"Treatment.Duration","text":"during administration"},{"annotation":"Treatment.Disorder","text":"frontal lobe epilepsy"},{"annotation":"Treatment.Drug","text":"zonisamide"},{"annotation":"Treatment.Dosage","text":"during administration"},{"annotation":"Treatment.Route","text":"during administration"},{"annotation":"Treatment.Time_elapsed","text":"during administration"},{"annotation":"Treatment.Duration","text":"during administration"},{"annotation":"Treatment.Disorder","text":"frontal lobe epilepsy"},{"annotation":"Treatment.Drug","text":"zonisamide"},{"annotation":"Treatment."}]}]}
{"id":"18166746_1","context":"Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"serotonin syndrome"},{"annotation":"Treatment","text":"methylene blue infusion during parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Disorder","text":"parathyroidectomy"},{"annotation":"Treatment.Duration","text":"during"},{"annotation":"Treatment.Drug","text":"parathyroidectomy"},{"annotation":"Treatment.Drug","text":"methylene blue"},{"annotation":"Treatment.Route","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"parathyroidectomy"},{"annotation":"Treatment.Time_elapsed","text":"during"},{"annotation":"Treatment.Time_elapsed","text":"parathyroidectomy"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"during"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"infusion"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"T"}]}]}
{"id":"868978_3","context":"Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"cerebellar dysfunction"},{"annotation":"Treatment","text":"5-fluorouracil (5-FU)"},{"annotation":"Treatment.Disorder","text":"disseminated adenocarcinoma of the colon"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Duration","text":"for"},{"annotation":"Treatment.Duration","text":"disseminated adenocarcinoma of the colon"},{"annotation":"Treatment.Dosage","text":"5-FU"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"neg"}]}]}
{"id":"11510798_4","context":"Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"negative"},{"annotation":"Treatment","text":"corticosteroids"},{"annotation":"Treatment.Disorder","text":"clinical and radiological abnormalities"},{"annotation":"Effect","text":"remission"}]}]}
{"id":"9886213_1","context":"Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"cysticercosis with myositis"},{"annotation":"Treatment","text":"praziquantel therapy"},{"annotation":"Treatment.Disorder","text":"disseminated muscular cysticercosis"},{"annotation":"Treatment.Drug","text":"praziquantel"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treatment.Dosage","text":"dosage not specified"},{"annotation":"Treat"}]}]}
{"id": "172214_1", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "events": [{"type": "Adverse_event", "annotations": [{"annotation": "Trigger", "text": "exacerbated"}, {"annotation": "Effect", "text": "cardiomyopathy"}, {"annotation": "Treatment", "text": "adriamycin"}, {"annotation": "Treatment.Disorder", "text": "cardiomyopathy"}, {"annotation": "Treatment.Drug", "text": "actinomycin-D"}, {"annotation": "Treatment.Drug", "text": "mithramycin"}, {"annotation": "Treatment.Combination.Trigger", "text": "and"}, {"annotation": "Treatment.Combination.Drug", "text": "actinomycin-D"}, {"annotation": "Treatment.Combination.Drug", "text": "mithramycin"}, {"annotation": "Subject", "text": "a patient"}, {"annotation": "Subject.Disorder", "text": "cardiomyopathy"}, {"annotation": "Treatment.Combination.Drug", "text": "adriamycin"}]}]}
{"id":"11485141_3","context":"Linear immunoglobulin A bullous dermatosis induced by gemcitabine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"bullous dermatosis"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Treatment.Disorder","text":"linear immunoglobulin A bullous dermatosis"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Response"},{"annotation":"Treatment","text":"gemcitabine"},{"annotation":"Treatment.Disorder","text":"linear immunoglobulin A bullous dermatosis"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"10573314_12","context":"The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"elevated"},{"annotation":"Effect","text":"INR"},{"annotation":"Treatment","text":"tolterodine"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Duration","text":"course"},{"annotation":"Treatment.Duration","text":"previous warfarin dose-INR response relationship"},{"annotation":"Treatment.Duration","text":"return"},{"annotation":"Treatment.Duration","text":"discontinuation"},{"annotation":"Treatment.Duration","text":"absence"},{"annotation":"Attribute","text":"other causes for the elevated INR were found in both patients"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"return"},{"annotation":"Treatment","text":"tolterodine discontinuation"},{"annotation":"Treatment.Disorder","text":"elevated INR"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Duration","text":"previous warfarin dose-INR response relationship"},{"annotation":"Attribute","text":"return"},{"annotation":"Attribute","text":"absence"},{"annotation":"Attribute","text":"other causes for the elevated INR were found in both patients"}]}]}
{"id":"15461766_2","context":"The harlequin color change and association with prostaglandin E1.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"color change"},{"annotation":"Effect","text":"harlequin color change"},{"annotation":"Treatment","text":"prostaglandin E1"},{"annotation":"Treatment.Drug","text":"prostaglandin E1"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes.negated","text":"not negated"}]}]}
{"id":"19336028_1","context":"A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"tuberculosis"},{"annotation":"Treatment","text":"Efalizumab and Etanercept"},{"annotation":"Treatment.Disorder","text":"refractory palmopustular psoriasis and psoriatic arthritis"},{"annotation":"Treatment.Drug","text":"Efalizumab"},{"annotation":"Treatment.Drug","text":"Etanercept"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"Efalizumab"},{"annotation":"Treatment.Combination.Drug","text":"Etanercept"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"refractory palmopustular psoriasis and psoriatic arthritis"}]}]}
{"id":"10225085_1","context":"Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"development of"},{"annotation":"Effect","text":"methemoglobinemia"},{"annotation":"Treatment","text":"local anesthetics"},{"annotation":"Treatment.Drug","text":"lidocaine"},{"annotation":"Treatment.Drug","text":"bupivacaine"},{"annotation":"Treatment.Combination.Trigger","text":"in combination with"},{"annotation":"Treatment.Combination.Drug","text":"metabolic acidosis"},{"annotation":"Treatment.Combination.Drug","text":"other oxidants"},{"annotation":"Subject","text":"patients"},{"annotation":"Subject.Disorder","text":"methemoglobinemia"}]}]}
{"id":"6851259_1","context":"Nephrotic range pseudoproteinuria in a tolmetin-treated patient.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"pseudoproteinuria"},{"annotation":"Treatment","text":"tolmetin"},{"annotation":"Treatment.Drug","text":"tolmetin"},{"annotation":"Treatment.Disorder","text":"nephrotic range pseudoproteinuria"},{"annotation":"Treatment.Drug","text":"tolmetin"}]}]}
{"id":"19318596_4","context":"With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"first dose"},{"annotation":"Treatment","text":"cyclosporine"},{"annotation":"Treatment.Drug","text":"cyclosporine"},{"annotation":"Effect","text":"leg pain"},{"annotation":"Treatment.Route","text":"infusion"},{"annotation":"Treatment.Frequency","text":"first dose"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Disorder","text":"cyclosporine-induced leg pain"},{"annotation":"Treatment.Duration","text":"cyclosporine dose"}]}]}
{"id":"15811174_3","context":"We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"acute rhabdomyolysis"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"cerivastatin"},{"annotation":"Treatment.Drug","text":"cerivastatin"},{"annotation":"Treatment.Disorder","text":"acute rhabdomyolysis"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Age","text":"acute"},{"annotation":"Subject.Disorder","text":"acute rhabdomyolysis"},{"annotation":"Treatment.Drug","text":"cerivastatin"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"}]}]}
{"id":"8124920_2","context":"In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurrence"},{"annotation":"Treatment","text":"low-dose methotrexate"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Side_effect","text":"acute megaloblastic anaemia"},{"annotation":"Treatment.Side_effect","text":"pneumonitis"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"rheumatoid arthritis"}]}]}
{"id":"11109149_3","context":"We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"progressing"},{"annotation":"Treatment","text":"combined chemotherapy (bleomycin and methotrexate)"},{"annotation":"Treatment.Disorder","text":"metastatic squamous cell carcinoma of the hypopharynx"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"combination"},{"annotation":"Subject","text":"a 57-year-old man"},{"annotation":"Subject.Disorder","text":"acral erythrocyanosis"},{"annotation":"Subject.Disorder","text":"acute digital ischemia"},{"annotation":"Subject.Disorder","text":"gangrene"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"progressing"},{"annotation":"Treatment","text":"combined chemotherapy (bleomycin and methotrexate)"},{"annotation":"Treatment.Disorder","text":"metastatic squamous cell carcinoma of the hypopharynx"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"combination"},{"annotation":"Subject","text":"a 57-year-old man"},{"annotation":"Subject.Disorder","text":"acral erythrocyanosis"},{"annotation":"Subject.Disorder","text":"acute digital ischemia"},{"annotation":"Subject.Disorder","text":"gangrene"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"progressing"},{"annotation":"Treatment","text":"combined chemotherapy (bleomycin and methotrexate)"},{"annotation":"Treatment.Disorder","text":"metastatic squamous cell carcinoma of the hypopharynx"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"combination"},{"annotation":"Subject","text":"a 57-year-old man"},{"annotation":"Subject.Disorder","text":"acral erythrocyanosis"},{"annotation":"Subject.Disorder","text":"acute digital ischemia"},{"annotation":"Subject.Disorder","text":"gangrene"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"progressing"},{"annotation":"Treatment","text":"combined chemotherapy (bleomycin and methotrexate)"},{"annotation":"Treatment.Disorder","text":"metastatic squamous cell carcinoma of the hypopharynx"},{"annotation":"Treatment.Drug","text":"bleomycin"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"combination"},{"annotation":"Subject","text":"a 57-year-old man"},{"annotation":"Subject"}]}]}
{"id":"2719905_2","context":"We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"intravenous administration of morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Effect","text":"respiratory depression"},{"annotation":"Treatment.Dosage","text":"long lasting"},{"annotation":"Treatment.Duration","text":"respiratory depression"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Subject","text":"7 year old girl with haemolytic uraemic syndrome"},{"annotation":"Subject.Disorder","text":"haemolytic uraemic syndrome"}]}]}
{"id":"18071101_1","context":"Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Effect","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Effect","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Effect","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Effect","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Effect","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Effect","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Effect","text":"leucocytopenia and thrombocytopenia"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":""}]}]}
{"id":"3720318_1","context":"Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"during"},{"annotation":"Effect","text":"pulmonary edema"},{"annotation":"Treatment","text":"intrabiliary infusion of mono-octanoin"},{"annotation":"Treatment.Disorder","text":"noncardiogenic pulmonary edema"},{"annotation":"Treatment.Drug","text":"mono-octanoin"}]}]}
{"id":"589261_1","context":"Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"prevent"},{"annotation":"Treatment","text":"cardiac glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"digoxin"},{"annotation":"Treatment.Drug","text":"ouabain"},{"annotation":"Treatment.Drug","text":"doxorubicin cardiomyopathy"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin cardiomyopathy"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin cardiomyopathy"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin cardiomyopathy"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin cardiomyopathy"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin cardiomyopathy"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin cardiomyopathy"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin cardiomyopathy"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Drug","text":"glycosides"},{"annotation":"Treatment.Drug","text":"doxorubicin cardiomyopathy"},{"annotation":"Treatment.Drug","text":"glycosides"}]}]}
{"id":"18262450_7","context":"Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"diabetic neuropathy"},{"annotation":"Effect","text":"painful"},{"annotation":"Treatment","text":"gabapentin"},{"annotation":"Treatment.Drug","text":"oxycodone"},{"annotation":"Treatment.Drug","text":"placebo"},{"annotation":"Treatment.Dosage","text":"maximum tolerated dose"},{"annotation":"Treatment.Duration","text":"12 weeks"},{"annotation":"Treatment.Disease_state","text":"diabetic neuropathy"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Treatment.Drug","text":"oxycodone"},{"annotation":"Treatment.Drug","text":"placebo"},{"annotation":"Treatment.Dosage","text":"maximum tolerated dose"},{"annotation":"Treatment.Duration","text":"12 weeks"},{"annotation":"Treatment.Disease_state","text":"diabetic neuropathy"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Treatment.Drug","text":"oxycodone"},{"annotation":"Treatment.Drug","text":"placebo"},{"annotation":"Treatment.Dosage","text":"maximum tolerated dose"},{"annotation":"Treatment.Duration","text":"12 weeks"},{"annotation":"Treatment.Disease_state","text":"diabetic neuropathy"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Treatment.Drug","text":"oxycodone"},{"annotation":"Treatment.Drug","text":"placebo"},{"annotation":"Treatment.Dosage","text":"maximum tolerated dose"},{"annotation":"Treatment.Duration","text":"12 weeks"},{"annotation":"Treatment.Disease_state","text":"diabetic neuropathy"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Treatment.Drug","text":"oxycodone"},{"annotation":"Treatment.Drug","text":"placebo"},{"annotation":"Treatment.Dosage","text":"maximum tolerated dose"},{"annotation":"Treatment.Duration","text":"12 weeks"},{"annotation":"Treatment.Disease_state","text":"diabetic neuropathy"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Treatment.Drug","text":"oxycodone"},{"annotation":"Treatment.Drug","text":"placebo"},{"annotation":"Treatment.Dosage","text":"maximum tolerated dose"},{"annotation":"Treatment.Duration","text":"12 weeks"},{"annotation":"Treatment.Disease_state","text":"diabetic neuropathy"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Treatment.Drug","text":"oxycodone"},{"annotation":"Treatment.Drug","text":"placebo"},{"annotation":"Treatment.Dosage","text":"maximum tolerated dose"},{"annotation":"Treatment.Duration","text":"12 weeks"},{"annotation":"Treatment.Disease_"}]}]}
{"id":"22552763_4","context":"We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"bleeding risk"},{"annotation":"Effect","text":"bleeding"},{"annotation":"Treatment","text":"thromboprophylactic dabigatran etexilate"},{"annotation":"Treatment.Drug","text":"NSAID"},{"annotation":"Treatment.Drug","text":"ASA"},{"annotation":"Treatment.Drug","text":"thromboprophylactic dabigatran etexilate"},{"annotation":"Treatment.Disorder","text":"bleeding risk"},{"annotation":"Treatment.Drug","text":"NSAID"},{"annotation":"Treatment.Drug","text":"ASA"},{"annotation":"Treatment.Disorder","text":"bleeding risk"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"negated","text":"no textual cues showing the event is negated"},{"annotation":"speculated","text":"uncertain or speculation as to whether an event will actually happen"},{"annotation":"severity","text":"not annotated for PTE events"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"negated","text":"not annotated for PTE events"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"negated","text":"not annotated for PTE events"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"negated","text":"not annotated for PTE events"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"negated","text":"not annotated for PTE events"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"negated","text":"not annotated for PTE events"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"negated","text":"not annotated for PTE events"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"negated","text":"not annotated for PTE events"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"negated","text":"not annotated for PTE events"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"negated","text":"not annotated for PTE events"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"negated","text":"not annotated for PTE events"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"}]}]}
{"id":"2532694_2","context":"Dapsone-induced erythroderma with Beau's lines.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erythroderma"},{"annotation":"Treatment","text":"dapsone"},{"annotation":"Treatment.Drug","text":"dapsone"},{"annotation":"Treatment.Disorder","text":"erythroderma"},{"annotation":"Treatment.Drug","text":"Beau's lines"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erythroderma"},{"annotation":"Treatment","text":"dapsone"},{"annotation":"Treatment.Drug","text":"dapsone"},{"annotation":"Treatment.Disorder","text":"erythroderma"},{"annotation":"Treatment.Drug","text":"Beau's lines"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erythroderma"},{"annotation":"Treatment","text":"dapsone"},{"annotation":"Treatment.Drug","text":"dapsone"},{"annotation":"Treatment.Disorder","text":"erythroderma"},{"annotation":"Treatment.Drug","text":"Beau's lines"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erythroderma"},{"annotation":"Treatment","text":"dapsone"},{"annotation":"Treatment.Drug","text":"dapsone"},{"annotation":"Treatment.Disorder","text":"erythroderma"},{"annotation":"Treatment.Drug","text":"Beau's lines"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erythroderma"},{"annotation":"Treatment","text":"dapsone"},{"annotation":"Treatment.Drug","text":"dapsone"},{"annotation":"Treatment.Disorder","text":"erythroderma"},{"annotation":"Treatment.Drug","text":"Beau's lines"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erythroderma"},{"annotation":"Treatment","text":"dapsone"},{"annotation":"Treatment.Drug","text":"dapsone"},{"annotation":"Treatment.Disorder","text":"erythroderma"},{"annotation":"Treatment.Drug","text":"Beau's lines"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erythroderma"},{"annotation":"Treatment","text":"dapsone"},{"annotation":"Treatment.Drug","text":"dapsone"},{"annotation":"Treatment.Disorder","text":"erythroderma"},{"annotation":"Treatment.Drug","text":"Beau's lines"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erythroderma"},{"annotation":"Treatment"}]}]}
{"id":"9870779_2","context":"Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hepatic necrosis"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis does not exist."}]}]}
{"id":"15516308_3","context":"We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"suicidal overdose deaths"},{"annotation":"Effect","text":"deaths"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"suicide"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"suicidal overdose deaths"},{"annotation":"Effect","text":"deaths"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"suicide"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"2830062_3","context":"Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"hypoadrenalism"},{"annotation":"Treatment","text":"o,p'-DDD and dexamethasone replacement therapy"},{"annotation":"Treatment.Disorder","text":"hypoadrenalism"},{"annotation":"Treatment.Drug","text":"o,p'-DDD"},{"annotation":"Treatment.Drug","text":"dexamethasone"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"o,p'-DDD"},{"annotation":"Treatment.Combination.Drug","text":"dexamethasone"},{"annotation":"Subject","text":"both patients"},{"annotation":"Subject.Disorder","text":"hypoadrenalism"}]}]}
{"id":"16046172_1","context":"In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"arthritis"},{"annotation":"Treatment","text":"single sodium hyaluronate injection"},{"annotation":"Treatment.Drug","text":"sodium hyaluronate"},{"annotation":"Treatment.Disorder","text":"knee arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Dosage","text":"single"},{"annotation":"Treatment.Dosage","text":"injection"},{"annotation":"Treatment.Dosage","text":"sodium hyaluronate"},{"annotation":"Treatment.Dosage","text":"arthritis"},{"annotation":"Treatment.Dosage","text":"injection"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{"annotation":"Treatment.Drug","text":"arthritis"},{}]}]}
{"id": "21729965_1","context": "Implanon failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.","events": [{"type": "Adverse_event","annotations": [{"annotation": "Treatment","text": "Implanon"},{"annotation": "Treatment.Drug","text": "Implanon"},{"annotation": "Treatment.Dosage","text": "failure"},{"annotation": "Effect","text": "two ectopic pregnancies"},{"annotation": "Treatment.Disorder","text": "HIV-positive woman"},{"annotation": "Treatment.Disorder","text": "antiretroviral therapy"},{"annotation": "Treatment.Combination","text": "Implanon"},{"annotation": "Treatment.Combination","text": "antiretroviral therapy"},{"annotation": "Treatment.Combination.Trigger","text": "resulting"},{"annotation": "Treatment.Combination.Drug","text": "Implanon"},{"annotation": "Treatment.Combination.Drug","text": "antiretroviral therapy"},{"annotation": "Treatment.Combination.Drug","text": "antiretroviral therapy"},{"annotation": "Treatment.Disorder","text": "HIV-positive woman"},{"annotation": "Treatment.Disorder","text": "antiretroviral therapy"},{"annotation": "Treatment.Disorder","text": "HIV-positive woman"},{"annotation": "Treatment.Disorder","text": "antiretroviral therapy"},{"annotation": "Treatment.Disorder","text": "HIV-positive woman"},{"annotation": "Treatment.Disorder","text": "antiretroviral therapy"},{"annotation": "Treatment.Disorder","text": "HIV-positive woman"},{"annotation": "Treatment.Disorder","text": "antiretroviral therapy"},{"annotation": "Treatment.Disorder","text": "HIV-positive woman"},{"annotation": "Treatment.Disorder","text": "antiretroviral therapy"},{"annotation": "Treatment.Disorder","text": "HIV-positive woman"},{"annotation": "Treatment.Disorder","text": "antiretroviral therapy"},{"annotation": "Treatment.Disorder","text": "HIV-positive woman"},{"annotation": "Treatment.Disorder","text": "antiretroviral therapy"},{"annotation": "Treatment.Disorder","text": "HIV-positive woman"},{"annotation": "Treatment.Disorder","text": "antiretroviral therapy"},{"annotation": "Treatment.Disorder","text": "HIV-positive woman"},{"annotation": "Treatment.Disorder","text": "antiretroviral therapy"},{"annotation": "Treatment.Disorder","text": ""}]}]}
{"id":"16341621_1","context":"Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Treatment","text":"periurethral injection of calcium hydroxylapatite for stress urinary incontinence"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Drug","text":"stress urinary incontinence"},{"annotation":"Treatment.Route","text":"periurethral injection"},{"annotation":"Treatment.Time_elapsed","text":"massive prolapse of the urethral mucosa"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"stress urinary incontinence"},{"annotation":"Effect","text":"massive prolapse of the urethral mucosa"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"massive prolapse of the urethral mucosa"},{"annotation":"Treatment","text":"stress urinary incontinence"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Route","text":"periurethral injection"},{"annotation":"Treatment.Time_elapsed","text":"massive prolapse of the urethral mucosa"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"stress urinary incontinence"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Route","text":"periurethral injection"},{"annotation":"Treatment.Time_elapsed","text":"massive prolapse of the urethral mucosa"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"stress urinary incontinence"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Route","text":"periurethral injection"},{"annotation":"Treatment.Time_elapsed","text":"massive prolapse of the urethral mucosa"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"stress urinary incontinence"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Route","text":"periurethral injection"},{"annotation":"Treatment.Time_elapsed","text":"massive prolapse of the urethral mucosa"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"stress urinary incontinence"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{"annotation":"Treatment.Route","text":"periurethral injection"},{"annotation":"Treatment.Time_elapsed","text":"massive prolapse of the urethral mucosa"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"stress urinary incontinence"},{"annotation":"Treatment.Drug","text":"calcium hydroxylapatite"},{}]}]}
{"id":"2532694_1","context":"A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erythroderma"},{"annotation":"Treatment","text":"dapsone"},{"annotation":"Treatment.Drug","text":"dapsone"},{"annotation":"Treatment.Disorder","text":"borderline leprosy"},{"annotation":"Subject","text":"a 35-year-old female"},{"annotation":"Subject.Age","text":"35 years old"},{"annotation":"Subject.Gender","text":"female"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Drug","text":"dapsone"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"borderline leprosy"},{"annotation":"Effect","text":"erythroderma"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"response"},{"annotation":"Treatment","text":"dapsone"},{"annotation":"Treatment.Disorder","text":"borderline leprosy"},{"annotation":"Treatment.Drug","text":"dapsone"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"8912599_8","context":"Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"toxicity"},{"annotation":"Treatment.Drug","text":"bone marrow suppression"},{"annotation":"Treatment.Drug","text":"oral and gastrointestinal ulceration"}]}]}
{"id":"18755414_1","context":"Hemorrhage from a falx meningioma after internal use of low-dose aspirin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"hemorrhage"},{"annotation":"Effect","text":"falx meningioma"},{"annotation":"Treatment","text":"internal use of low-dose aspirin"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"low-dose"},{"annotation":"Treatment.Drug","text":"internal"},{"annotation":"Treatment.Disorder","text":"falx meningioma"},{"annotation":"Treatment.Disorder","text":"meningioma"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"meningioma"}]}]}
{"id":"9671138_2","context":"Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"infection"},{"annotation":"Treatment","text":"fludarabine"},{"annotation":"Treatment.Drug","text":"fludarabine"},{"annotation":"Effect","text":"respiratory syncytial virus pulmonary infection"},{"annotation":"Treatment.Disorder","text":"chronic lymphocytic leukemia"},{"annotation":"Treatment.Disorder","text":"respiratory syncytial virus pulmonary infection"},{"annotation":"Treatment.Drug","text":"fludarabine"},{"annotation":"Treatment.Drug","text":"respiratory syncytial virus pulmonary infection"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"chronic lymphocytic leukemia"},{"annotation":"Subject.Disorder","text":"respiratory syncytial virus pulmonary infection"}]}]}
{"id":"9149614_2","context":"Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"polymorphous ventricular tachycardia"},{"annotation":"Treatment","text":"amiodarone therapy for atrial fibrillation complicating cardiomyopathy"},{"annotation":"Treatment.Disorder","text":"atrial fibrillation complicating cardiomyopathy"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"during therapy"},{"annotation":"Treatment.Frequency","text":"nonsustained"},{"annotation":"Treatment.Route","text":"during therapy"},{"annotation":"Treatment.Time_elapsed","text":"during therapy"},{"annotation":"Treatment.Duration","text":"during therapy"},{"annotation":"Treatment.Disorder","text":"atrial fibrillation"},{"annotation":"Treatment.Drug","text":"amiodarone"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"polymorphous ventricular tachycardia"},{"annotation":"Treatment","text":"amiodarone therapy for atrial fibrillation complicating cardiomyopathy"},{"annotation":"Treatment.Disorder","text":"atrial fibrillation complicating cardiomyopathy"},{"annotation":"Treatment.Drug","text":"amiodarone"},{"annotation":"Treatment.Dosage","text":"during therapy"},{"annotation":"Treatment.Frequency","text":"nonsustained"},{"annotation":"Treatment.Route","text":"during therapy"},{"annotation":"Treatment.Time_elapsed","text":"during therapy"},{"annotation":"Treatment.Duration","text":"during therapy"},{"annotation":"Treatment.Disorder","text":"atrial fibrillation"},{"annotation":"Treatment.Drug","text":"amiodarone"}]}]}
{"id":"8316494_1","context":"Severe abdominal pain in low dosage clofazimine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"low dosage clofazimine"},{"annotation":"Treatment.Drug","text":"clofazimine"},{"annotation":"Treatment.Effect","text":"abdominal pain"},{"annotation":"Treatment.Dosage","text":"low dosage"},{"annotation":"Treatment.Severity","text":"severe"}]}]}
{"id":"12908837_1","context":"Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"may include"},{"annotation":"Treatment","text":"clonazepam"},{"annotation":"Treatment.Drug","text":"clonazepam"},{"annotation":"Effect","text":"behavioral side effects"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"behavioral side effects"},{"annotation":"Effect","text":"agitation"},{"annotation":"Treatment","text":"clonazepam"},{"annotation":"Treatment.Drug","text":"clonazepam"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute.negated","text":"none"},{"annotation":"Attribute.negated","text":"none"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.severity","text":"low"}]}]}
{"id":"6671350_2","context":"Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with the use of"},{"annotation":"Treatment","text":"cephalosporin or moxalactam antibiotics"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Drug","text":"moxalactam"},{"annotation":"Treatment.Disorder","text":"acute and chronic renal failure"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Drug","text":"moxalactam"},{"annotation":"Treatment.Drug","text":"cephalosporin or moxalactam antibiotics"},{"annotation":"Treatment.Disorder","text":"acute and chronic renal failure"},{"annotation":"Treatment.Drug","text":"cephalosporin or moxalactam antibiotics"},{"annotation":"Effect","text":"coagulopathy"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with the use of"},{"annotation":"Treatment","text":"cephalosporin or moxalactam antibiotics"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Drug","text":"moxalactam"},{"annotation":"Treatment.Disorder","text":"acute and chronic renal failure"},{"annotation":"Treatment.Drug","text":"cephalosporin"},{"annotation":"Treatment.Drug","text":"moxalactam"},{"annotation":"Treatment.Drug","text":"cephalosporin or moxalactam antibiotics"},{"annotation":"Treatment.Disorder","text":"acute and chronic renal failure"},{"annotation":"Treatment.Drug","text":"cephalosporin or moxalactam antibiotics"},{"annotation":"Effect","text":"coagulopathy"}]}]}
{"id":"9865241_2","context":"Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"secondary to acute vitamin D poisoning"},{"annotation":"Disorder","text":"hypercalcemia"},{"annotation":"Treatment","text":"pamidronate therapy"},{"annotation":"Treatment.Drug","text":"pamidronate"},{"annotation":"Treatment.Dosage","text":"should be considered"},{"annotation":"Treatment.Duration","text":"for patients with hypercalcemia"}]}]}
{"id":"17090724_3","context":"Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"observed"},{"annotation":"Effect","text":"cardiac toxicity"},{"annotation":"Treatment","text":"amphotericin B deoxycholate therapy"},{"annotation":"Treatment.Drug","text":"amphotericin B deoxycholate"},{"annotation":"Attribute Attributes","text":"highly probable relationship"},{"annotation":"Attribute Attributes","text":"Naranjo probability scale"}]}]}
{"id":"16132305_1","context":"Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"pulmonary infiltrates with eosinophilia"},{"annotation":"Treatment","text":"captopril"},{"annotation":"Treatment.Disorder","text":"congenital heart disease"},{"annotation":"Treatment.Drug","text":"captopril"},{"annotation":"Treatment.Drug","text":"eosinophilia"},{"annotation":"Subject","text":"an infant"},{"annotation":"Subject.Disorder","text":"congenital heart disease"}]}]}
{"id":"15836666_1","context":"Chronic fentanyl application induces adrenocortical insufficiency.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induces"},{"annotation":"Effect","text":"adrenocortical insufficiency"},{"annotation":"Treatment","text":"chronic fentanyl application"},{"annotation":"Treatment.Drug","text":"fentanyl"},{"annotation":"Treatment.Dosage","text":"chronic"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"adrenocortical insufficiency"},{"annotation":"Treatment","text":"chronic fentanyl application"},{"annotation":"Treatment.Disorder","text":"adrenocortical insufficiency"},{"annotation":"Treatment.Drug","text":"fentanyl"}]}]}
{"id":"16132305_5","context":"After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.","events":[{"type":"Potential_therapeutic_event","annotations":[{"annotation":"Trigger","text":"discontinuing captopril and starting systemic steroids"},{"annotation":"Treatment","text":"systemic steroids"},{"annotation":"Treatment.Disorder","text":"symptomatology"},{"annotation":"Treatment.Drug","text":"captopril"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"rapidly improved"},{"annotation":"Effect","text":"resolved"},{"annotation":"Treatment","text":"systemic steroids"},{"annotation":"Treatment.Disorder","text":"eosinophilia"},{"annotation":"Treatment.Drug","text":"systemic steroids"},{"annotation":"Treatment.Drug","text":"captopril"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"12927328_1","context":"We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"suffering"},{"annotation":"Effect","text":"EPS"},{"annotation":"Treatment","text":"clozapine"},{"annotation":"Treatment.Drug","text":"clozapine"},{"annotation":"Subject","text":"a woman schizophrenic patient"},{"annotation":"Subject.Disorder","text":"schizophrenic"}]}]}
{"id":"17016002_3","context":"Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"pulmonary disease"},{"annotation":"Effect","text":"caused by"},{"annotation":"Treatment","text":"antihistaminic drug"},{"annotation":"Treatment.Drug","text":"calcium stearate"},{"annotation":"Treatment.Drug","text":"antihistaminic drug"},{"annotation":"Treatment.Disorder","text":"pulmonary disease"},{"annotation":"Treatment.Drug","text":"calcium stearate"}]}]}
{"id":"3343188_2","context":"Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"methemoglobinemia"},{"annotation":"Treatment","text":"benzocaine"},{"annotation":"Treatment.Drug","text":"benzocaine"},{"annotation":"Treatment.Species","text":"man, dogs, cats"}]}]}
{"id":"8151270_3","context":"We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"fulminant hepatic failure"},{"annotation":"Treatment","text":"didanosine (ddI)"},{"annotation":"Treatment.Disorder","text":"HIV-1 infection"},{"annotation":"Treatment.Drug","text":"didanosine"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"HIV-1 infection"},{"annotation":"Treatment.Drug","text":"didanosine (ddI)"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"fulminant hepatic failure"},{"annotation":"Treatment","text":"didanosine (ddI)"},{"annotation":"Treatment.Disorder","text":"HIV-1 infection"},{"annotation":"Treatment.Drug","text":"didanosine"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"HIV-1 infection"},{"annotation":"Treatment.Drug","text":"didanosine (ddI)"}]}]}
{"id":"11352235_2","context":"Leflunomide-associated weight loss in rheumatoid arthritis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Effect","text":"weight loss"},{"annotation":"Treatment","text":"leflunomide"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"leflunomide"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"low severity"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"low severity"}]}]}
{"id":"11450788_1","context":"Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hepatic steatosis and lactic acidosis"},{"annotation":"Treatment","text":"antiretroviral therapy"},{"annotation":"Treatment.Disorder","text":"antiretroviral-induced hepatic steatosis and lactic acidosis"},{"annotation":"Treatment.Drug","text":"antiretroviral therapy"},{"annotation":"Treatment.Drug","text":"antiretroviral therapy"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"antiretroviral therapy"},{"annotation":"Treatment.Combination.Drug","text":"antiretroviral therapy"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Disorder","text":"antiretroviral-induced hepatic steatosis and lactic acidosis"}]}]}
{"id":"1756352_1","context":"A woman developed delusional parasitosis when taking phenelzine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"phenelzine"},{"annotation":"Treatment.Drug","text":"phenelzine"},{"annotation":"Effect","text":"delusional parasitosis"},{"annotation":"Treatment.Disorder","text":"delusional parasitosis"}]}]}
{"id":"8308951_4","context":"Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"absorption"},{"annotation":"Treatment","text":"warfarin"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Effect","text":"coagulopathy"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Drug","text":"coagulopathy"},{"annotation":"Treatment.Combination.Trigger","text":"caused by"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Treatment.Combination.Drug","text":"coagulopathy"},{"annotation":"Subject","text":"three times in the past"},{"annotation":"Subject.Age","text":"past"},{"annotation":"Subject.Disorder","text":"coagulopathy"},{"annotation":"Treatment.Precaution","text":"protective measures"},{"annotation":"Treatment.Precaution","text":"gloves"},{"annotation":"Treatment.Precaution","text":"warfarin"},{"annotation":"Treatment.Precaution","text":"coagulopathy"},{"annotation":"Treatment.Precaution","text":"protective measures"},{"annotation":"Treatment.Precaution","text":"gloves"},{"annotation":"Treatment.Precaution","text":"warfarin"},{"annotation":"Treatment.Precaution","text":"coagulopathy"},{"annotation":"Treatment.Precaution","text":"protective measures"},{"annotation":"Treatment.Precaution","text":"gloves"},{"annotation":"Treatment.Precaution","text":"warfarin"},{"annotation":"Treatment.Precaution","text":"coagulopathy"},{"annotation":"Treatment.Precaution","text":"protective measures"},{"annotation":"Treatment.Precaution","text":"gloves"},{"annotation":"Treatment.Precaution","text":"warfarin"},{"annotation":"Treatment.Precaution","text":"coagulopathy"},{"annotation":"Treatment.Precaution","text":"protective measures"},{"annotation":"Treatment.Precaution","text":"gloves"},{"annotation":"Treatment.Precaution","text":"warfarin"},{"annotation":"Treatment.Precaution","text":"coagulopathy"},{"annotation":"Treatment.Precaution","text":"protective measures"},{"annotation":"Treatment.Precaution","text":"gloves"},{"annotation":"Treatment.Precaution","text":"warfarin"},{"annotation":"Treatment.Precaution","text":"coagulopathy"},{"annotation":"Treatment.Precaution","text":"protective measures"},{"annotation":"Treatment.Precaution","text":"gloves"},{"annotation":"Treatment.Precaution","text":"warfarin"},{"annotation":"Treatment.Precaution","text":"coagulopathy"},{"annotation":"Treatment.Precaution","text":"protective measures"},{"annotation":"Treatment.Precaution","text":"gloves"},{"annotation":"Treatment.Precaution","text":"warfarin"},{"annotation":"Treatment.Precaution","text":"coagulopathy"},{"annotation":""}]}]}
{"id":"10752888_2","context":"We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"pulmonary toxicity"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Effect","text":"fibrosis"},{"annotation":"Effect","text":"reticular pattern"},{"annotation":"Event_type","text":"Adverse_event"},{"annotation":"Subject","text":"two cases"},{"annotation":"Subject.Disorder","text":"nitrofurantoin-induced pulmonary toxicity"},{"annotation":"Treatment","text":"HRCT"},{"annotation":"Treatment.Imaging","text":"HRCT"},{"annotation":"Treatment.Imaging","text":"widespread reticular pattern"},{"annotation":"Treatment.Imaging","text":"distortion of lung parenchyma"},{"annotation":"Treatment.Imaging","text":"established fibrosis"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment.Drug","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"},{"annotation":"Treatment","text":"nitrofurantoin"}]}]}
{"id":"17619811_4","context":"Colchicine-induced rhabdomyolysis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"rhabdomyolysis"},{"annotation":"Treatment","text":"colchicine"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Treatment.Disease","text":"rhabdomyolysis"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Response"},{"annotation":"Treatment","text":"unknown"},{"annotation":"Treatment.Disorder","text":"unknown"},{"annotation":"Treatment.Drug","text":"unknown"}]}]}
{"id":"16678268_2","context":"We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"severe AVP"},{"annotation":"Effect","text":"AVP"},{"annotation":"Treatment","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"Crohn's disease"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Duration","text":"three weeks"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"Crohn's disease"}]}]}
{"id":"10573314_7","context":"In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"initiation of tolterodine"},{"annotation":"Effect","text":"increase in INR"},{"annotation":"Treatment","text":"tolterodine"},{"annotation":"Treatment.Drug","text":"tolterodine"},{"annotation":"Treatment.Duration","text":"10-14 days"},{"annotation":"Treatment.Time_elapsed","text":"10-14 days"},{"annotation":"Attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{"annotation":"attribute","text":"speculated"},{}]}]}
{"id":"9007910_4","context":"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Disorder","text":"cancer"},{"annotation":"Treatment","text":"5-FU"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"genetic deficiencies in DPD"},{"annotation":"Treatment.Drug","text":"standard doses of 5-FU"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-FU"},{"annotation":"Treatment.Disorder","text":"severe adverse reactions"},{"annotation":"Treatment.Drug","text":"5-F"}]}]}
{"id":"21515865_11","context":"According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Development of supratherapeutic INRs"},{"annotation":"Effect","text":"INRs"},{"annotation":"Treatment","text":"concomitant acetaminophen and moxifloxacin use"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acetaminophen"},{"annotation":"Treatment.Drug","text":"moxifloxacin"},{"annotation":"Treatment.Drug","text":"acet"}]}]}
{"id":"17921794_1","context":"Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"may be associated with"},{"annotation":"Effect","text":"myopathy"},{"annotation":"Treatment","text":"colchicine and statin therapy"},{"annotation":"Treatment.Disorder","text":"myopathy"},{"annotation":"Treatment.Drug","text":"colchicine"},{"annotation":"Treatment.Drug","text":"statin"},{"annotation":"Treatment.Duration","text":"several months"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute","text":"attribute"},{"annotation":"Attribute"}]}]}
{"id":"6671350_1","context":"Cephalosporins are most likely associated with Vitamin K deficiency.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"cephalosporins"},{"annotation":"Treatment.Disorder","text":"Vitamin K deficiency"},{"annotation":"Treatment.Drug","text":"cephalosporins"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"}]}]}
{"id":"18042092_2","context":"Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"embolism"},{"annotation":"Treatment","text":"subcutaneous injection of glatiramer acetate"},{"annotation":"Treatment.Drug","text":"glatiramer acetate"},{"annotation":"Treatment.Route","text":"subcutaneous"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Subject","text":"unknown"},{"annotation":"Subject.Population","text":"unknown"},{"annotation":"Treatment.Drug","text":"glatiramer acetate"},{"annotation":"Treatment.Route","text":"subcutaneous"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"embolism"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Att"}]}]}
{"id":"3084231_3","context":"Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"dementia"},{"annotation":"Treatment","text":"valproic acid"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"epilepsy"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Effect","text":"reversible"}]}]}
{"id":"17316891_1","context":"We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"status epilepticus"},{"annotation":"Treatment","text":"cisplatin and gemcitabine chemotherapy"},{"annotation":"Treatment.Disorder","text":"advanced non-small cell lung cancer"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Subject","text":"a 50-year-old woman"},{"annotation":"Subject.Age","text":"50"},{"annotation":"Subject.Disorder","text":"advanced non-small cell lung cancer"},{"annotation":"Treatment.Drug","text":"cisplatin"},{"annotation":"Treatment.Drug","text":"gemcitabine"}]}]}
{"id":"18628507_3","context":"Here, we report a case of angio-oedema associated with VRC therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"angio-oedema"},{"annotation":"Treatment","text":"VRC therapy"},{"annotation":"Treatment.Drug","text":"VRC"},{"annotation":"Treatment.Disorder","text":"angio-oedema"}]}]}
{"id":"18037876_2","context":"Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Treatment","text":"thalidomide"},{"annotation":"Treatment.Drug","text":"thalidomide"},{"annotation":"Effect","text":"syncopal episodes"},{"annotation":"Treatment.Drug","text":"thalidomide"},{"annotation":"Treatment.Holter_ECG","text":"Holter electrocardiogram"},{"annotation":"Treatment.Holter_ECG.Abnormalities","text":"multiple abnormalities"},{"annotation":"Treatment.Holter_ECG.Abnormality","text":"sustained ventricular tachycardia"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Treatment","text":"thalidomide"},{"annotation":"Treatment.Drug","text":"thalidomide"},{"annotation":"Treatment.Holter_ECG","text":"Holter electrocardiogram"},{"annotation":"Treatment.Holter_ECG.Abnormalities","text":"multiple abnormalities"},{"annotation":"Treatment.Holter_ECG.Abnormality","text":"sustained ventricular tachycardia"}]}]}
{"id":"9413296_1","context":"A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"manifestations"},{"annotation":"Treatment","text":"methysergide"},{"annotation":"Treatment.Drug","text":"methysergide"},{"annotation":"Treatment.Disorder","text":"retroperitoneal fibrosis"},{"annotation":"Subject","text":"a 25-year-old woman"},{"annotation":"Subject.Age","text":"25"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"retroperitoneal fibrosis"},{"annotation":"Effect","text":"manifestations"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"manifestations"},{"annotation":"Treatment","text":"methysergide"},{"annotation":"Treatment.Drug","text":"methysergide"},{"annotation":"Treatment.Disorder","text":"retroperitoneal fibrosis"},{"annotation":"Subject","text":"a 25-year-old woman"},{"annotation":"Subject.Age","text":"25"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"retroperitoneal fibrosis"},{"annotation":"Effect","text":"manifestations"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"manifestations"},{"annotation":"Treatment","text":"methysergide"},{"annotation":"Treatment.Drug","text":"methysergide"},{"annotation":"Treatment.Disorder","text":"retroperitoneal fibrosis"},{"annotation":"Subject","text":"a 25-year-old woman"},{"annotation":"Subject.Age","text":"25"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"retroperitoneal fibrosis"},{"annotation":"Effect","text":"manifestations"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"manifestations"}]}]}
{"id":"18569796_2","context":"Nodular scleritis following alendronate therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Effect","text":"nodular scleritis"},{"annotation":"Treatment","text":"alendronate therapy"},{"annotation":"Treatment.Drug","text":"alendronate"},{"annotation":"Treatment.Disorder","text":"nodular scleritis"},{"annotation":"Treatment.Drug","text":"alendronate"},{"annotation":"Treatment.Duration","text":"following"},{"annotation":"Treatment.Duration","text":"alendronate therapy"},{"annotation":"Treatment.Drug","text":"alendronate"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"nodular scleritis"}]}]}
{"id":"10573314_8","context":"Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"elevated INRs"},{"annotation":"Effect","text":"discontinuation of tolterodine"},{"annotation":"Treatment","text":"tolterodine"},{"annotation":"Treatment.Drug","text":"tolterodine"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"elevated INRs"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not specified"},{"annotation":"Attribute","text":"negated"},{}]}]}
{"id":"2022118_1","context":"However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.","events":[{"type":"Negated_Adverse_event","annotations":[{"annotation":"Negated","text":"However"},{"annotation":"Treatment","text":"use of lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Subject","text":"any patient who is purging"},{"annotation":"Subject.Disorder","text":"purging"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Attribute","text":"Negated"},{"annotation":"Attribute.Negated","text":"exacerbate the loss of intracellular potassium"},{"annotation":"Attribute.Negated","text":"increase the risk of cardiac toxicity"}]},{"type":"Negated_Adverse_event","annotations":[{"annotation":"Negated","text":"However"},{"annotation":"Treatment","text":"use of lithium"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Subject","text":"any patient who is purging"},{"annotation":"Subject.Disorder","text":"purging"},{"annotation":"Treatment.Drug","text":"lithium"},{"annotation":"Attribute","text":"Negated"},{"annotation":"Attribute.Negated","text":"exacerbate the loss of intracellular potassium"},{"annotation":"Attribute.Negated","text":"increase the risk of cardiac toxicity"}]}]}
{"id":"681921_2","context":"Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"elucidating"},{"annotation":"Treatment","text":"disulfiram"},{"annotation":"Treatment.Disorder","text":"catatonia"},{"annotation":"Treatment.Drug","text":"disulfiram"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not clear if disulfiram is the cause of catatonia"}]}]}
{"id":"10717401_1","context":"Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Effect","text":"thrombosis"},{"annotation":"Treatment","text":"L-asparaginase treatment"},{"annotation":"Treatment.Disorder","text":"transient free protein S deficiency"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Dosage","text":"transient"},{"annotation":"Treatment.Duration","text":"free protein S deficiency"},{"annotation":"Treatment.Disorder","text":"sagittal sinus thrombosis"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Dosage","text":"transient"},{"annotation":"Treatment.Duration","text":"free protein S deficiency"},{"annotation":"Treatment.Disorder","text":"sagittal sinus thrombosis"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Dosage","text":"transient"},{"annotation":"Treatment.Duration","text":"free protein S deficiency"},{"annotation":"Treatment.Disorder","text":"sagittal sinus thrombosis"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Dosage","text":"transient"},{"annotation":"Treatment.Duration","text":"free protein S deficiency"},{"annotation":"Treatment.Disorder","text":"sagittal sinus thrombosis"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Dosage","text":"transient"},{"annotation":"Treatment.Duration","text":"free protein S deficiency"},{"annotation":"Treatment.Disorder","text":"sagittal sinus thrombosis"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Dosage","text":"transient"},{"annotation":"Treatment.Duration","text":"free protein S deficiency"},{"annotation":"Treatment.Disorder","text":"sagittal sinus thrombosis"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Dosage","text":"transient"},{"annotation":"Treatment.Duration","text":"free protein S deficiency"},{"annotation":"Treatment.Disorder","text":"sagittal sinus thrombosis"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Dosage","text":"transient"},{"annotation":"Treatment.Duration","text":"free protein S deficiency"},{"annotation":"Treatment.Disorder","text":"sagittal sinus thrombosis"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Dosage","text":"transient"},{"annotation":"Treatment.Duration","text":"free protein S deficiency"},{"annotation":"Treatment.Disorder","text":"sagittal sinus thrombosis"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Dosage","text":"transient"},{"annotation":""}]}]}
{"id":"4063627_3","context":"This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"fenclofenac as well as aurothiomalate and sulphasalazine"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"fenclofenac"},{"annotation":"Treatment.Drug","text":"aurothiomalate"},{"annotation":"Treatment.Drug","text":"sulphasalazine"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"for selective IgA deficiency"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"for remission"}]}]}
{"id":"18262450_14","context":"This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"clinically meaningful effect"},{"annotation":"Effect","text":"painful diabetic neuropathy"},{"annotation":"Treatment","text":"co-administration of prolonged-release oxycodone and existing gabapentin therapy"},{"annotation":"Treatment.Disorder","text":"painful diabetic neuropathy"},{"annotation":"Treatment.Drug","text":"prolonged-release oxycodone"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"prolonged-release oxycodone"},{"annotation":"Treatment.Combination.Drug","text":"gabapentin"},{"annotation":"Treatment.Combination.Drug","text":"existing gabapentin therapy"},{"annotation":"Treatment.Combination.Disorder","text":"painful diabetic neuropathy"},{"annotation":"Treatment.Combination.Drug","text":"prolonged-release oxycodone"},{"annotation":"Treatment.Combination.Drug","text":"gabapentin"},{"annotation":"Subject","text":"painful diabetic neuropathy"},{"annotation":"Subject.Disorder","text":"painful diabetic neuropathy"}]}]}
{"id":"17504225_4","context":"In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"increase of sirolimus trough blood concentrations"},{"annotation":"Effect","text":"acute impairment of renal function"},{"annotation":"Treatment","text":"concomitant administration of clarithromycin and sirolimus"},{"annotation":"Treatment.Drug","text":"clarithromycin"},{"annotation":"Treatment.Drug","text":"sirolimus"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"clarithromycin"},{"annotation":"Treatment.Combination.Drug","text":"sirolimus"},{"annotation":"Treatment.Combination.Drug","text":"sirolimus"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Disorder","text":"renal function"}]}]}
{"id":"10190739_1","context":"In one case, the readministration of riluzole was followed by the relapse of hepatitis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"readministration of riluzole"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"riluzole"},{"annotation":"Treatment.Drug","text":"riluzole"},{"annotation":"Treatment.Disorder","text":"hepatitis"},{"annotation":"Treatment.Drug","text":"riluzole"},{"annotation":"Treatment.Combination.Trigger","text":"followed by"},{"annotation":"Treatment.Combination.Drug","text":"riluzole"},{"annotation":"Treatment.Combination.Drug","text":"hepatitis"},{"annotation":"Subject","text":"in one case"},{"annotation":"Subject.Disorder","text":"hepatitis"}]}]}
{"id":"16018164_3","context":"Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemorrhage"},{"annotation":"Treatment","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Disorder","text":"cerebral vascular malformation"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"associated with"},{"annotation":"Treatment.Time_elapsed","text":"a cerebral vascular malformation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"for ADE, the adverse effect does not exist"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemorrhage"},{"annotation":"Treatment","text":"pseudoephedrine"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Disorder","text":"cerebral vascular malformation"},{"annotation":"Treatment.Drug","text":"pseudoephedrine"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"associated with"},{"annotation":"Treatment.Time_elapsed","text":"a cerebral vascular malformation"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"for ADE, the adverse effect does not exist"}]}]}
{"id":"16490518_1","context":"PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"glaucoma"},{"annotation":"Treatment","text":"intravitreal injection of triamcinolone acetate"},{"annotation":"Treatment.Drug","text":"triamcinolone acetate"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Route","text":"intravitreal"},{"annotation":"Treatment.Disorder","text":"corticosteroid-induced glaucoma"},{"annotation":"Subject","text":"a 34-year-old man"},{"annotation":"Subject.Age","text":"34 years old"},{"annotation":"Subject.Gender","text":"unknown"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"unknown"},{"annotation":"Treatment.Drug","text":"triamcinolone acetate"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"intravitreal"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"corticosteroid-induced glaucoma"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"unknown"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute.speculated","text":"unknown"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute.severity","text":"unknown"}]}]}
{"id":"7369302_2","context":"A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"toxicity"},{"annotation":"Effect","text":"temporary pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials"},{"annotation":"Treatment","text":"quinine"},{"annotation":"Treatment.Drug","text":"quinine"},{"annotation":"Treatment.Duration","text":"temporary"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Drug","text":"quinine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Drug","text":"quinine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Drug","text":"quinine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Drug","text":"quinine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Drug","text":"quinine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Drug","text":"quinine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Drug","text":"quinine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Drug","text":"quinine"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"T"}]}]}
{"id":"10682234_6","context":"Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"coma"},{"annotation":"Treatment","text":"levomepromazine"},{"annotation":"Treatment.Drug","text":"levomepromazine"},{"annotation":"Treatment.Duration","text":"2 days"},{"annotation":"Treatment.Frequency","text":"2 days"},{"annotation":"Treatment.Route","text":"administered"},{"annotation":"Treatment.Time_elapsed","text":"2 days"},{"annotation":"Subject","text":"him"},{"annotation":"Subject.Age","text":"2 days"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"not specified"},{"annotation":"Treatment.Disorder","text":"coma"}]}]}
{"id":"9777751_1","context":"Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"aplastic anemia"},{"annotation":"Treatment","text":"third exposure"},{"annotation":"Treatment.Drug","text":"methimazole"},{"annotation":"Treatment.Drug","text":"recombinant human granulocyte colony-stimulating factor"},{"annotation":"Treatment.Duration","text":"successful treatment"},{"annotation":"Treatment.Disorder","text":"aplastic anemia"},{"annotation":"Treatment.Drug","text":"methimazole"},{"annotation":"Treatment.Drug","text":"recombinant human granulocyte colony-stimulating factor"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"aplastic anemia"},{"annotation":"Treatment","text":"methimazole"},{"annotation":"Treatment.Drug","text":"recombinant human granulocyte colony-stimulating factor"},{"annotation":"Treatment.Duration","text":"successful treatment"},{"annotation":"Treatment.Disorder","text":"aplastic anemia"},{"annotation":"Treatment.Drug","text":"methimazole"},{"annotation":"Treatment.Drug","text":"recombinant human granulocyte colony-stimulating factor"}]}]}
{"id":"18751717_2","context":"BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed after intravitreal triamcinolone acetonide (IVTA) injection"},{"annotation":"Effect","text":"acute syphilitic posterior placoid chorioretinitis"},{"annotation":"Treatment","text":"intravitreal triamcinolone acetonide (IVTA) injection"},{"annotation":"Treatment.Drug","text":"triamcinolone acetonide"},{"annotation":"Treatment.Dosage","text":"intravitreal"},{"annotation":"Treatment.Frequency","text":"one time"},{"annotation":"Treatment.Route","text":"intravitreal"},{"annotation":"Treatment.Time_elapsed","text":"after intravitreal triamcinolone acetonide (IVTA) injection"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"acute syphilitic posterior placoid chorioretinitis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed after intravitreal triamcinolone acetonide (IVTA) injection"},{"annotation":"Effect","text":"acute syphilitic posterior placoid chorioretinitis"},{"annotation":"Treatment","text":"intravitreal triamcinolone acetonide (IVTA) injection"},{"annotation":"Treatment.Drug","text":"triamcinolone acetonide"},{"annotation":"Treatment.Dosage","text":"intravitreal"},{"annotation":"Treatment.Frequency","text":"one time"},{"annotation":"Treatment.Route","text":"intravitreal"},{"annotation":"Treatment.Time_elapsed","text":"after intravitreal triamcinolone acetonide (IVTA) injection"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"acute syphilitic posterior placoid chorioretinitis"}]}]}
{"id":"14522628_2","context":"Skin rash and splinter hemorrhages from ganciclovir.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"from"},{"annotation":"Treatment","text":"ganciclovir"},{"annotation":"Treatment.Drug","text":"ganciclovir"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Effect","text":"skin rash and splinter hemorrhages"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"from"},{"annotation":"Treatment","text":"ganciclovir"},{"annotation":"Treatment.Drug","text":"ganciclovir"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Effect","text":"skin rash and splinter hemorrhages"}]}]}
{"id":"15368548_5","context":"We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"necrotizing pancreatitis"},{"annotation":"Treatment","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous drainage"},{"annotation":"Treatment","text":"percutaneous"}]}]}
{"id":"11804071_3","context":"Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Treatment","text":"INH therapy"},{"annotation":"Treatment.Drug","text":"INH"},{"annotation":"Effect","text":"anagen effluvium with lichenoid eruption"},{"annotation":"Treatment.Disorder","text":"INH therapy"},{"annotation":"Treatment.Drug","text":"INH"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"}]}]}
{"id":"10646879_3","context":"We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"We conclude"},{"annotation":"Treatment","text":"MB"},{"annotation":"Effect","text":"effective treatment for ifosfamide-induced encephalopathy"},{"annotation":"Treatment.Disorder","text":"ifosfamide-induced encephalopathy"},{"annotation":"Treatment.Drug","text":"ifosfamide"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"ifosfamide-induced encephalopathy"},{"annotation":"Effect","text":"encephalopathy"},{"annotation":"Treatment","text":"MB"},{"annotation":"Treatment.Drug","text":"MB"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"18354950_2","context":"Hyponatraemia during low-dose carbamazepine therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"during"},{"annotation":"Effect","text":"hyponatraemia"},{"annotation":"Treatment","text":"low-dose carbamazepine therapy"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Dosage","text":"low dose"},{"annotation":"Treatment.Duration","text":"therapy"},{"annotation":"Treatment.Disorder","text":"hyponatraemia"},{"annotation":"Treatment.Drug","text":"carbamazepine"},{"annotation":"Treatment.Dosage","text":"low dose"},{"annotation":"Treatment.Duration","text":"therapy"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Disorder","text":"hyponatraemia"}]}]}
{"id":"16697705_1","context":"Acute coronary syndrome induced by capecitabine therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"acute coronary syndrome"},{"annotation":"Treatment","text":"capecitabine therapy"},{"annotation":"Treatment.Drug","text":"capecitabine"},{"annotation":"Treatment.Disorder","text":"acute coronary syndrome"},{"annotation":"Treatment.Drug","text":"capecitabine"}]}]}
{"id":"3171334_1","context":"A case of severe visual loss following a single dose of vincristine is described.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"following"},{"annotation":"Treatment","text":"single dose of vincristine"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Effect","text":"severe visual loss"},{"annotation":"Treatment.Dosage","text":"single dose"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"a single dose of vincristine"},{"annotation":"Treatment.Duration","text":"a single dose"},{"annotation":"Treatment.Disorder","text":"severe visual loss"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Dosage","text":"single dose"},{"annotation":"Treatment.Duration","text":"a single dose"},{"annotation":"Treatment.Disorder","text":"severe visual loss"},{"annotation":"Treatment","text":"single dose of vincristine"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Dosage","text":"single dose"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"a single dose of vincristine"},{"annotation":"Treatment.Duration","text":"a single dose"},{"annotation":"Treatment.Disorder","text":"severe visual loss"},{"annotation":"Treatment","text":"single dose of vincristine"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Dosage","text":"single dose"},{"annotation":"Treatment.Duration","text":"a single dose"},{"annotation":"Treatment.Disorder","text":"severe visual loss"},{"annotation":"Treatment","text":"single dose of vincristine"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Dosage","text":"single dose"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"a single dose of vincristine"},{"annotation":"Treatment.Duration","text":"a single dose"},{"annotation":"Treatment.Disorder","text":"severe visual loss"},{"annotation":"Treatment","text":"single dose of vincristine"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Dosage","text":"single dose"},{"annotation":"Treatment.Duration","text":"a single dose"},{"annotation":"Treatment.Disorder","text":"severe visual loss"},{"annotation":"Treatment","text":"single dose of vincristine"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Dosage","text":"single dose"},{"annotation":"Treatment.Time_elapsed","text":"after"},{"annotation":"Treatment.Time_elapsed","text":"a single dose of vincristine"},{"annotation":"Treatment.Duration","text":"a single dose"},{"annotation":"Treatment.Disorder","text":"severe visual loss"},{"annotation":"Treatment","text":"single dose of vincristine"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Dosage","text":"single dose"},{"annotation":"Treatment.Duration","text":"a single dose"},{"annotation":"Treatment.Disorder","text":"severe visual loss"},{"annotation":"Treatment"}]}]}
{"id":"16357738_3","context":"We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"severe perspiration, headache, and seizure"},{"annotation":"Treatment","text":"cyclosporine"},{"annotation":"Treatment.Disorder","text":"SLE and thrombocytopenia"},{"annotation":"Treatment.Drug","text":"cyclosporine"},{"annotation":"Treatment.Dosage","text":"severe"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"12507063_1","context":"Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withdrawal"},{"annotation":"Effect","text":"seizures"},{"annotation":"Treatment","text":"gabapentin"},{"annotation":"Treatment.Disorder","text":"gabapentin withdrawal"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Treatment.Drug","text":"status epilepticus"},{"annotation":"Treatment.Duration","text":"withdrawal"},{"annotation":"Treatment.Duration","text":"gabapentin"},{"annotation":"Treatment.Duration","text":"status epilepticus"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"gabapentin withdrawal"},{"annotation":"Treatment.Disorder","text":"status epilepticus"}]}]}
{"id":"4014301_2","context":"Self-limited edema is a well-recognized complication of insulin therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"complication"},{"annotation":"Effect","text":"edema"},{"annotation":"Treatment","text":"insulin therapy"},{"annotation":"Treatment.Disorder","text":"diabetes"},{"annotation":"Treatment.Drug","text":"insulin"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"insulin therapy"},{"annotation":"Treatment.Disorder","text":"diabetes"},{"annotation":"Effect","text":"edema"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"15061230_1","context":"It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"development"},{"annotation":"Effect","text":"osteonecrosis"},{"annotation":"Treatment","text":"antiemetic drug regimen"},{"annotation":"Treatment.Drug","text":"dexamethasone"},{"annotation":"Attribute","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Attribute","text":"negated"}]}]}
{"id":"12397859_1","context":"A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"withdrawal"},{"annotation":"Effect","text":"benzodiazepine withdrawal symptoms"},{"annotation":"Treatment","text":"discontinuation of nefazodone"},{"annotation":"Treatment.Drug","text":"nefazodone"},{"annotation":"Treatment.Drug","text":"benzodiazepines"},{"annotation":"Treatment.Drug","text":"cytochrome P450 3A4 isoenzyme"},{"annotation":"Treatment.Drug","text":"inhibition"},{"annotation":"Treatment.Drug","text":"benzodiazepines"},{"annotation":"Treatment.Drug","text":"cytochrome P450 3A4 isoenzyme"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Age","text":"not specified"},{"annotation":"Subject.Disorder","text":"benzodiazepine withdrawal symptoms"},{"annotation":"Treatment.Disorder","text":"benzodiazepines"},{"annotation":"Treatment.Drug","text":"cytochrome P450 3A4 isoenzyme"}]}]}
{"id":"3156465_1","context":"Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"has been shown"},{"annotation":"Effect","text":"teratogenic effects"},{"annotation":"Treatment","text":"isotretinoin"},{"annotation":"Treatment.Drug","text":"isotretinoin"},{"annotation":"Treatment.Disorder","text":"acne"},{"annotation":"Treatment.Drug","text":"isotretinoin"}]}]}
{"id":"12022905_6","context":"The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"induce"},{"annotation":"Treatment","text":"zuclopenthixol"},{"annotation":"Treatment.Disorder","text":"priapism"},{"annotation":"Treatment.Drug","text":"zuclopenthixol"},{"annotation":"Treatment.Mechanism","text":"antagonist activity on alpha-adrenergic receptors"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"6572542_4","context":"Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Treatment","text":"high doses of CCNU"},{"annotation":"Treatment.Drug","text":"CCNU"},{"annotation":"Treatment.Dosage","text":"1100 mg/m2 and 1240 mg/m2"},{"annotation":"Effect","text":"fatal pulmonary fibrosis"},{"annotation":"Treatment.Drug","text":"CCNU"},{"annotation":"Treatment.Dosage","text":"1100 mg/m2 and 1240 mg/m2"},{"annotation":"Treatment.Disorder","text":"chronic myeloid leukemia"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Disorder","text":"chronic myeloid leukemia"}]}]}
{"id":"11724089_1","context":"CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"ofloxacin"},{"annotation":"Treatment.Drug","text":"ofloxacin"},{"annotation":"Effect","text":"toxic epidermal necrolysis"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"18755414_3","context":"Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hemorrhage"},{"annotation":"Treatment","text":"aspirin prophylaxis"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"prophylaxis"},{"annotation":"Treatment.Drug","text":"aspirin"},{"annotation":"Treatment.Drug","text":"meningioma"},{"annotation":"Treatment.Drug","text":"prophylaxis"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"meningioma"}]}]}
{"id":"10225085_2","context":"Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"methemoglobinemia"},{"annotation":"Treatment","text":"axillary block with bupivacaine and additional injection of lidocaine"},{"annotation":"Treatment.Drug","text":"bupivacaine"},{"annotation":"Treatment.Drug","text":"lidocaine"},{"annotation":"Treatment.Disorder","text":"methemoglobinemia"},{"annotation":"Treatment.Drug","text":"bupivacaine"},{"annotation":"Treatment.Drug","text":"lidocaine"}]}]}
{"id":"10812579_3","context":"Nonconvulsive status epilepticus: the role of morphine and its antagonist.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"nonconvulsive status epilepticus"},{"annotation":"Effect","text":"epilepticus"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment.Antagonist","text":"antagonist"},{"annotation":"Treatment.Drug","text":"antagonist"},{"annotation":"Treatment.Antagonist","text":"morphine"},{"annotation":"Treatment.Antagonist","text":"antagonist"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment.Drug","text":"antagonist"},{"annotation":"Treatment.Antagonist","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment.Drug","text":"antagonist"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment.Drug","text":"antagonist"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"antagonist"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"antagonist"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"antagonist"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"antagonist"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment.Drug","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treatment","text":"morphine"},{"annotation":"Treat"}]}]}
{"id":"8579054_1","context":"Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"evolving"},{"annotation":"Treatment","text":"hydroxyurea"},{"annotation":"Treatment.Drug","text":"hydroxyurea"},{"annotation":"Treatment.Disorder","text":"essential thrombocythemia"},{"annotation":"Treatment.Drug","text":"hydroxyurea"},{"annotation":"Treatment.Drug","text":"acute myeloid leukemia"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Disorder","text":"acute myeloid leukemia"},{"annotation":"Subject.Disorder","text":"essential thrombocythemia"},{"annotation":"Treatment.Disorder","text":"hydroxyurea"},{"annotation":"Treatment.Drug","text":"hydroxyurea"},{"annotation":"Treatment.Drug","text":"acute myeloid leukemia"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"evolving"},{"annotation":"Treatment","text":"hydroxyurea"},{"annotation":"Treatment.Drug","text":"hydroxyurea"},{"annotation":"Treatment.Disorder","text":"essential thrombocythemia"},{"annotation":"Treatment.Drug","text":"hydroxyurea"},{"annotation":"Treatment.Drug","text":"acute myeloid leukemia"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Disorder","text":"acute myeloid leukemia"},{"annotation":"Subject.Disorder","text":"essential thrombocythemia"},{"annotation":"Treatment.Disorder","text":"hydroxyurea"},{"annotation":"Treatment.Drug","text":"hydroxyurea"},{"annotation":"Treatment.Drug","text":"acute myeloid leukemia"}]}]}
{"id":"10698143_1","context":"Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"overdose"},{"annotation":"Effect","text":"central nervous system manifestations"},{"annotation":"Treatment","text":"ibuprofen"},{"annotation":"Treatment.Drug","text":"ibuprofen"},{"annotation":"Treatment.Drug","text":"naloxone"},{"annotation":"Treatment.Duration","text":"reversed"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"after the drug was administered to the occurrence of the (side) effect"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"oral"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"oral"},{}]}]}
{"id":"20465622_2","context":"BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"sirolimus therapy"},{"annotation":"Treatment.Disorder","text":"aphthous stomatitis"},{"annotation":"Treatment.Disorder","text":"mucocutaneous disorder"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":"Attribute.negated","text":"not negated"},{"annotation":""}]}]}
{"id":"18675768_4","context":"The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Treatment","text":"propafenone and citalopram"},{"annotation":"Treatment.Disorder","text":"propafenone adverse effects"},{"annotation":"Treatment.Drug","text":"propafenone"},{"annotation":"Treatment.Drug","text":"citalopram"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"propafenone"},{"annotation":"Treatment.Combination.Drug","text":"citalopram"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"propafenone adverse effects"}]}]}
{"id":"7949255_1","context":"Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"observed"},{"annotation":"Treatment","text":"chemotherapy with high-dose methotrexate (HD-MTX)"},{"annotation":"Treatment.Disorder","text":"osteogenic sarcoma"},{"annotation":"Subject","text":"one out of 23 patients"},{"annotation":"Subject.Population","text":"23 patients"},{"annotation":"Treatment.Drug","text":"high-dose methotrexate (HD-MTX)"},{"annotation":"Treatment.Dosage","text":"dosage of methotrexate"},{"annotation":"Treatment.Frequency","text":"one observation"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"osteogenic sarcoma"},{"annotation":"Effect","text":"temporary neurologic abnormalities"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"observed"},{"annotation":"Treatment","text":"chemotherapy with high-dose methotrexate (HD-MTX)"},{"annotation":"Treatment.Disorder","text":"osteogenic sarcoma"},{"annotation":"Treatment.Drug","text":"high-dose methotrexate (HD-MTX)"},{"annotation":"Treatment.Dosage","text":"dosage of methotrexate"},{"annotation":"Treatment.Frequency","text":"one observation"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"osteogenic sarcoma"},{"annotation":"Effect","text":"temporary neurologic abnormalities"}]}]}
{"id":"18675768_13","context":"This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"propafenone"},{"annotation":"Treatment.Drug","text":"propafenone"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"coronary artery disease"},{"annotation":"Treatment.Drug","text":"citalopram"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Interaction","text":"interaction"},{"annotation":"Effect","text":"propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"propafenone"},{"annotation":"Treatment.Disorder","text":"coronary artery disease"},{"annotation":"Treatment.Drug","text":"citalopram"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Interaction","text":"interaction"},{"annotation":"Treatment.Disorder","text":"coronary artery disease"},{"annotation":"Treatment.Drug","text":"citalopram"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Interaction","text":"interaction"},{"annotation":"Effect","text":"possible interaction between propafenone and citalopram"}]}]}
{"id":"1082426_1","context":"Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"peritonitis"},{"annotation":"Treatment","text":"intraarterial vasopressin therapy"},{"annotation":"Treatment.Drug","text":"vasopressin"},{"annotation":"Treatment.Disorder","text":"spontaneous bacterial peritonitis"}]}]}
{"id":"16685007_1","context":"Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"reduces"},{"annotation":"Treatment","text":"ciclesonide"},{"annotation":"Treatment.Disorder","text":"severe, persistent asthma"},{"annotation":"Effect","text":"need for oral steroid use"}]}]}
{"id":"8250714_1","context":"Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"subacute combined degeneration of the spinal cord"},{"annotation":"Treatment","text":"nitrous oxide anesthesia"},{"annotation":"Treatment.Disorder","text":"vitamin B12 deficiency"},{"annotation":"Treatment.Drug","text":"nitrous oxide"},{"annotation":"Treatment.Drug","text":"vitamin B12"},{"annotation":"Subject","text":"patients unsuspected of having vitamin B12 deficiency"},{"annotation":"Subject.Disorder","text":"vitamin B12 deficiency"}]}]}
{"id":"12022905_1","context":"CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erection"},{"annotation":"Treatment","text":"oral zuclopenthixol"},{"annotation":"Treatment.Drug","text":"zuclopenthixol"},{"annotation":"Treatment.Dosage","text":"acute"},{"annotation":"Treatment.Duration","text":"painful erection"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"erection"},{"annotation":"Treatment","text":"oral zuclopenthixol"},{"annotation":"Treatment.Drug","text":"zuclopenthixol"},{"annotation":"Treatment.Dosage","text":"acute"},{"annotation":"Treatment.Duration","text":"painful erection"}]}]}
{"id":"6401771_2","context":"Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"acute"},{"annotation":"Treatment","text":"long-term therapy with mitomycin C and 5-fluorouracil"},{"annotation":"Treatment.Drug","text":"mitomycin C"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Effect","text":"renal toxicity"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Drug","text":"mitomycin C"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Subject","text":"three patients"},{"annotation":"Subject.Disorder","text":"renal toxicity"}]}]}
{"id":"9870779_1","context":"A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"hepatic necrosis"},{"annotation":"Treatment","text":"MTX"},{"annotation":"Treatment.Disorder","text":"rheumatoid arthritis"},{"annotation":"Treatment.Drug","text":"MTX"},{"annotation":"Treatment.Duration","text":"6 month period"},{"annotation":"Subject","text":"a 40-year-old man"},{"annotation":"Subject.Age","text":"40"},{"annotation":"Subject.Disorder","text":"rheumatoid arthritis"}]}]}
{"id":"9627209_1","context":"In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"resulted"},{"annotation":"Effect","text":"toxicity"},{"annotation":"Treatment","text":"total daily dose of 25 mg sertraline"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Drug","text":"lamotrigine"},{"annotation":"Treatment.Dosage","text":"25 mg"},{"annotation":"Treatment.Dosage","text":"total daily dose"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Drug","text":"desmethylsertraline"},{"annotation":"Treatment.Drug","text":"nondetectable"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Drug","text":"desmethylsertraline"},{"annotation":"Treatment.Drug","text":"nondetectable"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Drug","text":"desmethylsertraline"},{"annotation":"Treatment.Drug","text":"nondetectable"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Drug","text":"desmethylsertraline"},{"annotation":"Treatment.Drug","text":"nondetectable"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Drug","text":"desmethylsertraline"},{"annotation":"Treatment.Drug","text":"nondetectable"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Drug","text":"desmethylsertraline"},{"annotation":"Treatment.Drug","text":"nondetectable"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Drug","text":"desmethylsertraline"},{"annotation":"Treatment.Drug","text":"nondetectable"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Drug","text":"desmethylsertraline"},{"annotation":"Treatment.Drug","text":"nondetectable"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Drug","text":"desmethylsertraline"},{"annotation":"Treatment.Drug","text":"nondetectable"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Drug","text":"desmethylsertraline"},{"annotation":"Treatment.Drug","text":"nondetectable"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Drug","text":"desmethylsertraline"},{"annotation":"Treatment.Drug","text":"nondetectable"},{"annotation":"Treatment.Drug"}]}]}
{"id":"7355327_3","context":"Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"relieved"},{"annotation":"Effect","text":"bronchospasm"},{"annotation":"Treatment","text":"discontinuation of propranolol and supportive bronchodilator therapy"},{"annotation":"Treatment.Drug","text":"propranolol"},{"annotation":"Treatment.Drug","text":"bronchodilator"},{"annotation":"Treatment.Disorder","text":"bronchospasm"},{"annotation":"Treatment.Drug","text":"propranolol"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"since the bronchospasm was relieved"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused by propranolol"},{"annotation":"Treatment","text":"propranolol"},{"annotation":"Treatment.Drug","text":"propranolol"},{"annotation":"Treatment.Disorder","text":"bronchospasm"},{"annotation":"Treatment.Drug","text":"bronchodilator"},{"annotation":"Treatment.Drug","text":"bronchodilator"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"since the bronchospasm was relieved"}]}]}
{"id":"6362443_2","context":"A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"manic episode"},{"annotation":"Treatment","text":"fluoxetine"},{"annotation":"Treatment.Disorder","text":"depression"},{"annotation":"Treatment.Drug","text":"fluoxetine"},{"annotation":"Treatment.Drug","text":"depression"},{"annotation":"Subject","text":"a woman"},{"annotation":"Subject.Disorder","text":"depressed"},{"annotation":"Treatment.Disorder","text":"bipolar illness"},{"annotation":"Treatment.Drug","text":"fluoxetine"}]}]}
{"id":"6725214_2","context":"Priapism associated with trazodone therapy: case report.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"trazodone therapy"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Effect","text":"priapism"},{"annotation":"Treatment","text":"case report"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Treatment.Drug","text":"therapy"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Disorder","text":"priapism"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"trazodone therapy"},{"annotation":"Treatment.Drug","text":"trazodone"},{"annotation":"Effect","text":"priapism"},{"annotation":"Treatment","text":"case report"},{"annotation":"Treatment.Drug","text":"trazodine"},{"annotation":"Treatment.Drug","text":"therapy"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Disorder","text":"priapism"}]}]}
{"id":"7639655_3","context":"OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurrence"},{"annotation":"Effect","text":"anterior ischemic optic neuropathy"},{"annotation":"Treatment","text":"interferon alfa"},{"annotation":"Treatment.Disorder","text":"anterior ischemic optic neuropathy"},{"annotation":"Treatment.Drug","text":"interferon alfa"},{"annotation":"Treatment.Duration","text":"treatment duration"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"severity"}]}]}
{"id":"8850251_4","context":"Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Drug","text":"chlorpromazine"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"absence of mequitazine-induced photosensitivity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"mequitazine"},{"annotation":"Treatment.Drug","text":"chlorpromazine"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"played a part similar to chlorpromazine"}]}]}
{"id":"15927910_2","context":"Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"pentamidine"},{"annotation":"Treatment.Drug","text":"pentamidine"},{"annotation":"Treatment.Disorder","text":"cardiotoxicity"},{"annotation":"Treatment.Drug","text":"second-degree heart block"},{"annotation":"Treatment.Drug","text":"pentamidine"},{"annotation":"Treatment.Drug","text":"cardiotoxicity"},{"annotation":"Treatment.Disorder","text":"pentamidine-induced cardiotoxicity"},{"annotation":"Attribute","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"second-degree heart block"},{"annotation":"Treatment","text":"pentamidine"},{"annotation":"Treatment.Drug","text":"pentamidine"},{"annotation":"Effect","text":"second-degree heart block"},{"annotation":"Treatment.Drug","text":"pentamidine"},{"annotation":"Treatment.Drug","text":"cardiotoxicity"},{"annotation":"Treatment.Disorder","text":"pentamidine-induced cardiotoxicity"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"23115227_6","context":"The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"mean weekly warfarin dose"},{"annotation":"Treatment","text":"emtricitabine monotherapy"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Drug","text":"emtricitabine"},{"annotation":"Treatment.Duration","text":"while"},{"annotation":"Treatment.Dose","text":"13.3 mg"},{"annotation":"Treatment.Dose","text":"12.7 to 13.8"},{"annotation":"Treatment.Dose","text":"95% CI"},{"annotation":"Treatment.Dose","text":"2.5 to 3.1"},{"annotation":"Treatment.Dose","text":"95% CI"},{"annotation":"Treatment.Dose","text":"2.8"},{"annotation":"Treatment.Dose","text":"INR"},{"annotation":"Treatment.Dose","text":"2.5 to 3.1"},{"annotation":"Treatment.Dose","text":"95% CI"},{"annotation":"Treatment.Dose","text":"2.8"},{"annotation":"Treatment.Dose","text":"INR"},{"annotation":"Treatment.Dose","text":"2.5 to 3.1"},{"annotation":"Treatment.Dose","text":"95% CI"},{"annotation":"Treatment.Dose","text":"2.8"},{"annotation":"Treatment.Dose","text":"INR"},{"annotation":"Treatment.Dose","text":"2.5 to 3.1"},{"annotation":"Treatment.Dose","text":"95% CI"},{"annotation":"Treatment.Dose","text":"2.8"},{"annotation":"Treatment.Dose","text":"INR"},{"annotation":"Treatment.Dose","text":"2.5 to 3.1"},{"annotation":"Treatment.Dose","text":"95% CI"},{"annotation":"Treatment.Dose","text":"2.8"},{"annotation":"Treatment.Dose","text":"INR"},{"annotation":"Treatment.Dose","text":"2.5 to 3.1"},{"annotation":"Treatment.Dose","text":"95% CI"},{"annotation":"Treatment.Dose","text":"2.8"},{"annotation":"Treatment.Dose","text":"INR"},{"annotation":"Treatment.Dose","text":"2.5 to 3.1"},{"annotation":"Treatment.Dose","text":"95% CI"},{"annotation":"Treatment.Dose","text":"2.8"},{"annotation":"Treatment.Dose","text":"INR"},{"annotation":"Treatment.Dose","text":"2.5 to 3.1"},{"annotation":"Treatment.Dose","text":"95% CI"},{"annotation":"Treatment.Dose","text":"2.8"},{"annotation":"Treatment.Dose","text":"INR"},{"annotation":"Treatment"}]}]}
{"id":"3806824_2","context":"We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"after intracavernous self-injection of a combination of phentolamine and papaverine"},{"annotation":"Treatment","text":"combination of phentolamine and papaverine"},{"annotation":"Treatment.Disorder","text":"penile fibrosis"},{"annotation":"Treatment.Drug","text":"phentolamine"},{"annotation":"Treatment.Drug","text":"papaverine"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"penile fibrosis"}]}]}
{"id":"6865827_3","context":"This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.","events":[{"type":"Potential_therapeutic_event","annotations":[{"annotation":"Trigger","text":"agranulocytosis"},{"annotation":"Effect","text":"followed treatment with both propylthiouracil and methimazole"},{"annotation":"Treatment","text":"propylthiouracil and methimazole"},{"annotation":"Treatment.Disorder","text":"agranulocytosis"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Disorder","text":"agranulocytosis"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"agranulocytosis"},{"annotation":"Treatment","text":"propylthiouracil and methimazole"},{"annotation":"Treatment.Drug","text":"propylthiouracil"},{"annotation":"Treatment.Drug","text":"methimazole"},{"annotation":"Effect","text":"agranulocytosis"}]}]}
{"id":"15522120_1","context":"Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"chocolate"},{"annotation":"Effect","text":"itch and skin rash"},{"annotation":"Treatment","text":"fluoxetine and sertraline"},{"annotation":"Treatment.Drug","text":"fluoxetine"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Subject","text":"patient"},{"annotation":"Subject.Age","text":"adult"},{"annotation":"Subject.Gender","text":"male"},{"annotation":"Subject.Population","text":"1 patient"},{"annotation":"Subject.Race","text":"Caucasian"},{"annotation":"Subject.Disorder","text":"none"},{"annotation":"Treatment","text":"fluoxetine and sertraline"},{"annotation":"Treatment.Drug","text":"fluoxetine"},{"annotation":"Treatment.Drug","text":"sertraline"},{"annotation":"Treatment.Dosage","text":"unknown"},{"annotation":"Treatment.Frequency","text":"unknown"},{"annotation":"Treatment.Route","text":"unknown"},{"annotation":"Treatment.Time_elapsed","text":"unknown"},{"annotation":"Treatment.Duration","text":"unknown"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Effect","text":"itch and skin rash"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"severity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"speculated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"neg"}]}]}
{"id":"18262450_11","context":"Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"association"},{"annotation":"Treatment","text":"oxycodone-gabapentin co-administration"},{"annotation":"Treatment.Disorder","text":"pain and sleep disturbance"},{"annotation":"Treatment.Drug","text":"oxycodone"},{"annotation":"Treatment.Drug","text":"gabapentin"},{"annotation":"Treatment.Effect","text":"less escape medication use"},{"annotation":"Treatment.Effect","text":"fewer nights of disturbed sleep"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.attribute","text":"P = 0.03"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.attribute","text":"P < 0.05"}]}]}
{"id":"6618859_2","context":"Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"gynecomastia"},{"annotation":"Treatment","text":"phenobarbital, phenytoin and fluoresone"},{"annotation":"Treatment.Disorder","text":"epileptics"},{"annotation":"Treatment.Drug","text":"phenobarbital"},{"annotation":"Treatment.Drug","text":"phenytoin"},{"annotation":"Treatment.Drug","text":"fluoresone"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"phenobarbital"},{"annotation":"Treatment.Combination.Drug","text":"phenytoin"},{"annotation":"Treatment.Combination.Drug","text":"fluoresone"},{"annotation":"Subject","text":"epileptics"},{"annotation":"Subject.Disorder","text":"epileptics"}]}]}
{"id":"3542612_1","context":"Captopril-induced lichen planus pemphigoides with pemphigus-like features.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment","text":"captopril"},{"annotation":"Treatment.Drug","text":"captopril"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Drug","text":"captopril"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Drug","text":"captopril"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemphigoides with pemphigus-like features"},{"annotation":"Treatment.Disorder","text":"lichen planus pemph"}]}]}
{"id":"6873616_3","context":"The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"cholestasis"},{"annotation":"Treatment","text":"thiabendazole"},{"annotation":"Treatment.Drug","text":"thiabendazole"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute","text":"negated"}]}]}
{"id":"8523340_2","context":"How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"mucocutaneous reactions"},{"annotation":"Effect","text":"reactions"},{"annotation":"Treatment","text":"gold"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Dosage","text":"very low"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"mucocutaneous reactions"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"mucocutaneous reactions"},{"annotation":"Effect","text":"reactions"},{"annotation":"Treatment","text":"gold"},{"annotation":"Treatment.Drug","text":"gold"},{"annotation":"Treatment.Dosage","text":"very low"},{"annotation":"Treatment.Dosage","text":"low"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"mucocutaneous reactions"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"23970584_3","context":"A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"epidural triamcinolone injection"},{"annotation":"Treatment","text":"epidural triamcinolone injection"},{"annotation":"Treatment.Drug","text":"triamcinolone"},{"annotation":"Treatment.Duration","text":"single injection"},{"annotation":"Treatment.Route","text":"epidural"},{"annotation":"Treatment.Disorder","text":"postherpetic neuralgia"},{"annotation":"Subject","text":"a 55-year-old HIV-positive African woman"},{"annotation":"Subject.Age","text":"55 years old"},{"annotation":"Subject.Gender","text":"African woman"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Race","text":"African"},{"annotation":"Treatment.Disorder","text":"postherpetic neuralgia"},{"annotation":"Treatment.Drug","text":"triamcinolone"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"response"},{"annotation":"Effect","text":"pain relief"},{"annotation":"Treatment","text":"epidural triamcinolone injection"},{"annotation":"Treatment.Drug","text":"triamcinolone"},{"annotation":"Treatment.Duration","text":"single injection"},{"annotation":"Treatment.Route","text":"epidural"},{"annotation":"Treatment.Disorder","text":"postherpetic neuralgia"},{"annotation":"Treatment.Drug","text":"triamcinolone"},{"annotation":"negated","text":"not negated"},{"annotation":"severity","text":"unknown"},{"annotation":"event_type","text":"Potential_therapeutic_effect"}]}]}
{"id":"6731466_2","context":"Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred"},{"annotation":"Effect","text":"anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis"},{"annotation":"Treatment","text":"zomepirac sodium"},{"annotation":"Treatment.Drug","text":"zomepirac sodium"},{"annotation":"Treatment.Disorder","text":"toothache"},{"annotation":"Treatment.Drug","text":"zomepirac sodium"}]}]}
{"id":"11341670_1","context":"During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"peripheral edema"},{"annotation":"Treatment","text":"continuous infusion of high doses of proton pump inhibitors omeprazole and pantoprazole together with large volumes of fluid"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Treatment.Drug","text":"pantoprazole"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Route","text":"continuous infusion"},{"annotation":"Treatment.Volume","text":"large volumes of fluid"},{"annotation":"Treatment.Combination.Trigger","text":"together with"},{"annotation":"Treatment.Combination.Drug","text":"omeprazole"},{"annotation":"Treatment.Combination.Drug","text":"pantoprazole"},{"annotation":"Treatment.Combination.Drug","text":"proton pump inhibitors"},{"annotation":"Treatment.Combination.Dosage","text":"high doses"},{"annotation":"Treatment.Combination.Route","text":"continuous infusion"},{"annotation":"Treatment.Combination.Volume","text":"large volumes of fluid"},{"annotation":"Subject","text":"three of six young female volunteers"},{"annotation":"Subject.Age","text":"young"},{"annotation":"Subject.Gender","text":"female"},{"annotation":"Subject.Population","text":"six volunteers"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"peripheral edema"},{"annotation":"Treatment","text":"continuous infusion of high doses of proton pump inhibitors pantoprazole and large volumes of fluid"},{"annotation":"Treatment.Drug","text":"pantoprazole"},{"annotation":"Treatment.Dosage","text":"high doses"},{"annotation":"Treatment.Route","text":"continuous infusion"},{"annotation":"Treatment.Volume","text":"large volumes of fluid"},{"annotation":"Treatment.Combination.Trigger","text":"together with"},{"annotation":"Treatment.Combination.Drug","text":"pantoprazole"},{"annotation":"Treatment.Combination.Drug","text":"proton pump inhibitors"},{"annotation":"Treatment.Combination.Dosage","text":"high doses"},{"annotation":"Treatment.Combination.Route","text":"continuous infusion"},{"annotation":"Treatment.Combination.Volume","text":"large volumes of fluid"},{"annotation":"Subject","text":"two of six young female volunteers"},{"annotation":"Subject.Age","text":"young"},{"annotation":"Subject.Gender","text":"female"},{"annotation":"Subject.Population","text":"six volunteers"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"10682234_7","context":"Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"ameliorated"},{"annotation":"Effect","text":"akathisia symptoms"},{"annotation":"Treatment","text":"intravenous levodopa"},{"annotation":"Treatment.Drug","text":"levodopa"},{"annotation":"Treatment.Dosage","text":"25 mg"},{"annotation":"Treatment.Frequency","text":"drastically"},{"annotation":"Treatment.Route","text":"intravenous"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"akathisia"}]}]}
{"id":"19318596_1","context":"Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"pain syndrome"},{"annotation":"Treatment","text":"hematopoietic stem cell transplant"},{"annotation":"Treatment.Drug","text":"cyclosporine"},{"annotation":"Treatment.Drug","text":"hematopoietic stem cell transplant"},{"annotation":"Treatment.Drug","text":"cyclosporine"},{"annotation":"Treatment.Drug","text":"hematopoietic stem cell transplant"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"cyclosporine"},{"annotation":"Treatment.Combination.Drug","text":"hematopoietic stem cell transplant"},{"annotation":"Subject","text":"a child"},{"annotation":"Subject.Age","text":"child"},{"annotation":"Subject.Disorder","text":"hematopoietic stem cell transplant"},{"annotation":"Treatment.Disorder","text":"cyclosporine-induced pain syndrome"}]}]}
{"id":"3171334_5","context":"Visual loss after a single small dose of vincristine has never been reported.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"Visual loss"},{"annotation":"Effect","text":"loss"},{"annotation":"Treatment","text":"single small dose of vincristine"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"reported"},{"annotation":"Effect","text":"never been reported"},{"annotation":"Treatment","text":"single small dose of vincristine"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"12786839_2","context":"Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"infectious mononucleosis-like syndrome"},{"annotation":"Treatment","text":"salazosulfapyridine"},{"annotation":"Treatment.Disorder","text":"infectious mononucleosis-like syndrome"},{"annotation":"Treatment.Drug","text":"salazosulfapyridine"},{"annotation":"Attribute","text":"genotypes"},{"annotation":"Attribute.Type","text":"acetylator genotypes"},{"annotation":"Attribute.Risk_factor","text":"possible risk factor"},{"annotation":"Attribute.Severity","text":"unknown"}]}]}
{"id":"23970584_8","context":"Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"DRESS syndrome"},{"annotation":"Treatment","text":"raltegravir"},{"annotation":"Treatment.Drug","text":"raltegravir"},{"annotation":"Treatment.Disorder","text":"DRESS syndrome"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"drug-drug interactions"},{"annotation":"Treatment","text":"protease inhibitor-based therapy"},{"annotation":"Treatment.Disorder","text":"drug-drug interactions"},{"annotation":"Treatment.Drug","text":"protease inhibitor-based therapy"}]}]}
{"id":"12504711_2","context":"CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"cause"},{"annotation":"Effect","text":"paradoxical raised IOP"},{"annotation":"Treatment","text":"topical brimonidine"},{"annotation":"Treatment.Drug","text":"brimonidine"},{"annotation":"Treatment.Dosage","text":"topical"},{"annotation":"Treatment.Duration","text":"follow-up"},{"annotation":"Treatment.Route","text":"topical"},{"annotation":"Treatment.Side_effect","text":"paradoxical raised IOP"},{"annotation":"Treatment.Negated","text":"not"},{"annotation":"Treatment.Severity","text":"paradoxical"},{"annotation":"Treatment.Disorder","text":"IOP"},{"annotation":"Treatment.Disorder","text":"paradoxical raised IOP"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not"},{"annotation":"Attribute","text":""}]}]}
{"id":"12659609_9","context":"Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"over-treatment"},{"annotation":"Effect","text":"chloroquine overdose"},{"annotation":"Treatment","text":"chloroquine"},{"annotation":"Treatment.Drug","text":"chloroquine"},{"annotation":"Treatment.Dosage","text":"initial over-treatment"},{"annotation":"Treatment.Dosage","text":"902 micro g/L"},{"annotation":"Treatment.Dosage","text":"maximum serum concentration"},{"annotation":"Treatment.Dosage","text":"fatal chloroquine overdose"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.attribute","text":"not fatal chloroquine overdose"}]}]}
{"id":"20925534_15","context":"There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"cardiovascular interaction"},{"annotation":"Treatment","text":"clopidogrel and omeprazole"},{"annotation":"Treatment.Disorder","text":"cardiovascular events"},{"annotation":"Treatment.Drug","text":"clopidogrel"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Treatment.Combination.Trigger","text":"but"},{"annotation":"Treatment.Combination.Drug","text":"PPI"},{"annotation":"Treatment.Combination.Drug","text":"clinically meaningful difference"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"clinically meaningful difference"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"cardiovascular events"},{"annotation":"Treatment","text":"clopidogrel and omeprazole"},{"annotation":"Treatment.Disorder","text":"cardiovascular events"},{"annotation":"Treatment.Drug","text":"clopidogrel"},{"annotation":"Treatment.Drug","text":"omeprazole"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"clinically meaningful difference"}]}]}
{"id":"18855892_2","context":"Anaphylactic/anaphylactoid reactions to methotrexate are rare.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"to methotrexate"},{"annotation":"Effect","text":"anaphylactic/anaphylactoid reactions"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"methotrexate-induced reaction"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"negated","text":"rare"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"rare"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"anaphylactic/anaphylactoid reactions"},{"annotation":"Treatment","text":"methotrexate"},{"annotation":"Treatment.Disorder","text":"methotrexate-induced reaction"},{"annotation":"Treatment.Drug","text":"methotrexate"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"rare"}]}]}
{"id":"1422497_3","context":"Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Effect","text":"treat bleeding urothelium"},{"annotation":"Treatment","text":"continuous bladder irrigation of a 1% alum solution"},{"annotation":"Treatment.Disorder","text":"bleeding urothelium"},{"annotation":"Treatment.Drug","text":"1% alum solution"},{"annotation":"Treatment.Route","text":"chemical cautery"},{"annotation":"Treatment.Time_elapsed","text":"continuous"},{"annotation":"Treatment.Duration","text":"simple and generally safe"},{"annotation":"Treatment.Combination.Trigger","text":"method"},{"annotation":"Treatment.Combination.Drug","text":"1% alum solution"},{"annotation":"Treatment.Combination.Route","text":"chemical cautery"},{"annotation":"Treatment.Combination.Time_elapsed","text":"continuous"},{"annotation":"Treatment.Combination.Duration","text":"simple and generally safe"}]}]}
{"id":"10759907_3","context":"The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"related"},{"annotation":"Effect","text":"spinal cord infarction"},{"annotation":"Treatment","text":"zolmitriptan"},{"annotation":"Treatment.Drug","text":"zolmitriptan"}]}]}
{"id":"1756352_2","context":"Delusional parasitosis associated with phenelzine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"phenelzine"},{"annotation":"Treatment.Drug","text":"phenelzine"},{"annotation":"Effect","text":"delusional parasitosis"},{"annotation":"Treatment.Drug","text":"phenelzine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"phenelzine"},{"annotation":"Treatment.Drug","text":"phenelzine"},{"annotation":"Effect","text":"delusional parasitosis"},{"annotation":"Treatment.Drug","text":"phenelzine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"phenelzine"},{"annotation":"Treatment.Drug","text":"phenelzine"},{"annotation":"Effect","text":"delusional parasitosis"},{"annotation":"Treatment.Drug","text":"phenelzine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"phenelzine"},{"annotation":"Treatment.Drug","text":"phenelzine"},{"annotation":"Effect","text":"delusional parasitosis"},{"annotation":"Treatment.Drug","text":"phenelzine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"phenelzine"},{"annotation":"Treatment.Drug","text":"phenelzine"},{"annotation":"Effect","text":"delusional parasitosis"},{"annotation":"Treatment.Drug","text":"phenelzine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"phenelzine"},{"annotation":"Treatment.Drug","text":"phenelzine"},{"annotation":"Effect","text":"delusional parasitosis"},{"annotation":"Treatment.Drug","text":"phenelzine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"phenelzine"},{"annotation":"Treatment.Drug","text":"phenelzine"},{"annotation":"Effect","text":"delusional parasitosis"},{"annotation":"Treatment.Drug","text":"phenelzine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"phenelzine"},{"annotation":"Treatment.Drug","text":"phenelzine"},{"annotation":"Effect","text":"delusional parasitosis"},{"annotation":"Treatment.Drug","text":"phenelzine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"phenelzine"},{"annotation":"Treatment.Drug","text":"phenelzine"},{"annotation":"Effect","text":"delusional parasitosis"},{"annotation":"Treatment.Drug","text":"phenelzine"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"phenelzine"},{"annotation":"Treatment."}]}]}
{"id":"8610807_2","context":"CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"hemorrhage"},{"annotation":"Effect","text":"hemorrhagic choroidal detachment"},{"annotation":"Treatment","text":"tissue plasminogen activator"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Treatment.Duration","text":"large extent"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Treatment.Drug","text":"responsible"},{"annotation":"Treatment.Drug","text":"hemorrhage"},{"annotation":"Treatment","text":"differential diagnosis"},{"annotation":"Treatment.Drug","text":"hemorrhagic choroidal detachment"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Treatment","text":"responsible"},{"annotation":"Treatment.Drug","text":"hemorrhagic choroidal detachment"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Treatment","text":"responsible"},{"annotation":"Treatment.Drug","text":"hemorrhagic choroidal detachment"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Treatment","text":"responsible"},{"annotation":"Treatment.Drug","text":"hemorrhagic choroidal detachment"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Treatment","text":"responsible"},{"annotation":"Treatment.Drug","text":"hemorrhagic choroidal detachment"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Treatment","text":"responsible"},{"annotation":"Treatment.Drug","text":"hemorrhagic choroidal detachment"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Treatment","text":"responsible"},{"annotation":"Treatment.Drug","text":"hemorrhagic choroidal detachment"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Treatment","text":"responsible"},{"annotation":"Treatment.Drug","text":"hemorrhagic choroidal detachment"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Treatment","text":"responsible"},{"annotation":"Treatment.Drug","text":"hemorrhagic choroidal detachment"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Treatment","text":"responsible"},{"annotation":"Treatment.Drug","text":"hemorrhagic choroidal detachment"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"},{"annotation":"Treatment","text":"responsible"},{"annotation":"Treatment.Drug","text":"hemorrhagic choroidal detachment"},{"annotation":"Treatment.Drug","text":"tissue plasminogen activator"}]}]}
{"id":"9007910_1","context":"Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"severe adverse reactions"},{"annotation":"Effect","text":"adverse reactions"},{"annotation":"Treatment","text":"5-fluorouracil-based chemotherapy"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Disorder","text":"dihydropyrimidine dehydrogenase deficiency"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Treatment.Disorder","text":"pharmacogenetic defect"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Disorder","text":"dihydropyrimidine dehydrogenase deficiency"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Disorder","text":"pharmacogenetic defect"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Treatment.Disorder","text":"pharmacogenetic defect"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Treatment.Disorder","text":"pharmacogenetic defect"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Treatment.Disorder","text":"pharmacogenetic defect"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Treatment.Disorder","text":"pharmacogenetic defect"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Treatment.Disorder","text":"pharmacogenetic defect"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Treatment.Disorder","text":"pharmacogenetic defect"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Treatment.Disorder","text":"pharmacogenetic defect"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Treatment.Disorder","text":"pharmacogenetic defect"},{"annotation":"Treatment.Drug","text":"5-fluorouracil"},{"annotation":"Treatment.Drug","text":"chemotherapy"},{"annotation":"Treatment.Disorder","text":"pharmacogenetic defect"},{"annotation":"Treatment.Drug","text":""}]}]}
{"id":"16393774_2","context":"Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis."},{"annotation":"Treatment","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Disorder","text":"multiple sclerosis"},{"annotation":"Treatment.Drug","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Dosage","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Duration","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Route","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Frequency","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Drug","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Dosage","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Duration","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Route","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Frequency","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Drug","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Dosage","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Duration","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Route","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Frequency","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Drug","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Dosage","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Duration","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Route","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Frequency","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Drug","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Dosage","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Duration","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Route","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Frequency","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Drug","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Dosage","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Duration","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Route","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treatment.Frequency","text":"Interferon-beta (IFN-beta)"},{"annotation":"Treat"}]}]}
{"id":"18071101_2","context":"Quetiapine-induced leucopenia and thrombocytopenia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Treatment","text":"quetiapine"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Effect","text":"leucopenia and thrombocytopenia"},{"annotation":"Treatment.Drug","text":"quetiapine"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment."}]}]}
{"id":"18425523_2","context":"CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurred after"},{"annotation":"Effect","text":"ocular hypertension"},{"annotation":"Treatment","text":"intravitreal ranibizumab"},{"annotation":"Treatment.Disorder","text":"severe and sustained ocular hypertension"},{"annotation":"Treatment.Drug","text":"ranibizumab"}]}]}
{"id":"18425523_1","context":"BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"occurrence"},{"annotation":"Effect","text":"ocular hypertension"},{"annotation":"Treatment","text":"injection of ranibizumab intravitreally"},{"annotation":"Treatment.Drug","text":"ranibizumab"},{"annotation":"Treatment.Dosage","text":"intravitreally"},{"annotation":"Treatment.Frequency","text":"in four patients"},{"annotation":"Treatment.Route","text":"intravitreally"},{"annotation":"Treatment.Time_elapsed","text":"after injection"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"ocular hypertension"}]}]}
{"id":"20234160_2","context":"Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as ","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Disorder","text":"methicillin-resistant Staphylococcus aureus infections"},{"annotation":"Treatment.Disorder","text":"vancomycin-associated adverse effects"},{"annotation":"Effect","text":"adverse effects"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Disorder","text":"vancomycin-associated adverse effects"},{"annotation":"Effect","text":"adverse effects"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Disorder","text":"vancomycin-associated adverse effects"},{"annotation":"Effect","text":"adverse effects"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Disorder","text":"vancomycin-associated adverse effects"},{"annotation":"Effect","text":"adverse effects"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Disorder","text":"vancomycin-associated adverse effects"},{"annotation":"Effect","text":"adverse effects"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Disorder","text":"vancomycin-associated adverse effects"},{"annotation":"Effect","text":"adverse effects"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"vancomycin"},{"annotation":"Treatment.Drug","text":"vancomycin"},{"annotation":"Treatment.Disorder","text":"vancomycin-associated adverse effects"},{"annotation":"Effect","text":"adverse effects"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated"},{"annotation":"Treatment","text":"vancomycin"},{"annotation":"Treatment.Drug"}]}]}
{"id":"15093850_2","context":"We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"unintentional overdose"},{"annotation":"Treatment","text":"oral pilocarpine tablets"},{"annotation":"Treatment.Drug","text":"pilocarpine"},{"annotation":"Treatment.Dosage","text":"overdose"},{"annotation":"Effect","text":"bradycardia, mild hypotension, and muscarinic symptoms"},{"annotation":"Treatment","text":"Sjogren's syndrome"},{"annotation":"Subject","text":"patient with Sjogren's syndrome"},{"annotation":"Subject.Disorder","text":"Sjogren's syndrome"}]}]}
{"id":"16357738_1","context":"Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"condition resembling RPLS"},{"annotation":"Treatment","text":"immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha"},{"annotation":"Treatment.Disorder","text":"condition resembling RPLS"},{"annotation":"Treatment.Drug","text":"immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha"}]}]}
{"id":"12854039_2","context":"Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"bilateral optic neuritis"},{"annotation":"Treatment","text":"recombinant interferon alpha-2a"},{"annotation":"Treatment.Disorder","text":"chronic active hepatitis C"},{"annotation":"Treatment.Drug","text":"recombinant interferon alpha-2a"},{"annotation":"Treatment.Duration","text":"seven-month"},{"annotation":"Treatment.Drug","text":"recombinant interferon alpha-2a"},{"annotation":"Treatment.Drug","text":"recombinant interferon alpha-2a"},{"annotation":"Treatment.Drug","text":"recombinant interferon alpha-2a"},{"annotation":"Subject","text":"a 62-year-old woman"},{"annotation":"Subject.Age","text":"62"},{"annotation":"Subject.Gender","text":"female"},{"annotation":"Subject.Disorder","text":"chronic active hepatitis C"},{"annotation":"Subject.Population","text":"a woman"}]}]}
{"id":"9550246_1","context":"A syndrome of increased affect in response to risperidone among patients with schizophrenia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"increased affect"},{"annotation":"Treatment","text":"risperidone"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Treatment.Disorder","text":"schizophrenia"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"increased affect"},{"annotation":"Treatment","text":"risperidone"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Treatment.Disorder","text":"schizophrenia"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"low severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"increased affect"},{"annotation":"Treatment","text":"risperidone"},{"annotation":"Treatment.Drug","text":"risperidone"},{"annotation":"Treatment.Disorder","text":"schizophrenia"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"low severity"}]}]}
{"id":"16393774_3","context":"Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Treatment","text":"IFN-beta"},{"annotation":"Treatment.Disorder","text":"autoimmune disorders"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"rarely associated"}]}]}
{"id":"18977778_1","context":"Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"venous thromboembolism"},{"annotation":"Treatment","text":"low-molecular-weight heparin"},{"annotation":"Treatment.Drug","text":"low-molecular-weight heparin"},{"annotation":"Treatment.Dosage","text":"during treatment"}]},{"type":"Adverse_event","annotations":[{"annotation":"Treatment","text":"antithrombotic effects"}]}]}
{"id":"18354950_1","context":"Hyponatraemia developed after rechallenge with controlled release carbamazepine.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"developed"},{"annotation":"Effect","text":"hyponatraemia"},{"annotation":"Treatment","text":"rechallenge with controlled release carbamazepine"},{"annotation":"Treatment.Drug","text":"controlled release carbamazepine"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"not specified"},{"annotation":"Subject","text":"not specified"},{"annotation":"Subject.Age","text":"not specified"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Population","text":"not specified"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Treatment.Disorder","text":"hyponatraemia"},{"annotation":"negated","text":"not specified"},{"annotation":"speculated","text":"not specified"},{"annotation":"severity","text":"not specified"}]}]}
{"id":"18505911_1","context":"Azathioprine-induced warfarin resistance.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"resistance"},{"annotation":"Treatment","text":"warfarin"},{"annotation":"Treatment.Drug","text":"azathioprine"},{"annotation":"Treatment.Disorder","text":"warfarin resistance"},{"annotation":"Treatment.Drug","text":"warfarin"},{"annotation":"Treatment.Drug","text":"azathioprine"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"azathioprine"},{"annotation":"Treatment.Combination.Drug","text":"warfarin"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"warfarin resistance"}]}]}
{"id":"3084231_2","context":"Reversible valproic acid-induced dementia: a case report.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"dementia"},{"annotation":"Treatment","text":"valproic acid"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Reversible"},{"annotation":"Effect","text":"dementia"},{"annotation":"Treatment","text":"valproic acid"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Treatment.Duration","text":"valproic acid"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"dementia"},{"annotation":"Treatment","text":"valproic acid"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"dementia"},{"annotation":"Treatment","text":"valproic acid"},{"annotation":"Treatment.Drug","text":"valproic acid"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"high severity"},{"annotation":"Attribute Attributes","text":"speculated"}]}]}
{"id":"6697887_1","context":"Parenteral-verapamil-induced sustained hypotension.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hypotension"},{"annotation":"Treatment","text":"parenteral verapamil"},{"annotation":"Treatment.Drug","text":"verapamil"},{"annotation":"Treatment.Duration","text":"sustained"},{"annotation":"Treatment.Dosage","text":"parenteral"},{"annotation":"Treatment.Route","text":"verapamil"},{"annotation":"Treatment.Time_elapsed","text":"after administration"},{"annotation":"Treatment.Side_effect","text":"hypotension"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"The adverse effect of verapamil-induced sustained hypotension does not exist."}]}]}
{"id":"1711090_6","context":"The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Effect","text":"low-grade fever"},{"annotation":"Effect","text":"localized pain"},{"annotation":"Effect","text":"myelo-suppression"},{"annotation":"Effect","text":"liver dysfunction"},{"annotation":"Treatment","text":"Lp-TAE combined with HT"},{"annotation":"Treatment.Drug","text":"Lp-TAE"},{"annotation":"Treatment.Drug","text":"HT"},{"annotation":"Treatment.Duration","text":"transient"},{"annotation":"Treatment.Duration","text":"eventually disappeared"},{"annotation":"Treatment.Disorder","text":"none"},{"annotation":"Treatment.Drug","text":"none"}]}]}
{"id":"6738830_2","context":"Unique behavioral change with cinepazide in parkinsonism.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"unique behavioral change"},{"annotation":"Effect","text":"behavioral change"},{"annotation":"Treatment","text":"cinepazide"},{"annotation":"Treatment.Disorder","text":"parkinsonism"},{"annotation":"Treatment.Drug","text":"cinepazide"}]}]}
{"id":"3171334_4","context":"The literature of vincristine optic nerve toxicity is reviewed.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"optic nerve toxicity"},{"annotation":"Treatment","text":"vincristine"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Disorder","text":"optic nerve toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Disorder","text":"optic nerve toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincristine"},{"annotation":"Treatment.Drug","text":"optic nerve"},{"annotation":"Treatment.Drug","text":"toxicity"},{"annotation":"Treatment.Drug","text":"vincrist"}]}]}
{"id":"7639655_4","context":"PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"experienced"},{"annotation":"Effect","text":"visual loss"},{"annotation":"Treatment","text":"interferon alfa"},{"annotation":"Treatment.Disorder","text":"malignant neoplasms"},{"annotation":"Treatment.Drug","text":"interferon alfa"},{"annotation":"Subject","text":"two patients"},{"annotation":"Subject.Age","text":"40 and 51 years"},{"annotation":"Subject.Population","text":"two patients"},{"annotation":"Treatment.Drug","text":"interferon alfa"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"malignant neoplasms"},{"annotation":"negated","text":"not negated"},{"annotation":"speculated","text":"not speculated"},{"annotation":"severity","text":"not specified"},{"annotation":"event_type","text":"Adverse_event"}]}]}
{"id":"14968106_2","context":"Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"toxic"},{"annotation":"Effect","text":"myelopathy"},{"annotation":"Treatment","text":"intrathecal injection of doxorubicin"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Dosage","text":"intrathecal injection"},{"annotation":"Treatment.Duration","text":"following toxic myelopathy"},{"annotation":"Treatment.Effect","text":"neurological improvement and rehabilitation potential"},{"annotation":"Treatment.Duration","text":"following toxic myelopathy"},{"annotation":"Treatment.Effect","text":"neurological improvement and rehabilitation potential"},{"annotation":"Treatment","text":"toxic myelopathy"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Dosage","text":"intrathecal injection"},{"annotation":"Treatment.Duration","text":"following toxic myelopathy"},{"annotation":"Treatment.Effect","text":"neurological improvement and rehabilitation potential"},{"annotation":"Treatment.Dosage","text":"intrathecal injection"},{"annotation":"Treatment.Duration","text":"following toxic myelopathy"},{"annotation":"Treatment.Effect","text":"neurological improvement and rehabilitation potential"},{"annotation":"Treatment","text":"toxic myelopathy"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Dosage","text":"intrathecal injection"},{"annotation":"Treatment.Duration","text":"following toxic myelopathy"},{"annotation":"Treatment.Effect","text":"neurological improvement and rehabilitation potential"},{"annotation":"Treatment.Duration","text":"following toxic myelopathy"},{"annotation":"Treatment.Effect","text":"neurological improvement and rehabilitation potential"},{"annotation":"Treatment","text":"toxic myelopathy"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Dosage","text":"intrathecal injection"},{"annotation":"Treatment.Duration","text":"following toxic myelopathy"},{"annotation":"Treatment.Effect","text":"neurological improvement and rehabilitation potential"},{"annotation":"Treatment.Duration","text":"following toxic myelopathy"},{"annotation":"Treatment.Effect","text":"neurological improvement and rehabilitation potential"},{"annotation":"Treatment","text":"toxic myelopathy"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Dosage","text":"intrathecal injection"},{"annotation":"Treatment.Duration","text":"following toxic myelopathy"},{"annotation":"Treatment.Effect","text":"neurological improvement and rehabilitation potential"},{"annotation":"Treatment.Duration","text":"following toxic myelopathy"},{"annotation":"Treatment.Effect","text":"neurological improvement and rehabilitation potential"},{"annotation":"Treatment","text":"toxic myelopathy"},{"annotation":"Treatment.Drug","text":"doxorubicin"},{"annotation":"Treatment.Dosage","text":"intrathecal injection"},{"annotation":"Treatment.Duration","text":"following toxic my"}]}]}
{"id":"14522628_1","context":"Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"associated with"},{"annotation":"Treatment","text":"ganciclovir therapy"},{"annotation":"Treatment.Drug","text":"ganciclovir"},{"annotation":"Effect","text":"generalised cutaneous rash"},{"annotation":"Treatment.Disorder","text":"ganciclovir therapy"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"severity"},{"annotation":"Attribute Attributes","text":"high"},{"annotation":"Attribute Attributes","text":"low"},{"annotation":"Attribute Attributes","text":"medium"}]}]}
{"id":"129501_1","context":"Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"injection of chymopapain"},{"annotation":"Effect","text":"anaphylaxis"},{"annotation":"Treatment","text":"chymopapain"},{"annotation":"Treatment.Drug","text":"chymopapain"},{"annotation":"Treatment.Duration","text":"1%"},{"annotation":"Treatment.Duration","text":"of such cases"},{"annotation":"Treatment.Disorder","text":"anaphylaxis"},{"annotation":"Treatment.Drug","text":"chymopapain"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Subject","text":"not specified"},{"annotation":"Subject.Age","text":"not specified"},{"annotation":"Subject.Disorder","text":"anaphylaxis"},{"annotation":"Treatment.Disorder","text":"chymopapain"}]}]}
{"id":"9253492_3","context":"Heat stroke-like episode in a child caused by zonisamide.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"caused by"},{"annotation":"Treatment","text":"zonisamide"},{"annotation":"Treatment.Drug","text":"zonisamide"},{"annotation":"Effect","text":"heat stroke-like episode"},{"annotation":"Treatment.Disorder","text":"child"},{"annotation":"Treatment.Drug","text":"zonisamide"},{"annotation":"Treatment.Drug","text":"zinc"}]}]}
{"id":"18166746_7","context":"An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Effect","text":"serotonin syndrome"},{"annotation":"Treatment","text":"methylene blue"},{"annotation":"Treatment.Drug","text":"serotonergic agents"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"methylene blue"},{"annotation":"Treatment.Combination.Drug","text":"serotonergic agents"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.negated","text":"not serotonin syndrome"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"interaction"},{"annotation":"Treatment","text":"methylene blue"},{"annotation":"Treatment.Disorder","text":"serotonin syndrome"},{"annotation":"Treatment.Drug","text":"serotonergic agents"}]}]}
{"id":"11236070_2","context":"These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"leukopenia or agranulocytosis"},{"annotation":"Effect","text":"during olanzapine treatment"},{"annotation":"Treatment","text":"olanzapine"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"dose-related"},{"annotation":"Treatment.Disorder","text":"leukopenia or agranulocytosis"},{"annotation":"Treatment.Disorder","text":"during olanzapine treatment"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"dose-related"},{"annotation":"Treatment.Disorder","text":"leukopenia or agranulocytosis"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"dose-related"},{"annotation":"Treatment.Disorder","text":"leukopenia or agranulocytosis"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"dose-related"},{"annotation":"Treatment.Disorder","text":"leukopenia or agranulocytosis"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"dose-related"},{"annotation":"Treatment.Disorder","text":"leukopenia or agranulocytosis"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"dose-related"},{"annotation":"Treatment.Disorder","text":"leukopenia or agranulocytosis"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"dose-related"},{"annotation":"Treatment.Disorder","text":"leukopenia or agranulocytosis"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"dose-related"},{"annotation":"Treatment.Disorder","text":"leukopenia or agranulocytosis"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"dose-related"},{"annotation":"Treatment.Disorder","text":"leukopenia or agranulocytosis"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"dose-related"},{"annotation":"Treatment.Disorder","text":"leukopenia or agranulocytosis"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"dose-related"},{"annotation":"Treatment.Disorder","text":"leukopenia or agranulocytosis"},{"annotation":"Treatment.Drug","text":"olanzapine"},{"annotation":"Treatment.Dosage","text":"dose-related"},{"annotation":"Treatment.Disorder","text":"leukopenia or agranulocytosis"},{"annotation":"Treatment.Drug","text":"olanz"}]}]}
{"id":"18371508_1","context":"Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"after"},{"annotation":"Effect","text":"respiratory distress syndrome"},{"annotation":"Treatment","text":"pegylated interferon alpha-2a and ribavirin"},{"annotation":"Treatment.Disorder","text":"treatment with pegylated interferon alpha-2a and ribavirin"},{"annotation":"Treatment.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Drug","text":"ribavirin"},{"annotation":"Treatment.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Drug","text":"ribavirin"},{"annotation":"Subject","text":"adult"},{"annotation":"Subject.Disorder","text":"respiratory distress syndrome"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Combination.Drug","text":"ribavirin"},{"annotation":"Treatment.Combination.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Combination.Drug","text":"ribavirin"},{"annotation":"Treatment.Combination.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Combination.Drug","text":"ribavirin"},{"annotation":"Treatment.Combination.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Combination.Drug","text":"ribavirin"},{"annotation":"Treatment.Combination.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Combination.Drug","text":"ribavirin"},{"annotation":"Treatment.Combination.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Combination.Drug","text":"ribavirin"},{"annotation":"Treatment.Combination.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Combination.Drug","text":"ribavirin"},{"annotation":"Treatment.Combination.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Combination.Drug","text":"ribavirin"},{"annotation":"Treatment.Combination.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Combination.Drug","text":"ribavirin"},{"annotation":"Treatment.Combination.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Combination.Drug","text":"ribavirin"},{"annotation":"Treatment.Combination.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Combination.Drug","text":"ribavirin"},{"annotation":"Treatment.Combination.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Combination.Drug","text":"ribavirin"},{"annotation":"Treatment.Combination.Drug","text":"pegylated interferon alpha-2a"},{"annotation":"Treatment.Combination.Drug","text":"ribavirin"},{"annotation":"Treatment.Comb"}]}]}
{"id":"16620273_1","context":"CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"increasing prevalence of Type 2 diabetes and its treatment with metformin"},{"annotation":"Treatment","text":"metformin"},{"annotation":"Treatment.Disorder","text":"Type 2 diabetes"},{"annotation":"Effect","text":"lactic acidosis"},{"annotation":"Attribute Attributes","text":"negated"}]},{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"result"},{"annotation":"Treatment","text":"metformin"},{"annotation":"Treatment.Disorder","text":"Type 2 diabetes"},{"annotation":"Effect","text":"lactic acidosis"},{"annotation":"Attribute Attributes","text":"negated"}]}]}
{"id":"18037876_3","context":"Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"sustained"},{"annotation":"Effect","text":"ventricular tachycardia"},{"annotation":"Treatment","text":"thalidomide"},{"annotation":"Treatment.Disorder","text":"primary plasma-cell leukemia"},{"annotation":"Treatment.Drug","text":"thalidomide"},{"annotation":"Treatment.Duration","text":"thalidomide-treated"},{"annotation":"Treatment.Duration","text":"primary plasma-cell leukemia"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"primary plasma-cell leukemia"},{"annotation":"Treatment.Drug","text":"thalidomide"},{"annotation":"Subject.Age","text":"a patient"}]}]}
{"id":"10579985_3","context":"The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"diagnosis"},{"annotation":"Treatment","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"nodular sclerosing Hodgkin's lymphoma"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Subject","text":"a 29-year-old man with CD"},{"annotation":"Subject.Disorder","text":"CD"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"diagnosis"},{"annotation":"Effect","text":"nodular sclerosing Hodgkin's lymphoma"},{"annotation":"Treatment","text":"infliximab"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Treatment.Disorder","text":"nodular sclerosing Hodgkin's lymphoma"},{"annotation":"Treatment.Drug","text":"infliximab"},{"annotation":"Subject","text":"a 29-year-old man with CD"},{"annotation":"Subject.Disorder","text":"CD"}]}]}
{"id":"16317298_6","context":"We suggest discontinuing gemcitabine if radiation recall is observed.","events":[{"type":"Potential_therapeutic_event","annotations":[{"annotation":"Trigger","text":"suggestion"},{"annotation":"Treatment","text":"discontinuing gemcitabine"},{"annotation":"Treatment.Disorder","text":"radiation recall"},{"annotation":"Treatment.Drug","text":"gemcitabine"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"speculated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes"}]}]}
{"id":"18523232_4","context":"OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"hepatitis"},{"annotation":"Treatment","text":"pulse itraconazole therapy"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Duration","text":"24 weeks"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"24 weeks"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"24 weeks"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"24 weeks"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"24 weeks"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"24 weeks"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"24 weeks"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.Dosage","text":"not specified"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Time_elapsed","text":"not specified"},{"annotation":"Treatment.Duration","text":"24 weeks"},{"annotation":"Treatment.Drug","text":"itraconazole"},{"annotation":"Treatment.D"}]}]}
{"id":"7712052_6","context":"These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"symptom complex"},{"annotation":"Treatment","text":"lithium"},{"annotation":"Treatment.Disorder","text":"PTSD"},{"annotation":"Effect","text":"treatment of this symptom complex"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"negated"},{}]}]}
{"id":"6928097_1","context":"She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"toxicity"},{"annotation":"Effect","text":"death"},{"annotation":"Treatment","text":"adjuvant Adriamycin (doxorubicin) chemotherapy"},{"annotation":"Treatment.Drug","text":"Adriamycin"},{"annotation":"Treatment.Dosage","text":"6 months"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"Adriamycin toxicity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.Attribute","text":"not specified"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"toxicity"},{"annotation":"Effect","text":"death"},{"annotation":"Treatment","text":"adjuvant Adriamycin (doxorubicin) chemotherapy"},{"annotation":"Treatment.Drug","text":"Adriamycin"},{"annotation":"Treatment.Dosage","text":"6 months"},{"annotation":"Treatment.Frequency","text":"not specified"},{"annotation":"Treatment.Route","text":"not specified"},{"annotation":"Treatment.Duration","text":"not specified"},{"annotation":"Treatment.Disorder","text":"Adriamycin toxicity"},{"annotation":"Attribute","text":"negated"},{"annotation":"Attribute.Attribute","text":"not specified"}]}]}
{"id":"12477460_2","context":"BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"arising"},{"annotation":"Treatment","text":"tamoxifen therapy"},{"annotation":"Treatment.Disorder","text":"ovarian cancer"},{"annotation":"Treatment.Disorder","text":"endometriotic cyst"},{"annotation":"Subject","text":"a postmenopausal woman"},{"annotation":"Subject.Disorder","text":"postmenopausal woman"}]}]}
{"id":"15368548_1","context":"L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"pancreatitis"},{"annotation":"Treatment","text":"L-asparaginase"},{"annotation":"Treatment.Disorder","text":"leukemia"},{"annotation":"Treatment.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Drug","text":"leukemia"},{"annotation":"Treatment.Combination.Trigger","text":"of"},{"annotation":"Treatment.Combination.Drug","text":"L-asparaginase"},{"annotation":"Treatment.Combination.Drug","text":"leukemia"},{"annotation":"Subject","text":"a patient"},{"annotation":"Subject.Disorder","text":"leukemia"}]}]}
{"id":"21515865_3","context":"An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"arrived"},{"annotation":"Treatment","text":"long-term anticoagulation with warfarin sodium"},{"annotation":"Treatment.Disorder","text":"anticoagulation"},{"annotation":"Treatment.Drug","text":"warfarin sodium"},{"annotation":"Treatment.Dosage","text":"19 mg"},{"annotation":"Treatment.Duration","text":"long-term"},{"annotation":"Treatment.Dosage.Units","text":"mg"},{"annotation":"Treatment.Duration.Units","text":"weeks"},{"annotation":"Subject","text":"an 89-year-old man"},{"annotation":"Subject.Age","text":"89 years old"},{"annotation":"Subject.Population","text":"1"},{"annotation":"Subject.Gender","text":"not specified"},{"annotation":"Subject.Race","text":"not specified"},{"annotation":"Subject.Disorder","text":"anticoagulation"}]}]}
{"id":"12851279_14","context":"Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.","events":[{"type":"Potential_therapeutic_effect","annotations":[{"annotation":"Trigger","text":"Treatment"},{"annotation":"Treatment.Disorder","text":"severe sepsis and high INR"},{"annotation":"Treatment.Drug","text":"tifacogin"},{"annotation":"Treatment.Duration","text":"all-cause mortality"},{"annotation":"Treatment.Drug","text":"tifacogin"},{"annotation":"Treatment.Drug","text":"high INR"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"no effect"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"Treatment"},{"annotation":"Treatment.Drug","text":"tifacogin"},{"annotation":"Effect","text":"no effect"},{"annotation":"Attribute Attributes","text":"negated"},{"annotation":"Attribute Attributes","text":"no effect"}]}]}
{"id":"6572542_1","context":"Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"CCNU"},{"annotation":"Treatment","text":"CCNU"},{"annotation":"Treatment.Drug","text":"CCNU"},{"annotation":"Effect","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"dose-related"},{"annotation":"Attribute Attributes","text":"not negated"},{"annotation":"Attribute Attributes","text":"not speculated"},{"annotation":"Attribute Attributes","text":"low severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"CCNU"},{"annotation":"Treatment","text":"CCNU"},{"annotation":"Treatment.Drug","text":"CCNU"},{"annotation":"Effect","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"dose-related"},{"annotation":"Attribute Attributes","text":"not negated"},{"annotation":"Attribute Attributes","text":"not speculated"},{"annotation":"Attribute Attributes","text":"low severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"CCNU"},{"annotation":"Treatment","text":"CCNU"},{"annotation":"Treatment.Drug","text":"CCNU"},{"annotation":"Effect","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"dose-related"},{"annotation":"Attribute Attributes","text":"not negated"},{"annotation":"Attribute Attributes","text":"not speculated"},{"annotation":"Attribute Attributes","text":"low severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"CCNU"},{"annotation":"Treatment","text":"CCNU"},{"annotation":"Treatment.Drug","text":"CCNU"},{"annotation":"Effect","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"dose-related"},{"annotation":"Attribute Attributes","text":"not negated"},{"annotation":"Attribute Attributes","text":"not speculated"},{"annotation":"Attribute Attributes","text":"low severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"CCNU"},{"annotation":"Treatment","text":"CCNU"},{"annotation":"Treatment.Drug","text":"CCNU"},{"annotation":"Effect","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"dose-related"},{"annotation":"Attribute Attributes","text":"not negated"},{"annotation":"Attribute Attributes","text":"not speculated"},{"annotation":"Attribute Attributes","text":"low severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"CCNU"},{"annotation":"Treatment","text":"CCNU"},{"annotation":"Treatment.Drug","text":"CCNU"},{"annotation":"Effect","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"dose-related"},{"annotation":"Attribute Attributes","text":"not negated"},{"annotation":"Attribute Attributes","text":"not speculated"},{"annotation":"Attribute Attributes","text":"low severity"}]},{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"CCNU"},{"annotation":"Treatment","text":"CCNU"},{"annotation":"Treatment.Drug","text":"CCNU"},{"annotation":"Effect","text":"pulmonary toxicity"},{"annotation":"Treatment.Drug","text":"dose-related"},{"annotation":"Attribute Attributes","text":"not negated"},{"annotation":""}]}]}
{"id":"11452245_11","context":"Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"increase"},{"annotation":"Treatment","text":"combined treatment with repaglinide"},{"annotation":"Treatment.Drug","text":"repaglinide"},{"annotation":"Treatment.Drug","text":"clarithromycin"},{"annotation":"Treatment.Drug","text":"other potent inhibitors of CYP3A4"},{"annotation":"Treatment.Combination.Trigger","text":"and"},{"annotation":"Treatment.Combination.Drug","text":"repaglinide"},{"annotation":"Treatment.Combination.Drug","text":"clarithromycin"},{"annotation":"Treatment.Combination.Drug","text":"other potent inhibitors of CYP3A4"},{"annotation":"Treatment.Combination.Drug","text":"repaglinide"},{"annotation":"Treatment.Combination.Drug","text":"clarithromycin"},{"annotation":"Treatment.Combination.Drug","text":"other potent inhibitors of CYP3A4"},{"annotation":"Treatment.Combination.Drug","text":"repaglinide"},{"annotation":"Treatment.Combination.Drug","text":"clarithromycin"},{"annotation":"Treatment.Combination.Drug","text":"other potent inhibitors of CYP3A4"},{"annotation":"Treatment.Combination.Drug","text":"repaglinide"},{"annotation":"Treatment.Combination.Drug","text":"clarithromycin"},{"annotation":"Treatment.Combination.Drug","text":"other potent inhibitors of CYP3A4"},{"annotation":"Treatment.Combination.Drug","text":"repaglinide"},{"annotation":"Treatment.Combination.Drug","text":"clarithromycin"},{"annotation":"Treatment.Combination.Drug","text":"other potent inhibitors of CYP3A4"},{"annotation":"Treatment.Combination.Drug","text":"repaglinide"},{"annotation":"Treatment.Combination.Drug","text":"clarithromycin"},{"annotation":"Treatment.Combination.Drug","text":"other potent inhibitors of CYP3A4"},{"annotation":"Treatment.Combination.Drug","text":"repaglinide"},{"annotation":"Treatment.Combination.Drug","text":"clarithromycin"},{"annotation":"Treatment.Combination.Drug","text":"other potent inhibitors of CYP3A4"},{"annotation":"Treatment.Combination.Drug","text":"repaglinide"},{"annotation":"Treatment.Combination.Drug","text":"clarithromycin"},{"annotation":"Treatment.Combination.Drug","text":"other potent inhibitors of CYP3A4"},{"annotation":"Treatment.Combination.Drug","text":"repaglinide"},{"annotation":"Treatment.Combination.Drug","text":"clarithromycin"},{"annotation":"Treatment.Combination.Drug","text":"other potent inhibitors of CYP3A4"},{"annotation":"Treatment.Combination.Drug","text":"repaglinide"},{"annotation":"Treatment.Combination.Drug","text":"clarithrom"}]}]}
{"id":"1888256_1","context":"Drug-induced fever due to diltiazem.","events":[{"type":"Adverse_event","annotations":[{"annotation":"Trigger","text":"induced"},{"annotation":"Effect","text":"fever"},{"annotation":"Treatment","text":"diltiazem"},{"annotation":"Treatment.Drug","text":"diltiazem"}]}]}
